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Abstract 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is a key process 
during development, wound healing and the female reproductive cycle. However, it is also a 
pathological feature of many diseases such as cancer, age-related macular degeneration and 
chronic inflammatory pathologies. Given the complexity underlying the fine regulation of this 
process, despite the great number of studies, our understanding of it is not yet exhaustive.  
Syndecans are heparan sulphate proteoglycans with roles in cell adhesion, migration and 
growth factor interactions. The aim of this body of work was to investigate the role of these 
molecules in the regulation of angiogenesis. For this purpose, in the first part of my project, I 
investigated the effects of the extracellular core proteins of all four syndecans on endothelial 
cell functions. These studies identified that all four proteins are able to inhibit angiogenesis 
and strongly suppress endothelial cell migration, invasion and tube formation. On the basis of 
these discoveries, I focused on the syndecan-2 extracellular core protein and showed that it is 
shed during inflammation and can interact with the endothelial cell surface tyrosine 
phosphatase receptor CD148. Upon binding to CD148, the syndecan-2 extracellular core 
protein reduces the expression of active β1 integrins on endothelial cell surface and inhibits 
endothelial cell migration. This provides a mechanism through which shed syndecan-2 can 
regulate angiogenesis. Critically, this is an entirely novel pathway for the reduction of 
angiogenesis which is independent to the main angiogenic factor VEGF. Lastly, since previous 
works suggested that the syndecan-4-null mouse may exhibit angiogenic defects, I set out to 
determine the role of syndecan-4 in angiogenesis. Here, I observed an up-regulation of 
syndecan-4 on endothelial cells in angiogenic settings both in vitro and in vivo. Furthermore, 
through analysis of in vivo models of pathological angiogenesis, I observed that syndecan-4 is 
critical for VEGF-A-mediated angiogenesis. This effect was partially explained by impaired 
activation of VEGFR2 in syndecan-4-null endothelial cells. This data suggests that syndecan-
4 is the main heparan sulphate proteoglycan to act as VEGFR2 co-receptor during pathological 
angiogenesis.  
Collectively, the findings of this research have identified previously unknown roles for 
syndecans in the regulation of angiogenesis. 
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GAG Glycosaminoglycan  
GST Glutathione S-Transferase 
HBD Heparin-Binding Domain 
HB-EGF Heparin-Binding Egf-Like Growth Factor 
HEK293T Human Embryonic Kidney 293 Cells 
HG Haemoglobin 
HGF Hepatocyte Growth Factor 
HIF Hypoxia-Inducible Factors 
HIV Human Immunodeficiency Virus 
HMEC Human Microvascular EC 
HRE Hypoxia-Responsive Element 
HRP Horseradish Peroxidase 
HS Heparan Sulphate 
HSPG Heparan Sulphate Proteoglycan 
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HUVEC Human Umbilical Vein ECs 
IGF Insulin-Like Growth Factor 
IL-8 Interleukin-8 
IPF Idiopathic Pulmonary Fibrosis 
KC Keratinocyte Chemoattractant 
MAP Mitogen-Activated Protein 
MIP-2 Macrophage Inflammatory Protein 2 
MLEC Mouse Lung EC 
MMP Matrix Metalloproteinase 
MT-MMP Membrane-Type MMP 
MvEC Mouse Vascular EC 
NDST N-Deacetylase–N-Sulphotransferase 
NO Nitric Oxide 
NRP Neuropilin 
ON Over-Night 
OST O-Sulphotransferase 
P/S Penicillin/Streptomycin 
PAGE Polyacrylamide Gel Electrophoresis  
PAI Plasminogen Activator Inhibitor 
PBS Phosphate-Buffered Saline 
PDGF Platelet-Derived Growth Factor 
PDH Pyruvate Dehydrogenase 
PECAM Platelet EC Adhesion Molecule 
PGE Prostaglandin 
PI3K Phosphoinositide 3-Kinase 
PKC Protein Kinase C 
PLA Proximity-Ligation Assay 
PlGF Placental Growth Factor 
PMA Phorbol 12-Myristate 13-Acetate 
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PTK Protein Tyrosine Kinase 
RANTES Regulated On Activation, Normal T Expressed And Secreted 
REF Rat Embryo Fibroblasts 
RGD Tripeptide Arg-Gly-Asp 
RNA Ribonucleic Acid 
RPE Retinal Pigmented Epithelium 
RPF Renal Periphery Fibroblast 
RT Room Temperature 
RT-PCR Reverse Transcription Polymerase Chain Reaction  
S1ED Syndecan-1 ectodomain 
S4 Syndecan-4 
SCID Severe Combined Immunodeficiency 
SDC Syndecan 
SDF Stromal Cell Derived Factor 
SDS Sodium Dodecyl Sulfate 
SSTN Synstatin 
syndecan-4 KO Syndecan-4 Knock-Out 
TBST Tris-Buffered Saline And Tween 20 
TGF Transforming Growth Factor 
TNF Tumor Necrosis Factor 
TRAP Thrombin Receptor-Activating Peptide 
TSP Thrombospondin 
uPA Urokinase-Type Plasminogen Activator  
UT Untreated 
VCAM Vascular Cell Adhesion Molecule 
VE-Cadherin Vascular Endothelial Cadherin 
VEGF Vascular Endothelial Growth Factor 
VN Vitronectin 
VPF Vascular Permeability Factor 
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WT Wild-Type 
ZO  Zona Occludens Protein 
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1. Introduction 
Heparan sulphate proteoglycans (HSPGs) are a class of glycoproteins composed of a core 
protein to which long linear heparan sulphate (HS) chains are attached. HSPGs can be found 
on the cell surface, anchored to the plasma membrane via a transmembrane domain as is the 
case for syndecans or via a glycosylphosphatidylinositol molecule as is the case for glypicans, 
or they can be directly released in the extracellular space like in the case of agrin, collagen 
XVIII and perlecan (Gallagher et al., 1986).  
HSPGs are absent in protista, plantae and fungi, and they only appear in the animal kingdom 
with the advent of eumetazoa, animals that display true tissues, where they are found to be 
ubiquitously expressed in all tissues and species analysed (Dietrich et al., 1983). HSPGs have 
therefore a long evolutionary history, which is usually indicative of fundamental roles. HSPGs, 
in fact, participate in many different activities in cells and tissues: ligand-receptor clustering 
and signalling, endocytosis and trafficking of cytoplasmic vesicles, cytoskeletal dynamics, cell 
adhesion and motility, basement membrane organisation, chemotactic gradient formation and 
cell-cell cross talk (Bishop et al., 2007; Sarrazin et al., 2011). 
Perhaps unsurprisingly, given their key roles in cell and tissue biology, HSPGs have often 
been associated with the pathogenesis of many diseases including cancer (Soares et al., 2015), 
arthritis (De Ceuninck et al., 2003), vascular diseases (David et al., 1995), dysregulated 
inflammation (Gordts and Esko, 2015) and Alzheimer’s disease (van Horssen et al., 2003). 
However, despite the large amount of studies aimed at understanding the roles of HSPGs in 
health and disease, our understanding of these structures is still elusive.  
This thesis aimed at examine the role of the syndecan family of HSPGs with a specific focus 
on how they impact on angiogenesis, the process of new blood vessel formation from pre-
existing ones. 
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1.1. The syndecan family 
Syndecans were discovered in 1989 while studying cell surface proteins substituted by HS and 
chondroitin-sulphate chains and were initially called Syndenins (“to link” in Greek, as it was 
thought to link the cytoskeleton to the interstitial matrix) (Saunders et al., 1989). Syndecans 
are HSPGs expressed at up to 1 million copies per cell in nearly every cell of the body as 
transmembrane proteins. Vertebrates possess 4 different syndecan genes each encoding one 
type of syndecan i.e. syndecan-1 (syndecan, CD138), syndecan-2 (fibroglycan, CD362), 
syndecan-3 (N-syndecan) and syndecan-4 (ryudocan, amphiglycan) (Fig. 1.1). 
 
  
Fig. 1.1 The mammalian syndecan family. The diagram shows the 4 members of the 
mammalian syndecan family. Based on sequence homology, the 4 syndecans are additionally 
grouped into 2 sub-families, one composed of syndecan-1 and -3 and one composed of 
syndecan-2 and -4. The syndecan numbers reflect the order in which the cDNAs for each 
family member were cloned. In red is shown the extracellular domain, in orange the 
transmembrane domain and in green the cytoplasmic domain. (Figure modified from De Rossi 
et al. 2013). 
 
27 
 
 
Each family member has a distinctive spatial and temporal expression pattern. Syndecan-1 is 
primarily expressed on epithelial and plasma cells, syndecan-2 on fibroblasts, endothelial cells 
(ECs), neurons and smooth-muscle cells, syndecan-3 is mainly expressed in the nervous 
system and on chondrocytes, while syndecan-4 is ubiquitous. However, new patterns of 
expression for each of the four vertebrate syndecan are continuously revealed, meaning that 
our current understanding of syndecan distribution is yet far from comprehensive. Syndecan 
functions have been difficult to discern, and the situation is compounded by the finding that 
syndecan-1 and -4 knock-out mice develop normally (Ishiguro et al., 2000b) (Stepp et al., 
2002). They both, however showed impairment in tissue repair, skin and cornea in the case of 
syndecan-1 (Pal-Ghosh et al., 2008) and skin in the syndecan-4 null mice (Echtermeyer et al., 
2001a). Long-term potentiation defects were noted in the syndecan-3 null mouse, the major 
syndecan of the neural tissue (Hienola et al., 2006). Interestingly, in the invertebrate 
Caenorhabditis elegans, the only syndecan present is also widely enriched in the developing 
and adult nervous system, suggesting that syndecan-3 is most closely related to the invertebrate 
member.  
 
1.1.1. Structure 
The 4 members that comprise the syndecan family in vertebrates originated after 2 gene 
duplication events of the invertebrate syndecan. The first duplication event produced what will 
later become 2 sub-families, syndecan-2 and -4 and syndecan-1 and -3 which in pairs share a 
high degree of homology (Chakravarti and Adams, 2006). All 4 members have a common 
linear structure and lack a  tertiary structure with their conformation determined by interacting 
molecules (Leonova and Galzitskaya, 2013). Syndecan-2 and -4 have a shorter polypeptide 
chain compared to syndecan-1 and -3 and are substituted only by HS chains, while syndecan-
1 and -3 may also possess chondroitin-sulphate chains. The polypeptide chain of the core 
protein is synthesized on membrane-bound ribosomes and then transferred to the lumen of the 
endoplasmic reticulum. Attachment of the sugar chains proceeds in the Golgi apparatus. The 
sugar chains are attached covalently to the syndecan extracellular core protein’s serine 
residues, provided that those are followed by a glycine in the sequence. The HS chains are 
composed of repetitions of the disaccharides N-acetylglucosamine plus glucoronic acid and 
N-acetylglucosamine plus iduronic acid, while chondroitin-sulphate consists of N-
acetylgalactosamine and glucuronic acid. The glycosaminoglycan (GAG) chains may contain 
50 to 200 repetitions of the afore mentioned disaccharides. Importantly, these GAG chains are 
substituted with sulphate groups conferring them a highly negative charge which is key to both 
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syndecan functions and structure. First, GAG chains repulse each other by which mean they 
can extend in space increasing their area of action; second, they can interact and sequester a 
large repertoire of positively charged molecules. Not much is known about the different 
sulphation patterns of syndecan GAG chains, but it is clear that there is an alternation of sites 
with low and high degrees of sulphation (Manon-Jensen et al., 2010) (Gallagher et al., 1992). 
 
Fig. 1.2 Syndecan ectodomain structure. Shown in red is syndecan ectodomain which 
projects outside the cellular space and is composed of a linear proteic backbone substituted by 
3 HS chains only, in the case of syndecan-2 and -4, or with the addition of 2 chondroitin-
sulphate chains in the case of syndecan-1 and -3. (Figure modified from De Rossi et al. 2013). 
 
The transmembrane domain of all syndecans contains a conserved motif GXXXG which is 
necessary for syndecan dimerization at the cell surface and for retaining cholesterol into lipid 
rafts (Barrett et al., 2012). Syndecan cytoplasmic domains are quite short (~33 aa) and do not 
possess any intrinsic enzymatic activity. They are divided into 3 regions, C1 and C2, which 
are very conserved amongst all 4 members, flanking a more variable region (V). At the C-
terminus of syndecan cytoplasmic domains, on the C2 region, are the 4 amino acids EFYA 
which represent a binding site for PDZ-containing proteins, such as synbindin (Ethell et al., 
2000), synectin (also known as GIPC1) (Gao et al., 2000) and syntenin (Grootjans et al., 1997). 
The C1 region also interacts with proteins, especially actin-binding ones (e.g. ezrin, moesin, 
etc.) (Beauvais and Rapraeger, 2004). The V region, as stated above, is quite divergent 
amongst vertebrate syndecans. Unfortunately, not much is known about its 
function/interactions. There are some indications suggesting that the syndecan-4 V region 
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interacts with phosphatidyl inositol 4,5 bisphosphate (PIP2) and protein kinase Cα (PKCα) 
(Horowitz et al., 1999; Keum et al., 2004; Lim et al., 2003). Interestingly, a single serine 
phosphorylation at the C1-V junction is able to promote a substantial shape change in the 
syndecan-4 cytoplasmic tail which seems to decrease the interaction with PIP2 and PKCα. On 
the other hand the afore mentioned phosphorylation appears to increase the affinity of the V 
region to another cytoskeleton protein, α actinin (Chaudhuri et al., 2005) (Choi et al., 2008) 
(Greene et al., 2003) (Okina et al., 2012), suggesting the presence of alternative binding 
partners depending on the phosphorylation status of syndecan-4 cytoplasmic domain. 
Syndecan ectodomains will be covered extensively in 1.1.7. 
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1.1.2.  Glycosaminoglycan chain biosynthesis 
The molecular interactions mediated by syndecan GAG chains (HS or/and chondroitin-
sulphate) are key to syndecan functions chains (Deepa et al. 2004). 
 
 
Fig. 1.3 GAG chains structure and assembly. GAGs are attached to a serine residue in the 
core protein by a tetrasaccharide linker (xylose–galactose–galactose–uronic-acid) on which 
the sugar chain is assembled. Synthesis of N-acetylgalactosamine (GalNAc)- and glucuronic 
acid (GlcA)-containing disaccharide units generates chondroitin sulphate (CS) or dermatan 
sulphate (DS); synthesis of N-acetylglucosamine (GlcNAc)- and GlcA-containing 
disaccharide units generates HS. Successive modification by epimerization of GlcA to 
iduronic acid, 2-O-sulphation, 4-O-sulphation and 6-O-sulfation in the case of CS or DS, and 
N-deacetylation–N-sulphation, epimerization, 2-O-sulphation, 6-O-sulphation and 3-O-
sulphation in the case of HS, results in mature GAG chains. Note that not all biosynthesis or 
modification steps occur in a linear sequence. Some modification steps depend on previous 
steps to occur first, whereas others are independent. The nature of the modification reactions 
leads to the generation of an almost infinite diversity of polysaccharide chains. NDST, N-
deacetylase–N-sulphotransferase; OST, O-sulphotransferase. 
 
The complex biosynthetic pathway that leads to the formation of HS chains of up to 100 kDa 
in weight begins with a linker tetrasaccharide composed of xylose, two galactoses and 
glucoronic acid residues. This is then elongated by the action of a heterodimeric complex of 
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EXT1 and EXT2 enzymes within the Golgi which will add an alternation of N-
acetylglucosamine (GlcNAc) and glucoronic acid (GlcA). During the elongation process, 
some of the GlcNAc is N-deacetylated and N-sulphated by the action of N-deacetylase/N-
sulphotransferas (NDST). Subsequently, some GlcA residues can undergo epimerization to 
Iduronic acid (IdoA), which can then be sulphated by 2-O sulphotransferases. Adjacent 
exosamine can then be further sulphated on 6-O and less frequently on 3-O (Murphy et al., 
2004) (Skidmore et al., 2008). Interestingly, these modifications lead to considerable 
heterogeneity in syndecan GAG chains which can potentially, and most likely, be regulating 
their affinity for ligands. Many genetic experiments in invertebrates and the mouse showed 
that HS is required in development. For example, the Ext1 and 2 proteins, which are the most 
piviotal enzymes involved in heparan synthesis, were shown to be essential in development 
(Lin et al., 2000) (Stickens et al., 2005). Deletion of the 2-O-sulphotransferase leads to renal 
agenesis in the mouse, a condition in which the pup is missing one or both kidneys at birth 
(Bullock et al., 1998).  
 
1.1.3.  Syndecan signalling 
Syndecans possess a short (less than 40 amino acids) cytoplasmic domain with no intrinsic 
enzymatic activity. This domain can be divided into 3 regions: a variable region V flanked by 
two conserved region C1 and C2 (Fig. 1.4).  The C1 region is proximal to the membrane, it is 
highly conserved across all syndecans and participates in linkage to the cytoskeleton. The C1 
region interacts with ezrin–radixin–moesin (ERM) proteins, tubulin, cortactin and Src 
(Kinnunen et al., 1998). In addition, the MKKK sequence of syndecan-1 seems to be alone 
required for clustering and endocytosis (Chen and Williams, 2013). The phosphorylation of 
tyr180 at the end of the C1 region of syndecan-4 has been shown to be a key control point for 
cell migration in fibroblasts. c-Src seems to be the kinase responsible for syndecan-4 
phosphorylation and its activity is probably initiated by ECM-interactions and/or growth factor 
receptors, although further studies are needed to elucidate this point. Nevertheless, c-Src-
mediated phosphorylation of syndecan-4 leads to suppression of the small G protein Arf6 
activity and promotes the movement of αVβ3 from the recycling endosomes to the plasma 
membrane while promoting the opposite route for α5β1. The resultant elevation in αVβ3 
engagement promotes stabilization of focal adhesions. On the other hand, when syndecan-4 is 
not phosphorylated the surface expression of α5β1 destabilizes adhesion complexes and 
disrupts cell migration (Morgan et al., 2013). The second conserved region C2 is located at 
the C-terminus of syndecan-4 and comprises a hydrophobic motif (FYA) that interacts with 
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PDZ-domain-containing proteins. Examples include syntenin, synectin and Ca2+/calmodulin-
associated serine/threonine kinase (CASK) (Multhaupt et al., 2009). 
 
 
Fig. 1.4 Syndecan cytoplasmic domain sequence and conservation. In the highly conserved 
cytoplasmic domains, a juxtamembrane C1 region is exactly conserved among the syndecan 
across all species and has been implicated in binding protein ezrin, radixin and moesin (ERM) 
domains. A C-terminal C2 region consisting of the amino acid sequence is present in all 
syndecans and binds to post-synaptic density 95, PSD-95; discs large, Dlg; zonula occludens-
1, ZO-1 (PDZ) domains in several proteins including calcium/calmodulin-dependent serine 
protein kinase (CASK), syntenin, synbindin and synectin. The variable (V) region is distinct 
for each of the four family members, but its syndecan-specific identity is conserved across 
species. The function of this domain is largely unknown except in the case of syndecan-4. 
 
The interaction of syndecans with syntenin seems to be important for syndecan trafficking and 
recycling (Zimmermann et al., 2005). Moreover, it has been recently described how a complex 
composed of syndecan, syntenin and ALIX regulates exosome formation (Baietti et al., 2012). 
Exosomes are considered signalling particles important in cellular communication and are 
recently attracting a lot of attention, particularly in the field of tumor–host crosstalk. 
Interestingly, exosome formation by tumor cells has been shown to be enhanced by 
heparanase, an enzyme which cleaves HS chains (Ramani et al., 2013; Thompson et al., 2013). 
Lately, it has also been shown that the Arf6 and its target phospholipase D are implicated in 
syntenin-based exosome biogenesis (Ghossoub et al., 2014).  
Synectin is another binding partner for syndecan-4 PDZ-binding domain. The formation of the 
synectin-syndecan-4 complex allows the binding of the inhibitor RhoGDI-α (Elfenbein et al., 
2009) which sequesters and suppresses the activity of the GTPases RhoG, Rac1 and RhoA 
33 
 
 
(Burridge and Wennerberg, 2004) leading to low rate of cell motility. However, upon ligand 
binding, such as fibronectin or growth factors, syndecan-4 oligomerizes promoting the 
activation of the kinase PKCα through a mechanism which will be described later. PKCα will 
in turn phosphorylate serine 96 on RhoGI-α which allows the release of RhoG and Rac1, 
leading to increased cell migration (Elfenbein et al., 2009).  
Between the two conserved regions C1 and C2, there is a variable region (V) which is specific 
to each syndecan but is conserved across species, for example zebrafish, avian and mammalian 
syndecan-4 V regions are highly homologous (Whiteford et al., 2008). Because these regions 
are divergent amongst syndecan family members, they probably assert different functions. V 
region functions, however, have so far only been elucidated for syndecan-4. The syndecan-4 
V region can bind and activate PKCα, and this interaction is dependent on phosphatidylinositol 
4, 5 bisphosphate (PIP2) (Oh et al., 1997a) (Oh et al., 1997b) (Oh et al., 1998). The conserved 
serine residue at position 183 (in human syndecan-4) is potentially phosphorylated by PKCδ 
(Murakami et al., 2002a). When serine 179 (in mouse syndecan-4) is phosphorylated, 
syndecan-4 cannot oligomerize, does not associate with PIP2 (Koo et al., 2006), cannot bind 
PDZ protein and in turn PKCα does not get activated (Horowitz and Simons, 1998). PKCα 
activation seems to be key for syndecan-4’s role in cell adhesion and several substrates for 
PKCα have been proposed, including p190RhoGAP and RhoGDI (Bass et al., 2008) (Dovas 
and Couchman, 2005). Phosphorylation of G proteins and their regulators, known to be 
essential in focal adhesion and microfilament bundle assembly (Dovas and Couchman, 2005), 
would explain the prominent role of syndecan-4 in the formation of these structures 
(Couchman, 2010). Interestingly, during wound healing, syndecan-4 seems to be responsible 
for increased fibroblast motility and therefore tissue repair. In fact, syndecan-4 interactions 
with the extracellular matrix (ECM) molecule fibronectin (abundant during tissue 
remodelling) induces association with PKCα and RhoG activation which in turn results in 
caveolin- and dynamin-mediated endocytosis of integrin α5β1 (Bass et al., 2011). The V 
region of syndecan-4 has also been shown to interact with a protein called syndesmos (Denhez 
et al., 2002), unfortunately little is known about this protein apart from it interacts with the 
focal adhesion protein paxillin. α-actinin also binds directly to syndecan-4 V region, and 
fibroblasts in which syndecan-4 has been knocked out show disordered α-actinin patterns, loss 
of microfilament bundles and fewer focal adhesions (Okina et al., 2012). It appears that the 
phosphorylation of a serine residue at position 183 favours interactions with α-actinin instead 
of that with PKCα (Chaudhuri et al., 2005). However, other studies didn’t support this 
hypothesis (Okina et al., 2012). 
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1.1.4. Syndecan shedding 
Shedding is an important regulatory mechanism of 
syndecan function, common to many cell surface 
molecules, that allows the generation of soluble 
ectodomains (Fig. 1.5).  These can have autocrine 
or paracrine effects and/or compete with their 
membrane-anchored counterpart for ligand-
binding. Not long after their discovery, syndecans 
were shown to undergo low-rate constitutive 
shedding in cultured cells (Jalkanen et al., 1987; 
Saunders et al., 1989) and since then a huge number 
of studies have emerged describing regulated 
syndecan shedding in vitro and in vivo highlighting 
its biological significance. 
 
1.1.4.1. Syndecan shedding during tissue injury 
Little was known concerning regulated shedding of syndecans during biological processes 
until Subramanian et al. tested agents active during wound healing for their ability to stimulate 
accelerated shedding of syndecan-1 and -4 from the cell surface of ECs (SVEC4-10). They 
could demonstrate that both HSPGs are shed upon the addition of Phorbol 12-Myristate 13-
Acetate (PMA), Epidermal growth factor (EGF), Heparing-binding EGF-like growth factor 
(HB-EGF), thrombin and plasmin but not upon addition of Vascular endothelial growth factor 
(VEGF), Fibroblast growth factor-2 (FGF-2) or Urokinase-type Plasminogen activator (uPA). 
Since thrombin, besides binding to its cell surface receptor, also has intrinsic proteolytic 
activity, it was unclear whether shedding occurred from direct cleavage or signalling. Given 
that the addition of TRAP, a peptide that activates thrombin R but has no proteolytic activity, 
increased syndecan shedding, it was suggested that both mechanisms were present. Moreover, 
shed syndecan-1 and -4 were found in the fluids that surround injured tissue. This was the first 
time a regulated shedding mechanism for syndecans in a biological process was described 
(Subramanian et al., 1997).  
The first indications of possible cleavage sites on the syndecan ectodomains was derived from 
cell-free system studies. In these settings, plasmin and thrombin cleave syndecan-4 in two 
sites, Lys114-ARg115 and Lys129-Val130. Surprisingly, no syndecan-1 is shed in these 
Fig. 1.5 Syndecan shedding. Diagram 
depicting syndecan ectodomain being 
shed from the cell surface by the action 
of protease. 
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conditions. This result, in apparent contrast with the data from Subramanian et al. showing 
that thrombin mediates syndecan-1 shedding from ECs, would suggest that thrombin-triggered 
shedding requires the thrombin receptor (Schmidt et al., 2005).  
An interesting aspect of syndecan shedding is that once syndecans are shed they can be further 
enzymatically modified: extracellular endosulfatases, for instance, can remove 6-O sulfate 
groups influencing shed syndecans binding properties (Ai et al., 2003) and heparanases can 
cleave heparan sulfate chains, releasing biologically active fragments (Ilan et al., 2006). The 
latter modification has great impact on the regulation of the syndecan-1 and FGF-2 interaction. 
Soluble S1ED is an inhibitor of FGF activation because of its poorly sulphated HS domains, 
however, during wound healing heparanase is released in the microenvironment where it 
cleaves the HS chains from the peptide backbone producing highly mitogenic heparin-like 
oligosaccharide fragments (Kato et al., 1998).  
In idiopathic pulmonary fibrosis (IPF), a disease characterized by progressive fibrosis of the 
lungs due to an uncontrolled healing response in the lungs, syndecan-1 may represent an 
important target for the development of a therapy. It was shown that extracellular superoxide 
dismutase (EC-SOD) binds syndecan-1 and this protects it from oxidative stress-induced 
cleavage. When EC-SOD expression is altered, like during IPF, syndecan-1 is cleaved and this 
induces neutrophil chemotaxis, impaired epithelial wound healing and fibrogenesis (Kliment 
et al., 2009; Kliment and Oury, 2011). In severely injured patients undergoing haemorrhagic 
shock, syndecan-1 is shed from the endothelial glycocalyx and this causes an increase in 
vascular permeability and disruption of ECs integrity (Haywood-Watson et al., 2011). These 
studies indicate that syndecan shedding is a feature of inflammation and that shed syndecan 
moieties are present in the inflamed tissue. 
 
1.1.4.2. Syndecan shedding during inflammation 
The first syndecan-1 sheddase identified was matrylisin (MMP-7). In 2002, a study on acute 
lung injury gave important insight into the role of shed syndecans in inflammation: they 
proposed a model in which, in response to lung injury, the chemokine KC gets anchored to 
syndecan-1 on epithelial cells and, at the same time, matrilysin, released from the wound-edge 
epithelia, cleaves syndecan-1; the complex composed of S1ED (syndecan-1 ectodomain) and 
KC is then transported to the apical surface to create a chemotactic gradient to direct 
inflammatory neutrophils to the site of injury (Li et al., 2002). Another study on syndecans in 
inflammation showed that IL-8, which is bound to ECs to form a gradient and direct neutrophil 
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trans-endothelial migration, is constitutively shed from ECs in culture as a complex with HS 
and syndecan-1. This study showed that the plasminogen activator system is involved in 
regulating the shedding of the cell-bound tri-molecular complex, thus influencing the 
formation of the chemoattractant form of IL-8 at the cell surface and therefore neutrophil 
recruitment (Marshall et al., 2003). Syndecan-1 and -4 shedding from lung epithelial cells is 
mediated by ADAM17. This enzyme was shown to mediate both constitutive shedding and 
that triggered by inflammatory stimuli such as PMA, thrombin or IFNγ/TNFα. Interestingly, 
shedding stimulated by IFNγ/TNFα requires longer treatment times than that by PMA, 
increased shedding is not mediated by an up-regulation of ADAM17 expression but rather 
changes in its activity. Moreover, syndecans undergo a sequential cleavage, ADAM17 releases 
the ectodomain, leaving a CTF (C-terminal cleavage fragment) which is then degraded by γ-
secretase (Pruessmeyer et al., 2010). In mice, shed syndecan-1 is often released in body fluids 
upon inflammatory stimulation. Syndecan-1 null mice show an exaggerated inflammatory 
response following allergen-exposure suggesting that syndecan-1 shedding is involved in the 
resolution phase of inflammation (Xu et al., 2005). Syndecan-1 seems to also have a protective 
role in LPS-induced multi-organ injury and mortality. In particular, syndecan-1 appears to be 
responsible for the clearance of KC and MIP-2 which regulates neutrophil infiltration. 
Interestingly, this function is only HS-dependent (Hayashida et al., 2009). Airway smooth 
muscle cells (ASMCs) augmented production of the chemokine CXCL10 has a key role in 
asthma pathogenesis. Interestingly, syndecan-4 on ASMC binds to CXCL10 and it is shed in 
response to inflammatory conditions, suggesting that syndecan-4 shedding could regulate 
CXCL10 availability during the development of the disease (Brightling et al., 2005; Tan et al., 
2012). In a recent study on mouse, shed syndecan-4 was found in the ECM of the heart after 
LPS injection. The authors could show that shed syndecan-4 plays part in the response to LPS 
in the heart via promoting immune cell recruitment (cytotoxic T-cells, in particular) and 
stimulating the synthesis of collagen by cardiac fibroblasts, affecting ECM remodelling 
(Strand et al., 2015).  
 
1.1.4.3. Syndecan shedding in cancer 
Syndecan shedding has been often associated with disease onset and progression. In pancreatic 
cancer MMP-7 mediates FGF-2-induced syndecan-1 shedding and then complexes with it. 
This phenomenon could have at least three implications: first, MMP-7 complexed with S1ED 
could be protected from the action of TIMPs; second, HS chains could enhance MMP-7 
proteolytic activity; third, in a manner similar to that of KC in epithelial cells (Li et al., 2002), 
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S1ED could help MMP-7 transportation to sites far from the tumor into the stroma (Ding et 
al., 2005). Notably, up-regulation of heparanase and soluble syndecan-1 was detected in 
tumors with poor prognosis (Yang et al., 2007). In aggressive myeloma, heparanase has been 
shown to induce syndecan-1 shedding via stimulation of ERK phosphorylation resulting in an 
up-regulation of MMP-9, which then acts as a syndecan-1 sheddase (Purushothaman et al., 
2008). Shed syndecan-1 then binds to VEGF when released by the tumor and navigate into the 
tumor microenvironment where it promotes EC invasion and angiogenesis. Syndecan-1 can 
mediate this effect by presenting VEGF to ECs and also interacting with integrins on the cell 
surface (Purushothaman et al., 2010). Another study using the fibrosarcoma cell line (HT1080) 
revealed that MT1-MMP shedding of syndecan-1increases cell migration and that the cleavage 
site resides between Gly245-Leu246 (Endo et al., 2003). Syndecan-3 is shed from rat Schwann 
cells by the action of an MMP. This occurs also in vivo in rat peripheral nerves in an age 
dependent way (shedding is lower in P10 nerves compared to P4 ones) and the inhibition of 
MMP activity not only decreases cell surface syndecan-3 but also the soluble form, suggesting 
that MMPs are also involved in the degradation of syndecan-3 once released in the ECM. 
Studies with chimeric syndecans also showed that the ectodomains contain the information 
necessary for their shedding (Asundi et al., 2003). Interestingly, carcinoma cells stimulate the 
expression of syndecan-1 on fibroblasts, syndecan-1 is then shed and diffuses to cancer cells, 
here S1ED stimulate cancer cell proliferation probably by forming a complex on the cell 
surface with FGF2 and FGFR1 (Su et al., 2007). The first study specifically aimed at 
understanding the intracellular signalling involved in syndecan shedding showed that the 
syndecan-1 cytoplasmic domain associates with Rab5, preferentially to the inactive GDP-
bound form. Interestingly, shedding stimuli such as PMA, induce the switch from GDP-Rab5 
to GTP-Rab5 which then dissociates from syndecan-1. Since Rab5 is involved in intracellular 
trafficking, it was speculated that Rab5 activation could induce the internalization of a cell 
surface receptor associated with syndecan-1 on the cell surface, if this receptor was protecting 
a cleavage site on the syndecan-1 ectodomain from the action of sheddases then it may explain 
why upon Rab5 activation syndecan-1 is shed (Hayashida et al., 2008). MCF-7 Cells (breast 
carcinoma cell line) engineered to over-express a soluble form of syndecan-1 are less 
proliferative but more invasive when compared to cells over-expressing an uncleavable mutant 
form of syndecan-1 (Nikolova et al., 2009). Syndecan-2 has been shown to activate MMP-7 
in colon cancer cells (Park et al., 2002), and in a negative feedback MMP-7 cleaves syndecan-
2 N-terminally at Leu149 in the extracellular domain (Choi et al., 2012). 
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Syndecan Cell type/tissue Stimuli Proteases Ref. 
Syn-1, -4 ECs PMA, EGF, HB-
EGF, Thrombin, 
Plasmin 
? (Subramanian et al., 1997) 
Syn-1, -4 ECs Cellular stress 
(hyperosmolarity 
and ceramide) 
TIMP-3-
sensitive 
MP 
(Fitzgerald et al., 2000) 
Syn-1, -4 Lung epithelial cells PMA, Thrombin, 
IFNγ/TNFα 
ADAM17 (Pruessmeyer et al., 2010) 
Syn-1 Myeloma cells PMA Non-matrix 
MP 
(Holen et al., 2001) 
Syn-1 Epithelial cells Acute lung 
injury 
MMP-7 (Li et al., 2002) 
Syn-1 Pancreatic tumor 
cells 
FGF-2 MMP-7 (Ding et al., 2005) 
Syn-1 Myeloma cells Heparanase MMP-9 (Purushothaman et al., 
2008) 
Syn-1 Fibrosarcoma  MT1-MMP (Endo et al., 2003) 
Syn-1 Lungs Oxidative-stress ? (Kliment et al., 2009; 
Kliment and Oury, 2011) 
Syn-2 Colon cancer cells  MMP-7 (Choi et al., 2012)  
Syn-3 Schwann cells  Matrix MP (Asundi et al., 2003) 
Syn-4 Airway smooth 
muscle cells 
IL-1β, TNFβ ? (Tan et al., 2012) 
Table 1 Syndecan shedding and associated sheddases.  
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1.1.5. Syndecans as extracellular matrix receptors 
Syndecans can interact with a large repertoire of ECM components; in most cases the HS 
chains are required (Fig. 1.6) but in some instances these interactions are mediated by 
syndecan ectodomains (reviewed in 1.1.7). The ECM is an intricate network for 
macromolecules (mostly proteins and polysaccharides) which is produced and secreted by 
cells and serve not only as a scaffold but has also an active role in regulating the behaviour of 
the cells that contact it. Each tissue contains specific amounts of different types of matrix 
macromolecules and the way in which they are organized is well-designed to the requirements 
of that particular tissue. Fibronectin for example is found abundantly in the serum and it is, 
together with fibrin, the main constituent of the matrix which forms during clotting. It has been 
shown that fibroblasts are able to attach and spread on fibronectin fragments containing the 
RGD domain, a binding site for integrin α5β1, but only the 
addition of the fragment containing the heparin-binding site 
allows the proper formation of focal adhesion via an 
integrative signal of syndecan-4 (Bass et al., 2008; Gopal et 
al., 2010; Okina et al., 2009; Xian et al., 2010). Similarly, co-
operation between integrin α5β1 and HS chains, possibly 
from syndecan 4, is necessary for fibroblast focal adhesion 
formation (Bax et al., 2007). This synergistic co-operation of 
syndecans and integrins in mediating cell adhesion is a 
recurrent mechanism which takes place on various ECM 
substrates. In the basement membrane, for example, 
syndecan-1 works closely with integrin α3β1 to promote 
keratinocyte adhesion on the precursor of Laminin-322. This 
co-operation allows the formation of fascin-containing 
protrusions, which is dependent on the GTPases Rac and 
Cdc42 (Bachy et al., 2008). Finally, collagens, the most 
abundant ECM proteins with 29 different types in several 
different classes, can interact with syndecans. Many collagen 
types, in fact, possess a heparin- and HS-binding domain. Interestingly, it has been shown that 
co-binding of syndecan-1 and integrin α2β1 to collagen promotes the transcription of the 
matrix-metalloproteinase-1 with implications for tissue remodelling (Vuoriluoto et al., 2008).   
 
 
Fig. 1.6 Syndecans as 
adhesion receptors. 
Syndecan can function as 
adhesion receptor by linking 
the ECM to the cell 
cytoskeleton. (Figure 
modified from De Rossi et al. 
2013). 
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1.1.6. Syndecans as co-receptors 
In addition to ECM molecules, syndecans can also interact with a large repertoire of 
pericellular molecules such as growth factors, cytokines, chemokines and pathogens (Fig. 1.7). 
Many growth factors possess a heparin-binding domain that can 
interact with syndecan HS chains. FGF2 has been thoroughly 
investigated in this context as its binding to FGF receptor 1 is 
facilitated by syndecan-1, -2 and -4 and the receptor activation 
increased. The binding of FGF2 to syndecan results in high 
concentration of FGF2 on the cell surface of mouse mammary 
epithelial cells (NMumG), which in turns facilitates the activation of 
FGFR (Reiland and Rapraeger, 1993) (Steinfeld et al., 1996). A 
similar function has been suggested for syndecan-2 in the context of 
VEGF-A-mediated signalling in zebrafish. Here, syndecan-2 is key 
for sprouting angiogenesis during development and the authors of 
the study provide good indication that syndecan-2 binds to VEGF-
A165 (the isoform of VEGF-A containing the heparin-binding 
domain) and presents it to its receptor VEGFR2 (Chen et al., 2004b) 
(Kaji et al., 2006). Syndecan-1, instead, has been reported to mediate 
HGF- and EGF-mediated signals in multiple myeloma, and members 
of the hepatocyte growth factor HGF and epidermal growth factor 
EGF family have been shown to associate with syndecan-1 for 
induction of cell survival and proliferation. The association of syndecan-1 with HGF or EGF 
has been shown to promote clustering and activation of their respective receptors (Mahtouk et 
al., 2006) (Andersen et al., 2005) (Mahtouk et al., 2004) (Derksen et al., 2002) (Seidel et al., 
2000a). Results from a recent study also suggest that syndecan-2 and -4 can bind HGF and 
FGF2, in this case mediating Sema3A expression in early‐differentiated myoblasts (Do et al., 
2015). 
Syndecan-1, -2, -3 interact with Interleukin-8 (IL-8) on the surface of ECs and the implication 
for the immune response is remarkable, as this interaction not only creates a gradient of IL-8 
that promotes neutrophil accumulation to the site of inflammation, but also protects the 
cytokine from proteolytic degradation (Halden et al., 2004; Marshall et al., 2003) (Goger et 
al., 2002; Patterson et al., 2005). Syndecan-2 has also been shown to facilitate the interaction 
of granulocyte-macrophage colony-stimulating factor (GM-CSF) with its receptor on the 
surface of osteoblasts (Modrowski et al., 2000). 
Fig. 1.7 Syndecans as 
co-receptors. 
Syndecan can act as 
co-receptor by 
presenting ligands to 
their receptors. 
(Figure modified from 
De Rossi et al. 2013). 
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Syndecan-1 interacts via its HS chains with the chemokines CCL7, CCL11 and CCL17 and 
this results in an inhibition of chemokine-mediated T cell migration and suppression of 
allergen-induced accumulation of Th2 cells in the lung (Xu et al., 2005). Moreover, disturbing 
syndecan-4 signalling (using blocking antibody or syndecan-4 knock-out mice) resulted in a 
diminished CCR7 expression on dendritic cells and in a reduced directional DC migration to 
the draining lymph nodes, leading to a reduced asthma phenotype (Polte et al., 2015). 
Syndecan-1, together with syndecan-4, has also been shown to associate with RANTES on 
macrophages, facilitating its interaction with CCR5 (Slimani et al., 2003a, b). Syndecan-4 is 
also able to interact with stromal-cell derived factor 1 (SDF-1) and the receptor CXCR4 on 
the cell surface of the hepatocarcinoma cells Huh7, leading to a mitogenic effect (Sutton et al., 
2007).  
Interestingly, syndecans can also interact with pathogens. All 4 syndecans, for example, have 
been shown to been able to capture HIV-1 via their HS chains (Bobardt et al., 2003). In 
addition, syndecan-2 also binds HIV-2 and simian immunodeficiency virus. Many other 
viruses exploit syndecans as attachment sites to facilitate their entry in the host cell, the list 
includes: herpes simplex virus, papilloma virus, dengue virus, human T-cell leukemia virus 
and hepatitis C virus (Bernfield et al., 1999a) (Hilgard and Stockert, 2000) (Pinon et al., 2003) 
(Shafti-Keramat et al., 2003). Syndecans can also bind and therefore participate in and 
influence the pathogenesis of several bacteria including Chlamidia trachomatis, 
Staphylococcus aureus, Pseudomonas aeruginosa, Neisseria gonorrhoeae and Neisseria 
meningitides (Freissler et al., 2000) (Chen et al., 2008). 
 
1.1.7. Syndecan ectodomains 
As discussed above, the two main functions of syndecans described to date are as adhesion 
receptors and co-receptors. Both of these roles are dependent on the ability of syndecans to 
interact with a large repertoire of molecules present in the extracellular space. These 
interactions are mainly mediated by the glycosaminoglycan chains of syndecans; however, the 
studies summarized in the following paragraphs will prove that the proteic component of 
syndecan ectodomain also possesses biological properties. These studies cover a variety of 
biological processes including cell adhesion, migration and morphology in many different cell 
types. 
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1.1.7.1. Syndecan-1 
Syndecan-1 was the first member of the syndecan family to be described in 1989. Early studies 
revealed a strong correlation between syndecan-1 and tumor cell proliferative, adhesive and 
invasive properties (Inki et al., 1994a; Inki et al., 1994b; Inki et al., 1994c). Syndecan-1 
presence on a mouse mammary tumor (S115), for example, inhibits its proliferative potential, 
a function for which the syndecan-1 ectodomain (S1ED) is required (Mali et al., 1994). 
Moreover, when ARH-77, a B-lymphoid cell line that expresses low amounts of HS, is 
transfected with syndecan-1 cell migration through the collagen layer is repressed.   
S1ED is sufficient to inhibit invasion and this effect is not solely due to the ability of syndecan-
1 to promote adhesion by engaging the substratum (Liu et al., 1998). Further studies 
characterized an “invasion regulatory domain” mapped to an AVAAV sequence (aa 222-226) 
on syndecan-1 extracellular core protein (Langford et al., 2005). 
Interestingly, transfection of syndecan-1 in Raji cells, a human lymphoblastoid cell line that 
does not express syndecan-1 and grows in suspension, is sufficient to stimulate attachment and 
spreading on both thrombospondin and fibronectin. More interestingly, attachment and 
spreading on Abs against S1ED occurs after heparinase addition (Lebakken and Rapraeger, 
1996). 
In MDA-MB-231 (human mammary carcinoma cells) syndecan-1 is required for cell 
spreading on Vitronectin (VN) via activation of αVß3. Moreover, since the addition of soluble 
S1ED or transfection with a mutant form of syndecan-1 lacking a portion of the ectodomain 
(mS1Δ88-252) inhibits cell spreading on VN, this implies S1ED interacts with a partner on 
the cell surface to activate αVß3 integrin (Beauvais et al., 2004). Further studies revealed that 
the minimal sequence able to block cell spreading on VN corresponds to aa 82 to 130 of the 
syndecan-1 extra-cellular core protein; this peptide is called Synstatin or SSTN, and it is able 
to inhibit co-precipitation of αVß3 with syndecan-1. More interestingly, it can also inhibit 
adhesion and spreading of B82L fibroblasts on VN, which is mediated only by αVß5. SSTN 
inhibits association of syndecan-1 with both integrins and it is also able to inhibit their 
activation in ECs, impeding their attachment and spreading. It is therefore unsurprising that 
SSTN is able to inhibit angiogenesis in vivo in the aortic ring outgrowth assay, in the corneal 
angiogenesis model and, also, in an in vivo orthotopic tumor model (MDA-MB-231 injected 
subcutaneously into a BALB/c nude mouse). Interestingly, syndecan-1 Knock Out mice are 
viable with no angiogenic defect, meaning that they have compensated for the loss of 
syndecan-1 by developing an alternative pathway for integrin activation (Beauvais et al., 
2009). Integrin is activated when a conformational change increases the affinity of its extra-
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cellular head for its ligand; this is usually triggered by an energy-dependent inside-out signal 
(O'Toole et al., 1994). Treatment of MDA-MB-231 with metabolic inhibitors showed that 
syndecan-1-mediated integrin activation is energy-dependent and, by the use of different 
kinase inhibitors, it became clear that there is an involvement of insulin-like growth factor-1 
receptor (IGF1R) in this process. In the model proposed by Beauvais and Rapraeger, 
syndecan-1, once clustered by engaging VN, interacts with αVß3 and ß5 integrin through its 
ectodomain, this complex is then able to engage with IGF1R. The formation of the syndecan-
1/integrin/IGF1R is an indispensable step for later events, in fact, it is essential for IGF1R 
auto-phosphorylation on Y1131, subsequent activation of Talin (cytoskeletal protein key for 
inside-out integrin activation) which then binds integrin ß subunit, triggers a conformational 
shift and activates it (Beauvais and Rapraeger, 2010). 
The correlation between syndecan-1 loss and poor prognosis in many human cancers could be 
well explained by the ability of this HSPG to promote adhesion and inhibit invasion as 
described above (Beauvais and Rapraeger, 2004; Sanderson, 2001). Nonetheless, in some 
tumors with poor prognosis the expression of syndecan-1 is up-regulated (Barbareschi et al., 
2003; Beauvais and Rapraeger, 2004; Burbach et al., 2003; Matsuda et al., 2001). Burbach et 
al, transfected syndecan-1 in three different human breast carcinoma cell lines to mimic 
syndecan-1 over expression, a characteristic often found in breast carcinomas in vivo. Upon 
transfection, cells which usually grow as adherent cohesive epithelial islands (T47D), spread 
poorly and assumed a rounded morphology in 2D and were more invasive in 3D culture. 
Interestingly, this effect was maintained regardless of the absence of GAG chains or 
transmembrane and cytoplasmic domains, and abolished when syndecan-1 was expressed as a 
mutant lacking aa 88-252 from the ectodomain. Moreover, since syndecan-1-dependent 
morphology change could be blocked by Genistatin (a protein tyrosin kinase inhibitor), this 
suggests the involvement of a signal transduction. They could show that carcinoma cells didn’t 
spread on integrin ligand and attachment was also blocked by Abs against the ß1 subunit, 
suggesting that syndecan-1 disrupts ß1-mediated signalling or attachment. Syndecan-1 
expression level alters adhesion signalling in epithelial cells (Burbach et al., 2004). 
Syndecan-1’s role in cell adhesion and migration is not limited to tumor cells, in fibroblasts 
(B82L), for example, spreading on a native matrix ligand is dependent on αVß5 integrin 
complexing with S1ED. This mechanism is similar to that proposed for the regulation of αVß3 
in epithelial tumor cells (Beauvais et al., 2004) although they differ in some features: in B82L 
syndecan-1 is probably constitutively associated with ß5 integrin through its extra-cellular 
core protein and only if the integrin is in a complex with S1ED then it can signal upon binding 
to VN or FN; in epithelial cells, instead, the engagement of syndecan-1 with a substratum 
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(through its HS chains) is necessary to bring S1ED and αVß3 together in a complex and signal 
and in this case αVß3, unlike αVß5 in fibroblasts, does not need a ligand (McQuade et al., 
2006). 
One of the most recent works on syndecan-1 added further evidence to support the presence 
of a close interaction between syndecan-1 extra-cellular core protein and integrins, in 
particular, they showed, in a human bronchial epithelial cell line (B2b), that S1ED promotes 
cell adhesion by activating the ß1 subunit and therefore regulating the affinity of α2ß1 integrin 
(Altemeier et al., 2012). 
 
1.1.7.2. Syndecan-2 
While in normal epithelium syndecan-2 is usually expressed at low levels, during epithelial 
cancer progression its expression increases; in colon carcinoma, for instance, syndecan-2 is 
highly expressed on cancer cells (both highly and weakly metastatic) when compared to 
normal colon cell lines. S2ED has specific roles in adhesion and tumorigenicity of these 
epithelial cancer cells. Not only can recombinant S2ED (HS chains free) inhibit tumor cell 
attachment to the ECM, but it can also promote cell cycle arrest through an up-regulation of 
p53, p21 and p27 and down-regulation of cyclin E and D2. Moreover, the addition of S2ED 
in the medium of colon cancer cells inhibits the EGF-mediated mitogen-activated protein 
kinase activation which is critical for the growth of many tumors (Park et al., 2002). 
Syndecan-2 also has key roles in the development of fibrosis. TGF-ß is a growth factor with 
multiple roles, among which is the ability to promote fibrosis by up-regulating matrix proteins 
and down-regulating metalloproteinases. TGF-ß RIII binds TGF-ß and transfers it to TGF-ß 
RII. Intriguingly, TGF-ß RII is a cell surface proteoglycan with very similar characteristics to 
syndecan-2. Since syndecan-2 controls left-right axis asymmetry in X. laevis through TGF-ß, 
a role for syndecan-2 in TGF-ß-induced fibrosis was suggested. Syndecan-2 was indeed shown 
to regulate TGF-ß mediated matrix deposition via its cytoplasmic domain which is 
fundamental for its interaction with TGF-ß R III. More interestingly, syndecan-2 in RPFs 
(renal periphery fibroblasts) was shown to interact with TGF-ß via its ectodomain (and 
partially through its HS chains) independently of the presence of the cytoplasmic domain 
(Chen et al., 2004c). In brain microvascular ECs, S2ED is also able to induce an increase in 
cell migration and tube formation on both fibronectin and growth factor-reduced Matrigel 
(Fears et al., 2006). 
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A broad-spectrum adhesion study revealed a tendency for mesenchymal cells to attach to GST-
mS2ED, while the epithelial ones fail to do so. When compared to those seeded on FN, REF 
(rat embryo fibroblasts) seeded on GST-mS2ED spread more slowly, formed less focal 
adhesions (FA) (and those formed were more peripheral) and showed reduced 
phosophorylation of FA components such as FAK and paxilin. Interestingly, REF attached to 
FN spread but didn’t form FA when treated with heparinase, whereas the same treatment on 
cells attached to S2ED has no effect, indicating that HS chains are important when cells are 
on native matrix ligands. Attachment could be avoided by the addition of ß1 blocking antibody 
(Ab), but since ß1 is expressed also by cells that didn’t adhere, this suggested the presence of 
one or more intermediate cell surface molecules able to interact with S2ED and communicate 
the adhesion signal to ß1 integrin (Whiteford et al., 2007). A parallel study on S4ED revealed 
that the phosphatase cell surface receptor CD148 is key to ß1-mediated adhesion to S4ED; a 
study with siRNA confirmed that this is also true for S2ED. Indeed, the addition of the soluble 
extracellular domain of CD148 (comprising the 8 N-terminal type III FN repeats) blocks cell 
attachment on S2ED but not on FN and a solid-phase binding assay could show that the 
extracellular part of CD148 interacts with the C-terminal 18 aa of S2ED. The same study 
showed that the adhesion regulatory domain comprises the last 18 aa at the C-terminal of S2ED 
(P124 -> F141), of particular importance seems to be the sequence DNLF. Solid-phase binding 
assays, however, demonstrated no direct interaction between ß1 integrin and CD148 and, 
moreover, cells weren’t able to adhere to CD148 extracellular domain when provided as a 
substrate, suggesting an involvement of an intra-cellular signalling pathway that functionally 
connects CD148 to ß1 integrin. Analysis of the possible intracellular substrates for CD148 
revealed that ß1-mediated adhesion requires activated Src and PI3k-C2ß and there is evidence 
for the involvement of a de-phosphorylation step of p85 (subunit of PI3K) (Whiteford et al., 
2011). 
 
1.1.7.3. Syndecan-3  
Whether the syndecan-3 ectodomain has biological properties remains unclear. Adhesion 
assays with human dermal fibroblasts, Swiss 3T3 and NIH 3T3 on immobilized GST fused to 
the syndecan-3 ectodomain suggested that this protein could not support the cell attachment 
and spreading responses seen with the syndecan-1, -2, and -4 ectodomains (McFall and 
Rapraeger, 1998). However, the syndecan-3 ectodomain is unique as it possesses a mucin rich 
domain which may be extensively substituted with O-linked sugars and confer novel 
functionality (Carey, 1996). Experiments to date have utilized fusion proteins expressed in 
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bacteria which would not be post-translationally modified in the same way as if they were 
expressed in eukaryotic cells. 
 
1.1.7.4. Syndecan-4 
RGD-dependent integrins (e.g. α5ß1) interact with the RGD sequence within the cell-binding 
domain (CBD) of fibronectin, promoting cell attachment and spreading (Burridge et al., 1992). 
Although the CBD fragment alone triggers fibroblast attachment, it is not sufficient, unlike 
intact fibronectin, to induce the formation of focal adhesions (FAs) (Woods et al., 1986). In 
both fibronectin (Woods et al., 1986) and laminin (Couchman et al., 1983) induction of FA 
formation requires the heparin binding domain (HBD) present in both molecules. This made 
syndecans plausible candidates for providing the second signal to generate FAs. Later it was 
found that Syndecan-4 is the only syndecan co-localizing with FAs (Baciu and Goetinck, 1995; 
Woods and Couchman, 1994). In 1999, an elegant work demonstrated that it is indeed 
syndecan-4 which provides the second signal for FA assembly in fibroblasts on fibronectin. 
Using FN-/- fibroblasts, the studies showed that, once fibroblasts are spread on the CBD, they 
can subsequently form FAs either when the HBD is provided (as expected) but also when a 
bivalent anti-body against S4ED is added to the medium (Saoncella et al., 1999). Syndecan-4 
is able to oligomerize on the cell surface and the clustering of S4 V region is necessary for its 
interaction with PKC-α (Oh et al., 1997a), therefore when HS chains are present, they can 
interact with HBDs, control S4 clustering on the cell surface allowing oligomerization of the 
V region and activation of PKC and finally promotion FA formation. Surprisingly, however, 
unglycanated syndecan-4 over-expression leads to the same effect (Echtermeyer et al., 1999), 
probably because once clustering reaches a critical level, oligomerization might be 
spontaneous and independent of ligand binding (Couchman and Woods, 1999) (Fig. 1.8).  
Interestingly, as evidences were accumulating delineating a role for the HS chains and the 
cytoplasmic domain of syndecan-4 in adhesion, McFall and Rapraeger were testing the 
ectodomain of syndecan-4 in a series of adhesion assays. Between 1997 and 1998, using a 
bacterially-derived (GAG-free) mS4ED, they were able to show that, in the presence of 
divalent cations, the ectodomain is able to bind a cell surface receptor through a domain 
mapped to aa 56-109, which is specific to S4 and the effect was conserved amongst species 
(mouse and chicken) and retained when syndecan-4 is physiologically shed. For the first time, 
it was speculated that S4ED could act in trans, as a matrix-embedded or soluble adhesive 
ligand for cells (McFall and Rapraeger, 1997, 1998). 
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Fig. 1.8  Syndecan-4 is required for the formation of focal adhesions in fibroblasts on 
fibronectin. Fibronectin contains domains that can specifically engage α5β1 integrin and 
heparin. Focal adhesion formation in fibroblasts requires both α5β1 integrin to engage the 
integrin binding domain and syndecan‐4 HS chains to engage the heparin binding domain. 
 
 
A decade later, Whiteford et al., further characterized S4ED adhesive properties and found 
that an NXIP motif, contained within the previously described cell-binding domain, is 
fundamental for attachment. Testing of different cell lines showed that only mesenchymal, 
Jurkat T-lymphocytes and ECs were able to attach to mS4ED, and not epithelial or other 
lymphoblastic lines. Interestingly, Jurkat cells were able to bind only after PMA treatment 
(PMA is necessary for Jurkat integrin activation, (Faull et al., 1994)) and addition of EDTA 
stopped adhesion of all cell lines suggesting a role for integrins which was later confirmed by 
showing that the use of Abs against ß1 integrin stopped mS4ED-dependent cell attachment 
(Whiteford and Couchman, 2006). Additional studies showed that adhesion of rat embryo 
fibroblasts (REF) to GST-mS4ED induced a polygonal morphology, slow forming peripheral 
focal adhesions and overall a slower spreading process. Also, FAs induced by S4ED contain 
ß1 integrin subunits both in REFs and Jurkat cells. In the case of Jurkat cells, adhesion is 
mediated by α4ß1; interestingly, REF, which lacks the α4 subunit, still attach to GST-mS4ED 
revealing that the α subunit which mediates S4ED adhesive properties might be cell-specific 
(Whiteford et al., 2007). 
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1.2. Angiogenesis 
Angiogenesis is the process that allows the formation of new blood vessels from pre-existing 
vasculature. This occurs throughout life in both health and disease. A well-organized and 
functional vascular system allows the diffusion of nutrients, metabolites and oxygen to 
metabolically active cells, which is why every cell in our body is no more than a few hundred 
micrometres away from a blood capillary. Angiogenesis is a dynamic process that allows 
growth and regression of capillaries in healthy tissues according to functional demands. 
Physical exercise, for example, stimulates angiogenesis in skeletal muscle and heart and an 
increase in the adipose tissue during weight gain demands an increase in capillarity too.  The 
correlation between metabolic demand and angiogenesis was already hypothesized in the late 
18th century when the Scottish surgeon John Hunter wrote: “In short, whenever Nature has 
considerable operations going on, and those are rapid, then we find the vascular system in a 
proportionable degree enlarged.” The study of angiogenesis, however, emerged as a new 
attractive field only 200 years later when Judah Folkman published in 1971 his results showing 
that tumor growth is angiogenesis-dependent (Folkman, 1971).  
 
Fig. 1.9 Papers on angiogenesis published over the years. Data analysis was performed on 
PubMed http://www.ncbi.nlm.nih.gov/pubmed/. 
 
0
1000
2000
3000
4000
5000
6000
7000
8000
1940 1950 1960 1970 1980 1990 2000 2010 2020
p
a
p
e
r 
c
o
u
n
t
year
49 
 
 
1.2.1. The angiogenic process 
1.2.1.1. Origin of blood vessels 
Angiogenesis is the process of formation and remodelling of new blood vessels from pre-
existing ones. The primary vascular network which develops at embryonic stage is in fact the 
result of a different process called Vasculogenesis. Vasculogenesis gives rise to the heart and 
the first primitive vascular plexus inside the embryo and in its surrounding membranes, as the 
yolk sac circulation (Risau, 1997).  
 
 
Fig. 1.10 Vasculogenesis. The cardinal veins assemble from precursor cells (blue) that remain 
in a lateral position (a). Artery precursor cells (pink) migrate toward a vascular endothelial 
growth factor A (VEGF-A) gradient secreted from cells in the midline (b). The migrating 
arterial angioblasts align into cords forming a plexus (c). Arterial angioblasts merge forming 
the dorsal aorta (d). Intersomite vessels are assembled from three types of ECs with different 
morphologies indicated as green, purple, and blue.  
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During vasculogenesis mesodermal derived hemangioblasts differentiate into hematopoietic 
stem cells and angioblasts; the latter will eventually differentiate into ECs but do not yet 
express EC markers at this stage. Angioblasts which are derived from the lateral mesoderm 
are committed to become arteries or veins. The cardinal veins assemble from precursor cells 
that endure in a lateral position. Artery precursor cells migrate following a VEGF gradient 
which is created by cells in the midline. The migrating arterial angioblasts align into cords 
forming a plexus. Arterial angioblasts merge forming the dorsal aorta. Intersomite vessels are 
made up of three types of ECs with different morphologies indicated as blue, purple, and green. 
(Hogan and Kolodziej, 2002). Angiogenesis is responsible for the remodelling and expansion 
of this network. 
 
1.2.1.2. Types of angiogenesis 
There are two types of angiogenesis which happen both in utero and in adults and are thought 
to occur in virtually all tissues and organs; these are called sprouting and intussusceptive 
angiogenesis. Sprouting angiogenesis is certainly better understood having been discovered 
around 200 years ago, while intussusceptive angiogenesis has only been recently described 
(Caduff et al., 1986) and therefore is less well characterized. The common feature is that both 
processes lead to formation of new blood vessels. However, while sprouting angiogenesis 
forms entirely new vessels, intussusceptive angiogenesis increases capillarity by splitting 
vessels which already exist. 
Intussusceptive angiogenesis is also called splitting angiogenesis because the vessel wall 
extends into the lumen causing a single vessel to split in two. Amongst the two, intussusceptive 
angiogenesis is generally considered the fast form of angiogenesis as it only requires 
reorganization of existing ECs rather than their proliferation and migration. It is therefore 
unsurprising that it plays a prominent role in embryonic development where growth is fast and 
resources are restricted (Kurz et al., 2003) (Djonov et al., 2003) (Djonov et al., 2002). Evidence 
for the occurrence of intussusceptive angiogenesis is based upon the presence of trans-
capillary tissue pillars. 
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Fig. 1.11 Trans-capillary tissue pillars in Mercox casts. (a) Fetal chicken lung 
microvasculature. (b) Rat lung microvasculature at postnatal day 44. The small holes indicated 
by arrows have diameters of about 2 µM. The holes correspond to tissue pillars that extend 
across the capillary lumina. Scale bars: (a) 12 and (b) 20 µM. From (Djonov et al., 2002). 
 
The regulation of intussusceptive angiogenesis is poorly understood compared with sprouting 
angiogenesis. This is partly due to its recent discovery (Caduff et al., 1986) but also to the fact 
that proving its presence involves determining the frequency of tissue pillars from scanning 
electron micrographs of vascular casts, which is challenging. However, since its discovery in 
postnatal lungs of rats and humans (Burri and Tarek, 1990; Caduff et al., 1986), 
intussusceptive angiogenesis has been revealed in other tissues, especially in capillary 
networks that are adjacent to an epithelial surface, e.g., choroid of the eye, vascular baskets 
around glands, intestinal mucosa, kidney, ovary, and uterus (Burri et al., 2004) (Patan et al., 
1992). In addition to forming new capillary structures, intussusceptive growth plays a major 
role in the formation of artery and vein bifurcations as well as pruning of larger microvessels. 
Interestingly, mechanical stresses related to increases in blood flow can initiate intussusceptive 
growth in some high flow regions of the circulation (Kurz et al., 2003) (Djonov et al., 2002). 
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Fig. 1.12 Intussusceptive angiogenesis in three dimensions (a–d) and two dimensions (a'–
d'). (a,b,a',b') The process begins with protrusion of opposing ECs into the capillary lumen. 
(c,c') An interendothelial contact is established and endothelial junctions are reorganized. 
(d,d') The endothelial (EC) bilayer and basement membranes (BM) are perforated centrally 
allowing growth factors to enter. Fibroblasts (Fb) and pericytes (Pr) migrate into the site of 
perforation where they produce collagen fibrils (Co) and other components of ECM forming 
a tissue pillar. From (Djonov et al., 2002). 
 
Angiogenesis may also take place in another way. Sprouting angiogenesis is commenced in 
poorly perfused tissues when oxygen sensing mechanisms perceive a level of hypoxia that 
demands the formation of new blood vessels to satisfy the metabolic requirements of 
parenchymal cells. The basic steps of sprouting angiogenesis include: tip cell selection, tip cell 
navigation, stalk elongation, tip cell fusion and pericyte stabilization. 
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1.2.1.3. Tip cell selection 
 
Fig. 1.13 Sprouting angiogenesis: Tip cell selection. ECs exposed to the highest VEGF-A 
concentration (blue gradient) become tip cells (central, light pink cell).  
 
In conditions of decreased oxygen tension, the cytoplasmic enzyme prolyl hydroxylase (PDH) 
becomes unable to hydroxylate Hypoxia Inducible Factor 1α (HiF1α), which is then not 
degraded and instead accumulates in the cell, forming heterodimers with HIF1β. HIFα and β 
are basic Helix-Loop-Helix (bHLH) transcription factors and HIFα/β heterodimers initiate the 
transcription of genes with a Hypoxia Responsive Element (HRE) in their promoter. Hypoxia 
responsive genes change the cellular behaviour leading to altered metabolism, erythropoiesis 
and, importantly, the induction of angiogenesis. One such gene is VEGF-A. When VEGF-A 
is released in the microenvironment some ECs within the vessel wall will sense high VEGF-
A concentration and will be selected for sprouting. These cells are called tip cells, they possess 
a migratory phenotype and they will guide the growth of the new vessel. Flanking the tip cell 
are the stalk cells whose phenotype favours proliferation and they will support sprout 
elongation. The specification of this two different types of ECs is regulated by the Notch 
pathway (Eilken and Adams, 2010; Phng and Gerhardt, 2009),  in particular low Notch 
signalling activity is present on tip cells while it is upregulated on stalk cells, conversely tip 
cells express high level of the Notch ligand DDL4. The mechanism by which Notch-DLL4 
directs EC behaviour seems to be linked to VEGF-A signalling. DLL4 expression by tip cells 
is in fact induced by their sensing of high concentrations of VEGF-A, while the activation of 
stalk cell-Notch by tip cell-DLL4 suppress the expression of VEGF-A receptor, VEGFR2, in 
the stalk cells (Sainson and Harris, 2008; Suchting et al., 2007). It is therefore lateral inhibition 
that select tip and stalk cells. Although there are several Notch receptors expressed on ECs, 
Notch1 is the main factor responsible for inhibiting tip cell behaviour in stalk cells (Moya et 
al., 2012). JAGGED1, another Notch ligand, is primarily expressed by stalk cells and, 
↓ oxygen tension 
↑HiF1α 
→HRE gene  
    transcription 
↑VEGF-A 
→Notch-DLL4 
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interestingly, it is a poor activator of the receptor hence it is thought to help maintain low 
Notch activation on tip cells by competing with DLL4 (Eilken and Adams, 2010). Tip cells, 
which express high levels of VEGFR2, will guide the new blood vessel formation by sensing 
a concentration gradient of VEGF-A anchored to the surrounding ECM. VEGF-A exists in 
different isoforms (which will be reviewed in 1.2.2.1.2), VEGF-A 165 in human (VEGF-A 
164 in mouse) possess a heparin-binding domain which allows it to interact with the ECM and 
provide directional guidance to the tip cell. On the other hand, VEGF-A 121 lacks this property 
but has been shown to be able to promote EC proliferation as opposed to tip cell guidance 
(Gerhardt et al., 2003; Ruhrberg et al., 2002).  
 
1.2.1.4. Tip cell navigation 
 
Fig. 1.14 Sprouting angiogenesis: Tip cell navigation. The tip cell (light pink) leads the 
developing sprout by extending numerous filopodia through the ECM (light blue) towards the 
VEGF gradient (blue).  
 
Endothelial and mural cells share a basement membrane comprised of ECM proteins that form 
an envelope around the vessels (Eble and Niland, 2009). This retains ECs in their positions. 
Once the tip cell has been selected, for angiogenesis to occur, ECs must therefore be liberated, 
a process requiring proteolytic breakdown of the basement membrane and detachment of 
mural cells. Basement membrane degradation is mediated by matrix metalloproteases (MMPs) 
such as MT-MMP1, enriched in tip cells. Proteolysis is finely regulated, too little and the ECs 
will not migrate, whereas excessive degradation of the ECM, as occurs in plasminogen 
activator inhibitor 1 (PAI1) deficiency, leaves too little matrix support for the branch to sprout 
(Blasi and Carmeliet, 2002). MMPs have another key function which is to release pro-
angiogenic growth factors that are sequestered in the matrix (Arroyo and Iruela-Arispe, 2010). 
They also generate anti-angiogenic molecules by cleaving plasma proteins, matrix molecules, 
↑MMPs 
↑angiopoietin-2 
→Cdc42, ROBO4 
→neuropilins,  
    semaphorins 
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or proteases themselves to prevent inappropriate sprouting and coordinate branching (Nyberg 
et al., 2005). Detachment of mural cells, such as pericytes, is stimulated by Angiopoietin-2 
(ANG2), a proangiogenic growth factor stored by ECs for rapid release (Augustin et al., 2009) 
(Huang et al., 2010). These steps are necessary for tip and stalk cells to liberate from the old 
vessels and migrate to the site where new blood vessels are needed. 
Tip cell migration is guided by filopodia, thin protrusions with a core of parallel bundles of 
actin filaments that extend from the plasma membrane. Little is known regarding the molecular 
mechanisms regulating tip cell filopodia, apart from that activation of Cdc42 by VEGF triggers 
their formation (De Smet et al., 2009). ECs express guidance receptors including ROBO4, 
UNC5B, PLEXIN-D1, NRPs, and EPH family members, which they use to probe the 
environment. ROBO4 is expressed in ECs and maintains vessel integrity, and ROBO4 
deficiency induces leakiness and hyper vascularisation (London et al., 2009). At the molecular 
level, ROBO4 inhibits the VEGFR2-mediated activation of Src kinase and therefore src-
mediated permeability. The ROBO4 ligand is unknown however, ROBO4 binds to UNC5B, 
another guidance receptor, and it is thought that ROBO4/ UNC5B maintains vessel integrity 
via UNC5B activation (Koch et al., 2011). UNC5B is a receptor for Netrins whose expression 
is enriched in tip cells. Netrin1 prompts filopodia retraction on ECs, consistent with a 
suppressive function of netrins and UNC5B on sprouting (Adams and Eichmann, 2010). 
Interestingly, when UNC5B is not engaged with a ligand, it induces EC apoptosis (Castets and 
Mehlen, 2010). Semaphorins are secreted or membrane-bound guidance cues that interact with 
receptor complexes, formed by Neuropilins (NRPs) alone or NRP/plexin family proteins 
(Carmeliet and Tessier-Lavigne, 2005). SEMA3E induces vessel repulsion through interaction 
with PLEXIN-D1. As ECs express PLEXIN-D1, its loss causes aberrant sprouting into 
SEMA3E-expressing tissues in zebrafish embryos (Adams and Eichmann, 2010). In the mouse 
retina, SEMA3E activates PLEXIN-D1 on tip cells to fine-tune the balance of tip and stalk 
cells necessary for even-growing vascular fronts by coordinating VEGF’s activity in a negative 
feedback (Kim et al., 2011). NRPs have several ligands in addition to semaphorins, including 
VEGF. The vessel abnormalities of NRP1-deficient embryos are in fact related to defective 
VEGF/NRP1 signalling (Fantin et al., 2009) as most semaphorins are suppressors of 
angiogenesis (Serini et al., 2009). EPH receptors and their ephrin ligands are regulators of cell 
contact-dependent signalling (Pitulescu and Adams, 2010). Eph-ephrin binding leads to 
bidirectional signalling in cells expressing the receptor (forward signalling) or ligand (reverse 
signalling). Eph-ephrins generate mostly repulsive signals. Ephrin-B2 is expressed in arterial 
ECs, whereas EphB4 is present on venous ECs. Both of them regulate vessel morphogenesis, 
and loss of ephrin-B2 or EphB4 leads to vascular remodelling defects (Pitulescu and Adams, 
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2010). Ephrin-B2-mediated reverse signalling has also been shown to regulate VEGFR 
internalization and tip cell behaviour. When eprhin-B2 is not knocked-out in ECs, they become 
unable to internalize VEGFR2 and VEGFR3 and cannot transmit VEGF signals properly, 
resulting in impaired sprouting (Sawamiphak et al., 2010) (Wang et al., 2010). 
 
1.2.1.5. Stalk elongation / lumen formation 
 
Fig. 1.15 Sprouting angiogenesis: Stalk elongation / lumen formation. The developing 
spout elongates by proliferation of endothelial stalk cells (purple) that trail behind the tip cell.  
 
Compared to tip cells, stalk cells produce fewer filopodia and are more proliferative. 
Importantly, they also form junctions with neighbouring cells and produce basement 
membrane components to ensure the integrity of the new vessel (Phng and Gerhardt, 2009). 
As stated before, stalk cell specification is regulated by Notch signalling (Jakobsson et al., 
2010). Upon activation, Notch receptor is cleaved leading to the release of the intracellular 
domain (NICD), forming a complex with the transcription factor RBPj/CBF1 and Mastermind-
like proteins to initiate the transcription of target genes. This mechanism not only drives 
targeted gene expression but also prevents continuous Notch activation on the cell surface. 
The Notch-regulated ankyrin repeat protein (NRARP) disassembles Notch complex and 
induce NICD degradation to counterbalance Notch activation. This balance in Notch activation 
is fundamental to stalk cell proliferation. NRARP also promotes Lef1/β-catenin pathway to 
preserve stability of nascent vessel (Phng et al., 2009). Reversible acetylation of NICD 
represents another level of Notch regulation (Guarani et al., 2011). Acetylation enhances 
Notch responses by interfering with NICD1 turnover, whereas deacetylation by SIRT1 
opposes NICD1 stabilization, thereby limiting Notch activity. 
↑NRARP 
↓ Notch 
↑Lef1/β-catenin 
→VEGF, ROCK,  
    RASIP1 
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A functional vessel possesses a luminal space which will allow the circulation of blood 
throughout the vascular network. Lumen formation can occur via different mechanisms 
(Iruela-Arispe and Davis, 2009; Zeeb et al., 2010). During development, for instance, ECs in 
intersomitic vessels form a lumen by coalescence of intracellular (pinocytic) vacuoles, which 
interconnect with vacuoles from neighboring ECs (cell hollowing). Recently, it has been 
observed that, in large axial vessels, ECs adjust their shape and reorganize their junctions to 
open up a lumen (cord hollowing). During this process, ECs first define apical-basal polarity, 
then the apical (lumenal) membrane starts expressing negatively charged glycoproteins that 
confer a repulsive signal, opening up the lumen. Subsequently, changes in EC morphology, 
driven by VEGF and Rho-associated protein kinase (ROCK), enlarge the lumen (Strilic et al., 
2009) (Zeeb et al., 2010). Ras-interacting protein 1 (RASIP1), a regulator of GTPase signalling 
controlling cytoskeletal rearrangements, adhesion, and EC polarity, seems also required for 
tube genesis (Xu et al., 2011).  
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1.2.1.6. Tip cell fusion 
 
Fig. 1.16 Sprouting angiogenesis: Tip cell fusion. The tip cells from two developing sprouts 
fuse and create a lumen. Blood flowing through the new capillary oxygenates the tissues, thus 
reducing the secretion of VEGF-A.  
 
Multiple newly formed vessels, guided by tip cells, will eventually converge to the site of the 
tissue with the highest concentration of angiogenic factors. At this point, a key step is 
represented by the interactions between the tip cells. Interestingly, macrophages have been 
shown to facilitate these interactions but are not strictly required (Fantin et al., 2010). 
Following the establishment of the first cell-cell contacts, new EC junctions are created. 
Subsequently, ECM is deposited into the basement membrane, supporting pericytes are 
recruited, EC proliferation decreases to basal level, and more cell junctions are formed. Blood 
will now start to flow in the new lumen and this is key to the shaping and remodeling of the 
vessel connections. Blood flow will also activate the shear stress-responsive transcription 
factor Krüppel-like factor 2 (KLF2). In zebrafish, KLF2 has been shown to upregulate the EC-
specific miR-126 that modulates PI3K and MAPK signalling which then promotes vessel 
remodelling (Nicoli et al., 2010). Following perfusion, oxygen and nutrient delivery reduces 
VEGF production and inactivates endothelial oxygen sensors (Hypoxia-inducible factors), 
together re-directing ECs toward a quiescent phenotype. 
↑KLF2 
↓ VEGF 
↓ HRE gene  
   transcription 
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1.2.1.7. Pericyte stabilization 
 
Fig. 1.17 Sprouting angiogenesis: Stalk elongation / lumen formation. The newly 
developed capillary is stabilized by pericyte recruitment (green), deposition of ECM, shear 
stress and other mechanical forces associated with blood flow and blood pressure. 
 
Functional vessels are the result of a maturation process which involves the formation of a 
vessel wall. This implicates recruitment of mural cells and deposition of ECM (Jain, 2003). 
ECs also acquire tissue-specific differentiation adapted to meet local homeostatic demands 
and thus differ in phenotype (Dyer and Patterson, 2010). Pericytes are in direct contact with 
ECs in capillaries and immature vessels, whereas vascular smooth muscle cells cover arteries 
and veins and are separated from ECs by a matrix (Gaengel et al., 2009). Transforming growth 
factor β (TGF-β) signalling plays a major role during vessel maturation. TGF-β stimulates 
mural cell induction, differentiation, proliferation, and migration and promotes production of 
ECM (Pardali et al., 2010). Unsurprisingly, loss of function of TGF-β receptor 2 (TGFBR2) 
in mice causes vessel fragility in part due to impaired mural cell development (Pardali et al., 
2010).  
Platelet-derived growth factor (PDGF) receptor-β (PDGFR-β) is instead key to recruitment of 
mural cells (Gaengel et al., 2009). Endothelial PDGFB signals to PDGFR-β expressed by 
mural cells, stimulating their migration and proliferation. In fact, inactivation of either Pdgfb 
↑TGF-β 
↑PDGF 
↑sphingosine-1 
↑angiopoietin-1 
↑ephrinB2 
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or Pdgfrb genes induces pericyte deficiency, vascular dysfunction, micro-aneurysm formation, 
and bleeding (Gaengel et al., 2009). Sphingosine-1-phosphate receptor (S1PR) signalling also 
controls EC/mural cell interactions. Endothelial-derived S1P binds to G protein-coupled 
S1PRs (S1PR1–5) (Lucke and Levkau, 2010) and promotes cytoskeletal and junctional 
changes affecting cell migration, proliferation, and survival. Disruption of S1PR1 or loss of 
both S1PR2 and S1PR3 in mice causes defective coverage of vascular smooth muscle cells 
and pericytes, a phenotype reminiscent of Pdgfb and Pdgfrb mutant mice. However, the main 
defect is related to ECs, where S1P1 controls trafficking of N-cadherin to the ablumenal side 
of ECs in order to reinforce EC-pericyte contacts.  
Angiopoietin-1 (ANG1), produced by mural cells, activates its endothelial receptor TIE2 
(Augustin et al., 2009) (Huang et al., 2009) and stabilizes vessels by promoting pericyte 
adhesion and tightening EC junctions. Mural cells also require ephrinB2 for association around 
ECs, as mural cell-specific ephrinB2 deficiency causes mural cell migration and vascular 
defects (Pitulescu and Adams, 2010). Notch signalling also controls maturation and arterial 
differentiation of vascular smooth muscle cells (Gridley, 2010).  
Recently, notch signalling (notch 1 and 3) has been shown to be required for proper pericyte 
coverage, interaction with the endothelium and vascular basement membrane formation in the 
mouse retina (Kofler et al., 2015).  
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1.2.2. Angiogenic factors 
1.2.2.1. Vascular Endothelial Growth Factors 
The identification of what is considered the strongest pro-angiogenic factor, VEGF or 
Vascular endothelial growth factor dates to 1983 when Senger et al. described for the first time 
a novel protein, partially purified from conditioned medium of a tumor cell line, which 
possessed the ability to induce vascular leakage in guinea pig skin and named it VPF or 
vascular permeability factor (Senger et al., 1983). Later that decade, Ferrara and Henzel 
(Ferrara and Henzel, 1989) discovered that pituitary follicular cells secrete a novel heparin-
binding growth factor specific for vascular ECs and named it VEGF or vascular endothelial 
growth factor. Soon after, cDNA cloning of VPF (Leung et al., 1989) and VEGF (Keck et al., 
1989) demonstrated that they were the same molecule. 
 
VEGF family 
Type Function 
VEGF-A 
 Angiogenesis 
 ↑ Migration of ECs 
 ↑ Mitosis of ECs 
 ↑ Matrix metalloproteinase activity 
 ↑ αvβ3 activity 
 Blood vessel lumen formation 
 Fenestrations 
 Chemotactic for macrophages and granulocytes 
 Vasodilation (indirectly by NO release) 
VEGF-B Embryonic angiogenesis in the myocardium 
VEGF-C Lymphangiogenesis 
VEGF-D 
Needed for the development of lymphatic vasculature surrounding lung 
bronchioles 
PlGF 
Important for Vasculogenesis, also needed for angiogenesis during 
ischemia, inflammation, wound healing, and cancer 
Table 2 Vascular endothelial growth factor family member functions. 
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The VEGF family comprises in mammals five members: VEGF-A, VEGF-B, VEGF-C, 
VEGF-D and placenta growth factor (PlGF). A number of VEGF-related proteins encoded by 
viruses (VEGF-E) (Ogawa et al., 1998) and in the venom of some snakes (VEGF-F) 
(Tokunaga et al., 2005) have also been discovered. 
 
1.2.2.1.1. VEGF-A activities 
VEGF-A is a potent mitogen for micro- and macro-vascular ECs from arteries, veins and 
lymphatics with a ED50 of 2-10 picomolar (Ferrara and Henzel, 1989). Although initially this 
effect seemed limited and very specific to ECs, hence the name vascular endothelial growth 
factor, further studies have demonstrated that other cell types are susceptible to VEGF-A 
mitogenicity, such as retinal pigment cells (Guerrin et al., 1995), pancreatic duct cells (Oberg-
Welsh et al., 1997) and Schwann cells (Sondell et al., 1999). 
Beside promoting growth of ECs, VEGF-A is also a survival factor. In vitro studies showed 
that VEGF-A is able to protect ECs from serum starvation-induced apoptosis via the activation 
of the PI3 kinase / Akt pathway (Gerber et al., 1998b); in addition, VEGF-A can induce the 
expression of the anti-apoptotic proteins Bcl-2, A1 (Gerber et al., 1998a), XIAP (Tran et al., 
1999) and Survivin (Tran et al., 2002) in ECs. Interestingly, in vivo the anti-apoptotic effect 
of VEGF-A seems to be limited to newly formed vessels, as such is important in neonatal 
vasculature in mice, but not in adult (Gerber et al., 1999), and in newly formed vessels within 
the tumors but not in fully established ones (Yuan et al., 1996). Since pericyte coverage marks 
the stabilization of newly formed blood vessels, this has been proposed to be the event that 
determines loss of VEGF-A dependency in ECs (Benjamin et al., 1999). 
VEGF-A has been shown on several occasions to be able to promote angiogenesis both in vivo 
and in vitro. EC tube formation, for instance, an in vitro assay that recapitulates key events 
during angiogenesis, is promoted by VEGF-A (Pepper et al., 1992) and so is the ex vivo 
sprouting of rat aortic ring (Nicosia et al., 1994) and chorioallantoic membrane (Leung et al., 
1989; Plouet et al., 1989). VEGF-A can also promote angiogenesis in vivo as shown in the 
rabbit cornea (Phillips et al., 1994), primate iris (Tolentino et al., 1996) and matrigel plug in 
mice (Mesri et al., 1995). 
As mentioned before, VEGF-A was originally described as a protein capable of inducing 
vascular leakage in the skin (Senger et al., 1983). The link between vascular permeability and 
angiogenesis is still a grey area, some believe that an increase in permeability is a step 
necessary for angiogenesis to occur as it allows the extravasation of fibrin which will serve as 
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a scaffold for EC proliferation and migration (Dvorak et al., 1987), however, some others 
could argue that factors such as bFGF can induce angiogenesis without having an effect on 
vascular permeability (Cao et al., 2004). Another confusing aspect of the matter is the reported 
dependency of VEGF-A-induced permeability on Src and Yes and yet mice lacking these two 
kinases display a normal angiogenic response to VEGF-A (Eliceiri et al., 1999).  
 
1.2.2.1.2. VEGF-A isoforms 
The VEGF-A gene is localized in humans on chromosome 6p21.3, it is composed of 8 exons 
which by undergoing alternative splicing result in the generation of 4 different isoforms: 
VEGF-A121, VEGF-A165, VEGF-A189, VEGF-A206 (where the numbers are indicative of 
the amount of amino acids they retain after signal peptide cleavage) (Houck et al., 1991) (Fig. 
1.18). 
 
Fig. 1.18 VEGF-A isoform exon composition. Signal sequence (1), N-terminus (2), VEGF-
R1 binding site, dimerization domain (3), VEGF-R2 binding site (4), Plasmin cleavage site 
(5), Heparin-binding site (6, 6’, 7), C-terminus (8). 
 
The 165 isoform is the predominant one, lacks the residues encoded by exon 6, and is a 
heparin-binding homodimeric glycoprotein of 45 kDa (Houck et al., 1992). Crystallography 
resolved VEGF homodimer structure showing their anti-parallel engagement by 2 disulphide 
bridges between cys-51 and cys-60 (Muller et al., 1997). An important difference between 165 
and 121 is the absence of the heparin-binding domain in the latter. This is due to lack of the 
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exon 7 in the VEGF-A121 transcript. The 121 isoform is acidic and freely diffusible, while 
isoforms 189 and 206 which are highly basic and bind to heparin with high affinity (Houck et 
al., 1992) are almost completely sequestered in the ECM. VEGF-A165 has intermediate 
properties as it is secreted but can diffuse or stay anchored to the cell surface or the ECM (Park 
et al., 1993). However, even the ECM-bound isoforms can become freely diffusible when 
cleaved by specific proteases such as plasmin or sugar-degrading enzymes like heparinase. 
Interestingly, when VEGF-A loses its heparin-binding properties this reflects in loss of its 
mitogenic activity (Keyt et al., 1996).  The importance of the predominant form of VEGF-A 
(165) became clear when it was shown to be the only isoform able to rescue a tumorigenic 
phenotype in mice lacking the VEGF gene (Grunstein et al., 2000), moreover, mice expressing 
only VEGF-A120 die shortly after delivery, emphasizing the importance of the heparin-
binding domain for VEGF properties. 
 
1.2.2.1.3. VEGF Receptors 
VEGF family members bind to their cognate receptor tyrosine kinases Vascular Endothelial 
Growth Factor Receptors (VEGFR) 1, 2 and 3, respectively encoded by the genes flt1, flk1and 
flt4 (Fig. 1.19).  
VEGFRs belong to the type III receptor tyrosine kinase family, single-pass transmembrane 
proteins containing seven extracellular immunoglobulin domains and a split intracellular 
tyrosine kinase domain. VEGF ligands have different affinities for the 3 receptors, with 
VEGFR1 binding VEGF-A, B and PLGF, VEGFR2 binding VEGF-A, C, E and D (following 
processing) and VEGFR3 with VEGFC and D (Olsson et al., 2006) (Fig. 1.19). These 
receptors are mainly expressed on ECs but VEGFR2 also plays a role in neuronal maturation 
(Khaibullina et al., 2004) and VEGFR1 is involved in macrophage migration (Sawano et al., 
2001). VEGFR3 drives lymphatic development but also has a role in developmental 
angiogenesis (Tammela et al., 2008). 
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Fig. 1.19 Vascular endothelial growth factor receptors and their ligands.  
 
Upon binding of VEGF dimers to VEGFR, the receptor itself dimerises and this is followed 
by trans-autophosphorylation on specific cytoplasmic tyrosine residues. Activation of 
VEGFR1 raises the levels of urokinase plasminogen activator (uPA) and plasminogen 
activator inhibitor-1 (PAI-1), which in turn regulate ECM degradation and cell migration. Both 
uPA and PAI-1 modulate the actin cytoskeleton dynamics via p38 MAPK, thus impacting EC 
migration (Robinson and Stringer, 2001) (Kanno et al., 2000) (Landgren et al., 1998b) 
(Olofsson et al., 1998). When VEGFR1is phosphorylated at residue Y1169, it can also recruit 
phospholipase Cγ1 (PLCγ1), generating a binding site for the Src homology (SH2) domains 
in PLCγ (Roskoski, 2007). However, ligand-activated VEGFR1 does not seem to directly 
affect cellular behaviour such as cell proliferation. 
6–7 tyrosine residues in the cytoplasmic tail of VEGFR2 can be phosphorylated, particularly 
residues Y1175, Y951 and Y1214 (Fig. 1.20). Phosphotyrosines will then function as binding 
sites for SH2 domain-containing proteins or phosphotyrosine binding domains. PLCγ1 binds 
to the pY1175 site and this promotes phosphatidylinositol-4,5-bisphosphate hydrolysis to 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3). IP3, in turn, activates the IP3 
receptor. IP3 acts as a calcium channel on the ER, by mediating IP3-activated translocation of 
calcium ions from the ER to the cytosol. In the meantime, DAG activates the protein kinase C 
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(PKC) enzyme, which activates the MAPK pathway and signalling. Moreover, VEGFR2 
phosphorylation promotes the activation of the phosphatidylinositol 3-kinase (PI3K) pathway, 
which leads to increased c-Akt (protein kinase B) activity, followed by endothelial nitric oxide 
synthase (eNOS) phosphorylation  resulting in the production of nitric oxide (NO) (Olsson et 
al., 2006; Roskoski, 2007). NO then induces the expression of the hypoxia inducible factor 
complex which stimulates the transcription of VEGF-A (Karar and Maity, 2011). Once PKC 
enzymes are activated they phosphorylate and activate MEK (MAPK and ERK kinases), 
which in turn phosphorylates and activates p42/44 MAPK, leading to changes in gene 
transcription culminating in cell proliferation. Interestingly, it has been shown that PKCe 
isoform is implicated in VEGF-A–induced phosphorylation and activation of c-Akt and eNOS 
(Rask-Madsen and King, 2008). Shb (SH2 domain-containing adaptor protein b) similarly 
binds to the VEGFR2-pY1175 and activates PI3K, which in turn activates c-Akt and eNOS, 
promoting cell survival and NO production, respectively. Binding of a T-cell–specific adaptor 
protein (TSAd) to VEGFR2-pY1175 is also implicated in c-Src–regulated EC migration and 
vascular permeability. The VEGFR2-pY1214 is linked to actin remodelling and cell migration 
through a pathway involving CDC42, p38 MAPK and heat shock protein 27 kDa. The 
phosphorylation of Y1214 site is also linked to focal adhesion dynamics and cell motility.  
VEGFRs can heterodimerise in a context and cell-specific manner, such as VEGFR2/3 
complexes (Tammela et al., 2008) (Nilsson et al., 2010) but the signalling events downstream 
of such heterodimers are yet to be elucidated. VEGFR2 and VEGFR3 effectively induce 
receptor phosphorylation and downstream signalling whereas VEGFR1 has weak signalling 
activity in ECs. VEGFR1 has a much higher binding affinity for VEGF-A, with Kd of 2-10pM 
whereas the affinity of VEGFR2 is at least one order of magnitude lower (Shibuya, 2006). 
This has led to the hypothesis that flt1 acts as a VEGF-A sink and sequesters it, thus preventing 
binding to VEGFR2 and activation of downstream signalling. VEGFR1 negatively regulates 
tip cell formation by antagonizing the effects on VEGF-A in zebrafish (Krueger et al., 2011). 
Expression of a soluble isoform of VEGFR1 results in decreased angiogenesis (Zygmunt et 
al., 2011), which is necessary to keep certain clear tissues avascular i.e. the cornea (Ambati et 
al., 2006). 
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Fig. 1.20 VEGFR2 signalling.  
 
Loss of VEGFR1 increases EC proliferation and network formation resulting in embryonic 
lethality by E9 (Fong et al., 1995), suggesting this may be due to increased VEGFR2-driven 
signalling. Loss of both VEGFR2 alleles induces embryonic lethality at E8.5, with defects in 
vascular network formation as in VEGF knockouts, but also defects in EC specification and 
early migration (Shalaby et al., 1995). Recently, a soluble isoform of VEGFR2 has been 
described and is important for modulation of lymphangiogenesis by blocking VEGF-C 
function (Albuquerque et al., 2009). Apart from its role in lymphangiogenesis VEGFR3 is 
involved in vasculogenesis, with associated embryonic lethality at E9.5 in knockout mice 
(Dumont et al., 1998), as well positively influencing angiogenic post-natal sprouting 
(Tammela et al., 2008), findings that have been observed in zebrafish (Ober et al., 2004). The 
longer isoforms of VEGF-A can bind neuropilins, single pass transmembrane receptors best 
known for their expression in the nervous system and ability to bind semaphorins (Larrivee et 
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al., 2009). Nrp1 and 2 are expressed during early vascular development with nrp2 becoming 
restricted to the lymphatic endothelium. Nrp1 co-immunoprecipitates with VEGFR2 whilst 
nrp2 associates with VEGFR2 and 3. Nrp1 deficiency leads to embryonic lethality caused by 
early heart and vascular defects, along with neuronal guidance defects (Kawasaki et al., 1999). 
These defects are dependent on aberrant sprouting and arterial differentiation but not EC 
proliferation. Accordingly, nrp1 becomes preferentially expressed in arterial ECs later in 
development (Stalmans et al., 2002). Similarly, in zebrafish loss of nrp1 expression abrogates 
VEGF-dependent ISA sprouting (Lee et al., 2002). Nrp2 loss affects the lymphatic vasculature 
but not the blood vasculature (Yuan et al., 2002). Overexpression of nrp1 induces ectopic 
vascular sprouting that ultimately leads to embryonic lethality, similar to loss of VEGFR1. 
The co-binding of Nrp1 to VEGF is not important in the activation of VEGFR2 and its 
phosphorylation (Larrivee et al., 2009), but recent work suggests a role in the sorting of the 
endocytosed receptors to different endosomal compartments in a synectin-dependent 
mechanism, leading to altered downstream signalling (Ballmer-Hofer et al., 2011). The 
guidance of EC tip cell migration is dependent on the presence of functional Nrp1 (Gerhardt 
et al., 2004). Evidence also points to the requirement of Nrp1 for p38MAPK phosphorylation 
downstream of VEGFR2, important for EC sprouting, branching and interaction with pericytes 
(Kawamura et al., 2008). A recent hypothesis on the VEGF-A specificity of Nrp1 hint that 
Nrp1 binds both VEGF-A164 and VEGF120, but the latter cannot induce Nrp1-VEGFR2 
complex formation and thus fails to activate downstream signalling (Pan et al., 2007). Overall 
the above data suggest nrp1 is an important player in sprouting angiogenesis through its 
interaction and effect on VEGFR2 downstream signalling. Blood flow can also influence 
VEGFR2 signalling through interactions with VE-cadherin and PECAM-1 (Tzima et al., 2005) 
and this mechanosensory complex can activate integrin-mediated shear stress responses. 
 
1.2.2.2. Fibroblast Growth Factors 
The Fibroblast growth factors (FGFs) are pleiotropic factors acting on different cell types, 
including ECs. They exert their biological activities by binding to high affinity tyrosine kinase 
receptors FGFRs on the surface of target cells. ECs from different vascular beds express 
FGFR1, in vitro at least, and in some cases FGFR2 while FGFR3 and FGFR4 expression has 
never been reported on ECs (Bastaki et al., 1997; Dell'Era et al., 2003; Javerzat et al., 2002). 
A lot of evidence suggests that members of the FGF family, in particular FGF1 and FGF2, can 
promote a pro-angiogenic switch in ECs in vitro. They can, for instance, promote EC 
proliferation. This involves the autophosphorylation of FGFR followed by the recruitment of 
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adaptor molecules such as Shc, FRS2 and Crk (Cross and Claesson-Welsh, 2001). In addition, 
activation of PKC is also required for FGF2 to exert a full mitogenic response in ECs (Presta 
et al., 1991). Interestingly, FGF1, FGF2 and FGF4 upregulate urokinase-type plasminogen 
activator (uPA) which is important for the matrix degradation phase at the initial stage of 
angiogenesis. Additionally, they modulate the expression of uPA receptor on the EC surface, 
allowing the localization of the proteolytic activity to the leading edge of the migratory EC 
(Mignatti et al., 1989). Moreover, FGF2 promotes the shedding of cell surface membrane 
vesicles containing MMP-2, MMP-9 and MMP-14, which, together with the uPA system, 
contribute to remodelling the ECM during angiogenesis (Taraboletti et al., 2002). FGF2 has 
also been shown to promote cell migration in ECs. This effect, similarly to that on EC 
proliferation, requires the activation of the MAPK signalling pathway and is abolished by 
downregulation of PKC (Daviet et al., 1990; Shono et al., 2001). Interestingly, the capacity of 
FGFR1 to mediate FGF2 chemotactic effect is independent of its auto-phosphorylation and 
requires the activation of a Wortmannin-sensitive pathway (Landgren et al., 1998a). FGF2 also 
regulates the expression of different integrins such as αVβ3 and cadherins. This happens in a 
very finely tuned manner, as a brief exposure of FGF2 disrupts EC junctions while a prolonged 
exposure promotes a slow redistribution of junctional adhesion molecules such as PECAM-1, 
VE-Cadherin and Plakoglobulin (Underwood et al., 2002). In contrast with the potent 
angiogenic response elicited by exogenous FGF2 in vitro, the role of endogenous FGF2 
remains uncertain. For one, fgf2 Knock-out mice are morphologically normal (Zhou et al., 
1998) and do not even show impairment in neovascularization after injury (Tobe et al., 1998) 
or hypoxia (Ozaki et al., 1998). The same is true for the double knock out fgf2/fgf1 (Miller et 
al., 2000). This may reflect compensatory effects amongst members of the FGF family or/and 
the contribution to angiogenesis of several other growth factors including VEGF. In this 
regard, an intimate cross-talk exists among FGF2 and different members of the VEGF family 
during angiogenesis. Several lines of evidence suggest that FGF2 induces new blood vessel 
formation indirectly by activation of the VEGF/VEGFR system. For instance, expression of a 
dominant negative FGFR1 or FGFR2 in glioma cells leads to decreased tumor angiogenesis 
and down-regulation of VEGF (Auguste et al., 2001). Moreover, VEGFR-2 antagonists not 
only inhibit VEGF but also FGF-mediated angiogenesis both in vitro and in vivo (Tille et al., 
2001), and FGF2 upregulates the expression of both VEGF (Seghezzi et al., 1998) and 
VEGFR2 (Gabler et al., 2004) in ECs. 
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1.2.2.3. Angiopoietins 
Angiopoietin-1 (Ang1) was first discovered in 1996 as the ligand of the previously orphan 
receptor TIE-2 (tyrosine kinase with immunoglobulin-like loop and EGF homology domains) 
expressed exclusively on ECs (Davis et al., 1996) and on leukocytes at early stage of 
development. Angiopoietin-2 (Ang2) was later discovered as a natural antagonist of Ang1 with 
similar binding affinity to TIE2 but diminished capacity to activate the receptor (Maisonpierre 
et al., 1997). Angiopoietins contain a C-terminal fibrinogen-like domain, bearing six cysteine 
residues, which is the site of interaction with TIE2. It has been shown the Ang1 and Ang2 
differ in the ability to activate TIE2 reside in this C-terminal domain. Ang1 is constitutively 
and widely expressed in adult highly vascularised tissues (Thurston et al., 2000), while Ang2 
is only expressed in the ovary, placenta and uterus, organs in which physiological angiogenesis 
happens (Maisonpierre et al., 1997), and in pathological conditions characterised by new blood 
vessel formation such as rheumatoid arthritis (Scott et al., 2002). Angiogenic factors such as 
VEGF, FGF2 and hypoxia up-regulate Ang2, while Ang1, TGFβ and Ang2 (in an autocrine 
fashion) promote its down-regulation (Mandriota and Pepper, 1998).  
Binding of angiopoietin clusters Tie2 molecules, a minimum of four monomers assembling in 
a tetrameric conformation is required to stimulate the tyrosine kinase domains (Kim et al., 
2005). Tie2 is ubiquitous in the vascular endothelium. Tie2 appears to be constitutively 
phosphorylated in quiescent vasculature (Wong et al., 1997), indicating an active role in 
vascular maintenance. Tie2 is also expressed to a variable extent on non-ECs, such as 
monocytes, synovial membrane cells, cancer cells and neurons (Brkovic et al., 2007) (Kosacka 
et al., 2005) (Nakayama et al., 2005) (Voskas et al., 2005) (Uchida et al., 2000). The cellular 
effects of ang1 are generally protective. The ligand inhibits endothelial apoptosis in response 
to a serum-deprivation and TNF-a (Kwak et al., 2000). Ang1 promotes migration of 
endothelial and some non-ECs such as smooth muscle cells (Iurlaro et al., 2003) (Jones et al., 
2003). Ang1 also induces sprouting and reorganisation of ECs into tubules (Kim et al., 2000a) 
(Koblizek et al., 1998). Ang1 exerts potent anti-inflammatory effects on ECs, suppressing 
VEGF-induced upregulation of E-selectin, ICAM- 1 and VCAM-1, and inhibiting leucocyte 
adhesion and transmigration in response to VEGF and TNF-a (Kim et al., 2001) (Gamble et 
al., 2000). Ang1 also reduces endothelial permeability in response to VEGF and thrombin in 
HUVECs (Gamble et al., 2000). Ang1 stimulates the localisation to cellular junctions of 
proteins involved in promoting junctional integrity, such as PECAM-1 (Gamble et al., 2000), 
occludin (Hori et al., 2004) and ZO-2 (Lee et al., 2009). Whilst ang1 is an agonist to Tie2, 
ang2 is a partial agonist, with high concentrations of ang2 leading to competitive inhibition of 
ang1 signalling through Tie2 (Yuan et al., 1999). As ang1 and ang2 form similar structural 
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complexes with Tie2 (Barton et al., 2006), the mechanisms for this have been suggested to be 
related to a greater ability of ang1 to dissociate the inhibitory co-receptor Tie1 (Seegar et al., 
2010) (Hansen et al., 2010), or possibly to the different oligomerisation patterns of ang1 and 
2 allowing differential receptor activation (Kim et al., 2005) (Kim et al., 2009). Ang2 is best 
currently regarded as an inducible inhibitor of endothelial quiescence, inhibiting the tonic 
vascular maintenance activities of ang1 at times where endothelial remodelling is required, for 
example during inflammation or angiogenesis.  
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1.2.3. Angiogenesis in diseases 
A well-organized and functional vascular system allows the diffusion of nutrients, metabolites 
and oxygen to metabolically active cells. Malignant tumors, for instance, are composed of fast-
growing highly-metabolic cells and without a good blood supply to bring nutrients and oxygen 
and remove waste products they wouldn’t grow larger than 1 to 2 mm across. For this reason, 
tumor cells produce and release pro-angiogenic factors which stimulate neighbouring blood 
vessels to grow new capillaries within the tumor mass. Tumor angiogenesis not only allows 
tumor growth but also represents a mechanism of tumor evasion and metastasis to distant 
organs (Weis and Cheresh, 2011). Angiogenesis is also characteristic of chronic inflammatory 
conditions such as Rheumatoid Arthritis. During Rheumatoid Arthritis, the highly proliferative 
synovial cells cause a growing metabolic demand for oxygen and nutrients. In addition, the 
accumulation of synovial fluid exacerbates hypoxia in an already ischemic environment. Such 
a combination of increased metabolic demand and hypoxia is a potent signal for angiogenesis. 
On the other hand during Rheumatoid Arthritis, angiogenesis in itself sustains the 
inflammatory response. New blood vessels allow more inflammatory cells to migrate from the 
circulation into the already inflamed synovium (Konisti et al., 2012). Age-related macular 
degeneration (AMD) is a progressive retinal disease associated with multiple environmental 
and genetic factors and the leading cause of central vision loss in developed countries, 
affecting 1 in 10 people older than 50 years. The late or more severe disease progression is 
often referred to as “wet” AMD. Wet AMD is caused by the growth of abnormal blood vessels, 
or choroidal neovascularisation (CNV), under the macula. These abnormal vessels leak fluid 
and blood into the tissue at the back of the eye, causing a blister to form in the retina. The 
resulting scar tissue leads first to distortion and eventually to retinal detachment and loss of 
central vision (van Lookeren Campagne et al., 2014). Also cardiovascular diseases, blindness, 
complications of AIDS, diabetes, Alzheimer's disease and more than 70 other major health 
conditions affecting children and adults worldwide are characterized by angiogenesis. 
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1.2.4. Anti-angiogenic therapies 
1.2.4.1. Targeting VEGF/VEGFR 
VEGF has become the prime antiangiogenic drug target with approval by the US Food and 
Drug Administration of several VEGF-  and VEGF receptor-based inhibitors for clinical use 
(Crawford and Ferrara, 2009). The anti-VEGF Ab Bevacizumab (Avastin) is approved in 
combination with chemotherapy or cytokine therapy for several advanced metastatic cancers, 
including non-squamous non-small cell lung cancer, colorectal cancer, renal cell cancer, and 
metastatic breast cancer. Based on a randomized phase II trial, bevacizumab monotherapy has 
been approved for recurrent glioblastoma. Additionally, four multi-targeted pan-VEGF 
receptor tyrosine kinase inhibitors (RTKIs) have been approved: Sunitinib (Sutent) and 
Pazopanib (Votrient) for metastatic renal cell carcinoma (RCC), Sorafenib (Nexavar) for 
metastatic RCC and unresectable hepatocellular carcinoma, and Vandetanib (Zactima) for 
medullary thyroid cancer. Sunitinib has also been recommended for treatment of advanced 
pancreatic neuroendocrine tumors. Beside several types of cancer, VEGF has been found 
overexpressed also in patients with wet AMD, and anti-VEGF Ab therapy is the current 
standard treatment (Group et al., 2011). Clinical agents for wet age-related macular 
degeneration, characterized by neovascularization of leaky vessels, include an anti-VEGF Fab 
Ranibizumab (Lucentis) and a VEGF aptamer Pegaptanib (Macugen), with Avastin being used 
off-label. Since 2013, Aflibercept (Eylea) has become the drug of choice for the treatment of 
Wet AMD. Aflibercept is a fully human fusion protein of VEGFR1 and VEGFR2. It uniquely 
blocks all forms of VEGF-A, as well as PlGF, each arm binding to each pole of an active 
growth factor dimer. This forms a stable and inert 1:1 complex. Its high affinity allows it to 
bind growth factors more tightly than naturally occurring VEGF receptors or antibodies, 
perhaps leading to more complete blockade of VEGF signaling and potentially an increased 
duration of efficacy. Aflibercept has demonstrated encouraging efficacy and safety in phase 1 
and 2 clinical trials in the treatment of wet AMD and in a phase 1 study for diabetic macular 
edema. Phase 3 studies for the treatment of exudative AMD (VIEW1 and VIEW2) have shown 
comparable efficacy of Aflibercept when injected every 2 months compared to Ranibizumab 
injected every month (Heier et al., 2012). 
VEGF blockade prolongs progression-free survival or overall survival of cancer patients in the 
range of weeks to months and improves visual acuity in patients with age-related macular 
degeneration. The clinical benefit of treatment with VEGF (receptor) inhibitors is attributable 
to several mechanisms. First, these blockers inhibit tumor vessel expansion by blocking 
vascular branching or inhibiting homing of BMDCs. Additionally, these drugs induce 
regression of pre-existing tumor vessels and sensitize ECs to effects of chemotherapy and 
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irradiation by depriving them of VEGF's survival activity. Normalization of abnormal tumor 
vessels by pruning immature pericyte-devoid vessels and by promoting maturation into more 
functional vessels is another mechanism (Goel et al., 2011). The resulting sensitization to 
cytotoxic or radiation therapies relying on conversion of oxygen to radicals in combination 
with improved chemotherapeutic delivery may explain partly why combination delivery of 
bevacizumab/cytotoxic agents is often superior (Jain, 2005). However, the importance of 
vessel normalization versus pruning for the overall anticancer effect of VEGF (receptor) 
inhibitor treatment requires future study. Furthermore, vessel normalization observed with 
treatment is transient, as these drugs induce excessive vessel regression, or tumor 
vascularization escapes VEGF blockade. In conditions where vascular leakage causes life-
threatening intracranial edema (e.g., in glioblastoma) or blindness (e.g., in wet age-related 
macular degeneration), restoration of normal barrier properties by VEGF (receptor) blockade 
may be a relevant mechanism (Goel et al., 2011). Besides targeting tumor vessels, these 
inhibitors also target tumor cells expressing VEGF (receptor), whose growth is stimulated by 
VEGF. 
Although anti-VEGF (receptor) therapies are the current standard in the clinic to treat both 
tumor angiogenesis and choroidal neovascularization in wet-AMD, therapies that target VEGF 
directly are raising several concerns. One of which is that VEGF not only drives new vessel 
growth but it also has an important role for trophic maintenance of the healthy vasculature. 
Prolonged anti-VEGF therapy for cancer treatment, for example, is associated with a number 
of severe adverse effects associated with endothelial dysfunction including: hypertension, 
microangiopathy, proteinuria in the kidney; cardiac ischemia/infarct, thromboembolic events 
in the heart, and bleeding in the gastrointestinal system (Meadows and Hurwitz, 2012). 
Moreover, Kurihara et al. have recently described a dramatic and rapid loss of ECs of the 
choriocapillaries and severe vision loss in mice following genetic deletion of the VEGF gene 
from the retinal pigment epithelial cells. These data suggesting that an indiscriminate 
suppression of VEGF signalling, an effect similar to that reached by the anti-VEGF therapies 
currently in use, might carry with it very dramatic side effects for the patients in the long run 
(Kurihara et al., 2012). This has highlighted the need to identify novel therapeutic targets to 
develop better therapies. 
 
1.2.4.2. Targeting Integrins 
Integrins have been shown to play key roles in tumor angiogenesis (Foubert and Varner, 2012), 
and antagonists of several integrins have shown promising results in pre-clinical studies on 
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several types of cancer. An attractive aspect of targeting integrins is that there are specific 
family members which are only expressed or activated in remodelling tissues such as tumors; 
targeting those has therefore the potential to spare toxic effect on the remaining healthy tissues. 
Anti-integrin blocking monoclonal Abs usually have high affinity and specificity and have 
been well-characterized over the years; these were, unsurprisingly, the first anti-integrin 
compounds to reach the clinic. Abegrin (MEDI-522), a humanised version of the anti-integrin 
αvβ3 monoclonal Ab LM609 (block angiogenesis by inducing apoptosis of tumor-associated 
ECs), was the first anti-integrin therapy to be tested in cancer clinical studies. The early version 
of MEDI-522, Vitaxin, was well-tolerated in phase I studies (Gutheil et al., 2000) (McNeel et 
al., 2005). Vitaxin led to disease stabilization in relapsed/refractory patients with metastatic 
cancer. However, in a second clinical study, Vitaxin did not show any anti-tumor activity in 
leiomyosarcoma patients. In 2001, MedImmune started clinical studies using Vitaxin 
(renamed MEDI-522 and Abegrin) and in 2003 initiated phase II trials in advanced metastatic 
melanoma and prostate cancer patients (Hersey et al., 2010). In one melanoma trial, 112 
patients with late stage melanoma received MEDI-522 weekly, a sub-group also received 
standard chemotherapy Dacarbizin. Both MEDI-522 treatment groups showed prolonged 
survival compared with historical clinical trial results (Hersey et al., 2010). Correlative science 
studies showed that MEDI-522 had functional efficacy by reducing FAK activity in blood 
vessels (Zhang et al., 2007). Based on these encouraging results, phase III cancer clinical trials 
are planned.  
Integrins αvβ3 and αvβ5 regulate angiogenesis and promote tumor cell invasion in pre-clinical 
studies (Brooks et al., 1997). The pharmaceutical company Centocor has developed CNTO 
95, a human monoclonal Ab directed against both αvβ3 and αvβ5 integrins. CNTO 95 reduced 
angiogenesis and tumor growth in human melanoma xenografts (mice) (Trikha et al., 2004) 
and showed little toxicity in preclinical safety studies (Macaca fascicularis) (Martin et al., 
2005). This Ab has completed phase I safety trials (Mullamitha et al., 2007) and is now under 
evaluation in phase II clinical trials for melanoma and prostate cancer. In addition, a cyclic 
RGD-peptide antagonist of αvβ3 and αvβ5, cilengitide (EMD 121974), has been developed as 
a potential tumor therapeutic. Phase I clinical trials showed a favourable safety profile (Nabors 
et al., 2007) and may work well in combination with radiotherapy in cancer patients (Albert et 
al., 2006). This drug was evaluated in phase I/II clinical trials for glioblastoma and 
significantly increased progression-free survival (Nabors et al., 2007). Cilengitide has gone to 
phase II trials for glioblastoma, non-small cell lung cancer, melanoma and pancreatic cancer 
and in phase I for different types of B cell malignancies (Beekman et al., 2006; Bradley et al., 
2011; Friess et al., 2006). Cilengitide has however failed clinical trial phase III in the treatment 
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of newly diagnosed glioblastoma. Therefore, two distinct αv integrin-targeting drugs offer 
promise as cancer therapeutics and the results of clinical trials are eagerly anticipated.  
As β1 integrins also have important roles in regulating angiogenesis, targeting these integrins 
in addition to αv integrins could be a beneficial therapeutic strategy to block tumor 
angiogenesis and progression. Antagonists of one β1 integrin, α5β1, have undergone clinical 
testing. A chimeric mouse–human anti-α5β1 Ab, M200 (volociximab) has shown low toxicity 
in phase I studies. M200 was evaluated in phase II trials for metastatic melanoma, renal cell 
carcinoma and non-small cell lung cancer (Kuwada, 2007). In renal cell carcinoma studies, 
M200 was well-tolerated and stable disease was noted in 87% of patients. In a melanoma trial, 
combining M200 with dacarbazine was well-tolerated and anti-cancer activity was noted in 
62% of patients. Another drug in clinical trials, ATN-161, is a peptide inhibitor of integrin 
α5β1. In animal models of colon cancer, ATN-161 reduced metastases and improved survival 
when combined with chemotherapy (Stoeltzing et al., 2003). In phase I safety trials, ATN161 
was well-tolerated and several patients exhibited stable disease. ATN-161 has currently 
completed phase II clinical trials for multiple myeloma and other tumors (Cianfrocca et al., 
2006). Thus, these two integrin α5β1-inhibiting drugs might offer future benefit to cancer 
patients.  
Despite some promising results in phase I and II clinical trials, clear evidence that integrin 
inhibitors are efficient in inhibiting tumor angiogenesis in cancer patients has yet to be 
obtained. In this regard, it is fundamental to bear in mind that integrins are widely expressed 
by cells within the tumor microenvironment and the effect seen in clinical trials are likely to 
be derived by the combinatorial effect of blocking both EC and tumor cell integrins. Moreover, 
studies have revealed that nanomolar concentrations of RGD-mimetic inhibitor cilengitide can 
actually enhance the growth of tumors in vivo by promoting VEGF-mediated angiogenesis 
(Reynolds et al., 2009). These results raise concerns about the use of these agents as anticancer 
drugs. In conclusion, although phase I and II clinical trials appear promising, further pre-
clinical studies are needed to elucidate the mechanism of action of anti-integrin drugs in regard 
to their target (tumor cells, tumor microenvironment, or both) and their optimal dosing.  
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1.3. Syndecans in angiogenesis 
1.3.1. Syndecan-1 
Syndecan-1 is probably the best characterized of the syndecans, it appears to be implicated in 
a variety of physiological processes associated with the endothelium both during development 
and adulthood. This is unsurprising since syndecan-1 is a major constituent of the endothelial 
glycocalyx (Zeng et al., 2014). In an interesting study, increased new blood vessel formation 
in syndecan-1 deficient mice was observed where corneal neo-vascularization was induced by 
inflammation rather than pro-angiogenic growth factors. However, a direct correlation 
between increased EC-leukocyte interactions in these animals and increased angiogenesis was 
observed which suggested that the increase in the latter is due to an increased local 
accumulation of leukocytes (Gotte et al., 2002). Other studies have shown that syndecan-1 can 
associate directly via its extracellular domain with the αVβ3 and αVβ5 integrins leading to 
their activation and this is true for a variety of cell types (Beauvais et al., 2004; Beauvais and 
Rapraeger, 2003; McQuade et al., 2006) including ECs from both mice and humans. In fact, 
immuno-precipitation experiments with HMEC (human microvascular ECs) revealed it was 
possible to co-precipitate β3 and β5 integrins in complex with syndecan-1 and that by silencing 
syndecan-1 expression HMEC-1 were not able to spread on the αVβ3 ligand Vitronectin (VN) 
(Beauvais et al., 2009). The same group previously showed that fibroblasts seeded on 
syndecan-1 Ab would spread and activate αVβ3 and αVβ5 even in the absence of integrin 
ligands (McQuade et al., 2006). They could replicate this result with ECs and show that 
integrin activation could be prevented by adding Synstatin (SSTN82-130 a peptide corresponding 
to aa 82-130 of the syndecan-1 extracellular core protein). Interestingly, the SSTN peptide 
showed promising results in being able to inhibit tumor angiogenesis in a mouse model of 
mammary carcinoma (Beauvais et al., 2009). 
Later, the same group discovered the mechanism through which syndecan-1 is able to activate 
αVβ3 and α5β3 integrins. They were able to co-precipitate syndecan-1 with αVβ3 and IGF1R 
(insulin like growth factor receptor 1) from ECs in a way which suggested integrin and 
syndecan-1 were acting as a docking site for IGFR1. Also, they showed the presence of this 
ternary complex on focal contacts when cells were plated on VN (Beauvais and Rapraeger, 
2010). In further investigations they found that SSTN, the peptide able to disrupt syndecan-1- 
αVβ3 interaction, can block VEGF-induced angiogenesis but only in the early phase (in the 
aortic ring assay) when EC dissemination is preceded by breakdown of adherens junctions. 
VEGF-stimulated migration of ECs depends on αVβ3 and can be blocked by SSTN, 
suggesting that syndecan-1 has a role VEGF-dependent migration in ECs. Indeed, stimulation 
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of cells with VEGF not only activates VEGFR2 but also IGFR1 and αVβ3, activation of the 
latter can be abolished by adding SSTN. They propose a model whereby during the early phase 
of angiogenesis, syndecan-1, in its ternary complex with αVβ3 and IGFR1, is necessary for 
VEGF-induced integrin activation. This is key to EC dissemination and can be prevented by 
SSTN but also by disruption of the VE-Cadherin homophilic interaction thus supporting the 
finding that SSTN is not able to stop angiogenesis in its late phase when adherens junctions 
are already disrupted (Rapraeger et al., 2013). A recent study has also revealed that melanoma 
cells which are able to perform vascular mimicry (in which cells of a highly aggressive 
malignant tumor can form vascular-like channels without the need for endothelial cells) are 
VEGFR2, CD144 and Syndecan-1 positive. Critically, the use of a syndecan-1 blocking Ab 
abolishes the vascular mimicry ability of melanoma cells (Orecchia et al., 2015). 
 
1.3.2. Syndecan-2 
The most important study linking syndecan-2 to angiogenesis dates back to 10 years ago when 
Chen et al. showed that lack of syndecan-2 in zebrafish (achieved by morpholino gene-
targeting approach) dramatically impairs developmental angiogenesis. In the least severe case, 
corresponding to a less efficient syndecan-2 knock-down, intersegmental vessels either 
sprouted abnormally or failed to form and the vascular plexus of the tail region was less 
complex compared with that of wild-type embryos. Primary formation of the axial vessels was 
normal. However while axial expression of fli-1, flk-1 and tie-1 was retained in the trunk, this 
was lost in the intersegmental vessels. In an elegant twist to the work, they not only showed 
that the phenotype could be reverted by injection of exogenous zebrafish syndecan-2 cDNA 
but that a similar effect could be obtained by injecting human syndecan-2 cDNA, giving clear 
clues of an important functional conservation amongst species. The exact mechanism through 
which syndecan-2 asserts its pro-angiogenic function remains unclear. However, they showed 
that injection of a cytoplasmically-truncated form of syndecan-2 phenocopied the lack of its 
full-length form, suggesting the importance of its cytoplasmic domain in syndecan-2 vascular 
function (Chen et al., 2004b). 
Syndecan-2 may also play a role in pathological angiogenesis. It was found up-regulated both 
on vessels in gliomas and from normal brain while not present in the surrounding parenchyma 
(Fears et al., 2006). The same study showed that knock-down of syndecan-2 in Murine vein 
ECs (MvEC) resulted in decreased migration on fibronectin and tube formation on matrigel. 
However, those same pro-angiogenic factors such as EGF, bFGF and VEGF, known to be up-
regulated in gliomas, showed an ability to promote syndecan-2 shedding from MvECs. Further 
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studies showed that the shed molecule can have pro-angiogenic effect on MvECs, suggesting 
that the vascular function of syndecan-2 might result from a quite complicated balance of its 
functions on the cell surface, the regulation of its shedding and a possible autocrine or 
paracrine role as a shed effector (Fears et al., 2006). 
Furthermore, Human microvascular ECs (HMEC-1) predominantly express syndecan-2 
(around 80% of all HSPG on the cell surface) and its expression is increased in response to 
angiogenic stimuli (especially FGF) and is dependent on the type of matrix cells are seeded 
on. Interestingly, down-regulation of syndecan-2 resulted in decreased cell attachment and 
spreading and accelerated cell migration but also impaired HMEC-1 cells’ ability to form 
capillary-like structures on Matrigel (Noguer et al., 2009). 
In light of these few but important studies, it appears that syndecan-2 plays a pivotal role in 
angiogenesis. Unfortunately, unlike the other three members of the syndecan family, a knock-
out mouse model for syndecan-2 has not yet been developed, therefore the question as to 
whether a syndecan-2 knock-out mouse would develop normally or die prematurely due to 
angiogenic defects is still left unanswered.   
 
1.3.3. Syndecan-3 
Syndecan-3 knock-out mice are viable and develop normally. Syndecan-3 is considered the 
main syndecan of the nervous system and as such it’s been mainly investigated in behavioural 
studies.  
However, a recent work highlighting a role for syndecan-3 in the inflammatory response of 
different tissues also served to demonstrate that its expression is not limited to the nervous 
system but it can also be found on the endothelium of different vascular beds (joints, dermis 
and cremaster muscle) (Kehoe et al., 2014). 
We recently showed a potential therapeutic effect of the syndecan-3 extracellular core protein 
in pathologies where angiogenesis is increased. Recombinant bacterially-derived (hence 
lacking the glycosaminoglycan chains) syndecan-3 extra-cellular domain was shown to being 
able to significantly inhibit angiogenesis in the ex vivo model of the aortic ring assay and also 
inhibit skin and brain EC tube formation and cell migration through collagen in 2D and 3D 
(De Rossi and Whiteford, 2013). These data support the idea that syndecan core proteins when 
released from the cell surface can act as important effectors of cell behaviour. 
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1.3.4. Syndecan-4 
Although syndecan-4 was found up-regulated throughout the granulation tissue during skin 
injury on ECs (Gallo et al., 1996b), the first clear evidence of a functional role in angiogenesis 
came from the work of Echtermeyer et al. in 2001. Here they generated a syndecan-4 knock-
out mouse which showed significantly delayed wound healing in a model of skin injury. 
Although the number of newly generated vessels populating the healing tissue was not affected 
by the lack of syndecan-4, the vessels were smaller compared to the wild-type littermates 
(Echtermeyer et al., 2001a).  
Syndecan-4 has later been found to be essential in mediating the pro-angiogenic effects of 
Thrombospondin-1 (TSP-1). The study proposed a model whereby two heparin-binding 
sequences contained within TSP-1 are able to compete with fibronectin for the interaction with 
syndecan-4, thus interfering with syndecan-4-mediated EC adhesion (Nunes et al., 2008). 
In vitro experiments on ECs have shown that syndecan-4 is also key player in FGF signalling 
(Murakami et al., 2002b; Volk et al., 1999). Interestingly, it is not just by facilitating the 
interaction between FGF2 and its receptor FGFR1, but syndecan-4 cytoplasmic domain seems 
to have a key role as chimeras and deletion mutants of this portion lacking the V or the C2 
regions fail to promote an effective intracellular response to FGF2. In particular, lack of the 
C2 region (which contains the PDZ binding domain) prevents the binding of GIPC/Synectin 
which results in a failure to activate Rac1 and thus inhibits EC migration (Tkachenko et al., 
2006; Tkachenko et al., 2004). 
Quite recently syndecan-4 has been shown to participate in the signalling initiated by another 
pro-angiogenic molecule, Prostaglandin E2 (PGE2). The study revealed that in murine ECs 
lacking syndecan-4 PGE2-mediated pro-angiogenic effects (i.e. EC migration and tube 
formation) were decreased. They also show that syndecan-4 activation of PKCα is necessary 
for the phosphorylation of ERK following PGE2 stimulation. This molecular mechanism was 
confirmed in vivo by showing a diminished angiogenic response to PGE2 both in the syndecan-
4 and in the PKCα knock-out mice compared to the wild type (Corti et al., 2013). 
  
81 
 
 
2. General aims of the work 
Angiogenesis, the formation of new blood vessels from pre-existing ones, is both a 
physiological process and a key pathological feature of many diseases such as cancer, chronic 
inflammatory conditions and diseases of the eye. As a consequence, numerous anti-angiogenic 
therapies have been developed over the past few years and are currently used in the clinic or 
are in the clinical trial phase. The principal targets of these therapies are the VEGF/VEGFR2 
pathway and the integrin family of adhesion receptors, as these molecules have pivotal roles 
in the process of new blood vessel formation. Unfortunately, anti-angiogenic therapies have 
not quite met with the expectations: their efficiency is very heterogeneous, with a large number 
of patient non-responders, and often produce toxic side effects due to unspecificity. 
Nonetheless, the huge potential of blocking new blood vessel formation to stop angiogenesis-
dependent disease progression or even revert it is undeniable. There is therefore a critical need 
to better understand the process of angiogenesis and endothelial cell biology to improve the 
current anti-angiogenic therapies or develop new therapeutic strategies.  
Why study the roles and effects of syndecans on endothelial cell biology during the process of 
angiogenesis? 
The studies reviewed in section 1.3 indicate important roles of the syndecan family of HSPGs 
in EC biology. The original work presented in this thesis aimed to build on these works by 
focussing on the role of syndecans in relation to EC biology and angiogenesis. The specific 
purpose of this work was not only to increase the understanding of the complex process of 
new blood vessel formation but also to test the potential of syndecans as substrates and/or 
targets for anti-angiogenic therapies. 
To this end, this thesis will describe two projects that I have carried out during the course of 
my PhD: 
Project 1 (sections 4.1 and 4.2) 
Key background: Contained within syndecan ectodomains are adhesion-regulatory domains. 
Aim 1: To establish whether the ectodomains of syndecan-1, -2, -3 and -4 can affect 
endothelial cell adhesion/migration and angiogenesis in vitro. 
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In addressing this aim, I observed that all 4 syndecan ectodomains possess anti-angiogenic 
properties. Because of time restrictions, I decided to only follow up one of the four members. 
I chose syndecan-2 because it is expressed in the vasculature; this formed the basis of aim 2. 
Aim 2: To investigate the anti-angiogenic properties of syndecan-2 ectodomain, aiming to 
characterise its mechanism of action and test its potential as an anti-angiogenic molecule in 
pathological models of angiogenesis in vivo. 
Project 2 (section 4.3) 
Key background: Syndecan-4 deficient mouse is viable, fertile and with no abnormalities; 
however, it develops a phenotype in certain pathologies characterised by an angiogenic 
response. 
Aim: Determine if the full-length syndecan-4 has a role in the angiogenic process. 
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3. Materials and methods 
3.1. Reagents 
3.1.1. Antibodies 
Reactivity Host - 
Isotype 
Target Stock 
Conc. 
Dilution / Fig. Company Catalogue 
number 
12 aa HA 
tag 
Mou 
IgG1 
HA tag 1 ug/ul 1:1000 /  
Fig. 4.13  
Fig. 4.21 
Covance MMS-101P 
Human (h)/ 
Mouse (m)/ 
Rat (r)  
poly 
Goat 
IgG 
CD148 0.5 ug/ul 1:200 / 
Fig. 4.33  
Fig. 4.34 
R&D AF1934 
h/m/r Mou 
IgG1 
β tubulin Unknown 1:1000 / 
Fig. 4.33  
Fig. 4.63 
Sigma T4026 
m Rat 
IgG2a,κ 
CD29 - β1 
integrin 
(9EG7) 
0.5 ug/ul 1:200 /  
Fig. 4.36  
Fig. 4.37  
Fig. 4.38 
BD 553715 
h Rat 
IgG2a,κ 
CD29 - β1 
integrin 
(Mab13) 
0.5 ug/ul 1:200 / 
Fig. 4.36 
BD 552828 
h/r Mou 
IgG2b 
CD29 - β1 
integrin 
(HUTS4) 
0.5 ug/ul 1:300 / 
Fig. 4.39 
Millipore MAB2079Z 
m Rat 
IgG2a, 
κ 
CD31 - 
PECAM-1 
(390) 
0.5 ug/ul 1:100 / 
Fig. 4.18  
Fig. 4.25  
Fig. 4.53   
1:400 / 
Fig. 4.27 
eBioscience 11-0311 
h/m/r Mou 
IgG2a 
α-SMA 
(1A4) 
15 - 55 
mg/ml 
1:200 / 
Fig. 4.43  
Fig. 4.44  
Fig. 4.48  
Fig. 4.49 
Sigma A2547 
 
m 
 
Rat 
IgG1κ 
  
0.5 ug/ul 
  
eBioscience 
 
14-1441 
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VE-
Cadherin 
(BV13) 
1:200 / 
Fig. 4.43  
Fig. 4.44  
1:100 / 
Fig. 4.68 
m Rat 
IgG2a,k 
syndecan-4 
(KY/8.2) 
0.5 ug/ul 1:200 / 
Fig. 4.48  
Fig. 4.49  
Fig. 4.62 
1:1000 / 
Fig. 4.62 
BD 550350 
m Rat 
IgG2a,κ 
Isotype 
control 
0.5 ug/ul 1: 200 / 
Fig. 4.49 
BD 553927 
h Poly 
Rab 
IgG 
syndecan-4 
(H-140) 
0.5 ug/ul 1:400 / 
Fig. 4.64  
Fig. 4.66 
Santa Cruz 15350 
m Poly 
Rab 
IgG 
syndecan-2 
N-term 
1 ug/ul 1:800 / 
Fig. 4.66 
Santa Cruz 15348 
h/m Rab 
IgG 
VEGFR2 Unknown 1:1000 / 
Fig. 4.63  
Fig. 4.67 
Cell 
Signalling 
9698 
h/m Rab 
IgG 
VEGFR2 
pY1059 
Unknown 1:1000 / 
Fig. 4.63  
Fig. 4.67 
Cell 
Signalling 
3817 
h/m Rab 
IgG 
VEGFR2 
pY1175 
Unknown 1:1000 / 
Fig. 4.67 
Cell 
Signalling 
3770 
m poly 
Goat 
IgG 
VEGFR2 - 
N-term 
0.5 ug/ul 1:400 / 
Fig. 4.64  
Fig. 4.66 
R&D AF644 
Table 3 Antibodies. 
 
 
3.1.2. Stimuli 
Stimulus Details and Company 
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Tumor necrosis factor-α (TNF-α) Mouse TNF-α, R&D Systems, 401-ML-010/CF 
Vascular endothelial growth factor A 
(VEGF-A) 
Recombinant Mouse VEGF 164 R&D Systems, 493-
MV-025 
Phorbol 12-myristate 13-acetate (PMA) Sigma, P8139 
Angiopoietin-2 Recombinant human angiopoietin-2 R&D Systems 
623-AN-025 
Basic Fibroblast growth factor (FGF-2 or 
bFGF) 
Invitrogen, PHG0026 
Table 4 Stimuli. 
 
3.1.3. General reagents 
Reagent Details and Company 
7-Aminoactinomycin D (7-AAD) Approximately 97%, Sigma (Poole, Dorset, UK) 
Agarose Invitrogen (Paisley, UK) 
BS1-Isolectin I21412 Invitrogen (Paisley, UK) 
Bovine serum albumin (BSA) New England Biolabs (Hitchin, UK) 
Calcein C3100MP Invitrogen (Paisley, UK) 
Dapi D9542 Sigma-Aldrich (Poole, Dorset, UK) 
Deoxynucleotide triphosphates 
(dNTPs) 
Bioline Reagents Ltd. (London, UK) 
DNA Ladder SmartLadder SF, Eurogentec (Southampton, UK) 
Draq5 Draq5TM nuclear dye, c= 5 mM, Biostatus limited (Shepshed, 
UK)  
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EDTA Sigma, E5134-100G 
Ethanol  
 
VWR (Soulbury, UK)  
 
Evans Blue dye  
 
VWR (Soulbury, UK)  
 
Phalloidin   A12380 Invitrogen (Paisley, UK) 
Formamide VWR (Soulbury, UK)  
 
GelRed Biotum, via Cambridge BioScience (Cambridge UK) 
Goat serum (GS) Normal GS, AbD Serotec (Kidlingdon, UK)  
Magnesium chloride (MgCl2) Bioline Reagents Ltd. (London, UK) 
Methanol VWR (Soulbury, UK) 
Paraformaldehyde (PFA) VWR (Soulbury, UK) 
Sodium Chloride (NaCl) Fluka BioChemica, Sigma-Aldrich (Poole, Dorset, UK)  
Sodium dodecyl sulphate (SDS) 10% SDS solution, Severn Biotech Ltd. (Kidderminister, 
UK)  
Tris-Acetate-EDTA (TAE) buffer UltraPureTM 10x TAE buffer Invitrogen (Paisley, UK) 
Tris-HCl 1 M Tris-HCl solution, pH 8.5, Severn Biotech Ltd. 
(Kidderminister, UK) 
Triton X-100 Sigma-Aldrich (Poole, Dorset, UK) 
Table 5 General reagents. 
3.1.4. Microscopes  
Zeiss LSM 5 PASCAL confocal laser-scanning microscope (Carl Zeiss Ltd, Welwyn Garden 
City, UK) and a 10X Plan-Neofluar objective (numerical aperture 0.30) or a 63X oil-dipping 
Plan-apochromat objective (numerical aperture 1.4). 
Olympus IX81 motorised inverted microscope (Olympus Medical, Southend-on-Sea, UK). 
3.2. In vitro methods 
3.2.1. RNA isolation 
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RNA was isolated from adherent cells using a RNeasy micro kit (QIAGEN). The RNeasy 
Micro Kit is designed for isolation of total RNA from small samples and comes with a series 
of buffers. Initially samples are lysed by addition of the buffer on the cell mono-layer and then 
homogenized. Ethanol is added to the lysate to provide ideal binding conditions. The lysate is 
then loaded onto the RNeasy MinElute spin column and RNA binds to the silica membrane. 
Rnase-free Dnase, provided in the RNeasy Micro Kit, enables simple and efficient on-column 
digestion of genomic DNA for sensitive applications. Then Dnase and any contaminants are 
efficiently washed away, and pure, concentrated RNA is eluted in 14 µl water. Following the 
isolation steps, RNA concentration and purity was measured using Nanodrop apparatus 
(Thermo Scientific). Concentrations varied within the range of 0.1-1 μg/μl and samples were 
considered pure from DNA contamination or other contaminants when with a A260/A230 
ratio around 2 and a A260/A290 ratio between 2.0-2.2, respectively. Samples were then stored 
at -80°C. 
 
3.2.2. cDNA synthesis 
cDNA Synthesis from mRNA was performed using the iSCRIPT Kit (BioRad). Briefly, X 
volume of RNA solution, corresponding to 1 μg of RNA sample, was mixed with the 5X 
iSCRIPT reaction mix containing oligo (dT) and random exomers, the 20X iSCRIPT reverse 
transcriptase and brought to a volume of 20 μl with nuclease-free water. 
Reagents Volume (μl) 
5x iSCRIPT reaction mix 4 
iSCRIPT reverse transcriptase 1 
Nuclease-free water 15-x 
RNA (1 μg) x 
TOT 20 
 
The samples were then processed in a thermocycler (DNAengine, Bio Rad) and the 
programme set as below: 
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Reagents Temperature Time 
iSCRIPT activation 25°C 5’ 
Annealing 42°C 30’ 
Extension 85°C 5’ 
 4°C ∞ 
 
3.2.3. RT-PCR 
To analyse the expression of syndecan-4 and GAPDH, cDNA samples were then diluted 1:5 
with nuclease-free water and 5 μl were used to perform RT-PCR using reagents provided by 
the KOD PCR kit (Novagen). Primer sequences were designed to anneal to two adjacent exons. 
Primers   Annealing T 
syndecan-4 forward 5'-3' GGT CTT GGC AGC TCT GAT C 55.6 
syndecan-4 reverse 5'-3' CAC CAG AAA GGT GAC TAG AG 52.1 
product length 299 bp 
  
Primers   Annealing T 
GAPDH forward 5'-3' TCG TGGA TCT GAC GTG CCG CCT G 75 
GAPDH reverse 5'-3' CAC CAC CCT GTT GCT GTA GCC GTA 72 
Product length 251 bp 
 
 
 
 
Reaction was set as follows: 
Reagents Volume (μl) 
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10x KOD buffer 5 
25mM MgSO4 3 
dNTPs 5 
Forward primer (5μM) 1.5 
Reverse primer (5 μM) 1.5 
KOD polymerase 1 
cDNA 5 
Water 28 
TOT 50 
 
The samples were then processed in a thermocycler (DNAengine, Bio Rad) with the 
programme set as below: 
Step Reagents Temperature Time 
1 KOD pol activation 95°C 2' 
2 denaturing 95°C 20'' 
3 annealing Ta 10'' 
4 extension 70°C 3’ 
5 Step 2 to 4   28 times 
6  4°C ∞ 
 
 
 
3.2.4. qPCR 
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cDNA was synthesized from 10ng total RNA using the iScript cDNA synthesis kit (Biorad) 
and quantitative real time PCR was performed on an ABI7900HT (Applied Biosystems) real 
time PCR machine and reactions were prepared using the iQ Sybr green supermix (Biorad). 
Primers used in this study are described in 3.2.3. 
Values were expressed as Increase relative to UT (2ΔΔCt), according to the following formula: 
2ΔΔCt    where ΔΔCt = (Ct S4 UT – Ct HK UT) – (Ct S4 T – Ct HK T) 
UT= untreated T=treated HK=house-keeping gene   S4=syndecan-4 gene 
 
3.2.5. Gel electrophoresis 
After amplification, blue agarose gel electrophoresis loading buffer (1:6) was added to the 
samples and 10 μl were run on a 3 % (w/v) agarose gel (in TAE buffer) supplemented with 2 
μl GelRed. A 100 – 1,000 bp DNA ladder was used as a marker. Gels were left running in an 
electrophoresis chamber (Mupid®-One electrophoresis system, Eurogentec, Southampton, 
UK) for approximately 45’ at 90 V. Subsequently, gel pictures were taken under ultraviolet 
light on a UV White Darkroom BioImaging system (UVP, Cambridge, UK). 
 
3.2.6. Protein analysis 
3.2.6.1. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)  
All samples were boiled at 100°C for 5’ in SDS-sample buffer, syringed with a 23.5 gauge 
needle to decrease viscosity, and loaded on a 7.5% polyacrylamide gel with 1x TGS running 
buffer. Precision Plus protein marker (Biorad, Hertfordshire, UK) was used as molecular 
weight standard and samples were run at 100 V for approximately 1h30’.  
 
3.2.6.2. Western Blotting 
Following SDS-PAGE separation, gels were equilibrated in cathode buffer (1,5 g Tris Base 
(Fisher BP152-1), 3 g Glycine (Sigma G8898), 10% Methanol, deionized water for at least 10’ 
and proteins were transferred to nitrocellulose membranes (Immobilon-P, Millipore), using a 
Biorad Trans Blot Cell apparatus. Prior to transfer, membranes were activated in 100% 
methanol for 30’’, washes in milliQ water for 3’ and equilibrated in anode buffer II (1,5 g Tris 
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Base (Fisher BP152-1), 10% Methanol, deionized water). The transfer sandwich was then set 
up as shown below (anode buffer I is composed of 18,5 g Tris Base (Fisher BP152-1), 10% 
Methanol, deionized water):  
 
Semi-dry transfer was run at 0.5 mA for 1h45’. Membranes were then blocked for 1h in 
blocking buffer (5% BSA in TBST or 3% milk and 1% BSA in TBST for β-tubulin). 
Subsequently, membranes were washed once in TBST and incubated overnight at 4°C with 
primary Ab in blocking buffer. Then membranes were washed 3 times in TBST and incubated 
for 1-2 hrs in secondary Ab conjugated to HRP in blocking buffer. After 3 washes in TBST, 
membranes were incubated 1’ in SuperSignal solution, as per the manufacturer’s instructions, 
and developed using an SRX-101A medical film processor (Konica Minolta, Tokyo, Japan). 
 
3.2.6.3.  Immunoprecipitation 
Medium was removed and adherent cells were gently washed with PBS. 1 ml of lysis buffer 
(1% Triton, Protease and Phosphatase Inhibitor 1X in PBS) was added to the plate and cells 
detached from the plate with a cell-scraper and collected in a 1.5 ml tube. Samples were then 
centrifuged at max speed for 10’ and supernatant moved to a new 1.5 ml tube. In the meantime, 
affinity bead (EZ view red protein G affinity gel, SIGMA) equilibration was carried out. 10 μl 
of bead solution (2/sample) were pipetted into a 1.5 ml tube and 1 ml of dH2O was added, 
samples were pulsed in the centrifuge for 10’’, supernatant discarded and beads resupended in 
1 ml of PBS and centrifuged again for 10’’ (wash in PBS was performed twice). One bead 
solution was resuspended in 50 μl of 1% triton in PBS, added to each supernatant and left on 
a rotator for 1 hour. The solution was then centrifuged for 10’’ and supernatant moved to a 
new 1.5 ml tube. The second bead solution was resuspended in 1 ml of PBS containing 5 μg 
of anti-HAtag Ab (Covance) and put on a rotator for 1 hour. Solution was then centrifuged for 
10’’ and resuspended in 50 μl of 1% triton. The Ab-coated beads were then added to the 
supernatant containing tubes and left over-night on a rotator at 4 °C. Tubes were then 
centrifuged at full speed for 3’ and the pellet washed in PBS and resuspended in 20 μl of SDS 
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loading buffer. Supernatant was kept for β-tubulin analysis. Samples were then boiled at 100 
°C and loaded on a 7.5% poly-acrylamide gel. Subsequently, gel electrophoresis and semi-dry 
transfer were carried out (see protocols above). 
 
3.2.6.4.  Dot blotting 
Samples were diluted in blotting buffer (0.15 M NaCl buffered to pH 4.5 with 50 mM sodium 
acetate, and with 0.1% Triton X-100) and applied under vacuum to cationic nylon membranes 
(GE; Amersham Hybond™-N+ ) inserted into a slot blot apparatus (Hoefer PR648). 
Membranes were washed three times with blotting buffer, blocked for 1 h in blocking buffer 
(3% milk, 0.5% BSA, 0.15 M NaCl in 10 mM TRIS, pH 7.4), incubated over night with 1 
ug/ml of mAb syndecan-2 (R&D) in blocking buffer plus 0.3 % Tween-20, washed with TBST 
three times (0.3% Tween-20), incubated for 2 hrs with HRP-conjugated anti-Rat IgG at 1:5000 
dilution (Invitrogen) in blocking buffer plus 0.3 % Tween-20, washed with TBST three times 
(0.3% Tween-20). Signals were detected after addition of ECL substrate (Thermo Scientific) 
according to manufacturer instructions. Quantification of the signal intensity was performed 
using ImageJ software (http://rsbweb.nih.gov/ij/index.html). 
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3.3. Cell-based methods 
3.3.1. Cell culture 
Brain ECs (bEND3.1) and skin ECs (sEND) were obtained from Health Protection Agency 
(HPA) UK and were grown in DMEM (PAA, GE Healthcare) supplemented with 10% FBS, 
2 mM l-glutamine, 1% non-essential amino acids, 1% Penicillin (10,000 u/ml)/ Streptomycin 
(10 mg/ml), 1 mM sodium pyruvate and 5 µM β-mercaptoethanol (all Invitrogen), at 37°C, 
10% CO2. 
HEK293T were purchased from HPA culture collection and grown in DMEM, as above. 
Human umbilical vein ECs (HUVEC) were obtained from HPA laboratories and were grown 
in in-house made medium (MLEC medium) which contained: 
• 40% ml Modified Eagles Medium low glucose (ref. 21885 Invitrogen) 
• 40% ml Hams F-12 medium (ref. 31765 Invitrogen) 
• 20% ml heat-inactivated Fetal Bovine Serum 
• 100 mg/l Heparin (sls, H3149-100KU) 
• 1% Penicillin (10,000 u/ml)/ Streptomycin (10 mg/ml). 
• 50mg/l EC growth supplement (Sigma, E2759)  
Opti-MEM® I Reduced Serum Medium (Invitrogen, 31985-054) was also used during cell 
treatments and for aortic ring and choroid explant assay. 
 
3.3.2. Expression of syndecan ectodomain GST-fusion proteins 
These constructs were designed, transformed into E. coli and purified by Dr. James Whiteford. 
The ectodomain sequences were amplified using the primer pairs indicated. Subsequently, 
PCR products were kinased and digested with indicated restriction enzymes prior to ligation 
into the bacterial expression vector pET-41 (Novagen). 
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Gene Primers Restriction enzymes 
hsyndecan-1 FOR ttaaggatcccagccggccctgccgc 
REV ttatataagcttctagaggaggccctgtgagg 
HindIII and Bam HI 
msyndecan-2 FOR ggagacgagaacagagctga 
REV tatatgaattcttaaaacagattgtctgaatgtttct 
EcoRi and PshA1 
hsyndecan-3 FOR ttaattgaattcgctcaacgctggcgcaatg 
REV ttaattaagcttctacagtatgctcttctgaggga 
EcoRI and HIndIII 
hsyndecan-4 FOR agagtcgatcccgagagactg  
REV taataaggatccaaagatgttgctgccctgca 
BamHI AND PshA1 
 
Human syndecan-1 (cDNA, ectodomain) 
>human SYNDECAN-1 cDNA 933 bp 
ATGAGGCGCGCGGCGCTCTGGCTCTGGCTGTGCGCGCTGGCGCTGAGCCTGCAGCCGGCCCTGCCGCAAA 
TTGTGGCTACTAATTTGCCCCCTGAAGATCAAGATGGCTCTGGGGATGACTCTGACAACTTCTCCGGCTC 
AGGTGCAGGTGCTTTGCAAGATATCACCTTGTCACAGCAGACCCCCTCCACTTGGAAGGACACGCAGCTC 
CTGACGGCTATTCCCACGTCTCCAGAACCCACCGGCCTGGAGGCTACAGCTGCCTCCACCTCCACCCTGC 
CGGCTGGAGAGGGGCCCAAGGAGGGAGAGGCTGTAGTCCTGCCAGAAGTGGAGCCTGGCCTCACCGCCCG 
GGAGCAGGAGGCCACCCCCCGACCCAGGGAGACCACACAGCTCCCGACCACTCATCTGGCCTCAACGACC 
ACAGCCACCACGGCCCAGGAGCCCGCCACCTCCCACCCCCACAGGGACATGCAGCCTGGCCACCATGAGA 
CCTCAACCCCTGCAGGACCCAGCCAAGCTGACCTTCACACTCCCCACACAGAGGATGGAGGTCCTTCTGC 
CACCGAGAGGGCTGCTGAGGATGGAGCCTCCAGTCAGCTCCCAGCAGCAGAGGGCTCTGGGGAGCAGGAC 
TTCACCTTTGAAACCTCGGGGGAGAATACGGCTGTAGTGGCCGTGGAGCCTGACCGCCGGAACCAGTCCC 
CAGTGGATCAGGGGGCCACGGGGGCCTCACAGGGCCTCCTGGACAGGAAAGAGGTGCTGGGAGGGGTCAT 
TGCCGGAGGCCTCGTGGGGCTCATCTTTGCTGTGTGCCTGGTGGGTTTCATGCTGTACCGCATGAAGAAG 
AAGGACGAAGGCAGCTACTCCTTGGAGGAGCCGAAACAAGCCAACGGCGGGGCCTACCAGAAGCCCACCA 
AACAGGAGGAATTCTATGCCTGA 
Human syndecan-1 (protein sequence, ectodomain) 
>human syndecan-1 311 aa 
  1 mrraalwlwl calalslqpa lpqivatnlp pedqdgsgdd sdnfsgsgag alqditlsqq 
 61 tpstwkdtql ltaiptspep tgleataast stlpagegpk egeavvlpev epgltareqe 
121 atprprettq lptthqastt tattaqepat shphrdmqpg hhetstpagp sqadlhtpht 
181 edggpsater aaedgassql paaegsgeqd ftfetsgent avvavepdrr nqspvdqgat 
241 gasqglldrk evlggviagg lvglifavcl vgfmlyrmkk kdegsyslee pkqanggayq 
301 kptkqeefya 
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Murine syndecan-2 (cDNA, ectodomain) 
>murine SYNDECAN-2 609 bp 
ATGCAGCGCGCGTGGATCCTGCTCACCTTGGGCTTGATGGCCTGTGTGTCCGCAGAGACG 
AGAACAGAGCTGACATCCGATAAGGATATGTACCTTGACAATAGCTCCATTGAGGAAGCT 
TCAGGAGTATATCCTATTGATGATGATGACTATTCTTCTGCCTCAGGCTCAGGAGCTGAT 
GAAGACATAGAGAGTCCAGTTCTGACAACATCCCAACTGATTCCAAGAATCCCACTCACT 
AGTGCTGCTTCCCCCAAAGTGGAAACCATGACGTTGAAGACACAAAGCATTACACCTGCT 
CAGACTGAGTCACCTGAAGAAACTGACAAGGAGGAAGTTGACATTTCTGAGGCAGAAGAG 
AAGCTGGGCCCTGCTATAAAAAGCACAGATGTGTACACGGAGAAACATTCAGACAATCTG 
TTTAAACGGACAGAAGTTCTAGCAGCCGTCATTGCTGGTGGTGTGATCGGCTTTCTCTTT 
GCCATTTTCCTCATCCTGCTATTGGTGTACCGCATGCGGAAGAAAGATGAAGGAAGCTAC 
GACCTTGGAGAACGCAAACCATCCAGCGCAGCTTACCAGAAGGCACCCACTAAGGAGTTT 
TATGCATAA 
Murine syndecan-2 (protein sequence, ectodomain, adhesion regulatory domain) 
>murine syndecan-2 204 aa 
  1 mqrawilltl glmacvsaet rteltsdkdm yldnssieea sgvypidddd yssasgsgad  
 61 ediespvltt sqlipriplt saaspkvetm tlktqsitpa qtespeetdk eevdiseaee  
121 klgpaikstd vytekhsdnl fkrtevlaav iaggvigflf aiflilllvy rmrkkdegsy 
181 dlgerkpssa ayqkaptkef ya 
 
>S2ED 
etrteltsdkdmyldnssieeasgvypiddddyssasgsgadediespvlttsqliprip
ltsaaspkvetmtlktqsitpaqtespeetdkeevdiseaeeklgpaikstdvytekhsd
nlf 
 
>S2ED∆P124-F141 
etrteltsdkdmyldnssieeasgvypiddddyssasgsgadediespvlttsqliprip
ltsaaspkvetmtlktqsitpaqtespeetdkeevdiseaeeklg 
 
>S2ED∆L73-G123 
etrteltsdkdmyldnssieeasgvypiddddyssasgsgadediespvlttsqpaikst
dvytekhsdnlf 
 
 
Human syndecan-3 (cDNA, ectodomain) 
>human syndecan-3 cDNA 1329 bp 
ATGAAGCCCGGGCCGCCGCGCCGCGGGACCGCACAGGGGCAGCGCGTGGACACCGCCACC 
CATGCGCCCGGGGCCCGCGGGCTGTTGCTGCCACCGCTGCTGCTGCTGCTGCTGGCCGGC 
CGCGCCGCGGGGGCTCAACGCTGGCGCAATGAGAACTTCGAGAGGCCGGTGGATCTTGAG 
GGCTCAGGGGATGACGACTCGTTTCCTGATGATGAACTAGACGACCTCTACTCGGGGTCA 
GGCTCTGGCTACTTCGAGCAGGAGTCCGGCCTTGAGACGGCCATGCGGTTCATCCCTGAT 
ATGGCCCTGGCTGCGCCCACTGCACCTGCCATGCTACCCACAACCGTTATCCAGCCCGTG 
GACACCCCATTTGAGGAACTCCTTTCTGAGCACCCCAGCCCTGAACCAGTCACCAGTCCC 
CCGCTGGTGACAGAGGTGACAGAGGTCGTAGAAGAGTCCAGCCAGAAAGCTACCACCATC 
TCTACCACCACATCTACCACCGCGGCCACCACCACAGGGGCCCCAACTATGGCCACAGCA 
CCTGCCACAGCAGCCACCACTGCCCCTAGCACTCCCGAGGCGCCCCCTGCCACGGCTACC 
GTGGCTGACGTAAGGACCACCGGCATACAGGGGATGCTGCCTCTTCCCCTGACCACAGCT 
GCCACAGCCAAGATCACTACCCCAGCAGCACCCTCACCACCCACTACTGTGGCTACCTTG 
GACACAGAGGCCCCGACACCTAGGCTGGTCAACACAGCTACCTCGAGGCCACGAGCCCTT 
CCTCGGCCAGTCACCACCCAGGAGCCTGATGTTGCTGAGAGGAGTACCCTGCCGTTGGGG 
ACCACGGCTCCTGGACCCACGGAGATGGCTCAGACCCCAACTCCAGAGTCCCTTCTGACC 
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ACCATCCAGGATGAGCCAGAGGTGCCAGTAAGTGGGGGGCCCAGCGGGGACTTTGAGCTT 
CAAGAAGAGACCACGCAGCCGGACACGGCCAATGAGGTGGTGGCTGTGGAAGGAGCCGCG 
GCCAAGCCGTCACCTCCACTGGGGACACTGCCCAAGGGTGCCCGCCCAGGCCCTGGCCTC 
CACGACAATGCCATCGATTCGGGCAGCTCGGCCGCCCAGCTCCCTCAGAAGAGCATACTG 
GAGCGGAAGGAGGTGCTCGTAGCCGTGATCGTGGGTGGGGTGGTGGGCGCCCTCTTCGCT 
GCCTTCCTGGTCACGCTGCTCATCTACCGCATGAAGAAGAAGGACGAAGGCAGCTACACC 
TTGGAAGAACCCAAGCAGGCAAGCGTCACGTACCAGAAACCTGACAAGCAGGAGGAGTTC 
TACGCTTAG 
 
Human syndecan-3 (protein sequence, ectodomain) 
>human syndecan-3 442 aa 
  1 mkpgpphrag aahgagagag aaagpgargl llppllllll agraagaqrw rsenferpvd 
 61 legsgdddsf pddelddlys gsgsgyfeqe sgietamrfs pdvalavstt pavlpttniq 
121 pvgtpfeelp serptlepat splvvtevpe epsqrattvs ttmattaats tgdptvatvp 
181 atvatatpst paappftatt avirttgvrr llplplttva tarattpeap sppttaavld 
241 teaptprlvs tatsrpralp rpattqepdi perstlplgt tapgptevaq tptpetfltt 
301 irdepevpvs ggpsgdfelp eeettqpdta nevvavggaa akassppgtl pkgarpgpgl 
361 ldnaidsgss aaqlpqksil erkevlvavi vggvvgalfa aflvtlliyr mkkkdegsyt 
421 leepkqasvt yqkpdkqeef ya 
 
 
Murine syndecan-4 (cDNA, ectodomain) 
>murine syndecan-4 cDNA 597 bp 
ATGGCCCCCGCCCGTCTGTTCGCGCTGCTGCTGTTCTTCGTAGGCGGAGTCGCCGAGTCGATCCGAGAGA 
CTGAGGTCATCGACCCCCAGGACCTCCTAGAAGGCCGATACTTCTCCGGAGCCCTACCAGACGATGAGGA 
TGTAGTGGGGCCCGGGCAGGAATCTGATGACTTTGAGCTGTCTGGCTCTGGAGATCTGGATGACTTGGAA 
GACTCCATGATCGGCCCTGAAGTTGTCCATCCCTTGGTGCCTCTAGATAACCATATCCCTGAGAGGGCAG 
GGTCTGGGAGCCAAGTCCCCACCGAACCCAAGAAACTAGAGGAGAATGAGGTTATCCCCAAGAGAATCTC 
ACCCGTTGAAGAGAGTGAGGATGTGTCCAACAAGGTGTCAATGTCCAGCACTGTGCAGGGCAGCAACATC 
TTTGAGAGAACGGAGGTCCTGGCAGCTCTGATTGTGGGTGGCATCGTGGGCATCCTCTTTGCCGTCTTCC 
TGATCCTACTGCTCATGTACCGTATGAAGAAGAAGGATGAAGGCAGCTATGACCTGGGCAAGAAACCCAT 
CTACAAGAAAGCCCCCACCAATGAGTTCTACGCGTGA 
Murine syndecan-4 (protein sequence, ectodomain) 
>Murine syndecan-4 198 aa 
  1 maparlfall lffvggvaes iretevidpq dllegryfsg alpddedvvg pgqesddfel 
 61 sgsgdlddle dsmigpevvh plvpldnhip eragsgsqvp tepkkleene vipkrispve 
121 esedvsnkvs msstvqgsni fertevlaal ivggivgilf avflilllmy rmkkkdegsy 
181 dlgkkpiykk aptnefya 
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Fig. 3.1 pET-41 plasmid for bacterial expression of syndecan ectodomains. 
  
 
Plasmids were then transformed into the Escherichia coli BL21 strain (Promega), and the 
bacteria were grown to an A600 of 0.6 at 37 °C prior to the addition of 0.25 ml/liter 1 M 
isopropyl 1-thio-β-D-galactopyranoside (Calbiochem) followed by a further 3 hours 
incubation. Bacteria were resuspended in phosphate buffered saline (PBS), lysed in a 
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sonicator, and GST syndecan ectodomain fusion proteins were purified on columns of 
glutathione-Sepharose 4B (GE Healthcare) as described in the manufacturer’s protocol.  
Fusion proteins were then run in a SDS-Page to verify the correct expression and molecular 
size (Fig. 3.2).  
 
 
Fig. 3.2 Syndecan ectodomains N-terminally fused to GST were produced in E.coli. 
Diagram shows the structure of the proteins used in the experiments. All 4 syndecan extra-
cellular core proteins were expressed and purified from E.coli and possess a Glutathione S-
transferase (GST) fused to their N-terminus. SDS-PAGE was used to verify the correct 
molecular weight of the proteins. 
 
3.3.3. Lentiviral transduction 
This constructs were designed and transfected into HEK293T cells by Dr. James Whiteford. 
Gene synthesis of the complete murine syndecan-2 cDNA and the cDNA encoding only the 
syndecan-2 ectodomain coding sequence was performed by GeneArt (Invitrogen). Both full-
length and truncated syndecan-2 cDNAs were mutated such that the HA epitope was inserted 
between D27 and K28. BamHI sites were also incorporated at the N and C end of the two 
synthetic genes. The cDNAs were cloned into the BamHI site of the lentiviral vector 
pLNTSFFV-MCS-EGFP (provided by Dr. Tristan MacKay, St. George’s University of 
London). Lentiviruses were produced in HEK293T cells and packaged into a VSVG coat using 
conventional procedures. HEK293T cells were transfected using the supernatant transfer 
method. Cells expressing high levels of eGFP were sorted by flow cytometry and these were 
cultured in DMEM as described above. 
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>murine syndecan-2 221 aa 
1   mqrawilltl glmacvsae19t  rteltsd27ypy  dvpdyak28dmy ldnssieeas gvypiddddy  
61  ssasgsgade diespvl73tts  qlipriplts   aaspkvetmt   lktqsitpaq tespeetdke 
121 evdiseaeek lgp124aikstdv ytekhsdnlf141* krtevlaavi  aggvigflfa iflilllvyr 
181 mrkkdegsyd lgerkpssaa   yqkaptkefy    a* 
 
Full length msyndecan-2  
HA tag 
mS2ED 
18 aa peptide 
stop codon * 
signal peptide 
 
 
Fig. 3.3 pLNTSFFV-MCS-EGFP lentiviral vector for expression of Syndecan-2 
constructs in eukaryotic system. 
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3.3.4. Scratch wound assay 
ECs (primary or cell lines) were plated in a 6-well tissue culture plate. When cells reached 
complete confluence, a 200 μl pipette tip was used to scratch a thin line along one direction of 
the well. Medium was then removed, cells washed once with PBS and fresh medium 
containing treatments was added. The plate was then placed inside the incubator chamber of 
an Olympus IX81 inverted microscope connected to the computer. The software Cell^m was 
set to take one picture every 30’ for 9 hrs of 2 spots per condition. At the end of the experiment, 
pictures were saved and analysed using Adobe Photoshop CS5. The gap area between the two 
cell fronts at time 0, 3, 6 and 9 hrs was selected and measured in pixels. The percentage of 
wound closure was calculated with the following formula: 
% wound closure at time x =  
𝑔𝑎𝑝 𝑎𝑟𝑒𝑎 𝑡𝑖𝑚𝑒 0
𝑔𝑎𝑝 𝑎𝑟𝑒𝑎 𝑡𝑖𝑚𝑒 0−𝑔𝑎𝑝 𝑎𝑟𝑒𝑎 𝑡𝑖𝑚𝑒 𝑥
% 
Cell speed was quantified by manually measuring the track of individual cells migrated for 9 
hours (20 cells per condition) using Adobe Photoshop, track lengths were then divided by the 
time to obtain cell speed. 
 
3.3.5.  Tube formation assay 
The ability of ECs to associate into tubules was assessed using the V2A Kit (Cellworks), 
according to manufacturer instructions. In brief, human ECs were co-cultured with other 
human cells in a 24-well plate in a specially designed medium and kept at 37°C in 5% CO2. 
The Kit provides positive control treatment (VEGF 2 ug/ml) and negative (Suramin 1 mM), 
together with medium, cells, plate, anti-CD45 Ab, secondary Ab conjugated to alkaline 
phosphatase and its substrate. Medium was changed every second day and at day 14 ECs were 
stained for CD31 to assess the formation of tubes. Pictures were taken on an Olympus IX81 
inverted microscope (10x objectives), tube length and branching points were quantified using 
Photoshop (Adobe).  
 
3.3.6.  Invasion assay 
EC invasion assay through collagen matrix was performed in 24-well plates with trans-well 
inserts (Millipore; 8 μm pore size, polyester (PET) membrane). Membranes were coated with 
10 μl of Collagen Type I mixture (Millipore; 1 mg/ml in E4 medium) containing 0.5 μM GST 
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or syndecan ectodomains. sEND cells were seeded on the gel in a homogenous single cell 
suspension of 5x103 cells/ insert in 200 μl of DMEM + 10% FBS; 1 ml of the same medium 
was added to the bottom well. Invasion was measured at 6 hours after which time gels were 
removed with a cotton swab, the filter washed in PBS and stained with Calcein (Invitrogen) 
and the number of cells attached to the filter was counted. 
 
3.3.7.  Proliferation assay 
Cell proliferation was measured using the CellTiter 96 AQueous Cell proliferation assay kit 
as described by the manufacturer (Promega). This method is based on the ability of viable cells 
to reduce a tetrazolium compound (MTS) into a formazan product which is soluble in tissue 
culture medium and whose absorbance at 490 nm can be measured directly from a 96-well 
plate without additional processing. The amount of 490 nm absorbance is directly proportional 
to the number of living cells in culture. 5000 cells in 100 μl of complete medium were seeded 
in each well of a 96-well plate (Corning). At the desired time point 20 μl of MTS was added 
to each well and plate incubated for 1-4 hours at 37°C and 5% CO2. The absorbance at 490 
nm was then measured using an ELISA reader. 
 
3.3.8. VE-Cadherin internalization assay  
VE-cadherin internalization in vitro was performed as described previously (Xiao et al. 2003) 
with some modifications. Cells were plated on glass slides and experiments were started once 
cells reached complete confluence. Cells were then washed with PBS and anti-VE-Cadherin 
Ab (BV13 clone) was incubated with cells at 4°C for 1h in medium containing 20 mM HEPES 
and 3% BSA. Unbound Ab was then rinsed with ice-cold medium and cells were incubated 
with 30 ng/ml of VEGF-A in serum-free medium or serum-free medium alone at 37°C for 5’ 
to allow the internalization of VE-Cadherin. An acid wash was then used to remove the Ab 
bound to cell-surface VE-Cadherin, this wash contained 25 mM glycine, 3% BSA in PBS (pH 
2.7). Slides were then fixed in MeOH for 5’ at -20°C, washed in PBS containing Draq5 
(1:5000) and mounted with prolong fixative (Life Technologies). 
 
 
 
102 
 
 
3.3.9. Proximity ligation assay 
Proximity ligation assay or PLA is a technique that allows the identification in situ of spots in 
which 2 proteins are in close proximity (less than 40 µm). The protocol requires the use of 2 
primary Abs raised in different species which recognize the target antigen or antigens of 
interest. Species-specific secondary Abs, called PLA probes, each with a unique short DNA 
strand attached to it, bind to the primary Abs. When the PLA probes are in close proximity, 
the DNA strands can interact through a subsequent addition of two other circle-forming DNA 
oligonucleotides. After joining of the two added oligonucleotides by enzymatic ligation, they 
are amplified via rolling circle amplification using a polymerase. After the amplification 
reaction, several-hundred fold replication of the DNA circle has occurred, and labelled 
complementary oligonucleotide probes highlight the product. The resulting high concentration 
of fluorescence in each single-molecule amplification product is easily visible as a distinct 
bright spot when viewed with a fluorescence microscope.  
Cells tested in the proximity ligation assay were treated as indicated in the results section. 
Following treatments, medium was taken off, cells washed in PBS at RT, fixed in 4% PFA for 
15’ at RT. After a 5’ wash in PBS, PFA was quenched by incubating cells with 0.1M NH4CL 
for 10’ at RT. Cells were then permeabilised in 0.1% triton x100 in PBS for 10 mins at RT. 
The PLA experiments were performed as per manufacturer’s instructions (Duolink, Sigma 
Aldrich). 
 
3.3.10. Flow cytometry 
Cells were washed twice with PBS, 3 ml of PBS-based dissociation buffer was added to a T75 
tissue culture flask and incubated at 37°C for 3-5’ until cells are detached. The cell-containing 
solution was then moved to a 50 ml tube and centrifuged at 1000 rpm for 3’ at RT. Pellets 
were then resuspended in 3-5 ml of ice-cold FACS buffer (PBS with 1% NGS [normal goat 
serum]). Cells were then counted with a Haemocytometer and plated at a concentration of 
5x104 cells/well in a 96-well round bottom plate. Plates were then left on ice for 10’, after 
which it was centrifuged at 1000 rpm for 3’ at RT. Supernatant was discarded and cells 
resuspended in 200 μl of FACS buffer containing the appropriate dilutions of the primary Ab. 
Plates were then left on ice for 20’ and then centrifuged at 1000 rpm for 3’ at RT. The 
supernatant was discarded and cells resuspended in 200 μl of FACS buffer containing the 
appropriate dilutions of the secondary Ab. Plates were then left on ice for 20’ and then 
centrifuged at 1000 rpm for 3’ at RT. Cells were then washed to remove unbound Ab by three 
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washes with FACS buffer (discard supernatant, resuspend in 200 μl of FACS buffer, centrifuge 
at 1000 rpm for 3’ at RT) after which, samples were transferred to FACS tubes, 10 μl of 7-
ADD was added to the side of the tubes and samples were read using a BD FACS Calibur and 
CellQuest Pro software (BD). 
 
3.3.11. β1 activation assay 
Confluent bEND3.1 cells were trypsinised and the trypsin inactivated with 5% BSA. Cells 
were re-suspended in Hank’s buffer (without Ca2+ and Mg2+) containing the treatments 
described (0.5 mM GST or S2ED) and incubated for 30’ at 37°C. Cells were then fixed in 2% 
PFA prior to FACS analysis for both total and active β1 integrin and the percentage of cells 
expressing active β1 calculated. First cells were gated using side (SSC-H) and forward (FSC-
H) scatter to exclude cell aggregates and debris, subsequently another gate was used to select 
the live cells based on the 7AAD staining (FL3-H). Cells were then analysed for their 
expression of β1 integrin (FL2-H) and active β1 integrin (FL1-H). Gates were made based on 
the isotype controls and this resulted into the distribution of cells in 4 quadrants: Q1 with cells 
negative for β1 positive for active β1 integrin, Q2 with cells double positive, Q3 with cells 
positive for β1 but negative for active β1 and Q4 with cells double negative. 
 
Fig. 3.4 Flow cytometry gating strategy for active β1 integrin analysis on bEND3.1 cells. 
 
For immunofluorescence staining of active β1 integrin, confluent monolayers of sEND cells 
were grown on microscope slides and scratch wounds were made and either 0.5 µM GST or 
S2ED was added. After 30’, cells were fixed with 4% PFA (Sigma) and permeabilized in 0.1% 
Triton X-100 (Sigma) in PBS. Samples were incubated with active β1-integrin-specific Ab 
9EG7 in 1% normal goat serum in PBS overnight at 4°C. Slides were washed in PBS and 
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incubated in anti-rabbit-IgG Ab conjugated to Alexa Fluor 488 (Molecular Probes) and DAPI, 
and images were captured on an Olympus IX81 inverted microscope. Fluorescent intensity 
profiles from the resulting images were calculated using ImageJ. For higher resolution images, 
cells were imaged using a PASCAL laser-scanning confocal microscope (Carl Zeiss) with a 
63X objective and the resulting stacks were processed using IMARIS software.  
HUVECs were seeded on coverslips coated with fibronectin (10 mg/ml) and collagen I (30 
mg/m) in 0.1% gelatin. Once 60% confluent, cells were washed with serum-free OptiMEM 
then treated either with or without 1 mM MnCl2 in the presence of either 0.5 mM GST or 
S2ED for 30’. Cells were then fixed in 2% PFA and stained using a monoclonal active b1-
integrin specific Ab (clone HUTS4, at 1:300). After washing, cells were stained with an anti-
mouse-IgG Ab conjugated to Alexa Fluor 594 (Molecular Probes). Cells were analysed by 
confocal microscopy as described above. 
  
105 
 
 
3.4. In vivo methods 
3.4.1. Animals 
Animals were housed and treated in Accordance with UK Home Office Regulations and all 
experiments were approved by the UK Home Office according to the Animals Scientific 
Procedures Act 1986 (ASPA).  
C57BL/6 wild-type mice were purchased from Charles River. 
SCID SHO mice were also purchased from Charles River. This animals were produced by 
inter-crossing the Crl:HA-Prkdcscid and Crl:SKH1-Hrhr stocks. They are homozygous for the 
Prkdcscid and the Hrhr mutations and thus exhibit the severe combined immunodeficiency 
phenotype characteristic of SCID mice and are also hairless. 
Syndecan-4 -/- (S4KO) mice were obtained from the Centre for Animal Resources and 
Development (CARD, Kunamoto University, Japan) with the kind permission of Professor 
Tetsuhito Kojima (Nagoya University, Japan). 
All mice were used at an age between 5-8 weeks at an average weight of 25g. As appropriate, 
age-matched control mice were litter mates or commercially purchased C57BL/6 wild-type 
mice.  
Wistar rats were purchased from Harlan Laboratories and used at 6-8 weeks of age (≈200 g). 
 
3.4.2. Cremaster muscle dissection 
The cremaster muscle is a thin layer of striated muscle that surrounds the testicle. To isolate 
this tissue, a midline incision was made in the scrotum making sure not to damage the 
underlying tissues and testis. The testicles were gently drawn out by separating the underlying 
connective tissue from the cremaster muscle. The distal end of the cremaster muscle was 
pinned to the viewing column of the microscope stage to keep the cremaster muscle 
exteriorised. An incision was made along the centre of the muscle, ensuring that the main 
artery and venule going into and out of the tissue was kept intact. The cremaster muscle was 
then opened and pinned flat over the viewing window. The connective tissue attaching the 
testis to the cremaster muscle was then cut to enable the testes to be laid toward the side so 
that the entire cremaster muscle microvasculature could be clearly observed.  
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3.4.3. Primary murine lung EC isolation 
This protocol was optimized to obtain a confluent T75 tissue culture flask of primary lung ECs 
(MLEC) from three mice in around 2-3 week time. 
Day 1 – Lung dissection and digestion - 6-8 week old mice were sacrificed by cervical 
dislocation. Fur was sprayed with 70% EtOH and a longitudinal incision was made along the 
chest area using a scalpel. Skin was peeled back and pinned down to reveal the rib cage. Fresh 
forceps and scissors were used to open the chest cavity and dissect out the lungs. Lungs were 
immediately put into a 50 ml tube containing Hams F12 medium and kept on ice for no longer 
than 6 hrs. At this point, procedures were carried out under a fume hood to decrease bacterial 
contamination. Lungs were removed from the tube using sterile forceps, sprayed with 70% 
EtOH and immediately put in MLEC medium.  Subsequently, lungs were placed on the 
inverted lid of a petri dish and minced using a sterile scalpel for no longer than 5’ to produce 
a homogenized. Minced lungs were transferred into a sterile 50 ml tube containing 10 ml of 
0.1% Type I Collagenase and placed in an incubator at 37 °C for 1 h, swirling tube 
occasionally. Later, 10 ml of MLEC medium were added to the solution which was then 
poured in a petri dish. A 20 ml syringe was used to draw up the digested lungs, a 19.5 gauge 
needle was then placed on the syringe and the solution was forced through the needle 4 times. 
The solution was then passed through a 70 µm cell strainer into a 50 ml tube containing 20 ml 
of MLEC medium and centrifuges for 5’ at 1200 rpm. Supernatant was then removed, cells-
containing pellet resuspended in 10 ml of fresh MLEC medium and the solution transferred 
into a 75 cm2 pre-coated with 0.1% Gelatin, 300 µg/ml of Vitrogen (Nutacon) and human 
plasma Fibronectin (Millipore) and incubated at 37 °C, 10% CO2 for 24 hrs.  
Day 2 – Negative sort against macrophages - Medium was removed from the flask and 
replaced with 5 ml of fresh MLEC medium. The flask was then incubated at 4°C for 20’. 
Medium was then replaced with 5 ml of PBS containing 5 µl of rat anti-mouse CD16/CD32 
Ab (BD 553142) and the flask was incubated at 4°C for 30’. The Ab solution was then 
removed, the flask was washed once with PBS and re-incubated at 4°C for 30’ with 5 ml of 
MLEC containing 25 µl of sheep anti-rat Dynabeads (Dynal DB M450). The bead-containing 
solution was then removed and flask washed three times with PBS. Cells were then detached 
from the flask by adding 2.5 ml of 0.25% Trypsin/EDTA and incubating at 37°C for 
approximately 5’. 9.5 ml of MLEC medium was then added and cells resuspended. The 
solution was then moved into a 15 ml tube inserted into a magnetic holder and left there for 5’ 
to allow the beads to attach to the side of the tube. The solution was then carefully moved from 
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the tube into a new pre-coated tissue culture flask, avoiding touching the tube. Medium was 
changed every 2 days until colonies of approximately 20 cells are apparent. 
Positive sort for ECs - Once colonies of approximately 20 cells appeared, medium was 
removed from the flask and replaced with 5 ml of fresh MLEC medium. The flask was then 
incubated at 4°C for 20’. Medium was then replace with 5 ml of PBS containing 5 µl of rat 
anti-mouse CD102 Ab (BD 553325) and the flask was incubated at 4°C for 30’. The Ab 
solution was then removed, the flask was washed once with PBS and re-incubated at 4°C for 
30’ with 5 ml of MLEC containing 15 µl of sheep anti-rat Dynabeads. The bead-containing 
solution was then removed and the flask washed three times with PBS. Cells were then 
detached from the flask by adding 2.5 ml of 0.25% Trypsin/EDTA and incubating at 37°C for 
approximately 5’. 9.5 ml of MLEC medium was then added and cells resuspended. The 
solution was then moved into a 15 ml tube inserted into a magnetic holder and left for 5’ to 
allow the beads to attach to the side of the tube. The solution was then carefully moved from 
the tube and discarded, ECs, attached to the beads, were then resuspended in 10 ml of fresh 
MLEC medium and plated on pre-coated tissue culture flask. Medium was changed every 2 
days. 
 
3.4.4. Aortic ring assay  
Angiogenic sprouts were induced from mouse or rat thoracic aortas according to the method 
of Nicosia and Ottinetti (Nicosia and Ottinetti, 1990a, b). 6-8 week old male mice or 180–200 
g male Wistar rats (Harlan Laboratories) were sacrificed by cervical dislocation. Fur was 
sprayed with 70% EtOH and a longitudinal incision was made along the chest area using a 
scalpel. Skin was peeled back and pinned down with scissors and forceps to reveal the rib 
cage. Aortas were then dissected using forceps and micro-scissors and put in a 50 ml pot with 
ice-cold PBS on ice. After a first wash in PBS to wash off the blood, the aorta was transferred 
into a petri-dish containing fresh PBS, here fat was carefully removed using forceps avoiding 
stretching the aorta, the long branches protruding from the aorta were also cut off using a 
scalpel. The aorta was then moved to a new petri-dish containing ice-cold serum-free Opti-
MEM (containing P/S) and cut into rings of 1-mm of diameter using a scalpel. Under a tissue 
culture hood, rings were moved into a fresh petri-dish and incubated overnight in serum-free 
Opti-MEM (containing P/S) at 37°C. On the next day, a coating gel was made by mixing type 
I collagen (1 mg/ml), 10% v/v E4 media (Invitrogen) in water. 150 μl of the gel was pipetted 
in each well of a 48-well plate (Corning). Rings were then quickly dried on the lid of the petri-
dish and carefully positioned in the middle of the well containing collagen. The plate was then 
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incubated at 37°C for 30’ to allow the Collagen to polymerize, after which time wells were 
supplemented with Opti-MEM with 1% FBS and VEGF (30 ng/ml for mouse rings, 10 ng/ml 
for rat rings) and incubated at 37°C, 10% CO2. Medium was changed every third day. 
Angiogenic sprouts from aortas were counted after 1 week and results were expressed as the 
number of sprouts per ring. 
 
3.4.5. Choroid explant neo-vascularisation assay 
Mice, 19 to 21 days old, were euthanized by cervical dislocation and eyes collected with 
curved forceps and transferred to PBS to wash away residual blood. Subsequently, eyes were 
fixed for 5’ in 4% PFA on ice and transferred again in new PBS were they can be stored for 
up to 1 month in the fridge. For choroid/RPE tissue isolation, the eye is punctured with a 19 
G needle below the iris so to facilitate the entrance of the forceps. A 1 mm incision is then 
made below the iris so that the periphery will be around 1 mm thick and using scissors cut 
around at that level. Iris/cornea/lens/retina are removed. Separate limbus from peripheral 1 
mm strip. Flatten the tissue along so that it’s easier to cut little 1 mm pieces. Cut choroid/sclera 
into approximately 1 mm×1 mm (~ 4 for central (quarters); 6 for peripheral). Around 6-8 
squares result from one eye, these can be transferred into sterile Optimem (with P/S) overnight. 
Then proceed as per Aortic ring assay. 
 
3.4.6. Miles assay for permeability  
Vascular permeability was assessed by measuring the accumulation of Albumin-bound Evans 
Blue dye in the dorsal skin of mice stimulated with locally injected permeability factors or 
PBS alone. 6-8 week mice were anesthetized by i.m. injection of 1 ml/kg ketamine (40 mg) 
and xylazine (2 mg) in saline solution. The back skin was shaved using an electric razor. Mice 
then received Evans Blue dye (0.5% in PBS, 5 μl per g bodyweight) i.v. through the tail vein. 
Afterwards, 50 ul of PBS containing either 100 ng of VEGF-A or 100 μg of Bradykinin or 
PBS alone were injected s.c. in the mouse dorsal skin. After 1h30’ animals were sacrificed by 
cervical dislocation. Dorsal skin was removed and injected sites were cut out as circular 
patches using a metal puncher (~8 mm in diameter). Samples were then incubated in 250 μl of 
formamide at 56°C for 24 h to extract Evans Blue dye from the tissues. The amount of 
accumulated Evans Blue dye was quantified by spectroscopy at 620 nm using a Spectra MR 
spectrometer (Dynex technologies Ltd., West Sussex, UK). Results are presented as the optical 
density at 620 nm (OD620) per mg tissue and per mouse. 
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3.4.7. Matrigel plug assay 
The matrigel plug assay is considered one of the gold-standard methods to test angiogenesis 
in vivo. On day 1, 400 μl of matrigel (BD Biosciences) was thawed on ice and mixed with 100 
μl PBS containing growth factors (100 ng/ml VEGF-A, 100 ng/ml bFGF) and 20 U/ml of 
Heparin to obtain a solution with a concentration of matrigel of ≈7.5 mg/ml.  
6-8 weeks old mice were anesthetized by i.m. injection of 1 ml/kg of body weight of ketamine 
(40 mg) and xylazine (2 mg) in saline solution. 500 μl of the matrigel solution was aspired 
using a 1 ml syringe without the needle, a 27 gauge needle was then added to the syringe and 
the solution was injected sub-cutaneously into the flank of the animal, roughly between the rib 
cage and the posterior leg. After 5 days, mice were sacrificed by cervical dislocation. A 
longitudinal incision was made from the chest to the genital area, skin was peeled and pinned 
down and plugs were revealed. Photographs were taken with a digital camera and plugs 
excised using scalpel and tweezers. Plugs were then weighed on a precision balance and 
incubated overnight at 4°C with 500 μl of dH2O. On the next day the amount of haemoglobin 
released from the plugs was measured using the Drabkin reagent kit (Sigma). 100 μl of samples 
was mixed with 100 μl of Drabkin solution and allowed to stand for 15’ at RT. A calibration 
curve using known concentrations of Haemoglobin was also used. Absorbance at 540 nm was 
read using a spectrophotometer and results were expressed as the concentration of 
haemoglobin per gram of plug (HG mg/ml/g). 
 
3.4.8. Xenograft HEK293T tumor-like model in SCID mice 
HEK293T cells stably expressing either the empty vector or S2ED were grown in complete 
medium (DMEM+10%FBS) until 70-80% confluent. 3-4 hrs before harvesting, medium was 
replaced with fresh one to remove dead and detached cells. Subsequently medium was 
removed and cells washed with PBS and detached from the plate with a minimum amount of 
trypsin-EDTA (enough to cover the cell whole plate). A single cell suspension was then made 
by adding fresh complete medium to the trypsin-EDTA solution (10:1). Cell suspension was 
then centrifuged at 1000 rpm for 3’, washed twice with PBS and stored on ice. Dilution was 
made appropriately to obtain a concentration of 3 x 107 cells/ml. 
6 week old SCID SHO mice (Charles River) were anesthetized by i.m. injection of 1 ml/kg of 
body weight of ketamine (40 mg) and xylazine (2 mg) in saline solution. Injection area (left 
flank, ribcage area) was cleaned and sterilized with ethanol and 100 μl of cell suspension was 
injected s.c. using a 27g needle and a 1 ml syringe. Mice were left for 21 days prior to sacrifice 
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by cervical dislocation. A longitudinal incision was made from the chest to the genital area, 
skin was peeled and pinned down and plugs were revealed. Photographs were taken with a 
digital camera and tumors excised using scalpel and tweezers. Samples were then weighed on 
a precision balance and diameter measured using a ruler. Samples were then snap frozen in 
liquid nitrogen and stored at -80°C. 
 
3.4.9. B16F1 tumor model in Wild-type and syndecan-4 KO mouse 
B16F1 mouse melanoma cells were grown in complete medium (DMEM+10%FBS) until 70-
80% confluent. 3-4 hrs before harvesting, medium was replaced with fresh to remove dead 
and detached cells. Subsequently medium was removed and cells washed with PBS and 
detached from the plate with a minimum amount of trypsin-EDTA (enough to cover the cell 
whole plate). A single cell suspension was then made by adding fresh complete medium to the 
trypsin-EDTA solution (10:1). Cell suspensions were then centrifuged at 1000 rpm for 3’, 
washed twice with PBS and stored on ice. Dilutions were made appropriately to obtain a 
concentration of 5 x 107 cells/ml. 
6 week old wild-type and syndecan-4 KO mice were anesthetized by i.m. injection of 1 ml/kg 
of body weight of ketamine (40 mg) and xylazine (2 mg) in saline solution. Injection area (left 
flank, ribcage area) was cleaned and sterilized with ethanol and 100 μl of cell suspension was 
injected s.c. using a 27g needle and a 1 ml syringe.  Mice were left for 7 days prior to sacrifice 
by cervical dislocation. A longitudinal incision was made from the chest to the genital area, 
skin was peeled and pinned down and plugs were revealed. Photographs were taken with a 
digital camera and tumors excised using scalpel and tweezers. Samples were then weighed on 
a precision balance and diameter measured using a ruler. Samples were then snap frozen in 
liquid nitrogen and stored at -80°C.  
 
3.4.10. Immunohistochemical staining 
3.4.10.1. Whole mount cremaster muscle and ear staining 
Cremaster muscles were dissected from the mouse and pinned out on a piece of wax. In some 
experiments the vasculature of the ear was also used. Tissues (cremaster and ear) were fixed 
in 4% PFA for 30 mins at 4°C. Immunofluorescent staining of whole mounted tissues was 
then performed. Tissues were permeabilized after fixation with blocking buffer (0.5 % Triton 
X-100 and 10 % foetal calf serum and 10 % goat serum in PBS) for 2 hours, at room 
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temperature on a gentle rotator. Tissues were then incubated with appropriate primary mAb 
overnight in cold room. Tissues were washed 3 times with PBST (PBS+0.1% Tween20) on a 
shaker and re-blocked in PBS containing 20% serum with appropriate secondary Ab for 2 
hour. Tissues were washed 3 times with PBST before a final wash in PBS, the tissues were 
then positioned on glass slides and viewed under the PASCAL laser-scanning confocal 
microscope (Carl Zeiss) with a 63X or 10X objective and the resulting stacks were processed 
using IMARIS software (Bitplane, Zurich, Switzerland). 
 
3.4.10.2. Quantification of vascular morphology parameters 
Vessel density was measured by drawing 2 orthogonal lines in the middle of each images and 
counting the number of vessels crossing the lines and dividing that value by the length of the 
line. The average of the horizontal and vertical density was calculated and average with that 
of at least 5 images per group. 
Percentage of capillaries (diameter <10 µm), arterioles and venules (diameter between 10-40 
µm) and arteries and veins (diameter >40 µm) was measured using Imaris (Bitplane, Zurich, 
Switzerland) 3D analysis software. Vessels were divided into 3 groups accordingly and their 
respective percentages were calculated. 
Pericyte coverage index was quantified as the percentage of vessel area covered by αSMA in 
both venules (10<40 µm) and veins (>40 µm) using ImageJ (National Institute of Health, 
Bethesda, Maryland, USA). 
  
3.4.10.3. Whole mount aortic ring and choroid explant staining 
Medium was removed from the wells; explants were washed 3 times in PBS and fixed in 100% 
Methanol for 30 mins at -20°C. Washed in PBS and blocked in PBS and 3% BSA for 1 hour. 
Tissues were then incubated with appropriate primary mAb overnight in a cold room at 4°C. 
Tissues were washed 3 times with PBST (PBS + 0.1% Tween20) on a shaker and re-blocked 
in PBS containing 3% BSA with appropriate secondary Ab for 2 hour. Tissues were washed 3 
times with PBST before a final wash in PBS, the tissues were then positioned on glass slides 
and viewed under a confocal microscope. Analysis of the staining was carried out using Imaris 
(Bitplane, Zurich, Switzerland) 3D analysis software. 
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3.4.10.4. HEK293T tumors, B16F1 tumors, Matrigel plugs sectioning and staining 
The specimen (tumor or Matrigel plug) is placed on a metal tissue disc which is then secured 
in a chuck and frozen rapidly to about –20 to –30 °C. The specimen is embedded in a gel like 
medium called OCT and consisting of poly ethylene glycol and polyvinyl alcohol; this 
compound when frozen has the same density as frozen tissue. At this temperature, most tissues 
become rock-hard. Subsequently, sample is cut frozen with the microtome portion of the 
cryostat, the section is picked up on a poly-lysine glass slide. Section thickness was 60, 50 and 
20 µm for HEK293T tumors, Matrigel plugs and B16F1 tumors, respectively. Slides were then 
fixed in 100% Methanol for 20’ at -20°C, blocked and permeabilized in 20% normal goat 
serum and 0.5% Triton in PBS for 1h in a humid chamber. Incubated with primary Ab solution 
over-night at -4°C, washed in PBS 3 times for 10’, incubated with secondary Ab solution for 
1h, washed in PBS 3 times for 10’, let to dry and finally mounted with ProLong Gold Anti-
fade fixative (Life technologies). 
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4. Results 
4.1. Syndecan extracellular core proteins have anti-angiogenic 
properties 
4.1.1.  Introduction 
During the angiogenic process, ECs collectively move and change their reciprocal positions 
as a response to both soluble stimuli (growth factors and cytokines) and the extracellular 
microenvironment. Cell motility is in fact a highly coordinated process that strongly relies on 
cell adhesion to the ECM components (Lamalice et al., 2007). Integrins belong to a large group 
of structurally related receptors for ECM components and immunoglobulin superfamily 
molecules. They are divalent cation-dependent heterodimeric membrane glycoproteins 
comprised of non-covalently associated α and β subunits, each subunit has an extracellular 
domain, a single transmembrane domain and a short cytoplasmic region. 18 α and 8 β subunits 
can combine into 24 heterodimers with distinct yet often overlapping substrate affinity (Hynes, 
2002). Central to integrin function in cell adhesion is their clustering on the cell surface which 
depends on (i) close proximity or periodicity of integrin-binding motifs within ECM 
components, (ii) lateral association of integrins and (iii) interactions of integrins cytoplasmic 
domains with adaptor molecules (Ziegler et al., 2008). In turn, the type of adaptors and enzyme 
recruited at the intracellular side of the clustered integrins will determine the signalling events 
and thereby cell-fate decisions (Burridge et al., 1992; Legate et al., 2006; Mitra and Schlaepfer, 
2006). In ECs α4β1, α5β1, αVβ3 and αVβ5 are most commonly expressed (DeHahn et al., 
2004; van der Flier et al., 2010). Since cell adhesion through integrins mediates migratory, 
adhesive and survival responses in ECs, it is unsurprising that integrins have key roles in 
angiogenesis. Several experimental approaches, for example, indicate that αVβ3 (a fibronectin 
and vitronectin receptor) and αVβ5 (a vitronectin receptor) have key roles in EC survival and 
migration during new blood vessel formation (Brooks et al., 1994); indeed, antagonists for 
these two integrins inhibit angiogenesis in cancer (Scaringi et al., 2012) and ischemic 
retinopathy (Hammes et al., 1996). However, whilst gene ablation of the αV subunit allows 
developmental vasculogenesis to proceed normally until E9.5 (Bader et al., 1998) after which 
it causes 100% lethality, mice lacking β3 and/or β5 reach adulthood but have enhanced tumor 
growth and angiogenesis, which would suggest that β3 and β5 play a negative role in 
pathological angiogenesis but not during development (Reynolds et al., 2002). Moreover, 
genetic experiments showed that successful vasculogenesis and angiogenesis depend on 
Fibronectin (George et al., 1993) and its main receptor α5β1(Francis et al., 2002) and 
interestingly this integrin is found overexpressed in blood vessels of human and mouse tumors 
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(Kim et al., 2000b). The importance of integrins in angiogenesis has made them an attractive 
target for anti-angiogenic therapy; drugs such as Voloxicimab (Ng et al., 2010) (targeting α5β1 
integrin), Cilengitide (Reardon et al., 2008) (targeting RGD integrins) and Intetimumab 
(O'Day et al., 2012) (αV antagonist) are already in clinical trials. 
 
Fig. 4.1 Syndecan ectodomains possess adhesion-regulatory sites. Diagram shows the 4 
syndecan ectodomains, the sites of glycosaminoglycan substitutions (GAG) and their 
respective adhesion-regulatory sites (blue) and invasion-regulatory site (green). To note, no 
adhesion-regulatory site has been described for syndecan-3. 
 
As reviewed in 1.1.7 evidence suggests that syndecan extra-cellular core proteins can regulate 
cell adhesion in an integrin-dependent fashion (Fig. 4.1). The works of Beauvais (Beauvais et 
al., 2004) and Mcquade (McQuade et al., 2006) showed how the direct interaction between 
syndecan-1 ectodomain and αVβ3 and αVβ5 integrin leads to spreading of human breast tumor 
cells (MDA-MB-231) and fibroblasts, respectively. Similarly, the ectodomain of syndecan-2 
and -4 possess an adhesion regulatory sequence which when expressed as glutathione S-
transferase (GST) fusion protein can promote attachment and spreading of mesenchymal cells. 
This is, again, dependent on integrins, specifically the β1 subfamily, but unlike in the case of 
S1ED, there is no direct interaction between S2ED or S4ED and β1integrins. Interestingly, 
this adhesive effect is cell specific as it is restricted to cells of mesenchymal origin. Moreover, 
S2ED and S4ED pathways are in some way distinct because addition of the alternate ED as a 
competitor in adhesion assays showed no effect suggesting the presence of different 
intermediates (Whiteford et al., 2007). Also in accordance with this hypothesis is the finding 
that S4ED requires the NXIP motif contained in its C-terminus for its adhesive effect which 
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is not present in the syndecan-2 extracellular core protein (Whiteford and Couchman, 2006). 
An intermediate for the S4ED and β1 integrin interaction has yet to be found, while in the case 
of S2ED the tyrosine phosphatase receptor CD148 appears to have a role in mediating β1 
integrin-driven cell responses to S2ED. This work also revealed that the amino acids residing 
between P124 and F141 of murine syndecan-2 are important for fibroblast responses to S2ED 
(Whiteford et al., 2011). 
 
4.1.2. Aims 
On the basis of the work described above, it is clear that regulatory sequences contained within 
syndecan ectodomains can influence cell behaviour through integrins. However, relatively 
little is known about how these sequences affect ECs and EC-dependent processes such as 
angiogenesis. 
The aims of the experiments which will be described in this first section of the thesis are as 
follows: 
1. Establish whether the ectodomains of syndecan-1, -2, -3 and -4 affect angiogenesis. 
2. Determine their associated mechanisms of action on ECs. 
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4.1.3. Results 
4.1.3.1. Syndecan ectodomains dose-dependently inhibit angiogenesis in the aortic ring 
model 
To establish whether syndecan ectodomains were able to influence EC processes, we used 
GST fusion proteins consisting of GST N-terminally fused to the extracellular core proteins of 
syndecan-1, -2, -3 and -4 in angiogenesis assays. The fusion proteins were expressed and 
purified from bacterial lysates. Despite many efforts to purify syndecan ectodomains in 
isolation, this has proved impossible due to solubility issues, for this reason we adopted the 
GST fusion approach. 
The aortic ring assay is an ex vivo model of angiogenesis which is widely used in the field; 
here, rat aortas are dissected from the animal and cut into small rings (ca. 1 mm width) which 
are then embedded in a thin layer of Collagen I and fed every 3 days with medium containing 
serum and VEGF-A as a pro-angiogenic factor. In a week’s time angiogenic sprouts develop 
from the rings and the number of those is considered directly proportional to the extent of the 
angiogenic response (Fig. 4.2). 
 
Fig. 4.2 Rat aortic ring assay. Rat thoracic aortas were  cut into rings which were embedded 
in 150 µl of Collagen type I (1 mg/ml) and 200 µl of OPTIMEM containing 10ng/ml of VEGF-
A. The number of sprouts was measured 7 days after embedding. Micrographs taken under a 
phase contrast microscope show an example of aortic ring at different magnifications, notably 
the tip cell extending 3 filopodia.  
 
To address the project’s objectives, a range of concentrations (0-0.5 µM) of murine syndecan 
ectodomains fused to GST or GST alone were embedded in collagen and sprout growth was 
measured after 7 days. It should be noted that GST unconjugated was bacterially-expressed 
and purified following the same protocols of the fusion proteins and was used as a control for 
endotoxin-dependent side effects in every experiment. 
117 
 
 
 
Fig. 4.3 Dose-dependent effect of syndecan ectodomains on angiogenic sprouting. Rat 
thoracic aortas were  cut into rings which were embedded in 150 µl of Collagen type I (1 
mg/ml) containing the syndecan core proteins (S1ED, S2ED, S3ED and S4ED)  or GST 
control at the concentration indicated in 200 µl of OPTIMEM containing 10ng/ml of VEGF-
A. The number of sprouts was measured 7 days after embedding. Each dot represents the 
number of sprouts of one ring, the short lines represent the mean number of sprouts at the 
concentration indicated and the long lines show the linear trend of the treatment dose-
dependent effect. Significant differences between untreated control (0 µM) group and groups 
treated with the highest dose of each substrate (0.5 µM) were determined using one-way 
Anova with Bonferroni correction for multiple comparisons. *P<0.05, ***P<0.001. 
 
An almost complete ablation of angiogenic sprout development was observed with 0.5 µM of 
all four syndecan ectodomains. Furthermore, lowering the dose of the proteins resulted in a 
progressive restoration of the angiogenic response, unlike the GST control for which a 
consistent strong angiogenic response was detected at all concentrations (Fig. 4.3). 
These results suggested a dose-dependent anti-angiogenic effect of all four syndecan 
ectodomains with the concentration of 0.5 µM of protein as the one with the maximum 
efficacy. Syndecan ectodomains were therefore used at the concentration of 0.5 µM in the 
following experiments. 
 
4.1.3.2. Syndecan ectodomains inhibit EC network formation  
The aortic ring model previously used to establish the effect of syndecan ectodomains on 
angiogenesis is an ex vivo model and importantly it is characterized by the participation of 
several cell types: ECs, smooth muscle cells, pericytes and often fat cells and blood cells which 
escape the dissection steps. A change in the number of sprouts could therefore be the result of 
an effect on one or more of these cell types, not necessarily ECs. To investigate whether the 
anti-angiogenic properties of syndecan ectodomains observed in the aortic ring model were 
the result of a direct effect on ECs, we tested these proteins in a tubule formation assay. Skin 
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ECs were seeded on a thin layer of Matrigel and left in complete medium containing syndecan 
ectodomains or GST for 24 hrs to allow them to organize into a spontaneous network of 
tubules. 
 
       
 
       
Fig. 4.4 Effect of syndecan ectodomains on EC tubule formation. 10000 Skin ECs (sEND) 
were seeded in a 24-well plate coated with 150 μl of Matrigel in complete medium containing 
the syndecan core proteins or GST at a concentration of 0.5 μM. After 24 hours Calcein was 
added to the medium to visualize cell (green) tubule network. Analysis was carried out on 
Photoshop (Adobe). Photographs were taken using a fluorescence microscope. Pictures are 
representative of 3 experiments were 4 pictures were analysed for each condition. Scale bar 
represents 500 µm. 
 
While the untreated and the GST control samples were capable of developing a tubule network 
during the time frame used, ECs grown in the presence of syndecan ectodomains failed to do 
so. This effect is clear both from the pictures showing much less articulated tubules in the 
treated groups but also from the derived quantification which highlights how tubules are 
shorter when ECs were in the presence of syndecan ectodomains (Fig. 4.4 and Fig. 4.5).   
This result suggested that syndecan ectodomains anti-angiogenic properties could be partially 
due to a direct effect on ECs, in particular to a negative regulation of their ability to migrate 
and organize into tubules. 
UT GST S1ED 
S2ED S3ED S4ED 
119 
 
 
 
Fig. 4.5 Effect of syndecan ectodomains on EC tubule formation. Pictures from the 
previous experiments, where sENDs were allowed to form tubules in the presence of 0.5 µM 
of GST or syndecan ectodomains, analysed on Photoshop (Adobe) where tubule length was 
measured. Bars show the mean and standard deviation of 3 experiments where 4 pictures per 
condition were analysed. Significant differences between untreated control (UT) and treated 
groups were determined using one-way Anova with Bonferroni correction for multiple 
comparisons. *P<0.05, **P<0.01. 
 
4.1.3.3. Syndecan ectodomains inhibit EC migration 
To develop a tubule network similar to that seen in the previous set of experiments, ECs need 
to both proliferate and migrate. Having established that syndecan ectodomains affect EC 
tubule formation, possible effects on EC migration and proliferation were investigated. A 
scratch wound assay is an easy way to measure cell migration in vitro. Here, ECs plated in a 
6-well plate are left to grow until confluence is reached. A scratch is then made in the centre 
of the well and cells are left to migrate for 9 hours. As previously, syndecan ectodomains or 
GST were added to the medium at the concentration of 0.5 µM right after the scratch was 
made. 
After 9 hours ECs left untreated or treated with GST completely “repaired” the scratch wound 
by migrating into the empty space, while cells treated with syndecan ectodomains failed to do 
so as evident by comparing the micrographs taken at time 0 and 9 hours (Fig. 4.6). 
Quantification of the percentage of wound area at 0, 3, 6 and 9 hours highlights a strong anti-
migratory effect of all syndecan ectodomains with that of S4ED being consistently higher at 
every time point (Fig. 4.7). To confirm these results, single cells were also analysed and their 
speed quantified. Cells migrating in the presence of syndecan ectodomains in the medium are 
slower than when treated with GST or left untreated (Fig. 4.8). 
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To avoid disturbing any of EC functions during migration, proliferation was not chemically 
inhibited by the addition of drugs (such as mytomycin C) in the experiments described above. 
Hence, to exclude that the effect seen in the scratch wound assay was due to syndecan 
ectodomains influencing EC mytogenic potential, a proliferation assay was carried out. Here, 
no statistically significant effect of syndecan ectodomains on EC proliferation at 9 hours was 
detected (Fig. 4.9), which suggested that the delay in the wound closure was due to inhibition 
of EC migration when in contact with syndecan ectodomains rather than to them being less 
proliferative. 
 
 
 
Fig. 4.7 Effect of syndecan ectodomains on EC migration. Confluent skin ECs (sEND) were 
scratched with a pipette tip in the middle of the well, washed in PBS and fresh medium 
containing 0.5 µM of the indicated proteins was added. Photographs of the same spot were 
taken on an inverted microscope straight after the addition of the treatment (0h) and after 3, 6 
and 9 hours. Wound area was calculated at each time point and expressed as percentage, with 
100% being the wound area at time 0h. Bars show the mean and standard deviation of 3 
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Fig. 4.6 Effect of syndecan ectodomains on EC migration. Confluent skin ECs (sEND) were 
scratched with a pipette tip in the middle of the well, washed in PBS and fresh medium 
containing 0.5 µM of the indicated proteins was added. Photographs of the same spot were 
taken on an inverted microscope straight after the addition of the treatment (0h) and after 9 
hours (9h). White lines were drawn to cover the initial scratch margins to better visualize cell 
migration at the final time point. Pictures are representative of 3 experiments where at least 2 
spots per condition were analysed. Scale bar represents 500 µm. 
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experiments where at least 2 spots per condition were analysed. Significant differences 
between untreated control (UT) and treated groups at each time point were determined using 
one-way Anova with Bonferroni correction for multiple comparisons. *P<0.05, ** P<0.01, 
***P<0.001, ****P<0.0001. 
 
Fig. 4.8 Effect of syndecan ectodomains on EC migration speed. Single cell movements 
from previous experiments, where sENDs were allowed to migrate in the presence of 0.5 µM 
of GST or syndecan ectodomains, were tracked using Photoshop (Adobe) and single cell speed 
was calculated by dividing the length of the movement by 540 minutes to obtain cell speed. 
Bars show the mean and standard error of the mean of 3 experiments where at least 10 cells 
per condition were analysed. Significant differences between untreated control (UT) and 
treated groups were determined using one-way Anova with Bonferroni correction for multiple 
comparisons. *P<0.05, ****P<0.0001. 
Fig. 4.9 The effect syndecan 
ectodomains on EC proliferation. EC 
proliferation was measured by using 
the Cell Titer 96 AQueous Cell 
proliferation assay kit. 5000 skin ECs 
(sEND) were seeded in 100 μl of 
complete medium containing 0.5 µM of 
the indicated protein in a 96-well plate. 
After 9 hours absorbance was read in an 
Elisa reader. Bars show the average 
corrected absorbance at 490 nm (final 
value/initial value) and its standard 
deviation from 2 experiments. No 
significant differences between 
untreated control (UT) and treated 
groups were determined using one-way 
Anova with Bonferroni correction for 
multiple comparisons.  
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4.1.3.4. Syndecan ectodomains inhibit EC invasion into collagen I 
To evaluate the impact of the anti-migratory effect of syndecan ectodomains on ECs in a tri-
dimensional situation, an invasion assay was carried out. In this set of experiments ECs were 
left to invade a thin layer of collagen I for 24 hours, after which the cells which had migrated 
through the collagen were counted. 
Syndecan ectodomains were added to the collagen to establish whether their presence could 
exert the same anti-migratory effect noticed in the scratch wound model. 
Far fewer ECs reached the bottom of the gel when syndecan ectodomains were added to the 
matrix compared to untreated or GST control, confirming that syndecan ectodomains are 
indeed able to inhibit EC migration both in a 2D (scratch wound assay) and a 3D system 
(invasion assay) (Fig. 4.10 and Fig. 4.11). 
 
 
 
 
 
  
 
S3ED 
 
UT GST S1ED 
S2ED S4ED 
Fig. 4.10 Effect of syndecan ectodomains on EC invasion into Collagen I. Skin ECs 
(sEND) were seeded on top of membranes previously coated with 10 μl of a Collagen 
Type I mixture (1 mg/ml) containing the syndecan core proteins or GST at a 
concentration of 0.5 μM. After 24 hours, Collagen was removed, Calcein was added to 
the medium to visualize cells (green) which reached the filter. Photographs were taken 
using a fluorescence microscope. Pictures are representative of 3 experiments where 
each condition was performed in triplicate. Scale bar represents 500 µm. 
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Fig. 4.11 Effect of syndecan ectodomains on EC invasion into Collagen I. Pictures from 
previous experiment, where sENDs were allowed to invade a collagen gel in the presence of 
0.5 µM of GST or syndecan ectodomains, were analysed on Photoshop (Adobe) and cells 
counted. Bars show the mean and standard deviation of 3 experiments where 3 filters per 
condition were analysed. Significant differences between untreated control (UT) and treated 
groups were determined using one-way Anova with Bonferroni correction for multiple 
comparisons. **P<0.01, ***P<0.001. 
 
  
UT GST S1ED S2ED S3ED S4ED
0
25
50
75
100
125
150
c
e
ll
s
/f
il
te
r
ns
***
*****
***
124 
 
 
4.1.4. Discussion  
The aim of the experiments described in this section was to investigate whether soluble forms 
of syndecan ectodomains could affect EC behaviour during angiogenesis. From the results 
obtained we can conclude that all four syndecan extracellular core proteins are able to inhibit 
angiogenesis in the ex vivo model of the aortic ring assay and strongly negatively regulate EC 
migration, invasion and tube formation in vitro. One of the most striking observations is that 
all four syndecan ectodomains have anti-angiogenic effects despite their lack of sequence 
homology. 
Previous works (Beauvais et al., 2004; McQuade et al., 2006; Whiteford et al., 2007; 
Whiteford et al., 2011) showed that the ectodomains of syndecan-1, -2 and -4 possess an 
adhesion-regulatory sequence which allow them to promote cell attachment when they are 
either immobilized on a plate or engaged by Ab. Interestingly, the adhesion-regulatory sites 
which have been identified in syndecan-1, -2 and -4 are unique to each syndecan. These studies 
also elucidated a requirement for integrins in these pathways, in particular αVβ3, αVβ5 for 
syndecan-1 and β1 families for syndecan-2 and -4. We also noticed an unanticipated anti-
angiogenic effect of S3ED, a protein which has never been assessed in adhesion studies; 
because syndecan-3 is structurally similar to syndecan-1, one could speculate it could mediate 
the same αVβ3 and αVβ5-dependent adhesion pathway. As discussed in the introduction to 
this section, integrins αVβ3, αVβ5 and β1 have key roles in angiogenesis and this is because 
their interactions with the ECM can regulate EC survival, migration and proliferation 
(Avraamides et al., 2008): integrins αVβ3 (a Fibronectin and Vitronectin receptor) and αVβ5 
(a Vitronectin receptor) antagonists have shown promising results in cancer, arthritis and 
ischemic retinopathy treatments and Fibronectin main receptor α5β1(Francis et al., 2002) is 
found overexpressed in blood vessels of human and mouse tumors (Kim et al., 2000b). So it 
is likely that syndecan ectodomain anti-angiogenic effects are caused by an increase in 
integrin-mediated EC adhesion which in turn slows down cell migration. 
The experiments described in this section are based on the use of soluble syndecan 
ectodomains; it would be therefore interesting to know whether the same pathways would be 
triggered in cis. Syndecans are in fact expressed on ECs, with syndecan-2 being the most 
abundant, and some evidence suggests that their expression can be regulated by angiogenic 
factors: TNF-α for example, which is a potent angiogenic factor in vitro and in vivo 
(Montrucchio et al., 1994; Norrby, 1996), increases syndecan-4 expression on ECs while 
suppresses that of syndecan-1 (Zhang et al., 1999); syndecan-4, in addition, is found 
upregulated in vivo in a range of inflammatory conditions characterized by an angiogenic 
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response like ischaemic myocardial injury (Cizmeci-Smith et al., 1997) and dermal wound 
healing (Gallo et al., 1996b). It is therefore tempting to speculate that syndecan ectodomains 
could be interacting in cis with binding partners on the EC surface, leading to a modulation of 
integrins activity thus affecting EC adhesion and migration; however, it is important to bear 
in mind that in this scenario the full length syndecan molecule will be substituted by large and 
heavily charged HS chains and this will likely make its adhesion-regulatory site inaccessible. 
There is however no experimental evidence to prove that this is the case. 
On the other hand, cell surface receptor cleavage is a common feature of many physiological 
and pathological processes and shed syndecans are often found in pathological fluids: elevated 
levels of syndecan-1 ectodomain are present in dermal wound fluid and in serum of patients 
with acute graft-vs-host disease (Seidel et al., 2003) and increased shed syndecan-1 in the sera 
of myeloma patients is indeed considered a marker of poor prognosis (Bayer-Garner et al., 
2001; Seidel et al., 2000b), syndecan-4 shedding can also increase in situations of chronic 
inflammation such as asthma (Brightling et al., 2005) and wound healing (Subramanian et al., 
1997) and syndecan-2 is readily shed from human colon cancer cells by MMP-7 (Choi et al., 
2012). So, conditions such as chronic inflammation, wound healing and cancer growth are 
characterized by both an angiogenic response and syndecan shedding. This could seem in 
disagreement with the results described in this section, showing that syndecan extra-cellular 
proteins effectively inhibit angiogenesis; however, it is key to point out that new blood vessel 
formation results from a highly coordinated balance of pro- and anti-angiogenic signals. In 
this scenario, shedding of syndecans from specific cell types, at a precise time and place, would 
result in ectodomain moieties anchored to the ECM (via HS-ECM interactions) which would 
then function as “stop” signal to guide  ECs to the site of tissue injury. 
Another interesting point which would require further investigation to address is the 
characterization of the proteases able to cleave syndecan ectodomains. An increased 
accumulation of extracellular proteases such as MMPs, ADAMs and ADAMTs is associated 
with physiological angiogenesis but also to those pathologies which include an angiogenic 
response (e.g. chronic inflammation and cancer). However, given the little sequence homology 
between syndecan ectodomains, it is very unlikely that the same protease/s would be able to 
shed all four. In addition, the adhesion-regulatory sites which have been identified in 
syndecan-1, -2 and -4 (Fig. 4.1) are all encoded in the very C-terminus of the respective 
extracellular core protein, hence, depending on the cleavage site, they could be either released 
together with the N-terminal domain, retained as a truncated extracellular domain on the cell 
membrane or cut in half if the cleavage site is contained within its sequence. This raises the 
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question as to whether physiological or pathological shedding can regulate the anti-angiogenic 
properties of syndecan ectodomains.  
The use of bacterially-derived syndecan ectodomains, which therefore lack 
glycosaminoglycan chains, allowed the identification of effects which are specific to the 
proteic domain, but was also a limitation. Syndecans are in fact likely to still be fully 
substituted by GAG chains once shed, so a question which is left unanswered is whether the 
presence of these substitutions would be inhibitory to the protein interactions. Moreover, 
murine sequences were used in the experiments to match the experimental design which took 
advantage of the rodents systems (rat aortic rings and murine cells in all the in vitro 
experiments), it would be therefore interesting to test whether human syndecan ectodomains 
would still retain the same activity we detected in the rodent counterpart. Notably, human and 
murine syndecan ectodomains share a sequence homology greater than 80%.    
Moreover, in light of the strong anti-angiogenic capacity of these proteins, it would be exciting 
to test whether syndecan ectodomains could have potential as an anti-angiogenic therapy in 
diseases such as rheumatoid arthritis and cancer. 
Further work is needed to answer these questions and more, but the data just presented 
represent a very encouraging starting point suggesting a novel regulatory role for syndecan 
ectodomains in angiogenesis. 
In conclusion, in this first results section of the thesis it has been shown that: 
1. All four syndecan ectodomains have anti-angiogenic properties. 
2. This most likely occurs via an inhibition of EC migration. 
3. We have identified adhesive function in the syndecan-3 ectodomain. 
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4.2. Shed syndecan-2 is a regulator of angiogenesis 
4.2.1.  Introduction 
Syndecan-2, also called Fibroglycan, was originally described as the main HS proteoglycan 
expressed by human lung fibroblasts (Marynen et al., 1989) and later shown to be 
characteristic of cells of mesenchymal origin (David et al., 1993), neurons (Ethell and 
Yamaguchi, 1999) and some types of cancer cells (Gulyas and Hjerpe, 2003). Syndecan-2 
participates in the formation of dendritic spines during hippocampal neuron differentiation 
(Ethell and Yamaguchi, 1999) and seems to mediate early decisions during development of 
left-right asymmetry in Xenopus (Kramer and Yost, 2002). Moreover, syndecan-2 was found 
to be up-regulated on colon cancer cells and is required for both cell cycle progression and 
cell-matrix interactions (Han et al., 2004). As described in 1.3.2, relatively few studies have 
associated syndecan-2 to angiogenesis. In the most notable work, syndecan-2 knocked down 
in zebrafish embryos was shown to dramatically impair angiogenic sprouting during vascular 
development.  In both loss and gain of function experiments, syndecan-2 appeared to be 
required for VEGF-mediated signalling. The angiogenic function of syndecan-2 shown in 
zebrafish is likely conserved in mouse and human as its expression is similarly localized to the 
mesenchyme surrounding major vessels and human syndecan-2, when expressed in zebrafish 
ECs, could mimic the effect of the endogenous one. Notably to exert its function during new 
blood vessel formation syndecan-2 needs to be present as a full length molecule as its pro 
angiogenic effects were abolished when syndecan-2 was expressed as a cytoplasmically 
truncated form (Chen et al., 2004a).  
In addition to its roles as a full length molecule, I described a novel function for the syndecan-
2 extracellular core protein in angiogenesis (section 4.1). In my studies, when the murine 
syndecan-2 ectodomain, short of both its transmembrane and cytoplasmic domain and without 
GAG substitution, is expressed as a GST-fusion protein and added to the medium of ECs, it 
strongly inhibits cell migration, tubule formation and ultimately angiogenesis in the ex vivo 
model of aortic sprouting. Previously, it was shown that fibroblast attachment to S2ED 
promotes the formation of focal structures and this is mediated by the cell surface tyrosine-
phosphatase CD148 and β1 integrins. Solid-phase binding assays showed that the extracellular 
domain of CD148 interacts with the last 18 aa of murine S2ED (P124 - F141) and in particular 
the sequence DNLF seems to be key to this interaction. Interestingly, direct binding between 
β1 integrins and CD148 does not occur and cells failed to adhere to the CD148 extracellular 
domain when provided as a substrate in adhesion assays, suggesting an involvement of an 
intra-cellular signalling pathway that functionally connects CD148 to ß1 integrin. Analysis of 
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the possible intracellular substrates for CD148 revealed that ß1-mediated adhesion requires 
activated Src and PI3k-C2ß and there is evidence for the involvement of a de-phosphorylation 
step of the p85 subunit of PI3K (Whiteford et al., 2011). 
CD148, also named DEP-1/PTPη, is a type III receptor protein tyrosine phosphatase that is 
composed of an extracellular domain containing 8 FN type III-like repeats, a transmembrane 
domain and a single cytoplasmic phosphatase domain (Ostman et al., 1994). The name DEP-
1, density enhanced phosphatase-1, was given to this protein since it appeared upregulated on 
human foetal lung fibroblasts (WI38) cells when grown to high cell density. Further studies 
were supportive of a role for CD148 in inhibiting cell growth especially in cancer cells. Loss 
of CD148, for example, often correlates with a more malignant cancer cell phenotype (Keane 
et al., 1996; Zhang et al., 1997). Of particular interest to my project, CD148 is abundantly 
expressed in vascular ECs (Borges et al., 1996; Takahashi et al., 1999) and mutant mice 
lacking catalytic activity of CD148 die with vascular defects (increased EC proliferation and 
vessel growth) during gestation (Takahashi et al., 2003). Consistent with these findings, 
CD148 has been shown to inhibit signalling of growth factor receptors such as VEGFR-2 
(Grazia Lampugnani et al., 2003) which is of paramount importance to angiogenesis. Notably, 
the CD148-null mice are viable and show no gross abnormalities (Takahashi et al., 2003a) 
suggesting the importance of the interaction between the CD148 ectodomain and its binding 
partners for its activity. In agreement with this hypothesis, engagement of CD148 extracellular 
domain with an agonistic Ab promotes its activation and suppresses EC growth in culture and 
angiogenesis in the cornea (Takahashi et al., 2006). Recently, thrombospondin-1 (TSP-1) has 
been identified as a CD148 agonistic ligand able to inhibit both epithelial and EC growth 
(Takahashi et al., 2012). In addition, further studies revealed that CD148 can play a role in 
inhibition of leukocyte cell migration (Zhu et al., 2011). 
In light of the studies just mentioned, we hypothesized that S2ED-mediated inhibition of EC 
migration and angiogenesis described in the previous section requires the involvement of both 
CD148 and β1 integrins. 
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4.2.2. Aims 
In the previous results section all four syndecan ectodomains were shown to directly affect EC 
migration and to strongly inhibit angiogenesis. The focus of this next section is one particular 
member of the family, syndecan-2, aiming to establish whether its anti-angiogenic properties 
are maintained in vivo and to explore in more detail the associated molecular mechanisms. 
The specific aims of the experiments described here are therefore as follows: 
1. Establish whether shed syndecan-2 can affect pathological angiogenesis in vivo. 
2. Determine whether physiological shedding of syndecan-2 ectodomain produce a 
cleavage product which still retains anti-angiogenic properties. 
3. Determine whether the heparan sulphate chains are important for shed syndecan-2 
functions in vivo and in vitro. 
4. Understand the mechanism of action; in particular, a possible involvement of CD148 
and β1 integrins. 
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4.2.3. Results 
4.2.3.1. Constitutively released syndecan-2 extracellular domain from HEK293T cells 
inhibits angiogenesis in a xenograft tumor model 
To determine the effect of shed syndecan-2 on new blood vessel formation in vivo, a model of 
tumor angiogenesis was employed. A human embryonic kidney derived cell line (HEK293T) 
was lentivirally transfected with either an empty vector or a vector containing the sequence 
for the murine syndecan-2 extracellular domain with an HA-tag inserted (Fig. 4.12). Since this 
construct lacks the transmembrane domain (and the cytoplasmic domain) it is not retained in 
the plasma membrane but constitutively shed in the extracellular space. To confirm this 
rationale, conditioned medium was collected from either HEK293T transfected with the empty 
vector (EV) or the vector containing the syndecan-2 extracellular domain (eS2ED) sequence 
and dot-blotted for the presence of ectopic syndecan-2. Results confirmed that eukaryotic 
syndecan-2 extracellular domain is expressed and released in the conditioned medium of 
HEK293T transfected with the eS2ED vector while it is absent in the control medium (EV) 
(Fig. 4.13). 
 
Fig. 4.12 Syndecan-2 extracellular domain diagram. The 
diagram shows the truncated form of syndecan-2 expressed in 
HEK293T cells. Notably, the protein is substituted by HS chains 
but lacks both the transmembrane and cytoplasmic domains hence 
it is not retained in the cell membrane but constitutively released in 
the extracellular space. (Figure from De Rossi et al., 2014). 
 
 
Fig. 4.13 Syndecan-2 extracellular domain is expressed 
and released in the extracellular space. After an overnight 
incubation in serum-free medium, conditioned medium from 
HEK293T cells transfected with the empty vector (EV) or the 
syndecan-2 extracellular core protein vector (eS2ED) (N-
terminally fused to an HA tag) were run in a dot blot assay 
using an anti-HA tag Ab. A strong signal was detected in the 
eS2ED sample while no signal was present in the EV control, 
as expected. (Figure from De Rossi et al., 2014). 
 
HEK293T cells were then injected sub-cutaneously in the flank of SCID mice and the 
xenograft tumors were allowed to develop. After 3 weeks, mice were culled and tumors 
excised. Notably, mice injected with HEK293T constitutively releasing eS2ED in the 
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surrounding cellular microenvironment grew far less than the control ones (Fig. 4.14). In fact 
tumors were significantly smaller both in size (Fig. 4.15) and in weight (Fig. 4.16) compared 
to the EV control. Interestingly, the decreased growth of those tumors constituted by 
HEK293T constitutively releasing eS2ED was unlikely due to a reduced proliferative potential 
of the tumor cells since the proliferation rate of those cells was tested in vitro and resulted 
similar to that of HEK293T transfected with empty vector (Fig. 4.17). 
On the other hand, when tumors from the two groups were sectioned and stained for the  EC 
marker CD31, far less CD31-positive structures were detected in the hek293t (eS2ED) tumors 
compared to the EV controls (Fig. 4.18 and Fig. 4.19).  
These results showed that in a xenograft tumor model, the presence of syndecan-2 extracellular 
domain in the microenvironment has a strong inhibitory effect on tumor growth and on tumor 
derived angiogenesis.  The fact that shed syndecan-2 had no effect on tumor cell proliferation 
in vitro would suggest that the reduced tumor growth is likely due to reduced angiogenesis 
which fails to provide tumor cells with enough nutrients and oxygen necessary for a higher 
growth rate. 
 
 
 
Fig. 4.14 Effect of syndecan-2 extracellular 
domain on tumor growth. HEK293T cells 
previously transfected with either an empty vector 
(EV) or the constitutively released syndecan-2 
extracellular domain (eS2ED) coding vector were 
injected s.c. into the flank of severe combined 
immuno-deficient (SCID) mice. Mice were culled 
after 3 weeks and the entire tumor excised and 
photographed. Image shows 5 tumors per group. 
Scale bar represents 1 cm. (Figure from De Rossi et 
al., 2014). 
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Fig. 4.15 Effect of syndecan-2 extracellular domain on 
tumor size. HEK293T cells previously transfected with either 
an empty vector (EV) or the constitutively released syndecan-
2 extracellular domain (eS2ED) coding vector were injected 
s.c. into the flank of severe combined immuno-deficient 
(SCID) mice. Mice were culled after 3 weeks and the entire 
tumor excised and the diameter measured. Bars show the mean 
and standard error of the mean of 5 animals per group. 
Significant differences between control tumors (EV) and 
treated tumors (eS2ED) were determined using unpaired t-test. 
**P<0.01. (Figure from De Rossi et al., 2014). 
 
 Fig. 4.16 Effect of syndecan-2 extracellular domain on 
tumor weight. HEK293T cells previously transfected with 
either an empty vector (EV) or the constitutively released 
syndecan-2 extracellular domain (eS2ED) coding vector were 
injected s.c. into the flank of severe combined immuno-
deficient (SCID) mice. Mice were culled after 3 weeks and the 
entire tumor excised and the diameter measured. Bars show the 
mean and standard error of the mean of 5 animals per group. No 
significant differences between control tumors (EV) and treated 
tumors (eS2ED) were determined using unpaired t-test. (Figure 
from De Rossi et al., 2014). 
  
 
Fig. 4.17 Effect of syndecan-2 extracellular domain on HEK293T cell proliferation. Equal 
numbers of HEK293T cells  previously transfected with either an empty vector (EV) or the 
constitutively released syndecan-2 extracellular domain (eS2ED) coding vector were cultured 
in a 96-well plate and their proliferation at 6, 24, 48 and 96 hours measured with the CellTiter 
96 AQueous kit (Promega). Lines show the cubic spline generated from the data points. Error 
bars represent the standard deviation of the mean from 4 replicates per condition. No 
significant differences between control tumors (EV) and treated tumors (eS2ED) were 
determined using two-way Anova with Bonferroni correction for multiple comparisons. 
(Figure from De Rossi et al., 2014). 
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Fig. 4.18 Effect of syndecan-2 extracellular domain on tumor angiogenesis. HEK293T 
cells  previously transfected with either an empty vector (EV) or the constitutively released 
syndecan-2 extracellular domain (eS2ED) coding vector were injected s.c. into the flank of 
severe combined immuno-deficient (SCID) mice. Mice were culled after 3 weeks and the 
entire tumor excised and immediately freezed in liquid nitrogen and stored at -80°C. Samples 
were then embedded in OCT and 60 µm sections were made using a cryotome. Sections were 
then fixed and blocked/permeabilized prior to staining with an anti-CD31 Ab (Red) to 
visualize ECs. HEK293T cells are GFP positive (green). Images are representative of 5 
animals per group. Scale bar represents 100 µm. (Figure from De Rossi et al., 2014). 
 
 
Fig. 4.19 Effect of syndecan-2 extracellular domain on tumor 
angiogenesis. Sections from the previous experiment were 
analysed to quantify new blood vessel formation. Image J was used 
to measure the area covered by CD31+ vessels and the value was 
then expressed as the percentage of CD31+ area over the whole 
image. Results are representative of 5 animals per group. Bars 
show the mean and standard error of the mean of 5 animals per 
group for which at least 4 images were analysed. Significant 
differences between control tumors (EV) and treated tumors 
(eS2ED) were determined using unpaired t-test. ****P<0.0001. 
(Figure from De Rossi et al., 2014). 
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4.2.3.2. Shed syndecan-2 from HEK293T cells has anti-angiogenic properties 
Syndecans are often shed from the cell surface as a result of pathological conditions such as 
inflammation, cancer and wound healing; however, little is known about the proteases 
responsible for this phenomenon and/or their cutting sites. The next set of experiments were 
set to determine whether once syndecan-2 is shed in a physiological way (e.g. as a result of an 
inflammatory stimulation) it would still retain its anti-angiogenic properties. 
The xenograft tumor model suggested an anti-angiogenic activity of the eS2ED molecule 
which was designed to contain the extracellular domain sequence of syndecan-2 in its entirety. 
To assess whether a physiologically shed form of syndecan-2 would retain the same properties, 
HEK293T cells were transfected with a vector containing the full-length murine syndecan-2 
sequence (Fig. 4.20) and subsequently exposed to increasing doses of TNFα which is a known 
pro-inflammatory factor and can stimulate syndecan shedding in vitro (Brightling et al., 2005; 
Pruessmeyer et al., 2010; Tan et al., 2012). Conditioned medium was then collected and dot-
blotted for the ectopic syndecan-2 using an Ab specific for the HA tag N-terminally fused to 
syndecan-2; HEK293T cells transfected with an empty vector showed no signal while 
HEK293T cells transfected with the full length syndecan-2 (eFLS2) secreted the molecule in 
a dose-dependent manner upon addition of TNFα in the medium (Fig. 4.21). 
The rat aortic ring assay was then employed to determine the anti-angiogenic activity of the 
TNFα-induced shed form of syndecan-2. Conditioned media from HEK293T transfected with 
an empty vector and treated with TNFα, HEK293T transfected with full length syndecan-2 
and treated with TNFα and HEK293T transfected with the constitutively shed syndecan-2 
extracellular domain were collected and the proteoglycans contained within were purified via 
anion-exchange. Subsequently, 10 µg of each purification product were added to the collagen 
matrix in which the aortic rings were embedded and angiogenic sprout growth was measured 
after 7 days. A strong decrease in the number of angiogenic sprouts, hence in angiogenesis, 
occurred in the groups treated with induced or constitutively shed forms of syndecan-2 (eFLS2 
and eS2ED, respectively) when compared to the control group (EV) (Fig. 4.22). Although the 
anion-exchange step only allowed the purification of a mix of proteoglycans not just syndecan-
2, by using the purification product derived from the conditioned medium from HEK293T EV 
and treated with TNFα as a control, the anti-angiogenic effect of both eFLS2 and eS2ED 
groups was most likely due to the presence of the extra amount of ectopic syndecan-2 in the 
medium. 
These results suggested that the anti-angiogenic properties of syndecan-2 extracellular domain 
seen in the xenograft tumor model are most likely retained when syndecan-2 is physiologically 
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shed. It is therefore reasonable to speculate that TNFα leads to syndecan-2 cleavage at its 
juxtamembrane region resulting in the release of the entirety of syndecan-2 extracellular 
domain. 
 
 
Fig. 4.20 Full length syndecan-2 diagram. The diagram shows the full 
length form of syndecan-2 expressed by HEK293T cells. The protein is 
substituted by HS chains in its extra-cellular domain and has 
transmembrane and cytoplasmic domains which anchor it to the cell 
membrane. (Figure from De Rossi et al., 2014). 
 
 
 
 
 
Fig. 4.21 Full length syndecan-2 shedding in response to Tumor necrosis factor α (TNFα). 
HEK293T cells expressing the empty vector (EV) or full length syndecan-2 (sFLS2) were 
incubated for 4 hours in serum-free medium with the indicated amount of TNFα. Conditioned 
media were then collected, run in a dot blot apparatus and probed with an anti-HA tag Ab. 
(Figure from De Rossi et al., 2014). 
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Fig. 4.22 Effect of induced and constitutively shed syndecan-2 on angiogenic sprouting. 
HEK293T cells expressing the empty vector (EV) or full length syndecan-2  (sFLS2) were 
incubated for 4 hours in serum-free medium with 200 ng/ml of TNFα while HEK293T 
expressing the constitutively shed eS2ED were left untreated in serum-free. Conditioned 
media were then collected, shed proteoglycans were purified via anion-exchange and 10 µg of 
each product were added into the collagen I layer of the rat aortic ring assay. Each bar 
represents the mean and standard deviation of 8 rings. Significant differences between control 
group (EV) and treated groups were determined using one-way Anova with Bonferroni 
correction for multiple comparisons. ****P<0.0001. (Figure from De Rossi et al., 2014). 
 
 
4.2.3.3. The syndecan-2 extracellular core protein inhibits angiogenesis 
Because syndecan-2 is a proteoglycan and as such is composed of a proteic backbone and 
sugar chains, we decided to establish whether the anti-angiogenic effect showed in vivo in the 
xenograft tumor model was mediated by the peptide alone (deprived of its HS chain 
substitutions) which had been previously shown to possess a cell adhesion regulatory 
domain(Whiteford et al., 2007) and to being able to inhibit angiogenesis ex vivo (4.1.3.1). To 
explore this hypothesis, we took advantage of the same substrates used in the previous section: 
syndecan-2 extracellular core protein N-terminally fused to GST and GST alone (Fig. 4.23). 
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Fig. 4.23 Experimental approach. The diagram 
depicts the experimental approach used to assess if 
the anti-angiogenic properties of shed syndecan-2 
are dependent on its proteic component. The 
extracellular core protein of syndecan-2 (aa E19 to 
F141) N-terminally fused to GST or GST alone 
were expressed in E.coli, subsequently purified 
using Sepharose columns and quantified via SDS-
Page. (Figure from De Rossi et al., 2014). 
 
 
These substrates were tested in an in vivo model of angiogenesis, namely the matrigel plug 
assay. Wild type mice were s.c. injected with Matrigel containing the same concentration of 
either GST or syndecan-2 ectodomain (S2ED) and the pro-angiogenic stimuli VEGF-A and 
bFGF. After 5 days mice were sacrificed, plugs were excised and incubated in deionized water 
over-night to extract the haemoglobin within them. It is clear from the photos that those plugs 
containing S2ED were far less red than the GST control group indicating the presence of a 
decreased amount of haemoglobin within them (Fig. 4.24). This suggested that less 
angiogenesis had happened in those plugs, in fact, when plugs were sectioned and stained for 
an EC marker (CD31) fewer ECs were detectable in the in the plugs containing S2ED (Fig. 
4.25 and Fig. 4.26). This suggested that the anti-angiogenic activity of S2ED previously shown 
ex vivo (4.1.3.1) is still maintained in vivo.  
 
Fig. 4.24 Effect of syndecan-2 extracellular core 
protein on angiogenesis in vivo. 500 μl of 7.5 mg/ml 
matrigel in PBS containing 100 ng/ml of VEGF-A, 
100 ng/ml of bFGF, 20 U/ml of Heparin and either 
0.5 μM of GST or syndecan-2 extracellular core 
protein (S2ED) was injected s.c. in the flanks of 6-8 
weeks old wild type mice. After 5 days mice were 
culled, plugs excised and left over-night in 500 μl of 
dH2O to allow haemoglobin to be released from the 
matrigel. The image shows the two plugs from one 
animal per group after the over-night incubation in 
dH2O and is representative of 4 animals per group. 
(Figure from De Rossi et al., 2014). 
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Fig. 4.25 Effect of syndecan-2 extracellular core protein on EC migration into the 
matrigel plug in vivo. 500 μl of 7.5 mg/ml matrigel in PBS containing 100 ng/ml of VEGF-
A, 100 ng/ml of bFGF, 20 U/ml of Heparin and either 0.5 μM of GST or syndecan-2 
extracellular core protein (S2ED) was injected s.c. in the flanks of 6-8 weeks old wild type 
mice. After 5 days mice were culled, plugs excised and frozen in liquid nitrogen. Plugs were 
then embedded in OCT and cryosections of 50 μm were cut. Sections were then fixed in 4% 
PFA, stained for ECs (PECAM-1, red) and nuclei (DRAQ5, blue) and photographed under a 
confocal microscope. Bottom images are magnifications of regions of interest from the top 
images, to highlight how in the control (GST) ECs (red) are already starting to organize into a 
tubule-like structure, while fewer cells and unorganized are present in the treated sample 
(S2ED). Scale bars represent 100 μm. Images are representative of 4 animals per group. 
(Figure from De Rossi et al., 2014). 
 
 
Fig. 4.26 Effect of syndecan-2 extracellular core protein on 
EC migration into the matrigel plug in vivo. Sections from the 
previous experiment were analysed to quantify EC infiltration 
into the matrigel plugs. Image J was used to count the number 
of cell nuclei present in the images (DRAQ5-positive) and the 
percentage of those nuclei which were also positive for PECAM 
(EC marker). Results are representative of 4 animals per group. 
Bars show the mean and standard error of the mean of 4 animals 
per group for which at least 4 images were analysed. Significant 
differences between control samples (GST) and treated sample 
(S2ED) were determined using unpaired t-test. ***P<0.001. 
(Figure from De Rossi et al., 2014). 
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To corroborate this finding, the effect of S2ED on tubule formation was established. Tubule 
formation is a widely used as an in vitro model of angiogenesis as it nicely resembles many 
important features which take place during the early steps of the angiogenic process in vivo, 
such as EC proliferation, migration and organization into a network of tubules. A tubule 
formation kit, commercially available, was used to test the effect of S2ED (at two 
concentrations) on this process. A co-culture of human dermal fibroblasts and ECs were 
seeded and grown for 2 weeks in the presence of different stimuli. The greatest tube formation 
response was unsurprisingly detected in the sample treated with VEGF-A which is a known 
pro-angiogenic factor and was therefore used as a positive control. Suramin instead, an angio-
suppressive agent used as a negative control, completely inhibited tubule formation (Fig. 4.27). 
Interestingly, S2ED inhibited this process both in terms of number of branching points (Fig. 
4.28) and tubule length (Fig. 4.29). This effect seemed to be dose dependent although the 
difference between the group treated with 0.1 µM of S2ED and the control group (medium 
only) was not statistically significant.  
Altogether these results suggested that the anti-angiogenic properties of shed syndecan-2 
reside in its proteic domain and that it likely to be a direct effect on ECs.  
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Fig. 4.27 Effect of syndecan-2 extracellular core protein on tubule formation. HUVECs 
and human dermal fibroblasts were co-cultured using the Cell Works V2a kit. Medium 
containing positive control compound VEGF, negative control compound Suramin, GST or 
S2ED at the concentrations indicated or medium only was changed every second day and at 
day 14 ECs were stained for PECAM-1 (black signal) to assess the tubule formation. Red 
arrows indicate examples of branching points. Imaging was performed using an inverted 
microscope. Images are representative of triplicates of which at least 3 pictures were taken. 
Scale bar represents 500 µm. (Figure from De Rossi et al., 2014). 
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Fig. 4.28 Effect of syndecan-2 extracellular core protein on tubule branching. HUVECs 
and human dermal fibroblasts were co-cultured using the Cell Works V2a kit. Medium 
containing positive control compound VEGF, negative control compound Suramin, GST or 
S2ED at the concentrations indicated or medium only was changed every second day and at 
day 14 ECs were stained for PECAM-1 (black signal) to assess the tubule formation. Tubule 
branching was quantified using Photoshop (Adobe). A branch point was defined as the point 
at which two or more tubules met. Each bar represents the mean with standard error of the 
mean of triplicates. Significant differences between untreated control (MEDIUM ONLY) 
group and treated groups were determined using one-way Anova with Dunnett correction for 
multiple comparisons. **P<0.01. (Figure from De Rossi et al., 2014). 
 
 
Fig. 4.29 Effect of syndecan-2 extracellular core protein on tubule length. HUVECs and 
human dermal fibroblasts were co-cultured using the Cell Works V2a kit. Medium containing 
positive control compound VEGF, negative control compound Suramin, GST or S2ED at the 
concentrations indicated or medium only was changed every second day and at day 14 ECs 
were stained for PECAM-1 (black signal) to assess the tubule formation. Tubule length was 
quantified using Photoshop (Adobe). A branch point was defined as the point at which two or 
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more tubules met, and the tubule length as the length of tubules between branch points. Each 
bar represents the mean with standard error of the mean of triplicates. Significant differences 
between untreated control (MEDIUM ONLY) group and treated groups were determined 
using one-way Anova with Dunnett correction for multiple comparisons. **P<0.01, 
***P<0.001. (Figure from De Rossi et al., 2014). 
 
 
4.2.3.4. The anti-angiogenic properties of S2ED are due to inhibition of EC migration 
and are mediated by amino acids P124-F141 
Because syndecan-2 ectodomain had previously been shown to possess an adhesion-regulatory 
domain (ARD) at the C-terminus of its extracellular domain (aa P124-F141) (Fig. 4.30) which 
when engaged promotes cell adhesion in both fibroblasts and ECs (Whiteford et al., 2007), we 
hypothesized that the anti-migratory effect that syndecan-2 extracellular core protein exerts on 
ECs, shown in the previous section (4.1.3.3), is mediated by the ability of the ARD to promote 
EC switch from a migratory to a more adhesive state. To test this hypothesis, 2 mutant forms 
of S2ED were produced and purified from E.coli.  S2EDΔP124-F141 lacks the last 18 aa (the 
ARD) while S2EDΔL73-G123 still possesses the ARD but lacks the region between the ARD 
and the HS chains substitution sites (Fig.4.30). Firstly, these constructs were tested in a rat 
aortic ring assay and interestingly only the construct containing the adhesion regulatory 
domain retained the S2ED anti-angiogenic effect while the one lacking those 18 aa had no 
effect on angiogenesis compared to both untreated and GST-treated controls (Fig. 4.31).   
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Fig. 4.30 Syndecan-2 extra-cellular core protein mutants N-terminally fused to GST were 
produced in E.coli. Diagram shows the structure of the proteins used in the experiments. 
Syndecan-2 extra-cellular core proteins were expressed and purified from E.coli and possess 
a Glutathione S-transferase (GST) fused to their N-terminus. The region coloured in green 
ranging from amino acid P124 to F141 has previously been described as the adhesion regulatory 
domain (ARD), the red region which comprises amino acid E19 to L73 is the region substituted 
by HS chains and it is separated from the ARD by the yellow region from L73 to P124. However, 
since these peptides are produced in E.coli, they are not substituted by HS chains. (Figure from 
De Rossi et al., 2014). 
 
 
Fig. 4.31 Effect of syndecan-2 adhesion regulatory domain on angiogenic sprouting. Rat 
thoracic aortas were  cut into rings which were embedded in 150 µl of Collagen type I (1 
mg/ml) containing 0.5 µM of syndecan-2 extra-cellular core protein (S2ED), its truncated 
mutant forms (S2EDΔP124-F141 and S2EDΔL73-G123) or GST control in 200 µl of OPTIMEM 
containing 10 ng/ml of VEGF-A. The number of sprouts was measured 7 days after 
embedding. Each bar represents the mean with standard deviation of 8 rings per group. 
Significant differences between untreated control (UT) group and treated groups were 
determined using one-way Anova with Dunnett correction for multiple comparisons. 
***P<0.001, ****P<0.0001. (Figure from De Rossi et al., 2014). 
m
e
a
n
 s
p
ro
u
ts
/r
in
g
U
T
G
ST
S
2E
D
S
2E
D
P
12
4 -F
14
1
S
2E
D
L
73 -G
12
3
0
5
10
15
***
****
144 
 
 
Having established that the previously characterized ARD is necessary for S2ED anti-
angiogenic effect, we further explored the aforementioned hypothesis that this was due to an 
effect on EC migration. We tested if skin endothelial (sEND) cells migratory potential was 
affected by the presence of the different S2ED mutant constructs in a scratch wound assay. 
After 9 hours control cells treated with GST or with S2EDΔP124-F141 lacking the ARD migrated 
and refilled the empty space created by the scratch, while those treated with S2ED or the 
shorter form S2EDΔL73-G123 which still possesses the ARD failed to do so (Fig. 4.32).  These 
results showed that S2ED effect on EC migration is dependent on the ARD contained within 
its last 18 aa. 
 
 
Fig. 4.32 Effect of syndecan-2 adhesion regulatory domain on EC migration.  Confluent 
skin ECs (sEND) were scratched with a pipette tip in the middle of the well, washed in PBS 
and fresh medium containing 0.5 µM of the indicated proteins was added. Photographs of the 
same spot were taken on an inverted microscope straight after the addition of the treatment 
(0h) and after 9 hours (9h). White lines were drawn to over the initial scratch margins to better 
visualize cell migration at the final time point. Pictures are representative of 3 experiments 
where at least 2 spots per condition were analysed. Scale bar represents 500 µm. (Figure from 
De Rossi et al., 2014). 
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4.2.3.5. S2ED interacts with CD148, resulting in inhibition of angiogenesis 
Previously it has been shown that S2ED is a novel ligand for the transmembrane tyrosine 
phosphatase CD148 in fibroblasts and the interaction between S2ED adhesion-regulatory 
domain and CD148 triggers fibroblast adhesion in a β1 integrin-dependent way (Whiteford et 
al., 2011). Since integrins are the main drivers of cell migration, we set to determine whether 
the pathway previously described for fibroblasts was also true for ECs. 
First we determined whether ECs express CD148, to this purpose ECs from three different 
vascular beds (brain, lung and skin) were lysed and immuno-blotted with an anti-CD148 Ab, 
results showing the presence of the protein in ECs from all three origins (Fig. 4.33). Next, cell 
lysates from sENDs were incubated with beads coated with GST, S2ED, S2EDΔP124–F141 or 
S2EDΔL73–G123 and the precipitate was subsequently immuno-blotted with an anti-CD148 Ab. 
The western blot showed that CD148 from ECs binds the last 18 aa of S2ED (Fig. 4.34). 
In light of these results, it was decided to test whether a soluble form of CD148 extracellular 
core protein could disrupt the interaction of the membrane-bound CD148 with S2ED and 
revert the anti-angiogenic effect. Surprisingly, when soluble CD148 alone was incorporated 
to the collagen in the rat aortic ring assay we noticed a strong anti-angiogenic effect which 
was further enhanced by the addition of S2ED (Fig. 4.35). 
 
 
Fig. 4.33 The expression of CD148 on ECs from 
different origins. Western blot of lysates from EC 
lines from murine brain (bEND3.1) and skin (sEND) 
and primary murine lung ECs were probed with Abs 
against CD148 or β-tubulin. The blot is 
representative of 4 experiments. (Figure from De 
Rossi et al., 2014). 
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Fig. 4.34 Binding of S2ED to CD148. Cell 
lysates from sEND cells were incubated with 
beads coated with GST, S2ED, S2EDΔP124–
F141 or S2EDΔL73–G123. Precipitates were 
analysed by western blotting for the presence of 
CD148. The blot is representative of 4 
experiments. (Figure from De Rossi et al., 
2014). 
 
 
 
Fig. 4.35 Effect of CD148 engagement on angiogenic sprouting. Rat thoracic aortas were  
cut into rings which were embedded in 150 µl of Collagen type I (1 mg/ml) containing 0.5 µM 
of syndecan-2 extra-cellular core protein (S2ED), soluble CD148 or both in 200 µl of 
OPTIMEM containing 10 ng/ml of VEGF-A. The number of sprouts was measured 7 days 
after embedding. Each bar represents the mean with standard deviation of 4 experiments with 
at least 5 rings per group. Significant differences between positive control (striped bar) group 
and treated groups were determined using one-way Anova with Dunnett correction for 
multiple comparisons. *P<0.05, **P<0.01. (Figure from De Rossi et al., 2014). 
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4.2.3.6. Active β1 integrin expression is reduced on ECs in the presence of S2ED 
In a previous work fibroblast adhesion to S2ED was shown to be dependent on β1 integrin 
since the use of a β1 integrin blocking Ab could ablate this process (Whiteford et al., 2011). 
The activation status of β1 integrins on ECs was therefore evaluated and, specifically, whether 
that was affected by S2ED. To this purpose, a suspension of brain endothelial (bEND) cells 
was treated with 0.5 µM of either GST or S2ED and analysed via FACS to evaluate the rate 
of activation of β1 integrins. The results showed that cells treated with S2ED had less active 
β1 compared to those treated with GST or left untreated (Fig. 4.36).  
 
 
 
Fig. 4.36 Effect of S2ED on β1 integrin activation – ECs in 
suspension. bEND3.1 were suspended and treated with 0.5 µM of 
GST or S2ED for 30’ at 37°C. Cells were then immunostained for 
both total and active β1 integrin (9EG7 Ab) and analysed by flow 
cytometry. Dot blots show the relative fluorescence intensity of 
active and total  β1 integrin expression on ECs treated with the 
different proteins. Vertical and horizontal lines were drawn based on 
the fluorescence intensity of the isotype controls. The percentage of 
cells which are positive for active β1 integrin after each treatment is 
shown in the bar graph and was calculated using the following 
equation 100*Q2/(Q2+Q3). (Figure from De Rossi et al., 2014). 
 
 
Next, the activation of β1 integrins when ECs are actively migrating was examined. A 
confluent monolayer of skin ECs was scratched and cell left to migrate for 30’ in the presence 
of either GST or S2ED before being fixed and stained for active β1 integrins (9EG7 Ab). 
Untreated control (UT) showed a strong active β1 integrin staining across the all plate, 
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especially on the leading edges of the wound which was reflected in the staining signal 
intensity quantified across an arbitrary straight line ran horizontally on the microgrpahs. 
Similar results were produced when cells were treated with GST, however cells treated with 
S2ED exhibited far less active β1 integrin staining (Fig. 4.37 and Fig. 4.38), which is in 
accordance to the previous FACS experiment. 
 
Fig. 4.37 Effect of S2ED on β1 integrin activation – adherent ECs. Confluent monolayers 
of sEND cells were grown in a 6-well plate and scratch wounds were made prior to the addition 
of either 0.5 mM GST or S2ED. After 30’, cells were fixed, permeabilised and immunostained 
for active β1 expression (9EG7 clone, green) and cell nuclei (DAPI, blue). Images were 
captured on an Olympus IX81 inverted microscope. Fluorescent intensity profiles were 
calculated over an arbitrary horizontal line (white line) using ImageJ. Scale bar represents 200 
µm. (Figure from De Rossi et al., 2014). 
 
Fig. 4.38 Effect of S2ED on β1 integrin activation – adherent ECs. Confluent monolayers 
of sEND cells were grown on glass slides and scratch wounds were made prior to the addition 
of either 0.5 mM GST or S2ED. After 30’, cells were fixed, permeabilised and immunostained 
for active β1 expression (green, 9EG7 clone), F-actin (red) and cell nuclei (DRAQ5, blue). 
Images captured on a Zeiss confocal microscope and processed on Imaris software are 
representative of at least 5 images per condition. Scale bar represents 20 µm. (Figure from De 
Rossi et al., 2014). 
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To gain more confidence over these results, we decided to use another EC line, namely 
HUVECs which is known to activate β1 integrins upon stimultation with Manganese. Again, 
the addition of S2ED in the medium, after stimulation with Manganese, resulted in a decrease 
in active β1 integrin compared to GST-treated or untreated control . Notably, these results 
were obtained using a different active β1-specific Ab (HUTS4) and nonetheless showed the 
same results seen previously with the 9EG7 Ab (Fig. 4.39). 
This suggested that S2ED impairs the activation of β1 integrins on ECs both during migration 
and when that is triggered artificially with Manganese. 
 
 
Fig. 4.39 Effect of S2ED on β1 integrin activation – adherent ECs. HUVECs were seeded 
on glass slides coated with fibronectin (10 µg/ml) and collagen I (30 µg/ml) in 0.1% gelatin. 
Cells were then treated with or without 1 mM MnCl2 in the presence of either 0.5 mM GST 
or S2ED for 30’. Cells were then fixed/permeabilised and immunostained for active β1 integrin 
(green, HUTS4 clone) and cell nuclei (DRAQ5, blue). Images were captured on a Zeiss 
confocal microscope and processed on Imaris software. Scale bar represents 20 µm. (Figure 
from De Rossi et al., 2014). 
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4.2.4. Discussion 
In the first section of this thesis, I provided evidence to show that all four syndecan 
ectodomains are strong negative regulators of angiogenesis in vitro. The fact that the syndecan 
ectodomain sequences share very little homology would suggest that their anti-angiogenic 
effect is achieved through four different pathways and previous studies (Whiteford et al., 2007) 
would suggest these pathways involve integrins of the αVβ3, αVβ5 and β1 subfamily. For this 
reason, each syndecan ectodomain would deserve to be studied separately; unfortunately, due 
to the time limitation of a 3-year PhD program, I decided to focus on and follow up only 
syndecan-2 and explore in more detail not only the mechanistic of its anti-angiogenic 
properties but also the feasibility of its potential therapeutic application in anti-angiogenic 
therapies.  
In this second section, I tried to answer experimentally the questions raised in the discussion 
to the previous section. For example, the anti-angiogenic effect of syndecan ectodomains was 
elucidated by using the aortic ring assay which is an ex vivo system at best, this obviously 
raised the question as to whether S2ED anti-angiogenic effect would hold true in vivo. Here 
we have shown that syndecan-2 ectodomain is a potent inhibitor of angiogenesis in vivo with 
extremely promising therapeutic potential in inhibiting tumor angiogenesis.  We have in fact 
shown that when HEK293T cells are grown in vivo in the presence of syndecan-2 ectodomains 
they develop a tumor 40% smaller than control. The fact that these tumors are also less 
vascularised is in agreement with our hypothesis that syndecan-2 ectodomain inhibits the 
formation of new blood vessels. 
In the previous section, it was discussed whether physiological shedding of syndecans would 
result in release of molecules with biological activity. This question was answered by over-
expressing full length syndecan-2 in HEK293T and subsequently promoting its shedding via 
addition of TNF-α to the medium. The proteoglycans contained in the conditioned medium 
were then purified and the purification product, enriched of physiologically shed syndecan-2, 
was shown to be anti-angiogenic compared to control. This certainly represents one of the 
most interesting results I obtained during this part of the project. The fact that syndecan-2 is 
shed in response to an inflammatory stimulus such as TNFα does not come as a surprise as 
inflammation has been shown to trigger syndecan cleavage in many systems (Andrian et al., 
2005; Pruessmeyer et al., 2010; Tan et al., 2012); syndecan shedding, however, has always 
been considered as a way to suppress syndecan functions on the cell surface and/or to release 
soluble competitors for ligand binding; here, for the first time, we showed that syndecan 
shedding has an additional consequence which has previously only been theorized and  is that 
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of releasing in the extracellular space a biologically active molecule which is able to affect 
other cells behaviour in a paracrine way. Moreover, inflammation and angiogenesis are often 
intertwined in physiological and pathological conditions: for example, angiogenesis enables 
the exaggerated influx of leukocytes in the tissue during chronic inflammation and, on the 
other hand, an inflammatory response (innate immunity, for the most part) is associated with 
new blood vessel formation (e.g. during wound healing or cancer growth) (Imhof and Aurrand-
Lions, 2006). It is therefore tempting to speculate that in these scenarios where inflammation 
and angiogenesis occur, shedding will release in the extracellular space shed syndecan-2 which 
will stay anchored to the ECM (via HS-ECM interactions) and would  function as a “stop” 
signal to ECs. Where, when and from which cells syndecan-2 is shed, could potentially 
determine both spatial and temporal regulation of new blood vessel formation.  
The use of HEK293T as an expression system for the production of syndecans was developed 
as part of my project for the first time and will represent an invaluable tool for future studies 
on syndecan biology in our lab. Studies on syndecan ectodomains have always taken 
advantage of bacterial expression systems and for this, syndecan ectodomains were studied as 
proteins lacking the HS-substitution. Our eukaryotic system enabled us to compare the effect 
on angiogenesis of syndecan-2 ectodomain (complete of its HS-substitutions), 
physiologically-shed syndecan-2 and bacterially-derived syndecan-2 ectodomain (without 
HS-substitutions) and led us to conclude that syndecan-2 ectodomain anti-angiogenic effect 
resides in its extracellular core protein, its independent of and unaffected by its HS chains.  
The experiments I conducted confirmed the hypothesis that S2ED-mediated inhibition of EC 
migration and angiogenesis described in the previous section requires the involvement of both 
CD148 and β1 integrins (Fig. 4.40 a). We could show that for S2ED to exert its anti-angiogenic 
function the adhesion regulatory domain, previously (Whiteford et al., 2011) mapped to P124 
to F141, must be present. This sequence contains the domain which was shown to directly 
interact with CD148 on fibroblasts and we showed by immuno-precipitation that this is also 
the case for endothelial CD148. We’ve also been able to show that the anti-migratory effect 
of S2ED on ECs was also accompanied with a reduction in active β1 integrins. We haven’t 
assessed whether other integrins might be activated or deactivated by S2ED, nor given direct 
evidence that deactivation of β1 integrins is what mediates S2ED anti-angiogenic effect. 
However, the fact that inhibition of EC migration by thrombospondin-1 type-1 repeats is 
mediated by β1 integrins (Short et al., 2005) and thrombospondin-1 (TSP-1) has identified as 
a CD148 agonistic ligand on ECs (Takahashi et al., 2012) are supportive of our hypothesis that 
S2ED engagement with CD148 may promote β1 integrin deactivation and lead to inhibition 
of EC migration and angiogenesis. 
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In Fig. 4.35, we came across a quite unexpected result when a soluble form of CD148, 
comprised of the N-terminal first five FN-like repeats, proved to be alone inhibitory of 
angiogenesis. With the information at hand, we can only hypothesize that soluble CD148 could 
form a dimer with the membrane bound CD148 on EC surface which activates the same 
signalling pathway that is activated by TSP-1 (Takahashi et al., 2012), S2ED (Whiteford et 
al., 2011) or anti-CD148 agonistic Ab (Takahashi et al., 2006) (Fig. 4.40 b).  
 
  
 
Fig. 4.40 CD148 activation hypotheses. a) Syndecan-2 ectodomain (S2ED) directly binds to 
the tyrosine phosphatase CD148, resulting in a decrease in the expression of active β1 integrins 
on the endothelial cell surface. b) Soluble CD148 (sol CD148) is also able to interact with its 
full length surface-bound counterpart and activate it. c) When both present in the medium, 
S2ED and sol CD148 act synergistically resulting in a stronger or wider activation of CD148. 
 
Surprisingly, when we added to the medium both soluble CD148 and S2ED we noticed an 
additive effect in reducing angiogenic sprouting. Why that is we cannot explain but one could 
speculate that soluble CD148 has more affinity to cell surface CD148 than to S2ED and 
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therefore fails to bind S2ED in the extracellular space and disrupt its interaction with 
membrane CD148. This would result in a synergistic double activation of CD148 (Fig. 4.40 
c) or in a single activation of more CD148 receptors by either S2ED or sol CD148. 
In my experiments, the same concentration of S2ED and soluble CD148 (0.5 µM) inhibits 
angiogenesis to the same extent, it would be interesting to test how this compares to the other 
known agonist of CD148, TSP-1 and the anti-CD148 Ab. This is particularly interesting in the 
optic of a potential anti-angiogenic therapy targeting CD148. Anti-VEGF therapies, which 
represent the vast majority of the anti-angiogenic treatments, have been developed with partial 
success (Kiselyov et al., 2007). Some patients in fact fail to respond to anti-VEGF drugs, 
possibly because angiogenesis is a multi-factorial process and as such a one-target therapeutic 
approach is unlikely to meet with the expectations. Here we have identified a novel pathway 
for the reduction of angiogenesis which is independent to VEGF and also identified S2ED as 
an activator of this pathway which can be potentially used in anti-angiogenic therapies. For 
this reason, we are now carrying out preliminary experiments to determine whether a 
syndecan-2 derived peptide could be used as an alternative or in combination with anti-VEGF 
drugs and whether this could rapidly translate into a more successful anti-angiogenic therapy 
in cancer. 
In conclusion, in this second results section of the thesis it has been shown that: 
1. Syndecan-2 ectodomain inhibits tumor growth and tumor-angiogenesis in vivo. 
2. Syndecan-2 is shed from HEK293T cells in response to TNFα. 
3. Physiologically shed syndecan-2 retains its anti-angiogenic activity. 
4.  The anti-angiogenic and anti-migratory properties of syndecan-2 ectodomain reside 
in its core protein, specifically in the last 18 aa (P124 to F141) corresponding to its 
adhesion-regulatory domain (ARD). 
5. The tyrosine phosphatase CD148 is expressed on ECs from three different vascular 
beds (lungs, skin and brain). 
6. The ARD of syndecan-2 can interact with EC CD148. 
7. A soluble form of CD148 extracellular core protein is inhibitory of angiogenesis but 
is unable to compete with cell surface CD148 for S2ED binding. 
8. Addition of S2ED to ECs (migrating or in suspension) results in a reduction of active 
β1 integrins. 
These results can be summerized in a model whereby upon syndecan-2 shedding from the cell 
surface of various tissue cells (e.g. fibroblasts, tumor cells, leukocytes, depending on the 
scenario), its ectodomain is released in the extracellular space. Here, its adhesion regulatory 
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domain (last 18 amino acids of the C-terminus of S2ED) engages in an interaction with the 
extracellular region of the tyrosine-phosphatase CD148 which is expressed on the surface of 
ECs. The extracellular engagment of CD148 is enough to promote a decrease in the activation 
of β1 integrin which in turn results in a reduction of EC migration, tube formation and in turn 
angiogenesis (Fig. 4.41). 
 
 
Fig. 4.41 Schematic of the model whereby shed syndecan-2 reduces angiogenesis. It is 
hypothesised that syndecan-2 is shed in inflammatory conditions from stromal cells (e.i. 
fibroblasts) and reaches the surface of endothelial cells on new blood vessels where it regulates 
β1 integrin activation via direct binding to CD148 tyrosine phosphatase. This modulation of 
β1 integrin activation status effectively suppresses endothelial cell migration, tube formation 
and angiogenesis (Figure from De Rossi et al., 2014).   
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4.3. Syndecan-4 is required for VEGF-A-induced angiogenesis 
4.3.1.  Introduction 
Syndecan-4, also known as Ryudocan and Amphiglycan, is the smallest member of the 
syndecan family with a core protein of 22 kDa and 3 HS chains attached to it. It was initially 
isolated from rat microvascular ECs as a molecule capable of binding antithrombin (Kojima 
et al., 1992a; Kojima et al., 1992b) but since then additional biological functions have been 
described, the vast majority of which are dependent on syndecan-4’s ability to interact with 
other adhesion receptors, ECM molecules and transferring these signals to the cytoskeleton 
via adaptor molecules (Woods and Couchman, 2001). Syndecan-4 is exceptional among the 
rest of the syndecan family in having a phosphatidylinositol-4,5-bisphosphate (PIP2) binding 
site that allows it to activate PKCα in the absence of changes in intracellular calcium levels 
(Horowitz et al., 1999; Horowitz and Simons, 1998; Oh et al., 1998). This activation of PKCα 
is key to several of syndecan-4 functions, including activation of RhoG and Rac1 and 
regulation of cell migration (Bass et al., 2007a) (Bass et al., 2011).  
 
 
Fig. 4.42 Syndecan-4 structural domains. Syndecan-4 is a linear single-pass transmembrane 
proteoglycan. It possesses a short cytoplasmic domain (green), a transmembrane domain 
(orange) and a longer ectodomain which consists of an extra-cellular core protein (red) 
substituted by 3 HS chains (yellow). (Figure modified from De Rossi et al., 2013). 
 
Syndecan-4 is ubiquitously expressed at very low level; however, its expression is highly 
inducible in certain situations. For example, it is found increased in the ischemic myocardium 
(Li et al., 1997), vascular tissues after injury (Nikkari et al., 1994) and in a variety of tumors 
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(Yoneda et al., 2012). Interestingly, the syndecan-4 Knock-Out (S4KO) mouse, which is 
viable, fertile and with no apparent abnormalities (Echtermeyer et al., 2001b), develops a more 
severe phenotype compared to wild-type littermates in those pathologies where angiogenesis 
is critical to the resolution phase of the disease; for example, these mice display delayed dermal 
wound healing associated with impaired angiogenesis and a cell migration defect 
(Echtermeyer et al., 2001b). The ability of syndecan-4 to regulate angiogenesis is also 
suggested by the observation of enhanced neovascularization in murine ischemic muscle 
following the combined delivery of basic Fibroblast growth factor and syndecan-4 (Jang et al., 
2012), and also by the notion that lack of syndecan-4 leads to foetal vessel degeneration in the 
placenta (Ishiguro et al., 2000a). Moreover, the syndecan-4 knock-out mouse shows increased 
mortality post myocardial infarction which is, again, associated with reduced number of 
capillary vessels in the healing tissue (Matsui et al., 2011).  
Quite recently syndecan-4 has been shown to participate in the signalling initiated by the 
inflammatory and pro-angiogenic molecule, Prostaglandin E2 (PGE2). The study revealed that 
in murine ECs lacking syndecan-4, PGE2-mediated pro-angiogenic effects (i.e. EC migration 
and tube formation) were decreased. They also showed that syndecan-4 activation of PKCα is 
necessary for the phosphorylation of ERK following PGE2 stimulation. This molecular 
mechanism was confirmed in vivo by showing a diminished angiogenic response to PGE2 both 
in the syndecan-4 and in the PKCα knock-out mice compared to the wild type (Corti et al., 
2013). 
In vitro experiments on ECs have also revealed that syndecan-4 is a key player in FGF 
signalling (Murakami et al., 2002b; Volk et al., 1999). Interestingly, this is not just by 
facilitating the interaction between FGF2 and its receptor FGFR1, but syndecan-4 cytoplasmic 
domain seems to also have a key role, as chimeras and deletion mutants of this portion lacking 
the V or the C2 regions fail to promote an effective intracellular response to FGF2. In 
particular, lack of the C2 region (which contains the PDZ binding domain) prevents the 
binding of GIPC/Synectin which results in a failure to activate Rac1 and thus inhibits EC 
migration (Tkachenko et al., 2006; Tkachenko et al., 2004). In contrast with the potent 
angiogenic response elicited by exogenous FGF2 in vitro, the role of endogenous FGF2 
remains uncertain. For one, fgf2 Knock-out mice are morphologically normal (Zhou et al., 
1998) and do not even show impairment in neovascularization after injury (Tobe et al., 1998) 
or hypoxia (Ozaki et al., 1998). It is therefore unlikely that syndecan-4 contribution to FGF2 
signalling can explain the dramatic angiogenic phenotype the syndecan-4 knock-out mice 
develop under pathological settings. 
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Moreover, syndecan-4 knock-out mouse is normal, viable and fertile; however, it develops a 
vascular phenotype in pathological settings, suggesting that either syndecan-4 is not 
expressed/needed during vascular development and only becomes fundamental during 
adulthood or that its function during vasculogenesis can be compensated by other molecules, 
possibly other syndecans.  
These open questions led to the present work aiming at investigate the role of syndecan-4 in 
angiogenesis. 
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4.3.2.  Aims 
In this section of my thesis I’ll describe the experiments I performed to determine the role of 
the EC heparan sulphate proteoglycan syndecan-4 during the angiogenic process. 
The aims of the experiments are as follows: 
1. Establish whether syndecan-4 knock-out mouse vasculature is normal; in other 
words, determine whether syndecan-4 has a role in vasculogenesis and/or vascular 
homeostasis. 
2. Challenge the syndecan-4 knock-out mouse in a model of aggressive cancer which 
relies on angiogenesis for its fast growth to determine whether lack of syndecan-4 
affects the pathology outcome. 
3. Test the syndecan-4 knock-out in in vivo and ex vivo models of angiogenesis to 
establish whether syndecan-4 is required for angiogenesis, if its role is tissue-specific 
and if it is specifically required for the angiogenic response driven by one or more 
pro-angiogenic factors. 
4. Look at the expression of syndecan-4 on ECs from homeostatic vasculature and 
angiogenic tissue. 
5. Determine the role of syndecan-4 in EC responses during angiogenesis. 
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4.3.3.  Results 
4.3.3.1. Characterization of syndecan-4 knock-out mouse vasculature 
Syndecan-4 knock-out mice do not present abnormalities at a glance and develop normally 
(Echtermeyer et al., 2001b). However, no detailed studies have been carried out to assess 
whether vasculogenesis in these animals occurs in such way to allow the formation of a 
vascular network comparable to that of wild-type littermates. 
To establish whether the syndecan-4 knock-out mouse quiescent vasculature is normal, the 
cremaster muscle and ear skin vascular beds were stained and several parameters were 
analysed. The cremaster muscle was chosen as this tissue has been characterized in depth by 
members of my lab and its thinness of around 600 µm allows optimal confocal microscopy 
imaging without the need for sectioning. Cremaster muscles and ears were excised and stained 
for VE-Cadherin, an EC trans-membrane protein which localizes to intra-cellular junctions, 
and α Smooth muscle actin, which is expressed in the cytoskeleton of pericytes and smooth 
muscle cells. Staining for these two markers helps distinguishing the different types of vessels 
in the vasculature: smooth muscle cells on arterioles are uniformly shaped, circumferentially 
arranged, closely packed, and tightly associated with the endothelium while pericytes on 
capillaries have two thin major processes that are oriented longitudinally along the vessel from 
which multiple minor process extend surrounding the capillary, capillary pericytes cover only 
a small proportion of the endothelial surface while pericytes on venules exhibit an irregular 
shape and extend numerous major processes covering a great part of the endothelial surface; 
VE-cadherin, on the other hand, is specific to ECs and therefore its staining is consistent and 
uniform on the EC junctions throughout the whole vascular network. 
160 
 
 
 
Fig. 4.43 Characterization of cremaster muscle quiescent vasculature of wild-type and 
syndecan-4 knock out mice. 6 Week old wild-type (WT) and syndecan-4 knock-out (S4KO) 
mice were culled and cremaster muscles excised, immediately fixed in 4% PFA, incubated for 
2 hrs in perm/block solution prior to immune-fluorescent staining with anti-αSmooth muscle 
actin (αSMA, red) and anti-VE-Cadherin (green) Abs. αSMA is a pericyte marker and 
therefore is not found on capillaries while VE-Cadherin is specific to EC junctions. All images 
shown are representative of 3 animals per group. Scale bar represents 100 µm.  
 
Confocal micrographs of wild-type and syndecan-4 knock-out cremaster muscle and skin 
vasculature (Fig. 4.43 and Fig. 4.44, respectively) show that no morphological differences can 
be detected by visual comparison; in addition, a more rigorous analysis of several parameters 
was carried out with the same result. Vessel density, vessel heterogeneity and pericyte 
coverage were evaluated (Fig. 4.45, Fig. 4.46 & Fig. 4.47) in both wild-type and syndecan-4 
knock-out vasculatures and in all instances values were not significantly different. 
In light of these results, we could conclude that syndecan-4 knock-out mice possess a 
morphologically normal vasculature, which would suggest that syndecan-4 does not play a 
major role in vascular development or that its role can be compensated, probably by other 
members of the syndecan family. 
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Fig. 4.44 Characterization of skin quiescent vasculature of wild-type and syndecan-4 
knock out mice. 6 Week old wild-type (WT) and syndecan-4 knock-out (S4KO) mice were 
culled and ear excised, immediately fixed in 4% PFA, incubated for 2 hrs in perm/block 
solution prior to immune-fluorescent staining with anti-αsmooth muscle actin (αSMA, red) 
and anti-VE-Cadherin (green) Abs. αSMA is a pericyte marker and therefore is very low 
expressed on capillaries while VE-Cadherin is specific to EC junctions. All images shown are 
representative of 3 animals per group. Scale bar represents 100 µm. 
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Fig. 4.45 Comparison of vessel density in wild-type 
and syndecan-4 knock-out mouse vasculature. An 
arbitrary line was drawn throughout the length of the 
micrographs (Fig. 4.43) and the number of vessels 
crossing that line counted and divided by the length of 
the line. At least 4 images per animal and 3 animals per 
group were analysed. No statistically significant 
differences were found between the 2 groups (WT vs. 
S4KO), according to Student’s t-test. 
 
 
Fig. 4.46 Comparison of vessel heterogeneity in 
wild-type and syndecan-4 knock-out mouse 
vasculature. Micrographs from Fig. 4.43 were 
analysed to assess the percentage of capillaries 
(diameter <10 µm), arterioles and venules (diameter 
between 10-40 µm) and arteries and veins (diameter 
>40 µm). Vessel diameter was measured and vessels 
were divided into 3 groups accordingly and their 
respective percentages were calculated. At least 4 
images per animal and 3 animals per group were 
analysed. No statistically significant differences were 
found between the 2 groups (WT vs. S4KO), according 
to Student’s t-test. 
 
Fig. 4.47 Comparison of pericyte 
coverage in wild-type and syndecan-4 
knock-out mouse vasculature. 
Micrographs from Fig. 4.43 were 
analysed to assess pericyte coverage 
index quantified as the percentage of 
vessel area covered by αSMA in both 
venules (10<40 µm) and veins (>40 µm). 
At least 4 images per animal and 3 
animals per group were analysed. No 
statistically significant differences were 
found between the 2 groups (WT vs. 
S4KO), according to two-way Anova. 
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Next, the presence of syndecan-4 on quiescent vasculature was examined. Syndecan-4 was 
found to be expressed at very low levels in the endothelium, both on venules and arteries, 
while it’s highly expressed on peri-vascular cells, possibly vessel-associated macrophages and 
fibroblasts (Fig. 4.48). Fig. 4.49 shows staining controls, left panel show a representative 
venule (top image) and artery (bottom image) stained with syndecan-4 Isotype control Ab 
(green), while red panel shows syndecan-4 knock out tissue stained with anti-syndecan-4 Ab.  
 
 
Fig. 4.48 Characterization of cremaster muscle quiescent vasculature of wild-type and 
syndecan-4 knock out mice. 6 Week old wild-type (WT) mice were culled and cremaster 
muscles excised,  immediately fixed in 4% PFA, incubated for 2 hrs in perm/block solution 
prior to immune-fluorescent staining with anti-αsmooth muscle actin (αSMA, red) and anti-
syndecan-4 (green) Abs. Left and right panels show a representative image of a venule and an 
artery, respectively. All images shown are representative of 3 animals per group. Scale bar 
represents 40 µm. 
 
 
 
 
 
 
 
 
WT WT 
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Fig. 4.49 Characterization of cremaster muscle quiescent vasculature of wild-type and 
syndecan-4 knock out mice. 6 Week old mice were culled and cremaster muscles excised, 
immediately fixed in 4% PFA, incubated for 2 hrs in perm/block solution prior to immune-
fluorescent staining. Left panel show a representative image of a wild-type (WT) venule and 
artery, top and bottom images respectively, stained with anti-αsmooth muscle actin (αSMA, 
red) and syndecan-4 Isotype control (green) Abs. Right panel shows staining of syndecan-4 
knock-out (S4KO) tissues with anti-αsmooth muscle actin (αSMA, red) and anti-syndecan-4 
(green) Abs. All images shown are representative of 3 animals per group. Scale bar represents 
30 µm.  
 
We also looked at cutaneous vascular permeability in response to a known vasodilator 
(bradykinin) as a measure of vascular functionality and no significant difference between wild-
type and syndecan-4 knock out animals was detected (Fig. 4.50).  
These data suggest that syndecan-4 is dispensable for vasculogenesis and vascular homeostasis 
(Fig. 4.43, Fig. 4.45, Fig. 4.46, Fig. 4.47) and function (e.g. regulation of vascular 
permeability) (Fig. 4.50). This idea is also supported by the fact that the level of expression of 
syndecan-4 on the homeostatic endothelium is extremely low (Fig. 4.48). Because of this, the 
angiogenic response of syndecan-4 knock-out mice and wild-type littermates were compared, 
on the basis that an eventual phenotype would be ascribed to a defect in angiogenesis and not 
to the vasculature being already abnormal. 
WT S4KO 
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Fig. 4.50 Vascular permeability in wild-type and syndecan-4 knock-out mice. Vascular 
permeability was assessed by measuring the accumulation of Albumin-bound Evans Blue dye 
in the dorsal skin of mice. 6-8 week wild-type (WT) and syndecan-4 knock-out (S4KO) mice 
received Evans Blue dye (0.5% in PBS, 5 μl per g bodyweight) i.v. through the tail vein. 
Afterwards, 50 µl of PBS containing either 100 μg of Bradykinin (BK) in PBS or PBS alone 
were injected s.c. in the mouse dorsal skin. After 1h30’ animals were sacrificed. Dorsal skin 
was then excised. Injected sites were cut out as circular patches using a metal puncher (~8 mm 
in diameter). Samples were then incubated in 250 μl of Formamide at 56°C for 24 h to extract 
Evans Blue dye from the tissue. The amount of accumulated Evans Blue dye was quantified 
by spectroscopy. Results are presented as the optical density at 620 nm (OD620) per mg tissue 
and per mouse. Values are expressed as mean ± s.e.m. of 5≤n≥7 animals per group. 
Statistically significant differences between PBS control and BK within each group (WT and 
S4KO) are represented by asterisks while differences between WT and S4KO within each 
condition are not statistically significant. *P<0.05, **P<0.01 according to two-away Anova 
with Sidak correction for multiple comparisons. 
 
4.3.3.2. Melanoma tumor growth is reduced in the syndecan-4 knock-out mice and 
correlates with decreased angiogenesis 
As reviewed in 1.2.3, angiogenesis is a feature of numerous diseases including cancer.  Skin 
cancer or Melanoma, is a form of aggressive cancer which strongly relies on angiogenesis. For 
this reason, melanomas were grown in syndecan-4 knock-out and wild-type mice to assess 
whether lack of syndecan-4 could impact the outcome of a pathology in which angiogenesis 
plays a key role. 
Melanoma B16F1 cells, a murine cell line derived from spontaneous skin tumor of C57BL/6J 
mice,  were injected into the flank of wild-type and syndecan-4 knock-out mice and tumors 
were allowed to grow for 1 and 2 weeks. At those time points mice were culled and tumors 
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photographed and measured. As clear from Fig. 4.51, tumors which developed in a syndecan-
4-free micro-environment grew far less than those in wild-type animals; this observation was 
confirmed by both measuring tumor volume and weight (Fig. 4.52). Notably, when tumors 
were sectioned and stained for tumor-associated new blood vessels, while the wild-type 
presented vessel-like structures with, in many cases, a well-defined lumen (white arrows in 
Fig. 4.53), in the syndecan-4 knock-out mice-derived tumors, ECs failed to organize into 
tubules and appeared randomly sparse throughout the tumor (Fig. 4.53). 
These results suggested that in a model of melanoma tumor, lack of syndecan-4 in the tumor 
microenvironment (to note that B16F1 cells are derived from wild-type animals) results in 
inhibition of tumor growth and is concomitant with impaired tumor angiogenesis. 
 
 
Fig. 4.51 Tumor growth in wild-type and syndecan-4 knock-out mice. 6 Week old Wild-
type and syndecan-4 KO mice were anesthetized and 100 μl of B16F1 cell suspension (5 x 107 
cells/ml in PBS) was injected s.c. into the mice flank. Mice were left for 7 days prior to 
sacrifice by cervical dislocation. Mice were shaved and pictures taken, skin was then excised 
and the tumor photographed. Images are representative of 6 mice per group. 
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Fig. 4.52 Quantification of tumor growth in wild-type and syndecan-4 knock-out mice. 6 
Week old Wild-type and syndecan-4 KO mice were anesthetized and 100 μl of B16F1 cell 
suspension (5 x 107 cells/ml in PBS) was injected s.c. into the mice flank. Mice were left for 
1 or 2 weeks prior to sacrifice by cervical dislocation. Volume of the tumors was measured 
with a ruler and weight was measured with a precision balance. To note, given the softness of 
the tumors, skin was cut together with it to maintain integrity of the samples. Values are 
expressed as means with standard error of 6 animals per group. Statistically significant 
differences between groups were found according to two-away Anova with Holm-Sidak 
correction for multiple comparisons. *P<0.05, **P<0.01, ***P<0.001.  
 
 
Fig. 4.53 Tumor angiogenesis in wild-type and syndecan-4 knock-out mice. 1-week tumors 
were snap frozen in liquid nitrogen and stored at -80°C. Subsequently, 20 µm-thick 
cryosections were cut, fixed in methanol and permabilized/blocked in normal goat serum prior 
to staining with an anti-CD31 Ab (red) and nuclei (draq5, blue). Arrows show the vessel lumen 
in the wild-type tumors. Scale bar represents 200 µm. 
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4.3.3.3. Syndecan-4 is required for VEGF-induced angiogenesis and its expression is 
increased by angiogenic stimuli 
To assess whether diminished angiogenesis in the context of decreased tumor growth in the 
syndecan-4 knock-out mice was causation or just correlation, new blood vessel formation 
alone was evaluated in several well-established model of angiogenesis, namely, in the in vivo 
Matrigel plug assay and in the ex vivo Aortic ring and Choroid explant assays. 
In the first set of experiments, both wild-type and syndecan-4 knock-out mice were injected 
with 500 µl of Matrigel containing PBS alone or with the angiogenic factors VEGF-A, bFGF 
or both. Because of the presence of the afore mentioned angiogenic factors, new blood vessels 
from the adjacent derma will respond to stimulus and invade the plug. After 5 days, all 3 
conditions were able to trigger an angiogenic response in the wild-type, as evident from the 
blood content of the plugs, qualitatively reflected in the redness of the samples (Fig. 4.54) and 
quantified via measuring the haemoglobin concentration in the plug (Fig. 4.55). Interestingly, 
the syndecan-4 knock-out mice behaved similarly to wild-type in all conditions except when 
angiogenesis was induced by VEGF-A alone; here, the syndecan-4 knock-out showed a very 
modest angiogenic response, almost as low as that induced by the PBS negative control and 
certainly much reduced compared to the VEGF-driven angiogenic response of wild-type 
littermates.  
 
Fig. 4.54 In vivo angiogenesis in wild-type 
and syndecan-4 knock-out mice. 
Angiogenesis was measured in vivo in wild-
type (WT) and syndecan-4 knock-out 
(S4KO) mice in the matrigel plug assay. 500 
µl of matrigel (7.5 mg/ml in PBS) 
containing 20 U/ml of Heparin plus growth 
factors (100 ng/ml VEGF-A, 100 ng/ml 
bFGF) as indicated were injected s.c. into 
the flanks of  6 weeks old mice and plugs 
were excised after 5 days. Picture shows the 
excised plugs. All images shown are 
representative of n=5-9 animals per group. 
Scale bar represents 1 cm.  
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Fig. 4.55 Quantification of angiogenesis in the Matrigel plug assay. After 5 days from the 
Matrigel injections, plugs were excised, weighted and incubated overnight at 4°C in dH2O. 
On the next day the amount of haemoglobin released from the plugs was measured using the 
Drabkin reagent kit and a spectrophotometer. Results show the concentration of haemoglobin 
per gram of plug (HG mg/ml/g). Values are expressed as mean ± s.e.m. of 5≤n≥9 animals per 
group. Statistically significant differences between PBS control and the different conditions 
within each group (WT and S4KO) are represented by asterisks while differences between the 
two groups within each condition are represented by hashtag. *P<0.05, **P<0.01, #P<0.001 
according to two-away Anova with Sidak correction for multiple comparisons. 
 
The results obtained in the dermal angiogenesis model were also observed in other models of 
angiogenesis in other tissues. These included the aortic ring assay, which takes advantage of 
the capacity of aortic grafts to develop an angiogenic response in vitro, in the form of aortic 
sprouts, when properly triggered by angiogenic factors. Similarly to dermal angiogenesis in 
the Matrigel plug, while the wild-type rings developed an angiogenic response when VEGF-
A, bFGF or both were used, aortic rings derived from syndecan-4 knock-out tissue showed 
impaired angiogenesis only when it was triggered by VEGF-A (Fig. 4.56, Fig. 4.57). 
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Fig. 4.56 Ex vivo angiogenesis in 
wild-type and syndecan-4 
knock-out mice. Aortas from 
wild-type and syndecan-4 knock-
out mice were cut into 1 mm rings 
and each ring singularly 
embedded into a thin layer of 
Collagen I containing the same 
conditions as for the Matrigel plug 
assay. Confocal micrographs of 
rings treated with VEGF-A 
showing angiogenesis reflected 
by the amount of angiogenic 
sprouts (ECs, BS1-Lectin-
positive, red) growing from the 
aortic ring in 1 week time. Images 
shown are representative of n=3-7 
animals per group. 
 
 
Fig. 4.57 Quantification of angiogenesis in the aortic ring assay. New blood vessel 
formation from the aortic ring experiments was quantified by counting the number of sprouts 
per ring 1 week from the embedding day. Values are expressed as mean ± s.e.m. of n=3-7 
animals per group where at least 5 rings per condition were used. Statistically significant 
differences between PBS control and the different conditions within each group (WT and 
S4KO) are represented by asterisks while differences between WT and S4KO within each 
condition are represented by hashtag. *P<0.05, **P<0.01, ##P<0.0001 according to two-away 
Anova with Sidak correction for multiple comparisons. 
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Fig. 4.58 Ex vivo choroid explant neovascularisation assay. Choroid explants from wild-
type (WT) and syndecan-4 knock-out (S4KO) mice were cut into 1 mm2 pieces and singularly 
embedded into a thin layer of Collagen I. Medium containing 1% FBS and 30 ng/ml of VEGF 
was added every 2 days. Confocal micrographs of choroid explants treated with VEGF-A 
showing angiogenesis reflected by the amount of angiogenic sprouts (ECs, BS1-Lectin-
positive, red and pericytes and fibroblasts, αSMA positive, green) growing from the choroid 
explant in 1 week time. Images shown are representative of n=3-7 animals per group. 
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Fig. 4.59 Quantification of angiogenesis in the choroid explant neovascularisation assay. 
New blood vessel formation from the choroid explants was quantified by counting the number 
of sprouts per explant 1 week from the embedding day. Values are expressed as mean ± s.e.m. 
of 3≤n≥7 animals per group where at least 6 explants per condition were used. Statistically 
significant differences between wild-type (WT) control and syndecan-4 het (S4HET) and 
knock-out (Syn4KO) are represented by asterisks. *P<0.05 According to one-away Anova 
with Dunnet correction for multiple comparisons. 
WT Syn4 -/-
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These experiments have generated a number of novel findings: first, they showed that 
syndecan-4 could have a potential role in tumor angiogenesis and therefore on tumor 
development; secondly, that syndecan-4 requirement to initiate an angiogenic response is 
limited to VEGF-A-driven responses; lastly, results were similar in different organs (e.g. skin, 
aorta and eye), suggesting that syndecan-4’s role in VEGF-A-induced angiogenesis is not 
tissue-specific. 
 
4.3.3.4. Syndecan-4 expression during angiogenesis 
Because an upturn in the biological activity of a molecule is often associated with its increased 
production, the expression of syndecan-4 during angiogenesis was next investigated.  
Previous works showed that wild-type aortic rings develop angiogenic sprouts when treated 
with VEGF-A for 7 days (Fig. 4.57). Staining of this aortic explants with anti-syndecan-4 Ab 
showed that syndecan-4 is found highly expressed on both ECs (counter-stained with BS1-
lectin) and stromal cells, possibly pericytes and smooth muscle cells. Notably, very low 
expression of syndecan-4 was observed in developed cremaster muscle ECs in vivo (Fig. 4.48) 
suggesting that syndecan-4 might be upregulated on ECs during angiogenesis. 
 
 
 
 
 
 
 
 
 
 
Fig. 4.60 Syndecan-4 is highly expressed on angiogenic sprouts. Wild-type aortic rings 
treated with VEGF-A for 7 days were fixed, permeabilized and subsequently stained with 
BS1-lectin (EC marker, red), Draq5 (nuclei, blue) and anti-syndecan-4 (green) Ab. Images 
shown are representative of 6 rings from 3 wild-type mice. Scale bar on the left is 40 µm and 
200 µm on the right. 
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To investigate this possibility, isolated primary murine ECs were isolated from the lungs of 
wild-type mice, cultured for 3 passages and treated for 2 and 4 hours with angiogenic stimuli, 
namely VEGF-A, bFGF and Angiogepoietin-2 and analysed for syndecan-4 expression. 
Analysis of the messenger RNA via qPCR revealed a progressive time-dependent upregulation 
of syndecan-4 gene transcription in all 3 settings, suggestive that syndecan-4 expression can 
indeed be positively regulated by angiogenesis, at least at the messenger level (Fig. 4.61).  
Concomitantly with increased syndecan-4 mRNA transcription, we also found, via FACS 
analysis, that upon VEGF-A treatment syndecan-4 is upregulated on EC surface. Notably, the 
increased presence of syndecan-4 on the cell membrane does not result in increased shedding, 
in fact no syndecan-4 is found in the conditioned media of ECs whether untreated or treated 
with VEGF-A, while shedding of syndecan-4 happens when cells are treated with a known 
shedding stimulator, Phorbol 12-myristate 13-acetate (PMA).  
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Fig. 4.61 Syndecan-4 expression in ECs is increased in vitro by angiogenic factors. 
Confluent wild-type primary lung ECs were treated for 2 and 4 hours with 20 ng/ml of VEGF-
A, bFGF or Angiopoietin-2 in serum-free medium. Syndecan-4 expression was normalised 
over GAPDH expression and graphed as increase relative to untreated control. Results are 
representative of 2 experiments, overall P value is 0.04 according to one-way Anova. 
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Fig. 4.62 Syndecan-4 expression on the surface of ECs increases upon VEGF-A treatment 
and does not result in shedding. Confluent wild-type primary mouse lung ECs were treated 
for 4 hours with 20 ng/ml of VEGF-A or PMA in serum-free medium. Cells were subsequently 
detached and analysed via FACS for syndecan-4 expression. Conditioned media was also 
collected prior to cell detachment and analysed for the presence of shed syndecan-4 via dot-
blot. Results are representative of 3 experiments, significant differences between untreated and 
VEGF-treated cells were determined using unpaired t-test. *P<0.05. 
 
These data provide strong indications that syndecan-4 is up-regulated on ECs during 
angiogenesis. This led us to investigate the role of syndecan-4 in EC responses during 
angiogenesis. 
 
4.3.3.5. Syndecan-4 is a co-receptor for VEGFR2 and is required for VEGF-A induced 
phosphorylation 
In the previous paragraph we have shown that syndecan-4 appears strongly up-regulated on 
ECs during angiogenesis and by angiogenic factors; in addition, we showed how the syndecan-
4 knock-out mouse is unable to develop an angiogenic response in reaction to VEGF-A. 
Notably, VEGF-A acts solely on ECs, as its receptor, VEGFR2, is only expressed on this cell 
type; upon VEGF-A binding, several tyrosine residues in VEGFR-2 become phosphorylated 
and this ignites a number of signalling cascades which affect EC behaviour. We hypothesised 
that syndecan-4 could play a role in VEGF-A/VEGFR2 activity. 
To test this hypothesis, primary lung ECs were isolated from wild-type and syndecan-4 knock-
out mice and grown to confluence in complete medium. Cells were then serum-starved for 6 
hours and treated with 30 ng/ml of VEGF-A for 5’. This time point and dose were chosen after 
several optimizations and literature research as they are able to induce the phosphorylation of 
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VEGFR2 upon addition of VEGF-A in wild-type primary lung ECs of murine origin. 
However, when the same dose of VEGF-A and incubation time were applied to syndecan-4 
knock-out ECs, these were found to be unable to produce the same response as their wild-type 
counter-parts, as evident from a representative Western blot film showing decreased 
phosphorylated (e.g. activated) VEGFR2 in syndecan-4 knock-out cells treated with VEGF-A 
(Fig. 4.63).    
Fig. 4.63 Endothelial syndecan-4 is 
required for VEGFR2 phosphorylation. 
Confluent wild-type (WT) and syndecan-4 
knock-out (S4KO) primary mouse lung ECs 
were serum-starved for 6 hours and then 
treated with 30 ng/ml of VEGF-A for 5’. 
Western blot of lysates from these cells were 
probed with Abs against total VEGFR-2 or 
phosphorylated VEGFR-2 (pVEGFR-2) or 
β-tubulin. The blot is representative of at 
least 4 experiments. Densitometry was 
performed on 4 blots and normalized against 
β-tubulin. Significant differences between 
untreated control and treated group were 
determined using two-way Anova with 
Tukey correction for multiple comparisons. 
*P<0.05. 
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It is described in the literature that VEGF-A binds to HS with high affinity (Robinson et al., 
2006b), and cells where HS has been enzymatically removed have abrogated VEGF-A 
signalling (Ashikari-Hada et al., 2005). In addition, VEGFR-2 also binds to HS, suggesting 
that HSPGs may play a role in facilitating the formation of an active signalling complex 
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between VEGF-A and VEGFR-2 (Nishiguchi et al., 2010). Collectively, these evidences led 
us to speculate that syndecan-4 could act as a co-receptor and facilitate the interaction of 
VEGF-A with its receptor VEGFR-2. 
A proximity ligation assay was used to investigate whether syndecan-4 and VEGFR-2 
associate in a complex in ECs upon VEGF-A treatment. This assay involves the use of two 
primary Abs raised in different species, species-specific secondary Abs, called PLA probes, 
each with a unique short DNA strand attached to it, bind to the primary Abs. When the PLA 
probes are in close proximity (< 40 µm), the DNA strands can interact through a subsequent 
addition of two other circle-forming DNA oligonucleotides. After joining of the two added 
oligonucleotides by enzymatic ligation, they are amplified via rolling circle amplification 
using a polymerase. After the amplification reaction, several hundred-fold replication of the 
DNA circle has occurred, and labelled complementary oligonucleotide probes highlight the 
product. The resulting high concentration of fluorescence in each single-molecule 
amplification product is easily visible as a distinct bright red spot when viewed with a 
fluorescence microscope. Confluent wild-type primary mouse lung ECs were serum-starved 
for 6 hours and then treated with 30 ng/ml of VEGF-A for 2’ and 5’. Subsequently, the 
proximity ligation assay was performed, following manufacturer instructions, to investigate 
the formation of complexes between syndecan-4 and VEGFR-2. Results showed that within 
2’ of VEGF-A treatment, there is a high increase in the formation of syndecan-4/VEGFR2 
complexes on ECs which then goes back to basal level at 5’ (Fig. 4.64, Fig. 4.65).   
 
Fig. 4.64 Syndecan-4 and VEGFR2 transiently go into close proximity upon VEGF 
stimulation in ECs. Confluent wild-type primary mouse lung ECs were serum-starved for 6 
hours and then treated with 30 ng/ml of VEGF-A for 2’ and 5’. Subsequently, the proximity 
ligation assay was performed, following manufacturer instructions, using anti-syndecan-4 and 
basal 2’ VEGF 5’ VEGF
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anti-VEGFR-2 Abs both specific for the N-terminal domain of the 2 molecules. Nuclei are 
stained with DRAQ5 (blue) while red dots (PLA dots) only appear when syndecan-4 and 
VEGFR-2 are in close proximity (< 40 µm). Images shown were captured on a Zeiss confocal 
microscope and processed on Imaris software and are representative of at least 5 images per 
condition. Scale bar 20 µm. 
 
Fig. 4.65 Syndecan-4 and VEGFR2 transiently go into close proximity upon VEGF 
stimulation in ECs. Confluent wild-type primary mouse lung ECs were serum-starved for 6 
hours and then treated with 30 ng/ml of VEGF-A for 2’ and 5’. Subsequently, the proximity 
ligation assay was performed, following manufacturer instructions, using anti-syndecan-4 and 
anti-VEGFR-2 Abs both specific for the N-terminal domain of the 2 molecules. In control 
samples the protocol was conducted using only the anti-VEGFR2 Ab. PLA dots only appear 
when syndecan-4 and VEGFR-2 are in close proximity (< 40 µm). Images were captured on a 
Zeiss confocal microscope and PLA dots were counted on Imaris software. Data are 
representative of at least 5 images per condition. Significant differences were determined using 
one-way Anova with Tukey correction for multiple comparisons. ***P<0.001. 
 
Having established that upon VEGF-A addition syndecan-4 and VEGFR2 go into close 
proximity, possibly forming a complex, in wild-type ECs, we set to determine what happens 
in the absence of syndecan-4. Critically, PLA experiments with syndecan-4 knock-out cells 
using anti-syndecan-2 Ab suggested a compensatory mechanism whereby, in the absence of 
syndecan-4, ECs can partially but not sufficiently compensate (note that the number of 
Syn2/VR2 in the syndecan-4 knock-out cells is much lower than that of Syn4/VR4 complexes 
in the wild-type cells) by using syndecan-2 as a co-receptor to VEGFR2 (Fig. 4.66). 
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Fig. 4.66 Syndecan-2 and VEGFR2 transiently go into close proximity upon VEGF 
stimulation in syndecan-4 knock-out ECs. Confluent wild-type and syndecan-4 knock-out 
primary mouse lung ECs were serum-starved for 6 hours and then treated with 30 ng/ml of 
VEGF-A for 2’. Subsequently, the proximity ligation assay was performed, following 
manufacturer instructions, using anti-syndecan-4 or anti-syndecan-2 Ab in combination with 
anti-VEGFR-2 Ab, all three specific for the N-terminal domain of the molecules. PLA dots 
only appear when syndecan-4 or syndecan-2 and VEGFR-2 are in close proximity (< 40 µm). 
Images were captured on a Zeiss confocal microscope and PLA dots were counted on Imaris 
software. Data are representative of at least 5 images per condition. Significant differences 
were determined using two-way Anova with Sidak correction for multiple comparisons. 
*P<0.05, ****P<0.0001. 
 
Collectively, the data presented in this paragraph showed that syndecan-4 is required for 
efficient VEGFR2 activation; moreover, proximity ligation assays gave strong indications that 
syndecan-4 is acting as a co-receptor facilitating the interaction between VEGF-A and 
VEGFR2. Also of note, syndecan-2 appears to be involved in a compensatory mechanism in 
syndecan-4-deficient EC to overcome the co-receptor role of syndecan-4.  
 
4.3.3.6. Soluble competitor of syndecan-4 can reduce angiogenesis 
Because our results suggest that VEGF-A-driven angiogenesis requires the formation of a tri-
molecular complex including syndecan-4, VEGFR-2 and VEGF-A on the cell surface of ECs, 
we decided to test the effect of the addition of soluble syndecan-4 ectodomain to the medium 
of wild-type cells to compete in the syndecan-4 interactions and dismantle the complex. 
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Treatment of wild-type ECs with syndecan-4 extra-cellular domain (solS4ED) diminished the 
activation of VEGFR2 in response to VEGF-A, confirming that syndecan-4 interacts with 
VEGFR2 on the cell surface rather than intracellularly (Fig. 4.67). Moreover, this effect has 
functional implications to VEGFR2-dependent signalling pathways; for example, one of 
VEGF-A effects on ECs is the promotion of VE-Cadherin internalization which leads to 
dissociation of cell-cell contacts (Gavard and Gutkind, 2006). When confluent MLECs were 
treated with VEGF-A164, VE-Cadherin started to disappear from the cell junctions and got 
internalized into cytoplasmic vesicles, but when soluble S4ED was added to the medium, such 
process appeared prevented, with VE-Cadherin still retained in EC adherens junctions after 
VEGF-A164 addition and not much of it being found inside cell vesicles (Fig. 4.68, Fig. 4.69). 
Finally, we tested soluble S4ED in the ex vivo model of neo-vascularisation of the mouse aortic 
ring assay and, notably, we observed a strong reduction in the angiogenic response (Fig. 4.70).  
Collectively, these results provide further evidence that syndecan-4 is indeed required on the 
EC surface using soluble syndecan-4 as a competitor of the membrane-bound form has the 
therapeutic potential of efficiently blocking VEGF-driven angiogenesis.  
Fig. 4.67 Soluble syndecan-4 ectodomain 
diminishes VEGFR2 phosphorylation. 
Confluent wild-type (WT) primary mouse 
lung ECs were serum-starved for 6 hours 
and then treated with 30 or 10 ng/ml of 
VEGF-A for 5’ in the absence or presence 
of soluble syndecan-4 ectodomain 
(solS4ED) 0.5 μM. Western blot of lysates 
from these cells were probed with Abs 
against total VEGFR-2 or phosphorylated 
VEGFR-2 (pVEGFR-2, tyrosine 1056). 
The blot is representative of at least 4 
experiments. Densitometry was performed 
on 4 blots and normalized against β-
tubulin. Significant differences between 
untreated control and treated group were 
determined using two-way Anova with 
Tukey correction for multiple 
comparisons. **P<0.01. 
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Fig. 4.68 Effect of soluble syndecan-4 ectodomain on VEGF-induced VE-Cadherin 
internalization in ECs. Primary mouse lung ECs were plated on glass slides; confluent cells 
were then washed with PBS and incubated with anti-VE-Cadherin Ab (BV13 clone) at 4°C 
for 1h in medium containing 20 mM HEPES and 3% BSA. Unbound Ab was then rinsed with 
ice-cold medium and cells were incubated with 30 ng/ml of VEGF-A in serum-free medium 
or serum-free medium alone at 37°C for 5’ to allow the internalization of VE-Cadherin. An 
acid wash was then use to remove the Ab bound to cell-surface VE-Cadherin, this wash 
contained 25 mM glycine, 3% BSA in PBS (pH 2.7). To assess the effect of soluble syndecan-
4, 0,5 µM of shed syndecan-4 was added in the VEGF-A incubation. Images shown were 
captured on a Zeiss confocal microscope and processed on Imaris software to show VE-
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cadherin in black and nuclei in red and are representative of at least 5 images per condition. 
Scale bar represents 20 µm. 
 
 
 
 
Fig. 4.69 Quantification of VE-Cadherin 
internalization. Images from previous 
experiments were analysed on Imaris software 
and black dots, indicative of VE-cadherin positive 
vesicles, were counted and divided by the amount 
of nuclei in the picture. At least 5 images per 
group were analysed. Statistically significant 
difference was found between cells treated with 
VEGF and those treated with VEGF in the 
presence of soluble syndecan-4. ****P<0.0001 
according to Student’s T-test. 
 
 
 
Fig. 4.70 Soluble syndecan-4 ectodomain inhibits 
aortic sprouting. Mouse thoracic aortas were  cut 
into rings which were embedded in 150 µl of 
Collagen type I (1 mg/ml) containing 0.5 µM of 
syndecan-4 ectodomain (S4ED) or PBS in 200 µl of 
OPTIMEM containing 30 ng/ml of VEGF-A. The 
number of sprouts was measured 7 days after 
embedding. Each bar represents the mean with 
standard deviation of at least 9 rings per group. 
Significant differences between untreated control 
and treated group were determined using one-way 
Anova with Dunnett correction for multiple 
comparisons. ***P<0.001. 
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4.3.4.  Discussion 
This section describes experiments conducted to investigate the role of the HS proteoglycan 
syndecan-4 in angiogenesis. 
Here, I have shown that: 
1. Syndecan-4 does not affect vasculogenesis of muscle or skin vasculature 
2. Syndecan-4 expression is low on the cremaster muscle homeostatic vasculature 
3. Skin vascular permeability is not affected by lack of syndecan-4 
4. Syndecan-4 knock-out mice develop smaller and less vascularised melanoma tumors 
5. Lack of syndecan-4 impairs specifically VEGF-A-driven angiogenesis 
6. Requirement for syndecan-4 for VEGF-A-driven angiogenesis is not tissue-specific 
7. Syndecan-4 is expressed on ECs in angiogenic tissues 
8. Syndecan-4 expression on ECs is increased by angiogenic stimuli both at messenger 
and protein level by angiogenic factors in vitro 
9. Syndecan-4 is retained on EC surface and it is not shed upon VEGF-A treatment in 
vitro 
10. Efficient VEGFR2 phosphorylation upon VEGF-A binding requires endothelial 
syndecan-4 in vitro 
11. Syndecan-4 and VEGFR2 go into close proximity upon VEGF-A stimulation of ECs 
in vitro 
12. Syndecan-2 could partially compensate for syndecan-4 in its absence as a VEGFR2 
co-receptor 
13. Addition of a soluble form of syndecan-4 ectodomain is effective in decreasing 
VEGFR2 phosphorylation, one of its downstream pathways and strongly inhibits 
angiogenesis ex vivo 
In summary, I have identified syndecan-4 as a key regulator of adult neo-vascularisation but 
dispensable for vasculogenesis and vascular homeostasis. I have shown that syndecan-4 is 
expressed at very low level on homeostatic vasculature, whereas its expression is markedly 
increased on angiogenic vessels and following in vitro stimulation of ECs with angiogenic 
factors. The data suggest that syndecan-4 acts as a co-receptor to facilitate the interaction of 
VEGF-A with its receptor VEGFR2 during angiogenesis. Finally, I have revealed that the 
treatment of ECs with a soluble form of syndecan-4 blocks VEGF-A signalling and inhibits 
ex vivo neo-vascularisation. 
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Fig. 4.71 Schematic of the model whereby syndecan-4 is required for VEGF-A-induced 
angiogenesis.  Syndecan-4 is found very low expressed on the endothelium; during 
angiogenesis, however, syndecan-4 expression increases and its presence on the endothelial 
cell surface is required to facilitate the interaction of VEGF-A with its receptor VEGFR-2. 
 
This model fits well with previous studies showing that syndecan-4 expression is found 
increased in pathologies featured by an angiogenic response, these include the ischemic 
myocardium (Li et al., 1997), vascular tissues after injury (Nikkari et al., 1994) and in a variety 
of tumors (Yoneda et al., 2012). Moreover, the syndecan-4 knock-out (S4KO) mouse develops 
a more severe phenotype compared to wild-type littermates in those pathologies where 
angiogenesis is critical to the resolution phase of the disease; for example, these mice display 
a delayed dermal wound healing associated with impaired angiogenesis and a cell migration 
defect (Echtermeyer et al., 2001b). The ability of syndecan-4 to regulate angiogenesis is also 
suggested by the observation of enhanced neovascularization in the ischemic muscle following 
the combined delivery of basic Fibroblast growth factor and syndecan-4 (Jang et al., 2012) and 
also by the notion that lack of syndecan-4 impairs foetal vessels in the placenta (Ishiguro et 
al., 2000a). Moreover, the syndecan-4 knock-out mouse shows increased mortality post 
myocardial infarction which is, again, associated with reduced number of capillary vessels in 
the healing tissue (Matsui et al., 2011). Because VEGF-A is the most potent pro-angiogenic 
factor  (Larrivee and Karsan, 2000) and because syndecan-4 is necessary for VEGF-A activity, 
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it is not surprising that the syndecan-4 null mice develop a dramatic phenotype in those 
pathological settings where new blood vessel formation is required. 
The VEGF-A gene is composed of 8 exons which by undergoing alternative splicing result in 
the generation of 4 different isoforms: VEGF-A121, VEGF-A165, VEGF-A189, VEGF-A206 
(where the numbers are indicative of the amount of amino acids they retain after signal peptide 
cleavage) (Houck et al., 1991). In all my experiments I have used VEGF-A165 (164 for work 
on murine cells) as this is the predominant isoform. This isoform is a heparin-binding 
homodimeric glycoprotein of 45 kDa (Houck et al., 1992). Interestingly, when VEGF-A loses 
its heparin-binding properties, this reflects in loss of its mitogenic activity (Keyt et al., 1996). 
The importance of VEGF-A 165 became clear when it was shown to be the only isoform able 
to rescue a tumorigenic phenotype in mice lacking the VEGF gene (Grunstein et al., 2000), 
moreover, mice expressing only VEGF-A120 (an isoform which does not have the heparin-
binding domain) die shortly after delivery, emphasizing the importance of the heparin-binding 
domain for VEGF-A properties. VEGF-A binds to HS with high affinity (Robinson et al., 
2006b), and cells where HS has been enzymatically removed have abrogated VEGF-A 
signalling (Ashikari-Hada et al., 2005). VEGF-A receptor, VEGFR2, also binds to HS, 
suggesting that HSPGs may play a role in facilitating the formation of an active signalling 
complex between VEGF-A and VEGFR2 (Nishiguchi et al., 2010). HSPGs are in fact 
regulators of VEGF-A gradients. It was however unknown whether this activity was common 
to all HSPG or specific to one or more. The data I’ve just presented certainly suggest that 
syndecan-4 possesses the ability to complex with VEGFR2 and the fact that soluble syndecan-
4 ectodomain is able to inhibit VEGF-A driven VEGFR2 phosphorylation would infer that the 
HS chains are important to this function (Fig. 4.64, Fig. 4.70). However, I do not possess at 
the moment solid data to conclusively say whether syndecan-4 HS chains actively interact with 
VEGF-A, VEGFR2 or both. It is tempting to speculate that they are all implicated in the 
formation of a tri-molecular complex. 
Another important aspect of VEGFR2 activity is represented by the regulation of its 
endocytosis and trafficking (Simons, 2012).  Upon entry into the cells, VEGFR2 continues to 
signal, first in early endosomes (APPL and Rab5 positive) and then transitions into endosomes 
which are positive for EEA1 (Santambrogio et al., 2011). EEA1+endosomes containing 
VEGFR2 undergo intracellular trafficking utilising the complex Synectin/Myosin VI. VEGF 
signalling and in vivo angiogenesis are impaired in both synectin- and myosin VI-null mice 
(Dedkov et al., 2007; Paye et al., 2009). It is, however, unclear at the moment how VEGFR2 
in the EEA1+ endosome interacts with synectin/myosin VI complex. Interestingly, synectin 
possesses a PDZ motif which is known to interact with a number of molecules including 
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syndecan-4. It would be therefore tempting to speculate that syndecan-4 is involved in 
VEGFR2 endocytosis and trafficking. An interesting approach to test this hypothesis would 
be to evaluate the effect of a syndecan-4 mutant lacking the PDZ binding domain on VEGF 
signalling and VEGFR2 trafficking. 
Given the critical importance of the VEGF signalling system to vascular development and its 
exquisite sensitivity to the level of the ligand (even a 50% reduction in VEGF levels during 
development leads to embryonic lethality), it is quite surprising that the syndecan-4 null mouse 
develops normally. There are however several possible explanations to this. For example, as 
mentioned above, an important difference between VEGF-A165 and 121 isoforms is the 
absence of the heparin-binding domain in the latter. While VEGF-A165 has intermediate 
properties as it is secreted but some diffuse and some stay anchored to the cell surface or the 
ECM, the 121 isoform is freely diffusible (Houck et al., 1992; Park et al., 1993). It is likely 
that the isoforms of VEGF-A that do not possess a heparin binding domain, including VEGF-
A-12, lack the capability to bind to syndecan-4 HS chains. This suggests that there may be 
syndecan-4 dependent and independent forms of VEGF signalling which in part may explain 
why developmentally the syndecan-4 knock-out mouse is normal. 
In addition, because of the strong sequence homology in the cytoplasmic and transmembrane 
domains and in the sugar chains, especially between syndecan-1 and -3 and syndecan-2 and -
4, it is commonly believed that syndecans have overlapping roles and can compensate for each 
other. A recent study, for instance, showed that syndecan-4 null mice have delayed bone 
fracture repair and, importantly, that, in the absence of syndecan-4, syndecan-2 gets 
upregulated in the developing cartilage (Bertrand et al., 2013). This situation could in many 
ways mirror what I’m seeing in the context of angiogenesis. An interesting question to address 
is whether syndecan-2 is upregulated during vasculogenesis since I saw a principle of 
compensatory mechanism when syndecan-4 null ECs formed syndecan-2/VEGFR2 
complexes upon VEGF-A addition (Fig. 4.66). In cartilage and vasculature development, 
syndecan-2 might be structurally similar enough to syndecan-4 to compensate for its absence 
but in pathological settings, maybe because the quick response requires higher efficiency, is 
inadequate. 
In vitro experiments on ECs have also shown that syndecan-4 is a key player in FGF2 
signalling (Murakami et al., 2002b; Volk et al., 1999). However, in contrast with the potent 
angiogenic response elicited by exogenous FGF2 in vitro, fgf2 Knock-out mice are 
morphologically normal (Zhou et al., 1998) and do not even show impairment in 
neovascularization after injury (Tobe et al., 1998) or hypoxia (Ozaki et al., 1998). It is 
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therefore unlikely that syndecan-4 contribution to FGF2 signalling can explain the dramatic 
angiogenic phenotype the syndecan-4 knock-out mice develop under pathological settings. 
Challenging the syndecan-4 knock-out mouse both in vivo (Matrigel plug assay) and ex vivo 
(aortic ring assay) models of angiogenesis hasn’t revealed any significant impairment in FGF-
driven responses, which can be explained by the fact that FGF2 can also bind other HSPGs, 
including syndecan-1 (Filla et al., 1998). 
Similarly to syndecan-4, syndecan-1 is also upregulated during skin wound healing (Gallo et 
al., 1996a), and lack of syndecan-1 results in delayed skin (Bernfield et al., 1999b) and corneal 
wound repair (Stepp et al., 2002). Again, likewise syndecan-4 null mice, syndecan-1 null mice 
are viable and fertile. The generation of a syndecan-1 and syndecan-4 double knock-out could 
shed light on whether these two HSPG provide complementary signalling pathways during 
wound healing.  
Angiogenesis is a key feature of many diseases, many of which are life-threatening.  Malignant 
tumors, for example, are composed of fast-growing highly-metabolic cells and without a good 
blood supply to bring nutrients and oxygen and remove waste products they wouldn’t grow 
larger than 1 to 2 mm across. For this reason, tumor cells are known to produce and release 
pro-angiogenic factors which will stimulate neighbouring blood vessels to grow new 
capillaries within the tumor mass. Angiogenesis is also characteristic of chronic inflammatory 
conditions such as Rheumatoid Arthritis where the highly proliferative synovial cells increase 
the metabolic demand for oxygen and nutrients, but also cardiovascular diseases, blindness, 
complications of AIDS, diabetes, Alzheimer's disease and more than 70 other major health 
conditions affecting children and adults worldwide. The idea of blocking angiogenesis by 
targeting the VEGF-A/VEGFR2 pathway has led to the development of a number of drugs: 
targeting VEGF-A directly (e.g. the humanized monoclonal Ab Bevacizumab) or targeting 
VEGFR2 signalling pathways (mainly small tyrosine-kinase inhibitors such as Sunitinib and 
Sorafenib). Although this is the only form of effective therapy currently in clinical use, 
therapies that target VEGF directly are raising several concerns. One of which is that VEGF 
not only drives new vessel growth but increasing evidence is suggesting that it also has an 
important role for trophic maintenance of the healthy vasculature. Prolonged anti-VEGF 
therapy for cancer treatment is associated with a number of severe adverse effects associated 
with endothelial dysfunction including: hypertension, microangiopathy, proteinuria in the 
kidney; cardiac ischemia/infarct, thromboembolic events in the heart, and bleeding in the 
gastrointestinal system (Meadows and Hurwitz, 2012). Moreover, Kurihara et al. have recently 
described a dramatic and rapid loss of ECs of the choriocapillaries and severe vision loss in 
mice following genetic deletion of the VEGF gene from the retinal pigment epithelial cells, 
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with alerting implications for the anti-VEGF therapy which is currently in use for the treatment 
of Wet Age related macular degeneration. These data would in fact suggest that an 
indiscriminate suppression of VEGF signalling, an effect similar to that reached by the anti-
VEGF therapies currently in use, might carry with it very dramatic side effects for the patients 
in the long run (Kurihara et al., 2012). This has highlighted the need to identify novel 
therapeutic targets to develop better therapies. In light of my results, it would be tempting to 
speculate that targeting syndecan-4 would still prove efficient in blocking VEGF signalling 
but unlike current anti-VEGF therapies, this effect would only be limited to the site of 
pathological neo-vascularisation with limited off-target side effects on the remaining healthy 
vasculature. This would represent an important translational advance for the treatment of 
angiogenesis-dependent diseases. 
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5. General discussion and Conclusions 
 
Fig. 5.1 Diagram depicting the proposed modes of action of syndecan ectodomains, shed 
syndecan-2 and endothelial syndecan-4 during angiogenesis, based on the results 
obtained during this PhD. 
 
In the first part of my project, I investigated the effects of the extracellular core proteins of 
syndecan-1, -2, -3 and -4 on EC function, particularly with regard to angiogenesis, and 
revealed that all four syndecan extracellular core proteins are able to inhibit angiogenesis ex 
vivo and strongly negatively regulate EC migration, invasion and tube formation in vitro (Fig. 
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5.1). In the second part of my project, I further characterized the anti-angiogenic properties of 
one family member, namely syndecan-2, and showed that these reside in its ability to interact 
with the EC surface tyrosine phosphatase CD148. Upon binding of S2ED to CD148, we 
observed reduced active β1 integrins resulting into inhibition of EC migration. EC migration 
is of paramount importance in angiogenesis and the anti-migratory effect of S2ED greatly 
reduces new blood vessel formation both in vitro and in vivo. Remarkably, this is an entirely 
novel pathway for the reduction of angiogenesis, which doesn’t directly act through VEGF 
(Fig. 5.1). Finally, since previous works suggested that syndecan-4-null mice may exhibit 
angiogenic defects I set out to determine the role of syndecan-4 in angiogenesis. Firstly, I 
observed an up-regulation of syndecan-4 on ECs upon stimulation with pro-angiogenic factors 
both in vitro and in vivo; then, by challenging syndecan-4 knock-out mice in in vivo models 
of angiogenesis, I revealed that these mice fail to respond specifically to VEGF-driven pro-
angiogenic signals. This effect can partially be explained by an impaired phosphorylation 
(hence activation) of VEGFR2 that we revealed in syndecan-4-null ECs treated with VEGF. 
We therefore propose a model whereby syndecan-4 is the main HS proteoglycan to act as co-
receptor for the VEGFR2/VEGF-A interaction (Fig. 5.1). 
 
5.1 Shedding and the fate of syndecan ectodomains 
 
Syndecan shedding is generally considered as a mechanism to promptly interrupt syndecan 
functions as co-receptor, chemo- and cytokine gradient regulator and adhesive receptor on the 
cell surface. Several proteinases, including MMPs and ADAMs, have been shown to being 
able to readily shed syndecans from a variety of cell types in specific conditions (e.g. tissue 
injury, inflammation, cancer). My work, and the work of others, has however highlighted that 
biological properties are contained within discrete regions of the syndecan ectodomains, 
properties which, depending on the reciprocal position of the active and the cleavage sites, can 
still be retained after syndecans are cleaved form the cell surface. Hence, shedding not only 
interrupts syndecan functions on the cell surface, but can also (or alternatively) release 
molecules in the extracellular space which are still bio-active and can interact with other cells 
in the surrounding tissue. It would therefore be interesting/necessary to re-evaluate all those 
studies which have looked at syndecan shedding only from a “loss of function” perspective. 
In mice, for example, shed syndecan-1 is often found in body fluids during inflammation. 
Syndecan-1 null mice show an exaggerated inflammatory response following allergen-
exposure suggesting that syndecan-1 shedding is involved in the resolution phase of 
inflammation (Xu et al., 2005). Syndecan-1 seems to also have a protective role in LPS-
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induced multi-organ injury and mortality. In particular, syndecan-1 shedding appears to be 
responsible for the clearance of KC and MIP-2 which regulates neutrophil infiltration 
(Hayashida et al., 2009). In this context would be interesting to investigate what the fate of 
shed syndecan-1 is: will it still stay in a complex with KC and MIP2 in the circulation? Can 
the sequestered chemokines interact with circulating leukocytes or with ECs? Could this 
mechanism promote off-site inflammation and distant organ damage? And what about cancer? 
Syndecans are expressed by most tumor cells and here they play important roles as adhesion 
receptors. It is therefore unsurprising that loss or increased expression of syndecans can affect 
both tumor cell adhesion and migration. However, not much is known about the autocrine 
effects of shed syndecans on tumor cells and even less about the paracrine effects of shed 
syndecans on the cells populating the tumor microenvironment. Recently, it has been shown 
that syndecan-2, shed from colon cancer cells, can act in an autocrine way to enhance cancer 
cell migration. We, on the other hand, have shown for the first time that shed syndecan-2 
negatively affect EC migration and can impede tumor angiogenesis in an in vivo model of 
melanoma. I have also revealed that primary lung fibroblasts shed syndecan-2 in response to 
inflammatory stimuli (data not shown). Not only tumor cells but also stromal cells, like 
fibroblasts, can therefore be a source of shed syndecans in the tumor microenvironment. 
Cancer cells are able to promote the conversion of stromal fibroblasts to cancer-associated 
fibroblasts (CAFs). CAFs are attracting a lot of interest lately as they have been shown to 
switch tumors to a more aggressive/metastatic phenotype through various mechanisms. One 
such mechanism is the promotion of angiogenesis. It would be therefore tempting to speculate 
that while healthy fibroblasts retain syndecan-2, activated fibroblasts release anti-angiogenic 
syndecan-2 under inflammatory conditions (e.g. cancer), when they switch to the CAF 
phenotype, they stop doing so. Of interest would also be to investigate whether shed syndecans 
have effects on resident immune cells that populate the tumor microenvironment. Notably, B 
lymphocyte express the phosphotyrosine CD148, it would therefore be extremely relevant to 
test the effect of shed syndecan-2 (which we have shown being able to interact with CD148) 
on these cells and on lymphoma.  
Further studies are critically needed to shed light on tumor syndecan shedding and how these 
moieties affect not only the tumor cells but also the surrounding cells; more thorough 
investigation would be needed especially to understand the temporal, spatial and dosage 
dependency of shed syndecan effects. On the basis of those results, development of anti-
angiogenic syndecan-derived therapeutic would have to be approached with a lot of caution as 
they might have undesirable side-effects on tumor growth and motility, depending on the 
tumor type.  
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5.2 A peptide based on syndecan-2 shows therapeutic efficacy in a 
murine model of wet Age-related macular degeneration 
 
The work I carried out to characterize the anti-angiogenic properties of syndecan-2 
extracellular domain have revealed that these lay within the last 18 aa of the protein. A small 
peptide that is capable of reducing β1 integrin activation in endothelial cell upon binding to 
the phosphatase inhibitor CD148. 
As β1 integrins have important roles in regulating angiogenesis, these integrins are an 
attractive target for anti-angiogenic therapies. Antagonists of one β1 integrin, α5β1, have 
undergone clinical testing. A chimeric mouse–human anti-α5β1 Ab, M200 (volociximab) has 
shown low toxicity in phase I studies. M200 was evaluated in phase II trials for metastatic 
melanoma, renal cell carcinoma and non-small cell lung cancer (Kuwada, 2007). Another drug 
in clinical trials, ATN-161, is a peptide inhibitor of integrin α5β1. In animal models of colon 
cancer, ATN-161 reduced metastases and improved survival when combined with 
chemotherapy (Stoeltzing et al., 2003). Thus, these two integrin α5β1-inhibiting drugs might 
offer future benefit to cancer patients. 
What advantages would the use of syndecan-2-peptide give compared to using M200 or ARN-
161 to inhibit angiogenesis? Although α5β1 integrin is found upregulated on ECs in the tumor 
vasculature, this integrin is widely expressed by many other cell types as it is the main receptor 
for the ECM molecule fibronectin. Thus targeting α5β1 integrin directly will carry with it 
unspecific side effects, due to the blocking of key functions on other cell types. Notably, the 
use of the syndecan-2-derived peptide will only block β1 integrins on those cells expressing 
CD148, which are endothelial cells and memory B-cells (according to our data and the 
literature). This will have the clear advantage of targeting the forming new blood vessels while 
sparing the remaining tissue.  
This rationale led us to further investigate whether an anti-angiogenic peptide-based therapy 
could be possible. We received funding from Queen Mary Innovation Ltd, Queen Mary 
University technology transfer company, to further test the syndecan-2-based peptide, now 
called QM107, in a range of angiogenesis assays before the filing of a patent. These studies 
have confirmed the ability of QM107 to inhibit angiogenesis both in vitro and ex vivo, and, 
more importantly, a first preliminary round of pre-clinical studies in a mouse model of wet 
age-related macular degeneration has shown that as little as 1 µM of QM107, injected intra-
vitreally, is able to attenuate choroidal neovascularisation by 30% with no visible side-effects. 
We are now looking forward to test higher doses and different times of injection to reach the 
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maximum efficacy possible for this potential therapeutic. Collectively, these data indicate that 
QM107 is a highly promising peptide-based anti-angiogenic therapeutic, which can be 
chemically synthesized and offer an alternative therapy to the current VEGF-based option. 
Furthermore, since it is a relatively small molecule compared to the existing Ab based 
therapeutics we envisage this could be administered in the form of eye drops as opposed to the 
current therapy which is administered via monthly injections into the eyes of patients. 
 
5.3 The identification of syndecan-4 as the main HSPG involved in 
the VEGF-A/VEGFR2 pathway 
 
There is a large body of evidence highlighting the importance of HS for an efficient VEGF-
A165/VEGFR2 signalling. These studies however failed to identify a particular HS-bearing 
molecule and rather assign this function to all HSPG. 
Importantly, growth factor binding to HSPG can serve four functions: (i) concentration of the 
growth factor at the cell surface and presentation to cell surface receptors, (ii) engagement of 
the HSPG in a co-receptor complex with altered binding or signalling properties compared to 
a minimal growth factor/receptor complex, (iii) control of growth factor diffusion to provide 
spatially restricted signalling cues and (iv) creation of a growth factor pool that can be released 
by shedding of either the HS chain or the growth factor (Iozzo, 2005).  
The interaction of VEGF-A165 with HS is determined by the exons 6 and 7 which code for 
the heparin binding domain (HBD) located to the carboxy-terminal and was shown to depend 
on basic residues. Site-directed mutagenesis studies have identified arginine residues R123, 
R124 and R159 of VEGF-A165 as crucial residues for the interaction with HS (Krilleke et al., 
2007). This finding is supported by the refined NMR structure of the HBD (Stauffer et al., 
2002), where these residues are localized on a contiguous binding surface on one face of the 
domain. Together with K125, K140, R145, R149 and R156 they form an electropositive patch 
positioned to interact with negatively charged HS.  
Several studies showed that both N-sulphation and 6-O-sulphation in the HS are crucial for 
VEGF-A165 binding, whereas 2-O-sulfate groups and carboxylate groups contribute to a 
lesser extent (Robinson et al., 2006a), a finding in agreement with earlier results obtained with 
heparin (Ono et al., 1999). VEGF-A binding to HS therefore differs from HGF and FGF-2 
which strictly require 2-O-sulfation. Notably, different patterns of HS chains could therefore 
contribute to the tissue specificity of growth factor signalling. 
193 
 
 
Soluble extracellular domain of VEGFR-2 isolated from conditioned medium is retained by 
heparin sepharose, suggesting direct binding to HSPG (Chiang and Flanagan, 1995). Although 
the involvement of other factors present in the medium could not be excluded, this interaction 
was ascribed to a short basic stretch between Ig-like domains 6 and 7 (Dougher et al., 1997).  
The importance of appropriately modified HS for cellular responses to VEGF-A165 has been 
well described. HUVEC cells treated with sodium chlorate, an inhibitor of HS sulphation, fail 
to proliferate in response to VEGF-A165 unless heparin (only sulphated forms) or sulphate is 
added back to the medium. Depletion of 6-O-sulfation by specific inactivation of the 
sulfotransferase HS6TS-2 results in abnormalities in branching morphogenesis of the caudal 
vein during embryogenesis in zebrafish (Ono et al., 1999). Interestingly, mammalian embryoid 
bodies derived from Ndst1/2−/− stem cells, lacking a sulphotransferase essential for HS 
biosynthesis, fail to respond to VEGF-A165 (Jakobsson et al., 2006) and the addition of 
exogenous HS could not substitute for the lack of correctly modified HSPG. Notably, co-
culture with cells expressing wild-type HSPG, but not VEGFR-2, resulted in rescue of VEGF-
A165 induced vascular development. Interestingly, VEGFR-2 activation was more persistent 
and this effect could not be elicited by binding of VEGF-A121. It’s tempting to speculate that 
HSPGs could trap the VEGFR2 in trans and prevent internalization and degradation, 
explaining the prolonged signalling.  
My studies would suggest that syndecan-4 is the main HSPG involved in VEGF-A165 
signalling. Proximity ligation experiments implied the formation of a syndecan-4/VEGF-
A165/VEGFR2 tri-molecular complex. Further work is however necessary to elucidate the 
exact interactions, of particular interest would be to understand what are the specific 
characteristic/modifications of syndecan-4 HS chains that make it such a strong VEGF co-
receptor compared, for example, to syndecan-2, to which syndecan-4 is extremely structurally 
similar. Syndecan HS chains can range from 80-200 kDa in mass and undergo a great number 
of enzymatic modifications. The HS chains of syndecan-4 could therefore represent the most 
variable component in the VEGF/VEGFR2 signalling complex. On the basis of this 
hypothesis, differential expression of the enzymes involved in the sulphation pathways of 
syndecan-4 HS chains could determine an additional, never described before, level of 
regulation of VEGF-induced angiogenesis. 
Ultimately, knowing which enzymes determine the optimal sulphation pattern on syndecan-4 
could also be translated in the clinic. My data clearly showed the pivotal role of syndecan-4 in 
pathological angiogenesis (melanoma and choroidal neo-vascularisation) and the additional ex 
vivo and in vitro studies would suggest that syndecan-4 pro-angiogenic functions are not 
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limited to the skin and choroid. A gene-therapy approach aimed at silencing the target 
sulphotransferase, for example, could prove efficient in blocking VEGF-induced 
angiogenesis. Alternatively, blocking Abs targeting syndecan-4 ectodomain could prove 
efficient to spatially dislodge syndecan-4 from the tri-molecular complex with VEGF-A and 
VEGFR2 and limit the downstream signalling, ultimately preventive the angiogenic response. 
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5.4   Conclusions 
 
Angiogenesis is feature of many diseases such as cancer, macular degeneration, cardiovascular 
diseases, blindness, complications of AIDS, diabetes, Alzheimer's disease and more than 70 
other major health conditions affecting children and adults worldwide.  
Like any biological process, angiogenesis is a complex process as it involves the participations 
of multiple cell types and molecules, working together to orchestrate the formation of a 
completely new blood vessel network. As part of its complexity, this process is tightly 
regulated and understanding how this is possible would allow us to switch it on and off when 
needed. 
During my PhD, I revealed that syndecan ectodomains can inhibit angiogenesis and that 
syndecan-4 can enhance this process. These basic science discoveries could aid future research 
that can be translated to improve anti-angiogenic therapy for the treatment of over one billion 
people affected by angiogenesis-dependent diseases worldwide. 
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Abstract
Syndecans are a four member family of multifunctional trans-
membrane heparan sulphate bearing cell surface receptors.
Each family member has common molecular architecture but
a distinct expression profile. Numerous molecular interactions
between syndecan heparan sulphate chains, growth factors,
cytokines, and extracellular matrix molecules have been
reported and syndecans are intimately associated with cell ad-
hesion and migration. Here, we describe the important emerg-
ing concept that contained within syndecan extracellular core
proteins are ‘‘adhesion regulatory domains.’’ Cell adhesion is
driven by the integrins and syndecan ectodomain adhesion
regulatory domains can alter integrin driven cellular
responses. Cell adhesion and migration is central to numer-
ous pathologies and an understanding of how syndecan ecto-
domains influence integrins will lead to novel therapeutic
strategies. VC 2013 BioFactors, 00(00):000–000, 2013
Keywords: syndecan; extracellular matrix; heparan sulphate;
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1. Introduction
1.1. The Syndecan Family
Syndecans are type I transmembrane heparan-sulphate pro-
teoglycan (HSPG) cell surface receptors. In invertebrates, the
syndecan family is represented by one member, while mam-
mals have four with different tissue- and cell-specific expres-
sion profiles: syndecan-1 is highly expressed on epithelial and
endothelial cells, monocytes, and fibroblasts, syndecan-2 is the
principal syndecan of mesenchymal cells, syndecan-3 is pres-
ent mostly in the nervous system, and syndecan-4 appears
ubiquitously expressed but at lower levels (Fig. 1a) [1–3].
Syndecans have roles in cell adhesion, migration, prolifer-
ation, and growth factor signaling and through these functions
contribute to important processes such as morphogenesis,
wound healing, angiogenesis, and tumor development. Many
of these activities are mediated by syndecan heparan-sulphate
(HS) chains, due to their interactions with a wide range of mol-
ecules, including extra-cellular matrix (ECM) components,
growth factors, chemokines and cytokines, enzymes, and so
forth. Syndecans lack an intrinsic enzymatic activity, however,
their cytoplasmic domains have several binding partners,
including phospho-lipids and kinases important for cell adhe-
sion and migration as well as forming a link between the ECM
and the actin cytoskeleton [4,5].
Syndecan family members contain a shared molecular
architecture. All possess a short highly conserved cytoplasmic
domain which can be further divided into three sub-domains,
the highly conserved C1 (membrane proximal) and C2 (mem-
brane distal) flank a V region. The V region sequence is dis-
tinct for each of the four syndecan family members and may
confer distinct functional characteristics for each molecule.
The C2 sub-domain has a canonical PDZ binding motif, and is
known to interact with several PDZ proteins including syntenin
and is of importance particularly with regard to syndecan
trafficking [6]. Syndecans exist on the cell surface as dimers
and the formation of these is driven mainly through residues
contained within the single pass syndecan transmembrane
domain. The extracellular core proteins of syndecans range in
size from 122aa (murine syndecan-4) to the largest 398aa
(murine syndecan-3). There is very little conserved sequence
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between syndecan family member ectodomains, however, all
four syndecans have Serine residues contained within Ser-Gly
motifs situated toward the N-terminus to which HS (and in some
cases chondroitin sulphate or dermatan sulphate) are covalently
linked. HS is a complex polysaccharide consisting of repeating
disaccharides (glucuronic acid and N-acetylglucosamine) which
can form chains of up to 150 repetitions. HS chains can be sul-
fated by the action of several transferases during its biosynthesis
which results in HS having a heterogeneous structure consisting
of alternating high and low sulfated regions. The extent to which
HS is sulfated can vary depending on tissue and cell type which
also has ramifications for the functionality of HSPGs in any given
tissue (for reviews see Refs. [7,8]).
The purpose of this review is to explore the biological roles
that have been identified for syndecan ectodomain core pro-
teins. There is a considerable body of work detailing syndecan
HS interactions and the role of the full length molecule in
pathology and development. These are briefly summarized in
the subsequent sections, however, the main focus will be to
examine the novel concept that regulatory protein sequences
exist in syndecan ectodomains which can influence cell
responses, particularly cell adhesion.
1.2. Syndecan Roles in Mammalian Development
and Disease
Transgenic animals in which syndecans have either been
deleted or their expression modified are viable, fertile, develop
normally, and have no gross abnormalities. However, distinct
phenotypes are observed in these animals after challenge or
insult. For example, syndecan-1 null mice are more resistant
to wnt-1 induced mammary tumorigenesis and show increased
resistance to intranasally administered P. aeruginosa [9,10]. In
models of inflammation syndecan-1 null mice also show
enhanced leukocyte adhesion in both the retinal and
mesenteric microvasculature and this enhanced leukocyte
accumulation is associated with enhanced angiogenesis [11].
Syndecan-1 has also been shown to attenuate allergic inflam-
mation in the lung. Airway epithelium detects allergenic adju-
vants and secretes chemokines that specifically recruit Th2
immune cells to the site of inflammation; deletion of syndecan-
1 promotes Th2 recruitment and ag-specific IgE responses.
Moreover, allergens trigger ectodomain shedding leading to
binding of CC chemokines inhibiting CCL-11 and 17-mediated
T-cell migration [12]. Syndecan-1 is abundant on stratified epi-
thelia and given its role in cell migration, several studies have
been conducted to assess its role in wound healing. Corneal
debridement wounds in syndecan-1 null mice re-epithelized
slower than wild type controls, although more inflammatory
cells were found beneath the wounds. In wildtype mice there
is an increase in epithelial cell proliferation after wounding
which decreases after 48 H, in contrast syndecan-1 null epi-
thelial cells exhibit enhanced proliferation rates but this does
not change in response to wounding [13]. Mice in which synde-
can-1 is over-expressed in all tissues also exhibit delayed
wound healing and this provides evidence that syndecan func-
tion may be dependent on gene dosage effects [14]. Evidence is
The syndecan family has adhesion regulatory domains within their extracellular core protein. (a) The syndecan family has four
members each with a short cytoplasmic domain (green), a transmembrane domain (orange), and an ectodomain (red). (b) Ad-
hesion regulatory domains (ARD) have been identified in the extracellular core proteins of syndecan-1, 2, and 4. In addition
an invasion regulatory domain (IRD) has also been identified in syndecan-1.
FIG 1
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also accumulating that there is a correlation between
decreased syndecan-1 expression and bad prognosis in poorly
differentiated malignant tumors [15].
To date no mouse null for syndecan-2 has been reported,
however, in zebrafish reduced expression of syndecan-2 leads
to defects in sprouting angiogenesis and in xenopus there is a
role for syndecan-2 in left/right axis formation [16,17].
Syndecan-3 is mainly expressed in the nervous system;
interestingly, its loss doesn’t affect mouse development, in par-
ticular basal synaptic transmission in hippocampus is compa-
rable to that of wild types. However, syndecan-3 KO mice
show an increased long-term potentiation (LTP) in the CA1 py-
ramidal neurons area of the hippocampus and impaired hippo-
campus-dependent memory, suggesting a role for syndecan-3
in suppressing LTP (probably through a mechanism involving
heparin-binding growth-associated molecules (HB-GAM)) and
in modulating hippocampus memory [18]. Syndecan-3 also has
roles in regulating feeding behavior and body weight and can
potentiate the activity of Agouti related protein or AgRP (an
antagonist of melacortin) and therefore regulate the circuit of
a-MSH (a-melanocyte stimulating hormone) and AgRP in the
hypothalamus [14]. A balance between the activities of orexi-
genic AgRP and the anorexigenic a-MSH neurons regulate food
intake, therefore, it is not surprising that the feeding behavior
of syndecan-3 null mice differ from their wildtype counterparts
[19]. Syndecan-3 null mice are hypersensitive to a-MSH and
exhibit increased activation of melanocortin neurons, probably
because in the hypothalamic paraventricular nuclei (PVN)
AgRP expression is reduced, suggesting that syndecan-3 may
have a role in the localization of AgRP in this hypothalamic
area [20].
In common with syndecan-1 null mice, syndecan-4 null
animals exhibit impaired wound healing. Syndecan-4 is
expressed at low levels in all adherent cells but is up-regulated
in the granulation tissue on endothelial cells and fibroblasts
during wound healing [21]. Excisional wounds on syndecan-4
null mice healed significantly slower than in wild type controls
and the granulation tissue is less vascularized. Syndecan-4 is
intimately associated with cell adhesion and migration and
syndecan-4 fibroblasts migrate slower and have both focal ad-
hesion and cytoskeletal defects [22,23]. Syndecan-4 null mice
are more susceptible to septic shock (induced by LPS) and this
is thought to be related to interactions between syndecan-4
and TGFb [24]. Syndecan-4 is known to modulate the activity
of certain MMPs and this is reflected in the null mice which
are more resistant to destruction of articular cartilage in mod-
els of osteoarthritis [25].
1.3. Syndecans as ECM Receptors
HS is known to interact with numerous ECM components such
as fibronectin, collagens, tenascins, fibrillins, and laminins and
key roles for syndecans have been identified during cellular
interactions with these matrix components. The best charac-
terized of these is the interaction between Fibronectin and the
HS chains of syndecan-4 during fibroblast adhesion. Engage-
ment of syndecan-4 HS chains leads to receptor clustering
which results in the up-regulation of a PKCa dependant signal-
ing pathway leading to cytoskeletal rearrangements and
changes in the activation state of small GTPases such as RhoA
and Rac1. This process occurs in conjunction with a5b1 integ-
rin signaling. Syndecans and integrins are intimately linked
during ECM interactions and it seems likely that syndecan sig-
naling can modulate integrin responses under these circum-
stances (Fig. 2), [for reviews see Refs. 5,7].
1.4. Syndecans as Growth Factor Co-Receptors
Growth factors such as VEGF, FGF, TGFb, and PDGF are all
known to interact with HS and there is strong evidence that
syndecan-1, 2,and 4 contribute to the presentation of FGF
to its receptor [26,27]. Furthermore, syndecan-2 has been
shown to promote the interaction of VEGF165 with VEGFR2
[28]. Many chemokines and cytokines also possess putative HS
binding motifs within their primary sequence and it is likely
that syndecans also have a role in facilitating their ligand
interactions. This is true of syndecan-1 HS chains which have
been shown to engage CCL7, CCL11, and CCL17 which affects
T-cell responses in allergic disease [12]. Studies on inverte-
brate syndecan have also shown that syndecan HS chains are
also important for establishing gradients for morphogens
which are essential for normal development and patterning
(Fig. 2) [29].
1.5. Syndecan Shedding
Of importance is the fact that syndecan ectodomains can be
shed from the cell surface by the action of MMPs. This process
is thought to occur for a number of reasons, first shedding of
cell surface syndecan results in the removal of growth factors
and cytokines associated with the syndecan HS. Additionally,
syndecan shedding will also result in the release of cells at
points of adhesion between the cell and the ECM, leading to a
more migratory cellular phenotype. It has also been suggested
that the shed syndecan moiety could compete for ligands with
its membrane anchored counterpart. It is also emerging that
the core proteins of syndecan ectodomains have cell adhesion
regulatory domains and these could exert their effects on cells
as mobile effectors of cellular responses in the ECM (Fig. 2, for
review see Refs. [30]).
2. Syndecan Ectodomains
It has been generally accepted that the extracellular core pro-
teins of syndecans provide only an inert support for GAG
chains and that all syndecan extracellular interactions are
mediated by HS rather than the core protein. However, recent
discoveries indicate that syndecan ectodomain core proteins
have biological functions and can modulate cell behavior inde-
pendent of HS. These adhesion regulatory sequences have
been proposed to act with both autocrine and paracrine mech-
anisms (Fig. 3) and could well represent novel targets for
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Modes of action for syndecans. Syndecans can act as growth factor co-receptors (a), can be shed from the cell surface by the
regulated action of proteases (b), can be act as adhesion receptors linking the ECM with the cytoskeleton (c), and finally can
act as a paracrine effector of cell responses.
Syndecan adhesion regulatory domains signal to integrins in a paracrine and autocrine fashion. (a) Shed syndecan-2 ectodo-
main acts as a mobile ligand for the protein tyrosine phosphatase receptor CD148. CD148 signals via isoforms of PI3 kinase to
b1 integrin leading to changes in cell adhesion and migration. (b) Syndecan-1 forms a complex with IGF1R and aVb3 or aVb5
integrin leading to changes in integrin activation state.
FIG 2
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therapeutic interventions, particularly in diseases such as can-
cer. The purpose of the remainder of this review is to summa-
rize the evidence demonstrating the importance of cell adhe-
sion and migration regulatory domains present in syndecan
extracellular core proteins and how these might be used as
novel factors to treat disease.
2.1. Syndecan-1 Ectodomain
The first evidence that the syndecan-1 ectodomain core pro-
tein has biological function came from studies with mouse
mammary tumor cells. A truncated mutant form of syndecan-1
lacking both the transmembrane and cytoplasmic domains
was expressed in S115 (Shionogi 115) cells which resulted in
soluble glycanated syndecan ectodomain being secreted into
the culture medium. S115 cells lose their epithelioid morphol-
ogy and become more proliferative when treated with testos-
terone, and this is thought to correlate with tumor growth.
Interestingly, testosterone treatment results in a reduction in
syndecan-1 expression in S115 cells. The epithelioid morphol-
ogy of these cells could be restored by the addition of condi-
tioned media containing the soluble syndecan-1 ectodomain to
testosterone treated cells. This effect was found to be HS
dependent but a role for the core protein was suggested since
the addition of HS or heparin alone failed to restore the pheno-
type. Soluble syndecan-1 ectodomains also appeared to sup-
press tumor growth in soft agar colony formation assays [31].
Syndecan-1 expression correlates with a reduction in the
invasiveness of cells into Collagen I matrices. The Human B
lymphoid cell line ARH77 expresses very low levels of synde-
can-1 and indeed other HSPGs, and is highly invasive. Expres-
sion of syndecan-1 in these cells inhibits migration through
collagen I gels and this effect is HS dependent [32]. However,
it also emerges that there is also an ‘‘invasion regulatory
domain’’ mapped to an AVAAV sequence (aa 222–226) on the
extracellular core protein of murine syndecan-1 [33]. ARH77
cells transfected with a mutant cDNA in which this motif had
been deleted migrated faster through Collagen I gels than cells
transfected with full length syndecan-1. Glypicans are another
group of cell surface heparan sulphate bearing proteoglycans.
Unlike syndecans they are linked to the cell surface by a glyco-
sylphosphatidylinositol (GPI) anchor and do not possess a cyto-
plasmic domain. Chimeric proteins consisting of the glypican-1
extracellular core protein and the syndecan-1 cytoplasmic
domain or the syndecan ectodomain fused to the glypican-1
GPI anchor were expressed in ARH77 cells and the effects on
invasion determined. Cells expressing the glypican-1 ectodo-
main and the syndecan-1 cytoplasmic domain were as invasive
as wild type cells, however, cells expressing the GPI-anchored
form of syndecan-1 exhibited the same inhibited invasiveness
that is characteristic of cells expressing full length syndecan-1
[34]. This data suggests that the syndecan-1 cytoplasmic do-
main is not required for the antimigratory properties of synde-
can-1 and that the key determinants are a combination of the
HS chains and regulatory motifs contained within the extracel-
lular core protein.
The human lymphoblastic Raji suspension cell line does
not express syndecan-1 but attaches and spreads on HS bind-
ing matrix substrates such as thrombospondin and fibronectin
when transfected with full length syndecan-1. Attachment and
spreading to these substrates is not dependent on the synde-
can-1 cytoplasmic domain since cells expressing cytoplasmic
domain deletion mutants attached and spread normally. Inter-
estingly, attachment and spreading in Raji cells expressing
syndecan-1 could also be observed in cells seeded on immobi-
lized antibodies which recognize the syndecan-1 ectodomain
and these effects could be observed even after treatment with
heparanases. This suggests that the syndecan-1 core protein
interacts with other cell surface receptors, leading to the for-
mation of adhesion regulatory complexes [35].
Integrins are the key drivers of cell adhesion and migra-
tion and can exist in different activation states on the cell sur-
face. Activated integrins are more able to engage their ECM
ligands and the extent to which an integrin can be activated
can be modulated by other cell surface receptors. For this rea-
son, integrins were hypothesized to form part of the adhesion
regulatory complexes stimulated by syndecan-1 extracellular
domain clustering with antibodies. Some studies suggested
that syndecans can trigger signaling leading to cell spreading
either by exposing binding sites on fibronectin for ß1 integrin
engagement [36] or by modulating the activation state of the
b1 integrin [37]. However, evidence linking the syndecan-1
extracellular core protein with aVb3 integrin emerged from
studies in which human mammary carcinoma cells (MDA-MB-
231) were seeded on immobilized syndecan-1 antibodies.
MDA-MB-231 cell adhesion to this antibody substratum
resulted in the activation of aVß3 integrin and this could be
inhibited by syndecan-1 extracellular fusion protein fused to
GST [38]. This work implies that syndecan-1 interacts with
integrins directly or indirectly on the cell surface via its extrac-
ellular core protein. The association between the syndecan-1
ectodomain and aVb3 driven cell adhesion is supported further
by the fact that the syndecan-1 ectodomain is required for
MDA-MB-231 cell spreading in response to vitronectin. Using
deletion mutant forms of cDNA it was possible to establish that
the amino acids lying between aa88 and aa252 (of murine syn-
decan-1) were required for the cell spreading response. This
leads to the hypothesis that engagement of syndecan-1 by the
ECM is a precursor step necessary for aVb3 activation and
subsequent cell spreading in epithelial cells [39].
In later work, the question of what the effect of providing
a native matrix ligand such as vitronectin or fibronectin on the
adhesion responses of MDA-MB-231 cells was addressed. It
was shown that syndecan-1 is directly responsible for cell
spreading on vitronectin (but not on fibronectin) via activation
of aVß3. Moreover, since the addition of soluble syndecan-1
ectodomain or transfection with a mutant form of syndecan-1
lacking a portion of the ectodomain (mS1D88–252) inhibits cell
spreading on vitronectin, implying that the syndecan-1 extrac-
ellular core protein interacts with a partner on the cell surface
to activate aVß3 integrin. This work resulted in a model
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defined by the following features: in epithelial cells, syndecan-
1 must engage a matrix ligand before triggering the activation
of aVß3 leading to cell spreading, this mechanism is dependent
on an unknown interaction mediated by motifs contained
within the syndecan-1 ectodomain and is specific for aVß3
integrin [38].
Interactions between the syndecan-1 ectodomain and
another integrin dimer aVb5 have also been reported. Fibro-
blasts (B82L) were shown to spread in response to anti synde-
can-1 ectodomain antibodies and this effect could be enhanced
by the addition of serum. Further investigation revealed that
B82L cell spreading on native matrix ligand 6 anti-syndecan-1
ectodomain antibodies is dependent on aVß5 integrin and that
the syndecan-1 ectodomain, independent of its HS chains or
transmembrane and cytoplasmic domains, forms a complex
with ß5 and that is sufficient and necessary to promote
spreading [40,41].
This model is similar to that proposed for the regulation of
aVß3 in epithelial cells [39] although they differ for some fea-
tures: in B82L syndecan-1 is probably constitutively associated
with ß5 through its extracellular core protein, only if integrin
is in complex with the syndecan-1 ectodomain can it signal
upon binding to vitronectin or fibronectin; in epithelial cells
the engagement of syndecan-1 with a substratum (through its
HS chains) is necessary to bring S1ED and aVß3 together in a
complex and signal; in this case aVß3, unlike aVß5 in fibro-
blasts, does not require a ligand [42].
Given the importance of aVß3 and aVß5 integrins in
angiogenesis, the possibility that syndecan-1 regulates these
integrins in vascular endothelial cells has been investigated.
Previously, it was shown that a GST-sydecan-1 fusion protein
could block activation of aVß3 in MDA-MB-231 cells and, by
doing so, spreading on vitronectin (spreading on fibronectin
wasn’t affected because the cells also express aVß1 [39]. The
minimum sequence necessary to mediate this effect corre-
sponds to aa82 to aa130 of the syndecan extra-cellular core
protein and this region was required in order to co-immuno-
precipitate aVb3. Peptides corresponding to this region (termed
synstatin) inhibit adhesion and spreading of B82L fibroblasts
on vitronectin, which is mediated only by aVß5.
Syndecan-1, aVb3, and aVb5 are all expressed on endothe-
lial cells and are also present on angiogenic sprouts derived
from aortic rings seeded ex vivo in ECM. Treatment of rings
with synstatin lead to a reduction in the angiogenic response
and this was also the case in corneal angiogenesis models.
The inhibition of angiogenesis has long been thought of as an
attractive target for therapeutic intervention in cancer. In an
orthotopic model of tumor formation in which MDA-MB-231
cells are subcutaneously injected into mice, synstatin treat-
ment resulted in tumors considerably smaller than the
untreated controls (Fig. 3) [41].
So does syndecan-1 activate integrin aVß3 and aVß5 by
stabilizing its extracellular structure or does it mediate an
inside-out signal? Treatment of MDA-MB-231 cells with meta-
bolic inhibitors showed that syndecan-1-mediated integrin
activation is energy-dependent and, by the use of different ki-
nase inhibitors, it became clear that insulin-like growth factor-
1 receptor (IGF1R) is involved in this process. In the model
proposed by Beauvais and Rapraeger, syndecan-1 is clustered
via engagement with vitronectin, interacts with aVß3 and ß5
integrin through its ectodomain and this complex is then
able to engage with IGF1R. The formation of the syndecan-1/
integrin/IGF1R is an essential step for later events and is
required for IGF1R autophosphorylation on Y1131, subsequent
activation of talin leading to inside out integrin activation
(Fig. 3) [43].
There is also evidence that interactions with the syndecan-
1 ectodomain can also lead to b1 integrin mediated effects. To
mimic syndecan-1 over-expression often seen in breast carci-
nomas in vivo, three different human breast carcinoma cell
lines were transfected with syndecan-1. The effect of synde-
can-1 over-expression was unexpected in that cells which usu-
ally grow as adherent cohesive epithelial islands, spread
poorly and assumed a rounded morphology in 2D culture and
were more invasive in 3D culture. This was observed even
when mutants were expressed lacking the GAG chains,
transmembrane or cytoplasmic domains. Only cells expressing
syndecan-1 lacking the ectodomain residues aa88–aa252
exhibited a wild type morphology. Moreover, the syndecan-1-
dependent morphology change could be blocked by genistatin
(a protein tyrosine kinase inhibitor), which is strongly indica-
tive of the involvement of a signal transduction pathway. To
determine whether the syndecan-1 extracellular core protein
can interfere with adhesion-mediated signals, cells expressing
a GPI-anchored form of the syndecan-1 ectodomain were
tested for their ability to attach and spread on either E-cad-
herin or laminin-5. Cell attachment to laminin was disrupted
in these cells confirming that the interactions with the synde-
can-1 ectodomain could block b1 mediated adhesion pathways
[40]. More recent evidence suggests there is an interaction
between integrin a2b1 and syndecan-1 via its extracellular
core protein in bronchial epithelial cells. In this instance, syn-
decan-1 ectodomain promotes cell adhesion through activating
b1 integrin [44].
2.2. Syndecan-2 Ectodomain
While in normal epithelium syndecan-2 is usually expressed at
low levels, during epithelial cancer progression its expression
increases; this is in contrast to syndecan-1 and syndecan-4
which for the most part exhibit reduced expression in malig-
nancies. In colon carcinoma, for instance, syndecan-2 is highly
expressed on tumor cells (both highly and weakly metastatic)
when compared with normal colon cell lines. Speculation as to
whether this HSPG was responsible for the poor prognosis of
this tumor, led to the finding that the syndecan-2 ectodomain
has specific roles in adhesion and tumorogenicity of epithelial
cancer cells. Not only does recombinant syndecan-2 ectodo-
main (HS free) inhibit tumor cell attachment to the ECM, but it
can also promote cell cycle arrest through an up-regulation of
p53, p21, and p27 and down-regulation of cyclin E and D2.
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Moreover, the addition of soluble syndecan-2 ectodomain to
the medium of colon cancer cells inhibits EGF-mediated mito-
gen-activated protein kinase activation which is critical for the
growth of many tumors [45].
Roles for syndecan-2 have also been identified in fibrosis.
TGF-ß is a growth factor with multiple roles, among which is
the ability to promote fibrosis by up-regulating matrix proteins
and metalloproteinase inhibitors and down-regulating metallo-
proteinases. As a ligand, it binds and signals upon forming a
complex with TGF-ß R I, II, and III. The latter (also known as
ß-glycan) binds TGF-ß and transfers it to TGF-ß R II and,
intriguingly, is a cell surface proteoglycan with very similar
characteristics to syndecan-2. Since syndecan-2 controls left-
right axis asymmetry in Xenopus through TGF-ß, a role for
syndecan-2 in TGF-ß-induced fibrosis was suggested. Synde-
can-2 was indeed found to regulate TGF-ß mediated matrix
deposition via its cytoplasmic domain which is fundamental for
its interaction with TGF-ß R III. Additionally, syndecan-2 in
renal periphery fibroblasts was shown to interact with TGF-ß
via its ectodomain (and partially through its HS chains) inde-
pendently of the presence of the cytoplasmic domain [46].
Experiments with a GST/syndecan-2 ectodomain protein
on brain microvascular endothelial cells (MvEC) in the context
of glioma revealed that addition of as little as 0.1 lM of the
protein to medium containing brain MvEC induced an increase
in cell migration and tube formation on both fibronectin and
growth factor-reduced matrigel [47].
Further studies with GST/syndecan-2 ectodomain fusion
proteins revealed that this protein could act as a substrate for
cell adhesion when immobilized on to culture dishes. Assays
with numerous cell lines suggested that adhesion to the synde-
can-2 ectodomain was a feature of mesenchymal cells [48].
Epithelial cell lines fail to attach and spread in response to this
substrate although it was later found that this could be over-
come if the cells were treated with neuraminidase, indicating
that N-linked sugars are important in mediating this interaction
[49]. Fibroblast attachment and spreading in response to GST/
syndecan-2 ectodomain substrates is characterized by the
formation of focal adhesions. Molecules associated with focal
adhesion formation such as focal adhesion kinase and paxillin
undergo phopshorylation and there is a requirement for RhoA
and Rho kinase. Most striking is that cell adhesion to the synde-
can-2 ectodomain has an absolute requirement for b1 integrin.
A direct interaction between the syndecan-2 ectodomain and b1
integrin could not be demonstrated indicating that an interme-
diary receptor was required for this interaction [48].
Further characterization of the processes driving fibroblast
attachment to the syndecan-2 ectodomain revealed that the
adhesion regulatory motif on the syndecan-2 ectodomain lies
in the membrane proximal region aa 124–141. The protein
tyrosine phosphatase receptor CD148 was found to be the
intermediary molecule which mediates the interaction with the
syndecan-2 ectodomain and b1 integrin. In this study it was
shown that engagement of CD148 with the syndecan-2 ectodo-
main lead to de-phopshorylation of the p85 subunit of PI3
kinase. This signal initiates a pathway involving Src kinase,
and PI3KC2b (a novel isoform of PI3K) leading to inside out b1
integrin mediated cell adhesion (Fig. 3 [49]).
2.3. Syndecan-3 Ectodomain
Whether the syndecan-3 ectodomain has biological properties
remains unclear. Adhesion assays with human dermal fibro-
blasts, Swiss 3T3 and NIH 3T3 on immobilized GST fused to
the syndecan-3 ectodomain suggested that this protein could
not support the cell attachment and spreading responses seen
with the syndecan-1, 2, and 4 ectodomians [50]. However,
the syndecan-3 ectodomain is unique as it possesses a mucin
rich domain which may be extensively substituted with
O-linked sugars and confer novel functionality [51]. Experi-
ments to date have utilized fusion proteins expressed in bacte-
ria which would not be post-translationally modified in the
same way as if they were expressed in eukaryotic cells.
2.4. Syndecan-4 Ectodomain
As is the case with the syndecan-2, the syndecan-4 ectodomain
when expressed as a GST fusion protein is a substrate for cell
adhesion. Using fibroblast cell lines it was demonstrated that
in the presence of divalent cations the syndecan-4 extracellu-
lar core protein is able to bind a cell surface receptor through
a domain mapped to aa 56–109 [50,52]. Subsequent work iso-
lated the key amino acids (NXIP) necessary for the syndecan-4
extracellular core protein to support cell adhesion and found
that this motif is functionally conserved amongst vertebrates
[53,54]. Syndecans form SDS insoluble dimers and one possible
hypothesis is that immobilized ectodomain interacts with
endogenous syndecan-4 on cells resulting in cell adhesive sig-
nals driven by full length syndecan-4 clustering. However,
fibroblasts null for syndecan-4 attach and spread in the same
manner as wild type cells when seeded on immobilized GST
syndecan-4 fusion protein, indicating that cell surface recep-
tors other than syndecan-4 are required for this adhesion
response [48]. Like syndecan-2 adhesion to syndecan-4 is a
characteristic of mesenchymal cells and some leukocytic cell
lines after stimulation with phorbol ester and there is an abso-
lute requirement for b1 integrin. In addition GST-syndecan-4
ectodomain can promote focal adhesion formation in fibro-
blasts in a Rho and Rho kinase dependant process. Jurkat
T-cell adhesion to the syndecan-4 ectodomain requires a4b1
integrin however solid phase binding assays between recombi-
nant a4b1 and GST-syndecan-4 ectodomain revealed that there
was no direct interaction between these two molecules which
led to speculation that an alternative receptor may be involved
[48]. Screening with siRNA revealed that the protein tyrosine
receptor CD148 may have a role in this process [49].
3. Discussion
Syndecans are involved in many aspects of cell behavior such
as adhesion, cell spreading, migration, proliferation, and
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morphology changes. Despite that, animals lacking one synde-
can are viable and with no gross abnormalities, suggesting
that syndecan loss is probably compensated during develop-
ment. Nonetheless, when animals null for a syndecan are chal-
lenged with pathological stimuli, dramatic phenotypes are
observed. Considerable attention has been focused on interac-
tions between syndecan HS chains and numerous bioactive
molecules such as chemokines, growth factors, and ECM com-
ponents. There is considerable evidence that these interactions
can contribute to syndecan signaling leading to changes in cell
behavior. In this review, we have described a more novel as-
pect of syndecan biology relating to the biological properties of
domains within the syndecan extracellular core protein. For
the most part these molecular interactions occur independent
of the HS chains. An adhesion regulatory domain within the
syndecan-1 ectodomain has been shown to interact with both
aVb3 and aVb5 integrins forming a complex with Insulin like
growth factor receptor 1 (IGFR1). An autocrine interaction as
described for syndecan-1 is thought to be a key priming step
for cellular interactions with extracellular matrix ligands and
blockade of this process can affect important processes such
as angiogenesis. Similar effects on cell adhesion are observed
in studies on adhesion regulatory domains contained within
the syndecan-2 and 4 extracellular core proteins. In this
instance a paracrine interaction is proposed in which synde-
can-2 and 4 ectodomains are shed into the ECM and become
mobilized ligands for the protein tyrosine phosphatase recep-
tor CD148. CD148 signaling leads to b1 integrin activation and
alterations in cell adhesive properties.
Cell adhesion and migration and have vital roles in devel-
opment and numerous pathologies and integrins are the key
drivers of these processes. The fact that sequences contained
within syndecan extracellular core proteins can modify or alter
integrin mediated processes present them as possible agents
for therapeutic use, indeed the synstatin peptide (derived from
syndecan-1) has already been shown to have beneficial effects
in tumor models. The amino acid sequences essential for the
biological activities of syndecan-1, 2, and 4 have been
mapped and they bear no homology to each other indicating
that they may have different roles. To date the bulk of studies
have focused on the effect of these syndecan adhesion regula-
tory domains in in vitro cell culture models. Attention should
now focus on how these biologically active syndecan moieties
affect biological processes in vivo. Syndecan adhesion regula-
tory domains affect cell behavior in a broad spectrum of cell
types. Leukocytes have been shown to interact with the extrac-
ellular core proteins of syndecan-2 and 4 and it would be in-
triguing to see how these molecules affect processes associated
with inflammation, such as leukocyte adhesion and extravasa-
tion. Furthermore the use of these proteins in tumor models
should be further investigated. The body of work described
here demonstrates that syndecan ectodomains are not simply
structural moieties whose only role is to support syndecan HS
chains but important molecules with great potential for thera-
peutic use in numerous pathologies.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-existing 
ones, occurs primarily during embryonic development and growth in 
order to remodel the primary network of vascular endothelial cells 
formed during vasculogenesis into a vast network of arteries, veins 
and capillaries that will form the blood circulatory system of the adult. 
Angiogenesis occurs during wound healing where angiogenic capillary 
sprouts invade the fibrin/fibronectin-rich wound clot and within 
a few days organize into a microvascular network throughout the 
granulation tissue. Additionally, in the female, angiogenesis happens 
during the reproductive cycle and pregnancy. In healthy unchallenged 
individuals angiogenesis is controlled by a fine balance of pro- and 
anti- angiogenic modulators. In particular conditions, such as tissue 
injury, the balance is tipped in favour of pro-angiogenic factors 
such as VEGF, FGF and angiopoietins. The quiescent vessels sense 
and respond to these molecules initiating the angiogenic process. A 
sequence of coordinated events culminate in the formation of a new 
capillary network: first, a so-called tip cell migrates from the vessel into 
the ECM guided by growth factor gradients; following the tip cell, stalk 
cells proliferate and eventually form the vessel lumen; mural cells such 
as pericytes and/or smooth muscle cells are recruited around the newly 
formed vessel and are necessary for its stabilisation. Angiogenesis 
involves the remodelling of the extracellular space through the action 
of proteases secreted by ECs and mural cells and is characterized by 
many interactions between adhesion receptors on the EC surface and 
ECM molecules [1-3].
Abnormal angiogenesis (either excessive or insufficient) is a 
common feature of many diseases such as cancer, cardiovascular 
and skin disorders, ischemia, retinopathies and arthritis and the 
importance of angiogenesis in these pathologies has led to considerable 
efforts to understand the mechanisms associated with new blood vessel 
formation in the hope that novel therapeutic targets for treatment can 
be established [1,4]. So far angiogenic and anti-angiogenic therapies 
have been developed but their efficiencies have rarely met expectations; 
a deeper understanding of the mechanisms underlying the angiogenic 
process is therefore crucial for designing better therapeutic strategies.
The aortic rings model of angiogenesis has been used to study 
new blood vessel formation [5-7]. Thoracic aortas from either rats 
or mice are dissected, sectioned and embedded in either a Collagen 
I or Matrigel matrix and angiogenesis is stimulated by the addition 
of pro-angiogenic factors such as VEGF or FGF. Angiogenic sprouts 
(new vessels) are visualised after 4-8 days in culture. In this study we 
describe the key factors that can affect this assay and show that the 
angiogenic response is different between males and females. This data 
has implications not only for experimental design of angiogenesis 
studies but also on the potential dosing of therapeutic interventions 
between male and female patients.
Materials and Methods
Aortic ring assay
Thoracic aortas dissected from cervically dislocated 180-200 g 
Wistar rats (Harlan laboratories) or C57BL/6 mice (Charles River) 
were sliced into 0.5 mm sections and incubated overnight in serum 
free OptiMEM (Invitrogen) at 37°C, 10% CO2. Male and female rats 
and mice were aged matched unless stated otherwise and animals were 
fed a standard chow diet and housed under a 12hour light and dark 
cycle. Aortic rings were embedded in type I collagen (1mg/ml) in E4 
media (Invitrogen). Wells were supplemented with OptiMEM with 
FBS (PAA) VEGF (R and D systems) at the concentrations indicated 
and incubated at 37°C, 10% CO2. Emergent angiogenic sprouts from 
rat and mouse aortas were counted after 4 days and 8 days in culture 
respectively. All animal experiments were conducted in accordance 
with the British Home Office regulations (Scientific Procedures) Act 
1986, United Kingdom.
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Angiogenesis is a feature of numerous pathologies including cancer and inflammatory conditions and as such is 
key therapeutic target for the treatment of disorders where excessive or insufficient formation of new blood vessels 
occurs. The study of angiogenesis in vivo provides many challenges, however the growth of new blood vessels in 
vitro from aortic explants has provided a highly useful model for the study of this process. In this manuscript we 
examine the critical factors which can affect this assay and demonstrate that aortas from both female rats and mice 
exhibit a reduced angiogenic response to males. These findings have implications not only for the experimental 
design of angiogenesis experiments but also in the use of therapies targeting angiogenesis in the treatment of 
pathologies, such as cancer.
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Imaging
Images were captured using an Olympus IX81 inverted microscope 
with a Hamamatsu Orca-ER digital camera. Image acquisition was 
performed using the CellM software (Olympus) and micrographs were 
prepared for publication using Adobe Photoshop.
Statistical analysis
Statistical analysis was performed using the Graphpad Prism 
software Version 6.0.
Results
The aortic ring model of angiogenesis is an ex vivo model and 
has been used extensively to study factors which affect angiogenesis 
particularly with regard to tumour angiogenesis [5-7]. The model entails 
growing blood vessels from sections of aorta. The resultant structures 
form branching tube like structures composed of both endothelial 
cells and pericytes (Figures 1A-1D). Rat aortas (Figure 1A) produce 
longer more branched sprouts than those obtained from murine aortas 
(Figures 1B-1D). Staining using a fluorescently labelled endothelial 
cell specific lectin from the bacteria Bandeiraea simplicifolia reveals, 
that the sprouts produced consist of vessel-like structures composed of 
endothelial cells surrounded by perivascular cells. These perivascular 
cells express the pericyte marker α-smooth muscle actin (αSMA) and 
envelop the newly formed vessel, as shown in Figure 1C and 1D in 
which sprouts have been induced from aortas from transgenic mice in 
which eGFP is under the control of the αSMA promoter.
Aortas from both rats and mice are used in these studies; rat aortas 
are longer and wider, enabling the collection of a greater number of 
rings and are more angiogenic in that they produce more sprouts and 
the chances of a given aortic section producing angiogenic sprouts is 
far higher than that observed in mice. Mice aortas are smaller, more 
susceptible to damage during dissection, particularly fat removal and 
there is a far higher chance of a given section failing to produce an 
angiogenic response (Figure 1E). The use of murine tissues is of course 
favourable owing to the number of genetically modified mice that are 
now available. Many factors can affect the aortic rings assay, and these 
can have major implications for the interpretation of the experimental 
data. The source of critical reagents can have an effect on the magnitude 
of the angiogenic response in these assays and it is inevitable that there 
will be differences between laboratories. We tried to standardize an 
aortic ring assay by examining the effect of VEGF, FBS and gender on 
the angiogenic response in tissues from both rats and mice (Figure 2).
Optimization of the rat aortic ring assay
As mentioned above rat aortas generally give a stronger angiogenic 
response than mice, indeed angiogenic sprouting can be observed in 
rings from male animals seeded in collagen only in the absence of FBS 
or VEGF. This response can be increased in the presence of 10ng/ml 
of VEGF. A similarly high response is observed in the presence of 30 
ng/ml of VEGF although there is a reduction in angiogenic sprouts 
when 60ng/ml of VEGF is added. Interestingly in all conditions the 
angiogenic response from aortic rings from female rats is greatly 
reduced. There is still a response to increased concentrations of VEGF 
but this is significantly reduced when compared to samples from male 
rats.
In a second set of experiments we tested the effect of foetal bovine 
serum on sprout formation from rat aortic rings. The combination 
of 1% serum and 10 ng/ml VEGF elicited the highest angiogenic 
response in both male and female aortic rings, although as previously 
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Figure 1: Angiogenic sprouts from both rat and mouse aortas from 
microvessels consisting of endothelial cells surrounded by pericytes. (A) 
Vessel out growth from a rat aortic ring seeded in Collagen I, in the presence 
of 1% FBS and 10ng/ml VEGF (Scale bar 200µ). Sprouts from rat aortic 
rings are longer in length and tend to be more branched (arrow). (B) Murine 
angiogenic sprout stained with Bandeiraea simplicifolia (BS) lectin (red) 
showing endothelial cells comprising the microvessel surrounded by pericytes 
(Scale bar 100µ). (C and D) Angiogenic sprouts from aortas from transgenic 
mice expressing eGFP under the control of the αSMA promoter. GFP 
expressing pericytes (green) are observed surrounding ECs (D). (E) Table 
comparing the use of mouse and rat aortas for the study of angiogenesis.
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Figure 2: In all conditions tested aortas from females gave a reduced 
angiogenic response compared to males. (A) VEGF promotes angiogenesis 
in rat aortas embedded in collagen I in serum free conditions. Age matched 
Male and female rat aortic rings were seeded as described and supplemented 
with the concentrations of VEGF indicated. (B) High level of FBS can be 
inhibitory to the angiogenic response from both male and female rat aortas. 
Rings were embedded in collagen I and supplemented with 10ng/ml VEGF 
and the concentrations (v/v) of FBS indicated. (C) The formation of angiogenic 
sprouts from murine aortas requires VEGF. (D) High levels of serum also inhibit 
angiogenic sprout formation from murine vessels. Murine aortic explants were 
supplemented with 30ng/ml VEGF and the concentrations of FBS indicated. 
In (A-D) angiogenic sprouts were counted 4 days (rat) and 8 days (mouse) 
post embedding. At least 10 rings/animal, were counted and the mean 
calculated, data presented for each condition represents the mean of mean 
sprout formation obtained from at least 3 different animals (n-numbers for 
each condition are shown above data bars). Error bars represent the standard 
error of the mean and significance between male and female samples at each 
condition was calculated using a 2-way ANNOVA comparison.
the response was significantly lower in females versus males. Increased 
serum concentration (2.5% and 5% v/v) resulted in an inhibition of this 
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response. One of the issues with the aortic rings assay is that in addition 
to angiogenic sprouts emerging from the ring section there is also a 
significant amount of fibroblasts and smooth muscle cells. Higher 
serum concentrations tend to favour the emergence of fibroblasts and 
when this is excessive it appears to be inhibitory to sprout formation.
Optimization of the mouse aortic ring assay
The use of mouse aortas for the study of angiogenesis is more 
technically challenging. Unlike rat aortic rings murine sections do not 
sprout in serum free conditions and require both serum and VEGF 
to elicit a response. We have found that the best response is obtained 
from rings treated with 1% serum and 30ng/ml of VEGF. Higher 
concentrations of VEGF (>30 ng/ml) and serum (>1%v/v) are largely 
inhibitory to the response. As in the rat system higher serum levels 
favour the emergence of fibroblasts and smooth muscle cells which is 
not conducive to new blood vessel formation. As is also the case aortas 
from female mice give a significantly lower angiogenic response than 
males, regardless of the treatment. The use of murine aortic ring is also 
dependant on the age of the mice used (Figure 3). Aortas from younger 
mice give a more robust angiogenic response than that observed from 
older mice (Older than 8 weeks).
Discussion
In the work presented here we have examined in detail the factors 
which can affect a rodent model of angiogenesis. Although the effects 
of serum and VEGF are well established in this model, we also highlight 
the fact that the angiogenic response in this assay is greatly different 
between males and female donors. Results clearly showed a decreased 
angiogenic response in both female mice and rats when compared to 
their male counterparts. This difference was persistent throughout all 
the experiments regardless of the different conditions (VEGF or serum 
concentration).
Gender differences in cellular responses particularly inflammation 
have been identified [8]; however, differences in angiogenesis are less 
well characterised, particularly in an ex vivo model such as the aortic ring 
model where the tissues are isolated from the normal hormonal factors 
present in vivo. The reason why female samples are less angiogenic is 
not clear; however, it is intriguing to speculate that angiogenesis, like 
other physiological processes or disorders might have an epigenetic 
component [9-11]. Sexual dimorphism in angiogenic response could 
be caused by a different hormone-induced DNA methylation or 
histone modification in male and female resulting in different gene 
regulation. Microarray-based epigenetic profiles might shed some light 
on this hypothesis. Angiogenesis has been shown to be affected by gene 
dosage affects and it may be that sex linked genes contribute to this 
effect. This observation is highly relevant to gender specific pathologies 
such as testicular and ovarian cancer. Moreover, these findings are of 
considerable importance both in terms of experimental design relating 
to the study of angiogenesis but also for the development of angiogenic 
and anti-angiogenic therapies and represent the start point for further 
investigation.
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Figure 3: In the murine model of angiogenesis aortas from older mice show 
a reduced angiogenic response. (A) Male mice (aged as indicated) were 
embedded in Collagen I and supplemented with 1% FBS and 30 ng/ml 
VEGF. Mean sprout formation was calculated from at least 10 rings each 
point represents the mean value from one animal. Error bars represent the 
standard error of the mean and significance was calculated using individual 
student T tests compared to the 6 week value.
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Syndecan-3 is one of the four members of the syndecan family of heparan
sulphate proteoglycans and has been shown to interact with numerous growth
factors via its heparan sulphate chains. The extracellular core proteins of
syndecan-1,-2 and -4 all possess adhesion regulatory motifs and we
hypothesized that syndecan-3 may also possess such characteristics. Here we
show that a bacterially expressed GST fusion protein consisting of the entire
mature syndecan-3 ectodomain has anti-angiogenic properties and acts via
modulating endothelial cell migration. This work identifies syndecan-3 as a
possible therapeutic target for anti-angiogenic therapy.
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Introduction
Angiogenesis is the process of new blood vessel formation from 
pre-existing vessels. This process is essential for embryonic devel-
opment but it is also a feature of pathologies such as cancer and 
chronic inflammation (reviewed in1). For angiogenesis to occur, 
the release of pro-angiogenic factors, which promote the transi-
tion of endothelial cells (ECs) from a quiescent to a proliferative 
and migratory phenotype, is required2–4. The best characterized 
pro-angiogenic molecules are: vascular endothelial growth factor 
(VEGF), fibroblast growth factor (FGF) and platelet derived growth 
factor (PDGF) (reviewed in5). Angiogenesis represents an attractive 
target for the treatment of cancer, as during tumour development 
new blood vessels permeate the tumour mass and provide oxygen 
and nutrients to further enhance tumour growth. Therapies aimed 
at blocking angiogenesis have focused on targeting VEGF and its 
related receptors, however the prohibitive cost of such treatments 
and their side effects mean that there is still a need to discover new 
therapeutic anti-angiogenic targets4.
Syndecans are a four member family of transmembrane adhesion 
receptors with diverse expression and functionality6,7. Syndecan-3 
is the least well understood of the four family members. Like other 
syndecans, it possesses a short, highly conserved cytoplasmic domain, 
a single pass transmembrane domain and a large extracellular 
domain containing 6 glycosaminoglycan attachment sites which 
can be substituted by both heparan sulphate (HS) and chondroitin 
sulphate (CS). Syndecan-3 has the largest extracellular core protein 
of the syndecans and, in addition to the HS and CS modifications, 
the molecule possesses a number of potential sites for O-linked 
glycosylation resembling a mucin-rich domain which may affect 
both the structure and molecular interactions of syndecan-38,9.
Syndecan-3 Knock-Out mice, in common with other syndecan-KO 
animals, develop normally and only under conditions of challenge 
or insult are different phenotypes observed6. Syndecan-3 is mainly 
found in the nervous system and has been shown to be a co-receptor 
for a number of important growth factors, including Agouti related 
protein (AgRP), heparin binding growth associated molecule 
(HB-GAM), glial cell line derived growth factor (GDNF), neurturin 
(NRTN), artemin (PSPN) and NOTCH, via interactions with its HS 
chains10–14. Interactions with AgRP, an antagonist of melanocortin, 
lead to altered feeding behaviours in the syndecan-3 null mouse14,15. 
In addition, syndecan-3 deficiency leads to the mice exhibiting 
more addictive behaviours to opiates such as cocaine, and this 
occurs as a result of its interaction with GDNF16. Syndecan-3 is also 
expressed on satellite cells, adult skeletal muscle progenitors and 
has roles in the development of normal adult muscle13,17–19.
An important emerging feature of syndecans is that sequences 
contained within their extracellular core domains have biological 
activity which can influence cell adhesion and migratory responses20. 
Such domains have been identified in syndecan-1, 2 and -421. The 
syndecans can be divided into two subfamilies based on sequence 
homology: syndecan-1 and -3 and syndecans -2 and -422. Since 
regions of the syndecan-1 core protein are anti-angiogenic, we 
hypothesized that the core protein of syndecan-3 may exhibit simi-
lar properties23–25. In this study we demonstrate that the syndecan-3 
extracellular core protein is able to inhibit angiogenesis by reducing 
the migratory potential of endothelial cells and as such may be a 
candidate for use in anti-angiogenic therapy.
Materials and methods
Cell culture: Brain endothelial cells (bEND3.1) and skin endothe-
lial cells (sEND) were obtained from Health Protection Agency UK 
and were grown in DMEM (PAA, GE Healthcare) supplemented 
with 10% FBS, 2 mM l-glutamine, 1% non-essential amino acids, 
1 mM sodium pyruvate and 5 μM β-mercaptoethanol (all Invitrogen), 
at 37°C, 10% CO2.
Syndecan-3 GST fusion protein: The full length syndecan-3 cDNA 
was obtained from Source BioScience. The entire length of the 
mature syndecan-3 ectodomain (A45-L380) was amplified by PCR 
using the primers S3forEcoRI (ttaattgaattcgctcaacgctggcgcaatg) 
and S3revHindIII (ttaattaagcttctacagtatgctcttctgaggga) (Integrated 
DNA Technologies) and the resultant product was digested with 
EcoRI and HIndIII and ligated into the equivalent sites of pET41 
(Novagen) according to Manufacturer’s instructions. Plasmids were 
verified by sequencing and transformed into the BL21 strain of 
Escherichia coli (Novagen). S3ED protein was purified from bacte-
rial cultures which had reached an OD600 of 0.4 prior to the addition 
of 0.1 M Isopropyl β-D-1-thiogalactopyranoside (IPTG) and subse-
quent outgrowth for 4 hours. Affinity purification of both GST and 
S3ED was performed using glutathione-sepharose 4B (GE Health-
care) as described by the manufacturers.
Aortic ring assay: Angiogenic sprouts were induced from rat tho-
racic aortas according to the method of Nicosia and Ottinetti26. 
Briefly, aortas were dissected from cervically dislocated 180–200g 
12 male Wistar rats (Harlan Laboratories) and sliced into 0.5 mm 
sections and incubated overnight in serum free OptiMEM (Inv-
itrogen) at 37°C. Aortic rings were embedded in type I collagen 
(1 mg/ml) in E4 media (Invitrogen) containing either GST or S3ED 
in 48 well plates (Corning). Wells were supplemented with Opti-
MEM with 1% FBS and 10 ng/ml VEGF (R and D systems) and 
incubated at 37°C, 10% CO2. Angiogenic sprouts from rat aortas 
were counted after 4 days and 8 days respectively. Animals were 
housed and treated in Accordance with UK Home Office Regulations.
EC tubule formation assay: Endothelial cell microtubule formation 
was measured as follows: ECs (5 × 104) were seeded into 24 well 
plates coated with 150 μl of Matrigel (BD sciences) in the presence 
of either GST or S3ED. Using the Cell-IQ controlled environmental 
chamber (CM technologies), the plates were incubated at 37°C, 
10% CO2 and images were captured every 15 minutes for 16 hours.
Scratch wound migration assay: Confluent monolayers of bEND 
cells were scratched with a pipette tip, cells were then washed twice 
with PBS prior to the addition of growth medium supplemented 
with 0.5 μM of either GST or S3ED. Wounds were monitored 
by time lapse microscopy using an Olympus IX81 Microscope 
Hamamatsu Orca ER digital camera. Images were acquired every 
30 minutes and subsequently analysed using Adobe Photoshop. 
Cell speed was quantified by manually measuring the track of 
individual cells migrated for 9 hours (20 cells per conditions) using 
Adobe Photoshop, track lengths were then divided by the time to 
obtain cell speed.
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Cell proliferation assay: EC proliferation was measured using the 
CellTiter 96 AQueous Cell proliferation assay kit as described by 
the manufacturer (Promega). bEND (5 × 103/spot) cells were seeded 
in a 96-well plate (Corning) and incubated in the presence of 
0.5 μM either GST or S3ED.
Invasion assay: EC invasion assays through collagen matrices 
were performed in 24-well plates with trans-well inserts (Millipore; 
8 μm pore size, polyester (PET) membrane). Membranes were 
coated with 10 μl of Collagen Type I mixture (Millipore; 1 mg/ml 
in E4 medium) containing 0.5 μM GST or S3ED. sEND cells were 
seeded on the gel in a homogenous single cell suspension of 5 × 103 
cells/ insert in 200 μl of DMEM + 10% FBS; 1 ml of the same 
medium was added to the bottom well. Invasion was measured after 
6 hours after which time gels were removed with a cotton swab, the 
filter washed in PBS and stained with calcein (Invitrogen) and the 
number of cells attached to the filter was counted.
Results
In keeping with previous studies from our group and others in the 
field25,27–29, we set out to determine whether the extracellular core 
protein of syndecan-3 (S3ED) had any effect on cellular responses 
such as cell adhesion or migration and in particular on angiogenesis. 
To do this we generated a fusion protein consisting of the entire 
length of the syndecan-3 extracellular core protein (A45-L380) fused 
at the N-terminus to GST (S3ED). S3ED was expressed and puri-
fied from bacteria and therefore was not substituted with GAGs, or 
O-linked sugars, since bacteria lack the necessary transferases to 
perform these post-translational modifications (Figure 1).
In the aortic ring assay, angiogenic sprouts are formed from 
sections of rat aortas when embedded into a collagen I matrix 
(Figure 2a and b). Sprouting occurs in the absence of VEGF although 
a more robust response is observed when this growth factor is 
included in the medium (Figure 2c). We incorporated 0.5 μM of 
either GST or S3ED into the collagen I matrices to see if they 
affected sprout formation. Significantly fewer sprouts were observed 
in the presence of S3ED compared to either the untreated control or 
GST treated rings. This was true for both rings grown in the pres-
ence or in absence of VEGF (Figure 2c). We then demonstrated that 
this inhibition of angiogenesis is dose dependent; as little as 0.5 μM 
of S3ED had an inhibitory effect (Figure 3). Although 0.1 μM of 
S3ED also showed a statistically significant anti-angiogenic effect 
in this assay, we decided to use the higher dose (0.5 μM) for further 
experiments.  
Figure 1. Syndecan-3 and S3ED-GST structures. Diagrammatic 
representation of the syndecan-3 fusion protein (S3ED) used in this 
study. The entire length of the syndecan-3 extracellular core protein 
(A45-L380) was fused at the N-terminus to GST. 
Figure 2. S3ED inhibits sprout formation in the rat aortic ring assay. (a) Low magnification (bar=500 µm) of a rat aortic ring and (b) high 
magnification (bar=100 µm) image of an angiogenic sprout grown under control conditions. (c) S3ED inhibits angiogenic sprout formation 
from rat aortic rings. Rat aortic rings were seeded in Collagen I gels with 0.5 µM of either S3ED or GST in the presence or absence of VEGF. 
Data is the mean taken from rings from 3 different animals and error bars represent the SEM. One-way ANOVA with Bonferroni multiple 
comparisons was used to compare S3ED to relative UT control.
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Tubular network formation in response to matrigel is another measure 
of angiogenesis30. Brain endothelial cells form highly branched 
networks when seeded on matrigel and this was unaffected when 
GST was added to the culture medium (Figure 4a). In the presence 
of S3ED (0.5 μM) far fewer branch points were evident and the 
length of the microtubules was greatly reduced (Figure 4b and c; 
and Movie 1 and Movie 2). Together these data suggest that S3ED 
has anti-angiogenic properties.
Figure 3. The anti-angiogenic effect of S3ED is dose dependant. Rat aortic rings were embedded in Collagen I with the indicated 
concentrations of either GST or S3ED in the presence of VEGF. Angiogenic sprouts were counted 4 days after seeding. Data is from 5 rings per 
condition. One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED 0.5 µM to S3ED 0 µM considered as a control.
Figure 4. S3ED inhibits EC network formation in response to Matrigel. bEND3.1 cells were seeded on Matrigel in media containing GST 
or S3ED (0.5 µM) and micrographs were obtained after 16 hours (a). Tube length (b) and branch points (c) were calculated and both were 
reduced in the presence of S3ED. Error bar represents SEM. T-test was used to compare S3ED to GST control.
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Movies 1 and 2
2 Data Files
http://dx.doi.org/10.6084/m9.figshare.870448
The ectodomains of syndecan-1,-2 and -4 have all been shown to 
affect cell behaviour through interactions with integrins (for review 
see21). For example, the anti-angiogenic properties of syndecan-1 
have been demonstrated to occur through interactions with the αV 
sub-family25. Integrins are the major drivers of cell migration31,32 so 
we set out to determine whether the inhibitory properties of S3ED 
were due to effects on EC migration. Scratch wound cell migration 
assays revealed that S3ED significantly inhibited brain endothelial 
cell migration as compared to GST and untreated controls 
(Figure 5a). This was reflected in both percentage of wound closure 
and single cell speed measurements (Figure 5b and c). We further 
confirmed that S3ED inhibits EC migratory potential by using a 
3D culture system where we observed that S3ED, when incorpo-
rated into a collagen I matrix, inhibited endothelial cell invasion 
through the collagen (Figure 6a and b). Although we demonstrate 
that S3ED inhibits EC migration, it could be argued that these 
effects may also be associated with anti-proliferative effects of this 
protein. To test this we performed proliferation assays on brain 
ECs in the presence of S3ED or GST and observed no differ-
ences in the proliferation of these cells compared with controls 
(Figure 7).
Figure 5. S3ED inhibits brain EC migration. Scratch wounds were made to confluent monolayers of bEND3.1 cells and micrographs were 
captured after 9 hours clearly showing that wound closure is reduced in the presence of S3ED 0.5 µM (a). Scratch wound closure (b) and 
single cell speeds (c) were calculated. Single cell speed was calculated from 15–25 cells per condition. Error bars represent SD for (a) and 
SED for (b). One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED to relative UT control.
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Discussion
Here we show for the first time that the ectodomain of syndecan-3, 
like the other syndecan family members, has cell adhesion regulatory 
properties and acts as an inhibitor of angiogenesis. This strongly 
suggests that adhesion regulatory domains in syndecan extra-
cellular core domains exist in all four family members and also 
provides further insight as to how these molecules function. In-
terestingly, there is very little sequence homology between 
syndecan ectodomains32, and the adhesion regulatory motifs iden-
tified in syndecan-1,-2 and -4 are not present in S3ED. In addition, 
syndecan-3 is unique amongst the family since its core protein 
possesses a mucin-rich domain and it is likely that these O-linked 
sugars will also have a role in its molecular interactions. Although 
syndecan-3 expression is mostly associated with cells of the nerv-
ous system, it has also been found to be associated with cells related 
to maternal and foetal circulation33. Vascular defects in the syndecan-3 
null mouse have not been reported but the identification of S3ED 
as a regulator of angiogenesis suggests that this may be a fertile 
area for future research. This work identifies syndecan-3 as a 
potential therapeutic target in pathologies where angiogenesis is 
a feature.
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Figure 6. S3ED inhibits EC invasion into Collagen I. 5 × 103 sEND cells were seeded on 10 µl of Collagen I and were allowed to migrate 
for 6 hours. Numbers of transmigrated cells are shown in (a) and micrographs of transmigrated Calcein-labelled cells are in (b). Error bars 
represent SD. One-way ANOVA with Bonferroni multiple comparisons was used to compare S3ED to relative UT control.
Figure 7. EC proliferation is unaffected by either GST or S3ED. 
5 x 103 bEND 3.1 cells were incubated in the presence of 0.5 µM 
of either GST or S3ED. Error bars represent SD. One-way ANOVA 
with Bonferroni multiple comparisons was used to compare S3ED 
to relative UT control showing no statistically significant difference 
between the two at after 9 and 24 hours.
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Shed syndecan-2 inhibits angiogenesis
Giulia De Rossi1, Alun R. Evans1, Emma Kay1, Abigail Woodfin1, Tristan R. McKay2, Sussan Nourshargh1 and
James R. Whiteford1,*
ABSTRACT
Angiogenesis is essential for the development of a normal
vasculature, tissue repair and reproduction, and also has roles in
the progression of diseases such as cancer and rheumatoid
arthritis. The heparan sulphate proteoglycan syndecan-2 is
expressed on mesenchymal cells in the vasculature and, like the
other members of its family, can be shed from the cell surface
resulting in the release of its extracellular core protein. The purpose
of this study was to establish whether shed syndecan-2 affects
angiogenesis. We demonstrate that shed syndecan-2 regulates
angiogenesis by inhibiting endothelial cell migration in human and
rodent models and, as a result, reduces tumour growth.
Furthermore, our findings show that these effects are mediated by
the protein tyrosine phosphatase receptor CD148 (also known as
PTPRJ) and this interaction corresponds with a decrease in active
b1 integrin. Collectively, these data demonstrate an unexplored
pathway for the regulation of new blood vessel formation and
identify syndecan-2 as a therapeutic target in pathologies
characterised by angiogenesis.
KEY WORDS: Angiogenesis, Inflammation, Syndecan, Integrin,
Endothelial cell migration
INTRODUCTION
Angiogenesis is a feature of development, wound healing,
tumorigenesis and chronic inflammatory conditions, such as
rheumatoid arthritis and atherosclerosis (Carmeliet, 2003; Mapp
and Walsh, 2012). The process requires the transition of
endothelial cells from a quiescent state to a migratory and
proliferative phenotype, and is stimulated and controlled by
growth factors, most notably vascular endothelial growth factor
(VEGF) (Sakurai and Kudo, 2011). Endothelial cell migration is a
crucial component of angiogenesis and integrins are the major
drivers of this response (Ramjaun and Hodivala-Dilke, 2009).
Integrins exist in various activation states on the cell surface and
this modulates the migratory and adhesive characteristics of cells
through interactions with the extracellular matrix (ECM). Other
cell surface receptors also interact with ECM ligands leading to
signalling cascades that can alter the activation state of integrins
(Streuli and Akhtar, 2009). The four-member syndecan family of
heparan sulphate proteoglycans (HSPGs) are an example of such
molecules.
The syndecans are a family of transmembrane receptors with
roles in cell adhesion, migration and growth factor signalling. In
common with the other family members, syndecan-2 has a short
cytoplasmic domain, a single-pass transmembrane domain and a
larger extracellular domain, which is modified toward the N-
terminus with heparan sulphate (HS) side chains and can be shed
from the cell surface. Many cell types shed syndecan ectodomains
through the action of matrix metalloproteinases (MMPs) in
response to a variety of stimuli including inflammatory
mediators, but the biological implications of this response are
not fully understood (Manon-Jensen et al., 2010). In the present
study, the possibility that shed syndecan-2 might be a regulator of
angiogenesis was investigated.
There is a considerable body of work to suggest that syndecan
extracellular core proteins have domains that influence cell
behaviour. For example, cell adhesion regulatory domains have
been identified in all four syndecan family members (De Rossi
and Whiteford, 2013a; De Rossi and Whiteford, 2013b; McFall
and Rapraeger, 1997; McFall and Rapraeger, 1998; Whiteford
et al., 2007; Whiteford and Couchman, 2006). How and when
these regulatory sequences function and their relevance to
biological processes has yet to be determined. Previously, we
have shown that the syndecan-2 extracellular core protein (S2ED)
can support fibroblast attachment and spreading (Whiteford et al.,
2007). Here, we show that S2ED shed from cells acts to inhibit
angiogenesis in both rodent and human models through a
paracrine interaction with the protein tyrosine phosphatase
receptor CD148. This interaction leads to a de-activation of b1
integrins resulting in a reduction in endothelial cell migration.
RESULTS
Constitutively released syndecan-2 ectodomain inhibits
angiogenesis in a xenograft tumour model
To investigate the potential effects of shed syndecan-2 on
angiogenesis we established a mammalian expression system in
which a constitutively released form of the molecule (lacking
both transmembrane and cytoplasmic domains, M1–F141, eS2ED)
was expressed in HEK293t cells (Fig. 1A). The HA epitope was
also incorporated into eS2ED between D27 and K28 enabling us to
readily detect eS2ED in conditioned media as compared to
controls transfected with empty vector (Fig. 1B; supplementary
material Fig. S1). Using these cell lines, we investigated the anti-
angiogenic properties of shed syndecan-2 in a xenograft tumour
model. Specifically, SCID-SHO mice were injected with empty
vector cells or cells that constitutively released syndecan-2
(eS2ED) and tumour sizes were quantified at 21 days. Mice
injected with control (empty vector) cells developed vascularised
tumours that were significantly larger both in terms of diameter
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Fig. 1. Constitutively released syndecan-2 extracellular core protein from HEK293t cells inhibits angiogenesis in a xenograft tumour model.
(A) Schematic diagram of syndecan-2 lacking both cytoplasmic and transmembrane domains (eS2ED), which is constitutively released from HEK293t cells.
(B) Dot blot of conditioned media from cells transfected with either empty vector (EV) or eS2ED constructs. Dot blots were probed with the anti-HA antibody,
and a strong signal is obtained from cells transfected with eS2ED. (C) Constitutively released syndecan-2 inhibits tumour growth. Micrograph of tumours
from SCID-SHO mice injected with either empty vector cells or eS2ED cells. Scale bar: 1 cm. (D) Tumours derived from eS2ED cells have smaller diameter.
Error bars represent the s.e.m. **P,0.01 (n55 tumours per condition, Student’s t-test. (E) Empty vector cells and S2ED cells have the same growth
kinetics over 96 h in culture. (F) Immunofluorescence staining of tumour sections derived from empty vector cells and eS2ED-transfected cells for the endothelial
cell marker CD31 (red; tumour cells are GFP positive). Considerably more CD31-positive structures are evident in tumours derived from cells transfected
with empty vector as compared the tumours in which syndecan-2 is constitutively released. Scale bar: 200 mm. (G) Quantification of the area of micrographs
positive for CD31 was performed and expressed as a percentage of the GFP-positive tumour cells. Data are the mean from three separate images from sections
of three tumours per group. Error bars represent the s.e.m. ****P,0.0001 (unpaired Student’s t-test).
RESEARCH ARTICLE Journal of Cell Science (2014) 127, 4788–4799 doi:10.1242/jcs.153015
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and weight as compared to tumours generated in mice injected
with the eS2ED cells (Fig. 1C,D; supplementary material Fig.
S2). We compared the growth kinetics in culture between empty
vector cells and eS2ED-transfected cell lines and found no
differences, indicating that cell proliferation defects were not the
reason tumours derived from eS2ED cells failed to develop
(Fig. 1E). Immunofluorescence staining of tumour sections for
the endothelial cell marker CD31 (also known as PECAM1)
revealed that tumours derived from empty vector control cells
contained CD31-positive structures consistent with blood vessels.
CD31-positive cells were greatly reduced in tumour sections
derived from cells constitutively releasing syndecan-2
(Fig. 1F,G). These findings suggest that constitutive release of
the syndecan-2 ectodomain in this model is inhibitory to
angiogenesis.
The shed syndecan-2 ectodomain inhibits angiogenesis
We next explored the possibility that the syndecan-2 ectodomain
cleaved from the cell surface in response to a known inducer of
syndecan shedding, the pro-inflammatory mediator TNFa, could
regulate angiogenesis (Pruessmeyer et al., 2010). HEK293t cells
transfected with full-length HA-tagged syndecan-2 cDNA (eFLS2,
Fig. 2A) expressed an abundance of cell surface syndecan-2 as
demonstrated by flow cytometry, and the presence of HS chains
was confirmed by western blotting (supplementary material
Fig, S3B,C). These cells were stimulated with TNFa for 4 h and
the medium was analysed for the HA-tagged shed syndecan-2
ectodomain. TNFa was found to induce shedding of syndecan-2 in
a concentration-dependent manner (Fig. 2B). To investigate the
potential impact of the shed molecule on angiogenesis, we
performed anion exchange on conditioned media to isolate the
HSPGs from empty vector and eFLS2-transfected cells stimulated
with TNFa, and also on conditioned media from cells
constitutively releasing eS2ED. The resulting HSPG-enriched
samples were incorporated into collagen matrices into which rat
aortic rings were embedded. Rings grown in the presence of empty
vector eluates exhibited normal sprout formation. However, eluates
containing shed syndecan-2, either TNFa-induced (eFLS2) or
constitutively released (eS2ED), strongly inhibited angiogenic
sprout formation (Fig. 2C). These data suggest that the anti-
angiogenic properties of the syndecan-2 ectodomain are retained
when syndecan-2 is shed from the cell surface.
The anti-angiogenic properties of shed syndecan-2 reside in
the extracellular core protein of the molecule
In the following series of experiments, we further explored the
impact of the extracellular core protein moiety of shed syndecan-
2 on angiogenesis. For this purpose, we used a bacterial
expression system to produce a fusion protein consisting of the
extracellular core protein [of murine syndecan-2 (E19–F141) fused
at the N-terminus to GST (S2ED, Fig. 3A) (Whiteford et al.,
2007; Whiteford et al., 2011)]. The resulting protein is easily
purified using glutathione and is not modified with HS chains
because prokaryotes lack the requisite transferases (Whiteford
et al., 2007). We incorporated S2ED into Matrigel plugs injected
sub-dermally in the abdomen of C57BL/6 mice. After 5 days,
plugs containing GST alone contained both CD31+ endothelial
cells and blood, a possible indication of new blood vessel
formation (Fig. 3B,C). In contrast plugs containing S2ED showed
a notable reduction in angiogenesis as indicated by a reduced
number of CD31+ endothelial cells (Fig. 3B,C). In addition,
analysis of Matrigel plugs for haemoglobin content indicated less
blood, indicative of reduced vascular formation in plugs
incorporating S2ED as compared to those with GST alone
(Fig. 3B; supplementary material Fig. S4A).
Having demonstrated the regulatory effects of S2ED on
angiogenesis in vivo, we expanded these studies to both ex vivo
and in vitro models of angiogenesis. Rat aortic explants were
embedded into collagen I gels in which either GST (control) or
S2ED was incorporated in the presence of VEGF. Whereas S2ED
inhibited sprout formation in a concentration-dependent manner,
rings grown in the presence of GST were unaffected by this
treatment and sprouted to the same degree as untreated controls
(Fig. 3D). S2ED also inhibited VEGF-induced angiogenesis in a
model employing aortic rings from C57BL/6 mice (supplementary
material Fig. S4B). The effect of S2ED in vitro was tested on
Fig. 2. Shed syndecan-2 from HEK293t cells has anti-angiogenic properties. (A) Schematic diagram of full-length HA-tagged syndecan-2 (eFLS2), which
was expressed in HEK293t cells. (B) Syndecan-2 is shed from HEK293t cells after stimulation with TNFa in a dose-dependant manner. eFLS2 cells were
incubated for 4 h in serum-free media with the indicated concentration of TNFa, and conditioned media were assayed by dot blot using the anti-HA antibody. EV,
empty vector. (C) Shed syndecan-2 is anti-angiogenic. Empty vector cells and eFLS2 cells were treated with TNFa (200 ng/ml) for 4 h and the shed
proteoglycans were purified by anion exchange. Proteoglycans were also isolated from conditioned media from eS2ED transfected cells using the same
methodology. 10 mg of each protein preparation was incorporated into collagen I gels and then seeded with rat aortic rings as described in the Materials and
Methods. Sprouts from eight rings were counted and results are mean6s.e.m. ****P,0.0001 (one-way ANOVA comparing to empty vector controls using the
Tukey’s camparisons test).
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human umbilical vein endothelial cell (HUVEC) tube formation
when in 3D co-culture with human dermal fibroblasts using the
commercially available V2A vasculogenesis to angiogenesis kit.
After 2 weeks in culture under control conditions, tubule structures
were formed with branch points (Fig. 3E). This effect could be
augmented with the addition of VEGF and inhibited by the addition
of Suramin. The addition of GST to the culture medium had little
effect on either the length of tubules formed or the number of
branch points as compared to the control medium. In contrast, in
the presence of S2ED a significant reduction in tubule length and
branch points was noted (Fig. 3F,G). Taken together, these results
demonstrate that the syndecan-2 extracellular core protein has
Fig. 3. See next page for legend.
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anti-angiogenic properties in both rat, murine and human model
systems.
The anti-angiogenic properties of S2ED reside in the
syndecan-2 adhesion regulatory domain
Given that we have previously shown that fibroblast adhesion to
S2ED is regulated by the C-terminal 18-amino-acid domain
between P124 and F141 of murine syndecan-2 (Whiteford et al.,
2011), we hypothesised that this adhesion regulatory region of
syndecan-2 might also be responsible for the inhibition of
angiogenesis. This was initially investigated by performing rat
aortic ring assays with deletion mutants of S2ED (Fig. 4A). Full
length S2ED, S2EDDP124–F141 (lacking the adhesion regulatory
domain) or S2EDDL73–G123 (a truncated form containing only
the adhesion regulatory residues) were incorporated into collagen
matrices in which aortic ring sections were embedded
(Fig. 4A,B). Although angiogenic sprouts were observed in
both untreated and GST controls, sprout formation was severely
compromised when rings were embedded in matrices with S2ED
or S2EDDL73–G123 both of which contain the regulatory 18-
amino-acid motif (Fig. 4B). These data indicate that the anti-
angiogenic properties of S2ED are dependent on the adhesion
regulatory domain lying between P124 and F141 of murine
syndecan-2.
S2ED inhibits endothelial cell migration
As endothelial cell migration is a crucial component of
angiogenesis, the following series of experiments aimed to
investigate the effect of S2ED on this response. To establish
whether the anti-angiogenic effect of S2ED is due to the
inhibition of endothelial cell migration by residues contained
within the 18-amino-acid regulatory domain, we performed
migration assays on brain endothelial cells in the presence of
either S2ED or the truncated forms of this protein (S2EDDP124–
F141 and S2EDDL73–G123). As found with the full-length protein,
the truncated fusion protein containing only the adhesion
regulatory domain (S2EDDL73–G123), inhibited endothelial cell
migration (Fig. 4C,D). In contrast, the mutant protein lacking the
syndecan-2 adhesion regulatory domain did not affect cell
migration, with the wound closure being equivalent to that
noted with cells treated with GST alone. The inhibitory effect of
S2ED on endothelial cell migration was evident regardless of the
vascular bed from which the endothelial cells originated because
both skin and lung endothelial cells responded to S2ED and the
mutant proteins in a similar manner (supplementary material Fig.
S4C). Taken together, these data show that the effect of S2ED on
endothelial cell migration is regulated by the C-terminal 18-
amino-acid regulatory domain.
We also tested the effects of S2ED on endothelial cell invasion
into collagen I gels and observed that cell invasion was greatly
inhibited when S2ED was incorporated as compared to controls
(Fig. 4E). Of importance, neither protein impacted upon cell
proliferation (Fig. 3F). These data are in disagreement with the
findings of a previous report (Fears et al., 2006) in which it was
suggested that S2ED could promote endothelial cell invasion
and stimulate longer microtubules in networks formed when
endothelial cells are seeded on Matrigel. In trying to recapitulate
this work we observed that S2ED inhibited endothelial cell
invasion through Matrigel and had no measurable effect on
network formation when sEND cells were seeded on Matrigel
(supplementary material Fig. S4D,E). These results also show an
inhibitory effect on endothelial cell invasion by S2ED and this is
likely to be through inhibition of cell migration.
The inhibition of angiogenesis by S2ED is driven by CD148,
leading to changes in b1 integrin activation
In fibroblasts the protein tyrosine phosphatase receptor CD148
(also known as PTPRJ) interacts directly with the adhesion
regulatory domain of S2ED leading to b1-integrin-mediated cell
attachment and spreading (Whiteford et al., 2011). To determine
whether CD148 is a mediator for endothelial cell responses to
S2ED, we first confirmed that endothelial cells from brain, lung
and skin expressed CD148. Western blot analysis using an
antibody directed to the cytoplasmic domain of CD148 revealed
that all three cell lines expressed this receptor (Fig. 5A). We then
demonstrated that there was an interaction between CD148 and
the syndecan-2 ectodomain by performing a pulldown assay using
GST–S2ED beads as bait. No CD148 was evident in precipitates
in which GST- or GST–S2EDDP124–F141-coated beads were used
(Fig. 5B). S2ED and S2EDDL73–G123, which both contain the C-
terminal 18-amino-acid adhesion regulatory domain successfully
pulled down CD148 from endothelial cell lysates indicating that
the interaction point between CD148 and S2ED resides in this
region of the molecule.
We next performed rat aortic ring experiments using a purified
recombinant form of the CD148 extracellular domain comprising
the first five type III fibronectin repeats of the human form of this
molecule. This also proved inhibitory to angiogenesis to the same
degree as S2ED, and when used in conjunction with S2ED the
anti-angiogenic effect appeared enhanced (Fig. 5C).
The impact of S2ED on endothelial cell b1 integrin activation
was examined next. Endothelial cells treated with S2ED showed
reduced binding of the b1 integrin activation marker, the
monoclonal antibody (mAb) 9EG7, as demonstrated by
fluorescence activated cell sorting (FACS) (Fig. 6A). Using this
antibody for immunofluorescent staining of endothelial cells, a
substantial reduction in active b1 integrins was observed in cells
treated with S2ED (Fig. 6B,C). Interestingly this effect was most
pronounced at the leading edge of scratch wounds, where the
highest expression of active b1 integrins was noted in control and
GST-treated cells. We further tested the effect of S2ED on b1
Fig. 3. The syndecan-2 extracellular core protein inhibits angiogenesis.
(A) Schematic diagram of S2ED consisting of GST fused to the syndecan-2
ectodomain core protein. (B) Angiogenesis is inhibited by S2ED when
incorporated into Matrigel. C57BL/6 mice were given sub-dermal injections of
Matrigel supplemented with VEGF and FGF containing either 0.5 mM of
S2ED or GST. Excised sections of Matrigel plugs were immunostained for
CD31 (endothelial cells) and DRAQ5 (all cell nuclei) and analysed by
confocal microscopy, and the percentage of cells positive for CD31
calculated. Less endothelial cells migrate into Matrigel plugs containing
S2ED. Error bars represent the s.e.m. of four separate images. *P,0.05
(Mann–Whitney t-test). (C) Photographs of plugs after excision. (D) The anti-
angiogenic effects of S2ED are dose dependant. Rat aortic rings were
seeded in collagen I containing the indicated concentrations of GST or
S2ED and the angiogenic sprouts counted after 4 days. Data were obtained
from at least 10 rings from four separate rats per condition. *P,0.05,
**P,0.01 (one-way ANOVA comparing to untreated controls using the
Tukey’s comparisons test). (E) S2ED inhibits tubule formation in a HUVEC
co-culture system. Using the V2a kit, HUVECs and fibroblasts were co-
cultured in the presence of VEGF, Suramin, S2ED and GST. Micrographs,
showing fewer tubules, were obtained in the presence of S2ED and these
were shorter (F) and less branched (G; branch points denoted by arrows).
Scale bar: 500 mm. Error bars represent the s.e.m. of four separate images.
*P,0.05, **P,0.01, ****P,0.0001 (Mann–Whitney t-test).
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integrin activation in HUVECs. Stimulation of HUVECs with
Mn2+ lead to an increase in structures that bound the mAb
HUTS4 and this was unaffected by the addition of GST. Positive
staining was greatly reduced when cells were treated with S2ED
(Fig. 6D). Taken together, these results suggest that the anti-
migratory effects of S2ED on endothelial cells might be mediated
by CD148 signalling, an interaction that could lead to a reduction
in active b1 integrins on the surface of endothelial cells (Fig. 6).
DISCUSSION
The use of inhibitors for the suppression of pathological
angiogenesis is well established, although clinical evidence
Fig. 4. See next page for legend.
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suggests that there are a number of complications and side effects
(Duda et al., 2007). There is therefore a need for greater
understanding of the regulatory mechanisms that both promote
and inhibit new blood vessel formation in order to develop new
more effective therapeutic targets. We propose a previously
unreported role for syndecan-2, in that, in its shed form,
syndecan-2 can act to inhibit angiogenesis by slowing
endothelial cell migration, through an interaction with CD148
leading to changes in b1 integrin activation (Fig. 7). The
identification of the syndecan-2 adhesion regulatory domain as
a strong negative regulator of angiogenesis mean that both it and
its binding partner CD148 are potential novel therapeutic targets
in pathologies where angiogenesis is a feature, such as
atherosclerosis, arthritis and cancer.
Angiogenesis requires the action of numerous pro- and anti-
angiogenic factors that collectively provide the signals necessary
for the generation of new blood vessels. Here, we demonstrate
that one such factor is the extracellular core protein of syndecan-2
that, when shed from cells, can negatively regulate angiogenesis.
Syndecan shedding is a feature of many cell types and occurs in
response to stimuli such as inflammatory mediators and growth
factors (Manon-Jensen et al., 2010; Pruessmeyer et al., 2010).
Both MMP-7 and MMP-9 have been identified as having a role in
the shedding of syndecan-2 (Fears et al., 2006; Kwon et al.,
2014). As yet the cleavage sites for syndecan-2 shedding have not
been identified; however, the eukaryotic expression system
described here will provide an useful tool to address this
important question. Shedding studies on syndecan-4, the most
closely related member of this family to syndecan-2, suggest that
the entire ectodomain can be cleaved from the cell surface
(Manon-Jensen et al., 2013). The fact that shed syndecan-2
influences angiogenesis and that the regulatory region resides
between P124 and F141 of the ectodomain, close to the syndecan-2
transmembrane domain, suggests that, like syndecan-4, the entire
ectodomain is shed in response to inflammatory stimuli.
Fig. 4. The anti-angiogenic properties of S2ED are due to inhibition of
endothelial cell migration and are mediated by amino acids P124–F141.
(A) Diagram of the mutant proteins used in this study. Full-length syndecan-2
extracellular core protein S2ED comprising E19–F141, a truncated form of
S2ED lacking the adhesion regulatory domain, S2EDDP124–F141 (green),
and a mutant containing only the GAG attachment domain and the C-
terminal adhesion regulatory domain, S2EDDL73–G123. (B) The adhesion
regulatory domain of syndecan-2 inhibits angiogenic sprout formation. Rat
aortas were seeded in collagen I matrices containing 0.5 mM of GST, S2ED
or the mutant forms of S2ED. Sprouts from eight rings per condition were
counted and the mean calculated. Error bars represent the s.e.m.
***P,0.005, ****P,0.0001 (one-way ANOVA with Bonferroni multiple
comparison). (C,D) Scratch wound migration assays were performed in the
presence of 0.5 mM of the indicated fusion proteins on brain endothelial cells.
(D) Endothelial cell migration speed is reduced in the presence of S2ED
proteins containing the 18-amino-acid regulatory domain. Cell speed data
represents mean6s.e.m. measurements from at least 25 individual cells at
the leading edge per treatment. (E) S2ED inhibits endothelial cell invasion
into collagen I matrices. GST or S2ED (0.5 mM) were incorporated into
collagen I matrices in transwells. After 6 h, cells that had migrated were
counted and the data represents the mean6s.e.m. of triplicate assays.
*P,0.05 (by Student’s t-test). (F) Cell proliferation is unaffected by S2ED.
Confluent monolayers of sEND cells were grown in the presence of 0.5 mM of
the proteins indicated and mean proliferation measurements were calculated
from four wells per condition.
Fig. 5. S2ED interacts with CD148, resulting in the inhibition of angiogenesis. (A) bEND3.1, MLEC and sEND cells express CD148. Western blot of
lysates from the endothelial cell lines indicated were probed with antibodies against CD148 or b-tubulin. (B) CD148 interacts with S2ED. Cell lysates from
sEND cells were incubated with beads coated with GST, S2ED, S2EDDP124–F141 or S2EDDL73–G123. Precipitates were analysed by western blotting for the
presence of CD148. CD148 was only pulled down by forms of S2ED which contain the C-terminal 18-amino-acid adhesion regulatory domain. The blot is
representative of four experiments. (C) Soluble CD148 inhibits angiogenesis. Rat aortic rings were embedded in collagen I with either 0.5 mM S2ED or 0.5 mM of
soluble (sol) CD148, or both proteins in combination, in the presence of VEGF. Both S2ED and soluble CD148 inhibited sprout formation to the same degree,
and also inhibited angiogenesis when used in combination. Data are the mean from aortas from five animals and errors bars reflect the s.e.m. *P,0.05,
***P,0.001 (Student’s t-test comparing values to the untreated VEGF control).
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Regulatory sequences in the syndecan-1 and, more recently,
the syndecan-3 ectodomain have been identified and these have
also been shown to be anti-angiogenic (Beauvais et al., 2004;
Beauvais et al., 2009; De Rossi and Whiteford, 2013b). However,
the evidence presented here suggests that shed syndecan-2 acts on
endothelial cells through a mechanism distinct to that associated
with syndecan-1 and -3. Syndecan-1 is thought to interact directly
with aV integrins, leading to changes in cell adhesion
Fig. 6. See next page for legend.
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characteristics through an autocrine interaction with IGFR-1
(Beauvais and Rapraeger, 2010; Rapraeger et al., 2013). We
propose that shed syndecan-2 acts in a paracrine fashion given
that the adhesion regulatory domain of syndecan-2 is situated
very close to the transmembrane domain of the full-length
molecule. The presence of glycosaminoglycan (GAG) chains and
the respective sizes of the receptors involved make it hard to
envisage how an autocrine interaction between these CD148 and
syndecan-2 could occur. Whether regulation of angiogenesis is a
common feature of all four syndecan ectodomains is an attractive
possibility that requires further investigation.
We showed that the anti-angiogenic effect of the syndecan-2
ectodomain is observed in both rodent and human models of
angiogenesis, and involves the interaction with the protein
tyrosine phosphatase receptor CD148 on the surface of
endothelial cells, which corresponds with the inactivation of b1
integrins. b1 integrins are intimately associated with angiogenesis
and endothelial cell migration (Mettouchi and Meneguzzi, 2006).
Our previous work using fibroblasts has shown that engagement
of CD148 with S2ED leads to the de-phosphorylation of the
p85 subunit of phosphoinositide 3-kinase (PI3K) and that there
is a requirement for Src kinase in this process. Furthermore,
clustering of CD148 with cognate antibodies leads to b1-integrin-
mediated fibroblast adhesion responses (Whiteford et al., 2011).
It is likely that this same signalling pathway is functional in
endothelial cells, and that these signalling molecules are involved
in the reduction in active b1 integrins on the surface of
endothelial cells in response to S2ED. CD148 is known to be
involved in the inhibition of cell migration in leukocytes, notably
neutrophils and macrophages (de la Fuente-Garcı´a et al., 1998;
Zhu et al., 2008; Zhu et al., 2011), and, here for the first time we
show it also has a role in regulating endothelial cell migration.
Another ECM component, thrombospondin, has also been
identified as a ligand for CD148, and this molecule is also
known to bind HS, and is an inhibitor of angiogenesis (Takahashi
et al., 2012). It is tempting to speculate that these three molecules
are involved in some form of cell migration regulatory complex
within the ECM, particularly as endothelial cell responses to
thrombospondin-1 have been shown to involve b1 integrin.
Syndecan-2 and CD148 are molecules intimately associated
with the vasculature. Syndecan-2 is expressed on fibroblasts,
leukocytes and endothelial cells, and studies in zebrafish have
revealed that syndecan-2 is essential for branching angiogenesis
(Chen et al., 2004). Here, we show that CD148 is present on
endothelial cells from three distinct vascular beds (brain, skin and
lung). CD148-null mice are viable and show no gross defects;
however, a knock-in mouse expressing a catalytically dead form
of CD148 in which the cytoplasmic domain is replaced by eGFP
dies early in development due to a failure in vascularisation
(Takahashi et al., 2003; Trapasso et al., 2006). Quite why the
cytoplasmically mutated form of CD148 elicits such a strong
Fig. 6. Active b1 integrin is reduced on endothelial cells in the presence
of S2ED. (A) Active b1 integrin on sEND cells positive for total b1 integrin is
reduced in S2ED-treated cells as measured by FACS. The number of
endothelial cells with active b1 integrin (as recognised by the monoclonal
antibody 9eG7) was expressed as a percentage of total b1-integrin-
expressing cells and plotted on the bar chart (right) left and dot blots
corresponding to each treatment (left). (B) Micrographs of scratch wounds
showing that active b1 integrin is reduced in endothelial cells treated with
S2ED. Active b1 integrin is shown in green and DAPI in blue. Scratch
wounds were performed on confluent monolayers and were incubated in the
presence of the indicated proteins (0.5 mM) for 30 min prior to staining.
Graphs represent the fluorescent intensity profile of active b1 integrin across
the scratch wounds. The data was obtained from the section represented by
the lines indicated on the micrographs. Scale bar: 200 mm. (C) Higher
magnification micrographs (636) of endothelial cells treated as indicated.
Scale bar: 10 mm. Cells were stained for F-actin (red), DRAQ5 (blue) and
active b1 integrin (green). (D) S2ED causes a reduction in active b1 integrin
on HUVECs. HUVECs were treated with 1 mM MnCl2 in the presence of
0.5 mM GST or S2ED. Untreated cells or cells treated with GST showed an
increase in structures recognised by the monoclonal antibody HUTS4
(green). This was not the case with cells treated with S2ED. Inlays show
DAPI staining (blue) and merged images. Scale bar: 20 mm.
Fig. 7. Engagement of CD148 by shed
syndecan-2 corresponds with a reduction in
active b1 integrin in endothelial cells leading
to inhibition of cell migration and
less angiogenesis.
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phenotype is not clear. Our study suggests that engagement of
CD148 by its ligands results in an ablation of the angiogenic
process and this is supported by the fact that antibodies targeting
CD148 have anti-angiogenic affects (Takahashi et al., 2006). We
hypothesize that this CD148-driven response to S2ED represents a
signal whereby new blood vessel formation is halted, for example
at the site of tissue injury. In as much as promoting new blood
vessel formation is an important feature of wound healing, the
cessation of this process also represents an important step.
Syndecan-null animals also breed normally, are fertile and have
no gross abnormalities and it is only under challenge or insult that
these animals exhibit phenotypes (Ishiguro et al., 2002). It is
conceivable that the CD148-null mouse would exhibit similar
responses. An intriguing question would be how this mouse would
respond to wounding or models where excessive angiogenesis
occurs, such as in retinal angiogenesis or tumour models. This
work presents an unreported pathway for the inhibition of
angiogenesis and presents an alternative therapeutic target for
anti-angiogenic therapy to those currently on the market.
MATERIALS AND METHODS
Fusion proteins and antibodies
GST, S2ED, S2EDDP124–F141, S2EDDL73–G123 and soluble CD148 were
purified as described previously (Whiteford et al., 2011). Antibodies used
were anti-CD148 (R and D Systems), anti-CD29 clone 9EG7 (BD
Pharmingen), anti-mouse CD29 clone HMb1-1 (Biolegend), anti-CD29
clone HUTS4 (Millipore), Anti-HA (clone HA.11, Covance), anti-
syndecan-2 (AF6585, R and D systems) and anti b-tubulin (clone
TUB2.1, Sigma) antibodies, and Alexa-Fluor-488-conjugated anti-mouse
CD31 antibody (Clone MEC 13.3, Biolegend). Alexa-Fluor-568-
conjugated phalloidin was from Life Technologies.
Cell culture
All cells used in this study were grown at 37 C˚ under 10% CO2 in
Dulbecco’s modified Eagle’s medium (DMEM; PAA), supplemented
with 10% FBS, 2 mM L-glutamine, 1% non-essential amino acids, 1 mM
sodium pyruvate and 5 mM b-mercaptoethanol (all Invitrogen). Primary
murine lung endothelial cells were isolated and maintained as described
previously (Reynolds et al., 2002). HUVECs (HPA laboratories) were
grown and maintained in Endothelial Growth Medium (HPA
laboratories) and maintained as above.
Generation of syndecan-2-expressing cell lines
Gene synthesis of the complete murine syndecan-2 cDNA and the cDNA
encoding only the syndecan-2 ectodomain coding sequence was
performed by GeneArt (Invitrogen). Both full-length and truncated
syndecan-2 cDNAs were mutated such that the HA epitope was inserted
between D27 and K28 (supplementary material Fig. S1). BamHI sites were
also incorporated at the 59 and 39 end of the two synthetic genes. The
cDNAs were cloned into the BamHI site of the lentiviral vector pLNT-
SFFV-MCS-EGFP (available from T.R.M.). Lentiviruses were produced
in HEK293t cells and packaged into a VSVG coat using conventional
procedures. HEK293t cells were transfected using the supernatant
transfer method. Cells expressing high levels of eGFP were sorted by
flow cytometry and these were cultured in DMEM as described.
Tumour xenograft model
Six-week-old SCID SHO mice (Charles River) were subcutaneously
injected in the left flank with 36106 HEK293t cells stably transfected
with either empty vector or eS2ED in 100 ml PBS. Mice were left for 21
days prior to being killed by cervical dislocation. All experiments were
performed under the UK legislation for the protection of animals in
accordance with UK Home Office regulations. Tumours were dissected
and photographed and tumour mass and diameter was measured.
Tumours were then snap-frozen in liquid nitrogen prior to embedding
in OCT and sectioning (20 mm sections). Sections were fixed using
ice-cold methanol and immunostained with anti-CD31 antibodies
conjugated to Alexa Fluor 564 and imaged using a PASCAL laser-
scanning confocal microscope (Carl Zeiss) with a 106 objective.
Matrigel plug assay
Male 6-week-old C57BL/6 mice were given subdermal abdominal
injections consisting of 600 ml of Matrigel (BD Biosciences) mixed with
100 ml of PBS containing 100 ng/ml VEGF, 100 ng/ml FGF and 20 U/ml
of heparin and 0.5 mM of either GST or S2ED (following the method
described in Passaniti et al., 1992). Mice were killed after three days and
the plugs excised, photographed and incubated overnight in PBS.
Haemoglobin was quantified using Drabkin’s reagent (Sigma) as
described by the manufacturer. All experiments were performed under
the UK legislation for the protection of animals, and at the end of all in
vivo procedures involving anaesthesia, animals were humanely killed by
cervical dislocation in accordance with UK Home Office regulations.
Excised plugs were frozen in liquid nitrogen and subsequently embedded
in ice cold OCT, 15-mm sections were made using a cryostat at 220 C˚.
Following fixation with 4% paraformaldehyde (PFA) for 5 min and
blocking with 10% normal goat serum for 15 min, sections were stained
for nuclei (DRAQ5) and the endothelial cell marker CD31 overnight.
Images were captured using a PASCAL laser-scanning confocal
microscope (Carl Zeiss, 106objective). Quantification was performed
using the IMARIS software and Photoshop (Adobe), endothelial cells
were identified by co-localization of nuclei with CD31 staining.
Aortic ring assay
Thoracic aortas dissected from cervically dislocated 180–200 g male
wistar rats (Harlan laboratories) or 6-week-old C57BL/6 mice (Charles
River), and were sliced into 0.5-mm sections and incubated overnight in
serum-free OptiMEM (Invitrogen) at 37 C˚. Aortic rings were embedded
in type I collagen (1 mg/ml) in E4 medium (Invitrogen) containing GST,
syndecan-2 mutant proteins or peritoneal exudates in 48-well plates.
Wells were supplemented with OptiMEM with 1% FBS and 10 ng/ml
VEGF (R and D systems, 30 ng/ml for murine rings) and incubated at
37 C˚ under 10% CO2. Angiogenic sprouts from rat and mouse aortas
were counted after 4 days and 8 days respectively (method based on that
of Nicosia and Ottinetti, 1990 and modified in De Rossi et al., 2013).
In vitro tubule formation assays
HUVECs and human dermal fibroblasts were co-cultured using the Cell
Works V2a kit (Caltag Media Systems as described by the manufacturer).
Medium containing control compounds, GST or S2ED was changed
every second day and at day 14 endothelial cells were stained for CD31
to assess the tube formation. Imaging was performed using an Olympus
IX81 inverted microscope (106objective); tube length and branch points
were quantified using Photoshop (Adobe). A branch point was defined as
the point at which two or more tubules met, and the tubule length as the
length of tubules between branch points. In a second type of microtubule
assay, sEND cells (56104) were seeded into 24-well plates coated with
150 ml of Matrigel (BD sciences) in the presence of either GST or S2ED.
Using the Cell-IQ controlled environmental chamber (CM technologies)
plates were incubated at 37 C˚ under 10% CO2 and images were captured
every 15 min for 16 h.
Scratch wound migration assays
Scratch wound migration assays were performed on confluent
monolayers of endothelial cells. Wounds were made using a pipette
tip, and fusion proteins were added to the medium and images were
captured every 30 min for 12 h by time lapse microscopy using an
Olympus IX81 microscope. Percentage wound closure was calculated
and individual cells were tracked using Image J.
Invasion assay
Invasion assays through collagen and Matrigel matrices were performed
in 24-well plates with transwell inserts [Millipore; 8-mm pore size,
polyester (PET) membrane]. Membranes were coated with 10 ml of a
collagen type I mixture (Millipore; 1 mg/ml in E4 medium) containing
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0.5 mM GST or S2ED. sEND cells were seeded on the gel in a
homogenous single cell suspension of 5,000 cells/insert in 200 ml of
DMEM plus 10% FBS; 1 ml of the same medium was added to the
bottom well. Invasion was measured after 6 h after which time gels were
removed with a cotton swap, the filter washed in PBS and stained with
calcein (Invitrogen) and the number of cells attached to the filter counted.
Proliferation
Cell proliferation was measured using the CellTiter 96 AQueous Cell
proliferation assay kit as described by the manufacturer (Promega).
CD148 pulldown and western blotting
Confluent bEND3.1 cells were lysed in 1% Triton X-100 in Tris-buffered
saline (TBS) containing HALT protease and phosphatase inhibitors (Pierce).
GST and S2ED were bound to glutathione–Sepharose beads (GE Healthcare)
and were added to cell lysates and incubated for 1 h. Beads were isolated by
centrifugation and washed twice in TBS, prior to incubation in Laemmli
buffer and analysis by western blotting using standard procedures.
Dot blotting
Samples were diluted in blotting buffer (0.15 M NaCl buffered to pH 4.5
with 50 mM sodium acetate, with 0.1% Triton X-100) and applied under
vacuum to cationic nylon membranes (GE Healthcare; Amersham
HybondTM-N+). Membranes were washed three times with blotting
buffer, blocked for 1 h in blocking buffer (3% milk, 0.5% BSA, 0.15 M
NaCl in 10 mM Tris-HCl pH 7.4) and incubated overnight with primary
antibody in blocking buffer plus 0.3% Tween-20. After washing, blots
were incubated for 2 h with the appropriate horseradish peroxidase
(HRP)-conjugated secondary antibody and signals were detected by
chemi-luminescence using conventional procedures. Quantification of
the signal intensity was performed using ImageJ software.
FACS and immunofluorescence staining for active integrin
Confluent bEND3.1 cells were trypsinised and the trypsin inactivated
with BSA. Cells were re-suspended in Hank’s buffer (without Ca2+ and
Mg2+) containing the treatments described (0.5 mM GST or S2ED) and
incubated for 30 min at 37 C˚. Cells were then fixed in 2% PFA prior to
FACS analysis for both total and active b1 integrin and the percentage of
cells expressing active b1 calculated. For immunofluorescence staining
of active b1 integrin, confluent monolayers of sEND cells were grown on
microscope slides and scratch wounds were made and either 0.5 mM GST
or S2ED was added. After 30 min, cells were fixed with 4% PFA (Sigma)
and permeabilised in 0.1% Triton X-100 (Sigma) in PBS. Samples were
incubated with active b1-integrin-specific antibody 9EG7 in 1% normal
goat serum in PBS overnight at 4 C˚. Slides were washed in PBS and
incubated in anti-rabbit-IgG antibody conjugated to Alexa Fluor 488
(Molecular Probes) and DAPI, and images were captured on an Olympus
IX81 inverted microscope. Fluorescent intensity profiles from the
resulting images were calculated using ImageJ. For higher resolution
images, cells were imaged using a PASCAL laser-scanning confocal
microscope (Carl Zeiss) with a 636 objective and the resulting stacks
were processed using IMARIS software. HUVECs were seeded on
coverslips coated with fibronectin (10 mg/ml) and collagen I (30 mg/m) in
0.1% gelatin. Once ,60% confluent, cells were washed with serum-free
OptiMEM then treated either with or without 1 mM MnCl2 in the
presence of either 0.5 mM GST or S2ED for 30 min. Cells were then
fixed in 2% PFA and stained using a monoclonal active b1-integrin-
specific antibody (clone HUTS4, at 1:300). After washing, cells were
stained with an anti-mouse-IgG antibody conjugated to Alexa Fluor 594
(Molecular Probes). Cells were analysed by confocal microscopy as
described above.
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        CCGAACTACCGGACACACAGGCGTCTCTGCTCTTGTCTCGACTGTAGGCTAATAGGTATA 15 
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   HA epitope insertion 17 
     1: D  V  P  D  Y  A__K  D  M  Y  L  D  N  S  S  I  E  E  A  S__ 18 
        GACGTGCCAGACTATGCTAAGGATATGTACCTTGACAATAGCTCCATTGAGGAAGCTTCA 19 
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 23 
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        CCTCATATAGGATAACTACTACTACTGATAAGAAGACGGAGTCCGAGTCCTCGACTACTT 27 
 28 
 29 
     1: D  I  E  S  P  V  L  T  T  S  Q  L  I  P  R  I  P  L  T  S__   30 
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        CTGTATCTCTCAGGTCAAGACTGTTGTAGGGTTGACTAAGGTTCTTAGGGTGAGTGATCA 33 
 34 
 35 
     1: A  A  S  P  K  V  E  T  M  T  L  K  T  Q  S  I  T  P  A  Q__   36 
        GCTGCTTCCCCCAAAGTGGAAACCATGACGTTGAAGACACAAAGCATTACACCTGCTCAG 37 
    301 ---------!---------!---------!---------!---------!---------! 360 38 
        CGACGAAGGGGGTTTCACCTTTGGTACTGCAACTTCTGTGTTTCGTAATGTGGACGAGTC 39 
 40 
 41 
     1: T  E  S  P  E  E  T  D  K  E  E  V  D  I  S  E  A  E  E  K__   42 
        ACTGAGTCACCTGAAGAAACTGACAAGGAGGAAGTTGACATTTCTGAGGCAGAAGAGAAG 43 
    361 ---------!---------!---------!---------!---------!---------! 420 44 
        TGACTCAGTGGACTTCTTTGACTGTTCCTCCTTCAACTGTAAAGACTCCGTCTTCTCTTC 45 
 46 
                                                        47 
     1: L  G  P  A  I  K  S  T  D  V  Y  T  E  K  H  S  D  N  L  F__*__   48 
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    421 ---------!---------!---------!---------!---------!---------! 480 50 
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 70 
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 76 
Murine syndecan-2 cDNA with HA tag insertional mutation (white text, red background). 77 
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with the addition of a stop codon (red). 79 
Journal of Cell Science | Supplementary Material
 De Rossi et al., 2014: Syndecan-2 and Angiogenesis 
 
2 
 
Supplemental Figure 2 1 
 2 
 3 
Tumours derived from eS2ED cells have smaller diameter and mass. Error bars represent 4 
the SEM and significance was calculated using a Students t test. 5 
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Supplemental Figure 3 1 
 2 
 3 
Characterisation of the syndecan-2 expressing HEK293t cell lines. (A) Schematic 4 
diagram of the lentiviral expression cassette used for transfection. (B) Expression of full 5 
length syndecan-2 was demonstrated by western blot using anti-HA antibodies. A high 6 
molecular weight smear is observed in cells expressing eFLS2 indicating that the protein is 7 
substituted with HS. No smear or band is evident in lysates from cells transfected with 8 
eS2ED (eS2EDlys) however HSPGs isolated from the conditioned media  by anion exchange 9 
(eS2EDcon) contain a high molecular weight smear indicating that the constitutively secreted 10 
syndecan-2 core protein is glycanated.  (C) The full length form of syndecan-2 is expressed 11 
on the cell surface. Flow cytometry using the anti-HA antibody was performed on the cell 12 
lines indicated.  13 
 14 
  15 
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Supplemental Figure 4 1 
 2 
A) Quantification of haemoglobin content of Matrigel plugs. Plugs containing S2ED 3 
(white bar) contained less blood than GST control (black bar). Error bars represent the 4 
highest and lowest mean measurements obtained from 2 mice injected with 2 plugs. 5 
B) S2ED is inhibitory to angiogenic sprout formation from murine aortas. Murine aortic 6 
rings were seeded in collagen I gels containing 0.5μM of GST or S2ED and supplemented 7 
with 1% FBS and VEGF. (Statistical analysis was performed using a Student’s t-test, n=5; 8 
p<0.05). 9 
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C) S2ED inhibits migration of ECs from different vascular beds. Scratch wound 1 
migration assays were performed in the presence of 0.5µM of the fusion proteins indicated on 2 
the EC cell lines from brain, lung and skin. Percentage scratch wound closure was measured 3 
after 9 hours of incubation. Proteins containing the adhesion regulatory domain S2ED (white 4 
bars) and S2EDΔL73-G123 (black bars) inhibit EC migration whereas migration is unaffected 5 
by treatment with GST (grey bars) and S2EDΔP124-G123 (light grey bars). 6 
D) S2ED slows EC migration through Matrigel. S2ED inhibits EC invasion through 7 
Matrigel. GST or S2ED (0.5µM) was incorporated into Matrigel layers in transwells. After 6 8 
hours migrated cells were counted and the data represents the mean of triplicate assays.  9 
E) EC microtubule formation is not affected by S2ED. sEND cells were seeded on layers 10 
of Matrigel and micrographs were obtained at the times indicated. 11 
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Abstract
Syndecans are multifunctional heparan sulfate proteoglycans (HSPGs) with roles in cell adhesion, migration,
receptor trafﬁcking and growth-factor interactions and signalling. Studies using syndecan null animals have
revealed limited roles for syndecans during development; however, under conditions of challenge or insult,
several phenotypes have emerged. Angiogenesis is an important process both in development and in wound
healing, but also in pathologies such as cancer and chronic inﬂammatory conditions. In the present paper,
we summarize the main studies elucidating the role of syndecans in angiogenesis and their potential as
novel therapeutic targets.
Introduction
Syndecans are type I transmembrane glycoproteins that
belong to the heparan sulfate proteoglycan (HSPG) super-
family. Four members have been characterized in vertebrates
with different functions and expression profiles. Most cell
types, with the exception of erythrocytes, possess at least
one syndecan; although syndecan-1 appears principally in
epithelia and in some leucocyte subsets, syndecan-2 is mainly
expressed in mesenchymal tissues, syndecan-3 is primarily
neuronal whereas syndecan-4 is ubiquitously expressed but
at lower levels comparedwith the other three [1–3].However,
this traditional description of syndecan expression profiles is
being challenged by new studies (some of which are reviewed
in the present paper) showing that syndecan expression is
more plastic and not only dependent on cell type, but also on
the developmental stage, the environment and stimuli present.
Syndecans possess a linear single-pass transmembrane
protein core which includes a highly conserved short
cytoplasmic domain, a transmembrane domain and a more
divergent (except for the sugar-attachment sites) syndecan-
specific extracellular domain which varies in length among
the four members (with syndecan-4 being the shortest
and syndecan-3 being the longest) and this is covalently
substitutedwith heparan sulfate (HS) chains (and chondroitin
or dermatan-sulfate chains, in some cases). The HS chains
consist of 50–150 repetitions of disaccharide units (mainly
glucoronic acid and N-acetylglucosamine) with alternating
high- and low-sulfated domains attached to conserved Ser-
Gly dipeptides in the extracellular core protein [4].
Syndecans have the ability to interact with a great
repertoire of ligands including extracellular matrix (ECM)
Key words: angiogenesis, endothelial cell, heparan sulfate, integrin, syndecan.
Abbreviations: EGF, endothelial growth factor; FGF, ﬁbroblast growth factor; HMEC, human
microvascular endothelial cell; HS, heparan sulfate; HSPG, heparan sulfate proteoglycan; MvEC,
murine vein endothelial cell; PGE2, prostaglandin E2; PKCα, protein kinase Cα; SSTN, synstatin;
TSP-1, thrombospondin-1; VEGF, vascular endothelial growth factor; VN, vitronectin.
1To whom correspondence should be addressed (email g.derossi@qmul.ac.uk).
molecules, growth factors, enzymes, cytokines, chemokines
and pathogens. These interactions occur mainly through
syndecan HS chains and there are a considerable number
of angiogenesis-related growth factors, cytokines and
chemokines that have heparin-binding properties, including
fibroblast growth factors (FGFs), platelet-derived growth
factor (PDGF), vascular endothelial growth factors (VEGFs),
pleiotrophin, placental growth factor (PlGF), platelet factor-
4 (PF-4), heparin-binding endothelial growth factor (EGF)-
like growth factor, interleukin-8 (IL-8), hepatocyte growth
factor (HGF), macrophage inflammatory protein-1 (MIP-
1), transforming growth factor-β (TGF-β) and interferon-γ
(IFN-γ ). Surprisingly, no direct interaction between many
of these molecules and syndecans has been reported yet,
possibly because of the technical challenges and limited
knowledge of the specific sugar composition and level of
modification of the four different syndecans HS chains.
The cytoplasmic domain of syndecans is composed of two
conserved regions (C1 and C2) flanking a variable region
(V), unique for each syndecan. These domains can interact
with a number of cytoplasmic proteins and lipids and as
such promote specific cell functions. The V region generally
confers syndecan-specific properties whereas the C-terminus
(C2) domain contains a PDZ-binding domain shared among
the four members [5].
It is becoming increasingly evident that many functions
of syndecans depend on their extracellular domains [6].
Once engaged in an interaction, syndecans can act as cell-
surface receptors transmitting signals to inside the cell
(although they do not possess intrinsic enzymatic activity),
as co-receptors presenting the ligand to another receptor
and, upon ectodomain shedding, as soluble effectors. It is
then unsurprising that syndecans can regulate a number of
complex signalling events contributing to cell proliferation,
differentiation, adhesion and migration [1,5,7].
The formation of new blood vessels from pre-existing
ones, also known as angiogenesis, is a complex process
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which involves all the cell processes mentioned above and
more. The basic steps of angiogenesis include enzymatic
degradation of capillary basement membrane, endothelial
cell proliferation and migration, tubulogenesis, vessel fusion
and stabilization [8–10]. A large number of factors and
cell types participate in the regulation of this important
physiological (and pathological) process; the purpose of the
present article is to summarize the recent findings on how
syndecan functions can affect endothelial cell behaviour in
the context of angiogenesis.
Syndecan-1
Syndecan-1 is probably the best characterized of the
syndecans; it appears to be implicated in a variety of
physiological processes associated with the endothelium,
both during development and during adulthood. This is
unsurprising since syndecan-1 is a major constituent of the
endothelial glycocalyx [11]. In an interesting study, increased
new blood vessel formation in syndecan-1-deficient mice
was observed where corneal neovascularization was induced
by inflammation rather than pro-angiogenic growth factors.
However, a direct correlation between increased endothelial
cell–leucocyte interactions in these animals and increased
angiogenesis was observed which suggested that the increase
in the latter is due to an increased local accumulation of
leucocytes [12]. Other studies have shown that syndecan-
1 can associate directly via its extracellular domain with
the αVβ3 and αVβ5 integrins leading to their activation.
This has been shown to happen in a variety of cell types
[13–15] including endothelial cells from both mice and
humans. In fact, immunoprecipitation experiments with
human microvascular endothelial cells (HMECs) revealed
that it was possible to co-precipitate β3 and β5 integrins
in complex with syndecan-1 and that by silencing syndecan-
1 expression, the HMEC-1 line was not able to spread on
the αVβ3 ligand vitronectin (VN) [16]. The same group
previously showed that cells seeded on syndecan-1 antibody
would spread and activate αVβ3 and αVβ5 even in the
absence of integrin ligands [15]. They could replicate this
result with endothelial cells and show that integrin activation
could be prevented by adding synstatin (SSTN82–130, a peptide
corresponding to amino acids 82–130 of the syndecan-1
extracellular core protein). Interestingly, the SSTN peptide
showed promising results in being able to inhibit tumour
angiogenesis in a mouse model of mammary carcinoma [16].
Later, the same group discovered the mechanism through
which syndecan-1 is able to activateαVβ3 andα5β3 integrins.
They were able to co-precipitate syndecan-1 with αVβ3
and insulin-like growth factor receptor 1 (IGF1R) from
endothelial cells in a way which suggested integrin and
syndecan-1 were acting as a docking site for IGFR1. Also,
they showed the presence of this ternary complex on focal
contacts when cells were plated on VN [17]. In further
investigations, they found that SSTN, the peptide able to
disrupt syndecan-1–αVβ3 interaction, can block VEGF-
induced angiogenesis, but only in the early phase (in the
aortic ring assay) when endothelial cell dissemination is
preceded by breakdown of adherens junctions. VEGF-
stimulated migration of endothelial cells depends on αVβ3
and can be blocked by SSTN, suggesting that syndecan-1
has a role VEGF-dependent migration in endothelial cells.
Indeed, stimulation of cells with VEGF activates not only
VEGFR2, but also IGFR1 and αVβ3; activation of the
latter can be abolished by adding SSTN. They propose
a model whereby during the early phase of angiogenesis,
syndecan-1, in its ternary complex with αVβ3 and IGFR1,
is necessary for VEGF-induced integrin activation. This is
key to endothelial cell dissemination and can be prevented
by SSTN and also by disruption of the vascular endothelial
(VE)–cadherin homophilic interaction, thus supporting the
finding that SSTN is not able to stop angiogenesis in its late
phase when adherens junctions are disrupted [18].
Syndecan-2
Themost important study linking syndecan-2 to angiogenesis
dates back to 10 years ago when Chen et al. [19] showed
that lack of syndecan-2 in zebrafish (achieved bymorpholino
gene-targeting approach) dramatically impairs developmental
angiogenesis. In the least severe case, corresponding to a
less efficient syndecan-2 knockdown, intersegmental vessels
either sprouted abnormally or failed to form and the vascular
plexus of the tail region was less complex compared with
that of wild-type embryos. Primary formation of the axial
vessels was normal. However, although axial expression of
fli-1, flk-1 and tie-1 was retained in the trunk, this was lost
in the intersegmental vessels. In an elegant twist to the work,
they not only showed that the phenotype could be reverted
by injection of exogenous zebrafish syndecan-2 cDNA but
also that a similar effect could be obtained by injecting
human syndecan-2 cDNA, giving clear clues of an important
functional conservation among species. The exact mechanism
throughwhich syndecan-2 asserts its pro-angiogenic function
remains unclear. However, they showed that injection of a
cytoplasmically-truncated form of syndecan-2 phenocopied
the lack of its full-length form, suggesting the importance of
its cytoplasmic domain in syndecan-2 vascular function [19].
Syndecan-2 may also play a role in pathological
angiogenesis. It was found to be up-regulated both on vessels
in gliomas and from normal brain whereas not present in
the surrounding parenchyma [20]. The same study showed
that knockdown of syndecan-2 in murine vein endothelial
cells (MvEC) resulted in decreased migration on fibronectin
and tube formation on Matrigel. However, those same
pro-angiogenic factors such as EGF, basic FGF (bFGF)
and VEGF, known to be up-regulated in gliomas, showed
an ability to promote syndecan-2 shedding from MvECs.
Further studies showed that the shed molecule can have a
pro-angiogenic effect onMvECs, suggesting that the vascular
function of syndecan-2might result from a quite complicated
balance of its functions on the cell surface, the regulation of
its shedding and a possible autocrine or paracrine role as a
shed effector [20].
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Furthermore, the HMEC-1 line predominantly expresses
syndecan-2 (∼80% of all HSPG on the cell surface) and
its expression is increased in response to angiogenic stimuli
(especially FGF) and is dependent on the type of matrix cells
are seeded on. Interestingly, down-regulation of syndecan-
2 resulted in decreased cell attachment and spreading and
accelerated cell migration but also impaired the HMEC-1
line’s ability to form capillary-like structures onMatrigel [21].
In the light of these few but important studies, it
appears that syndecan-2 plays a pivotal role in angiogenesis.
Unfortunately, unlike the other three members of the
syndecan family, a knockoutmousemodel for syndecan-2 has
not yet been developed; therefore the question as towhether a
syndecan-2-knockout mouse would develop normally or die
prematurely due to angiogenic defects is still left unanswered.
Syndecan-3
Syndecan-3-knockout mice are viable and develop normally.
Syndecan-3 is considered the main syndecan of the nervous
system and as such it is been mainly investigated in
behavioural studies.
However, recent work highlighting a role for syndecan-3
in the inflammatory response of different tissues also served
to demonstrate that its expression is not limited to the nervous
system but it can also be found on the endothelium of differ-
ent vascular beds (joints, dermis and cremaster muscle) [22].
We recently showed a potential therapeutic effect of the
syndecan-3 extracellular core protein in pathologies where
angiogenesis is increased. Recombinant bacterially-derived
(hence lacking the glycosaminoglycan chains) syndecan-3
extracellular domain was shown to be able to significantly
inhibit angiogenesis in the ex vivo model of the aortic ring
assay and also inhibit skin and brain endothelial cell-tube
formation and cell migration through collagen in 2D and 3D
[23]. These data support the idea that syndecan core proteins,
when released from the cell surface, can act as important
effectors of cell behaviour.
Syndecan-4
Although syndecan-4 was found up-regulated throughout
the granulation tissue during skin injury on endothelial cells
[24], the first clear evidence that it could play a functional
role in angiogenesis came from the work of Echtermeyer
et al. [25]. They generated a syndecan-4-knockout mouse
which showed significantly delayedwoundhealing in amodel
of skin injury. Although the number of newly generated
vessels populating the regenerating tissue was not affected
by the lack of syndecan-4, the vessels were smaller compared
with the wild-type littermates.
Syndecan-4 has since been found to be essential in
mediating the pro-angiogenic effects of thrombospondin-
1 (TSP-1). The study proposed a model whereby two
heparin-binding sequences containedwithinTSP-1 are able to
compete with fibronectin for the interaction with syndecan-
4, thus interfering with syndecan-4-mediated endothelial cell
adhesion [26].
In vitro experiments on endothelial cells have shown that
syndecan-4 is also key player in FGF signalling [27,28].
Interestingly, this is achieved not just by facilitating the
interaction between FGF2 and its receptor FGF receptor 1
(FGFR1), but the syndecan-4 cytoplasmic domain seems to
have a key role, as chimaeras and deletion mutants of this
portion lacking the V or the C2 regions fail to promote
an effective intracellular response to FGF2. In particular,
lack of the C2 region (which contains the PDZ binding
domain) prevents the binding of GAIP (Gα-interacting
protein)-interacting protein C-terminus (GIPC)/synectin,
which results in a failure to activate Rac1 and thus inhibits
endothelial cell migration [29,30].
Quite recently, syndecan-4 has been shown to participate
in the signalling initiated by another pro-angiogenic
molecule, prostaglandinE2 (PGE2). The study revealed that in
murine endothelial cells lacking syndecan-4, PGE2-mediated
pro-angiogenic effects (i.e. endothelial cellmigration and tube
formation) were decreased. It also showed that syndecan-
4 activation of protein kinase Cα (PKCα) is necessary
for the phosphorylation of extracellular-signal-regulated
kinase (ERK) following PGE2 stimulation. This molecular
mechanism was confirmed in vivo by showing a diminished
angiogenic response to PGE2, both in the syndecan-4- and in
the PKCα-knockout mice compared with the wild-type [31].
Concluding remarks
The studies demonstrate the importance of syndecans in
endothelial cell biology during the process of angiogenesis.
Remarkably, despite sharing a common structure, the four
members of the syndecan family appear to have specific
functions, and studies using knockout animals clearly show
that lack of one syndecan can be compensated by another
structurally-similar member (at least during adulthood and
in pathophysiological conditions).
In the light of the few but promising results summarized
in the present review, a more thorough investigation of
syndecan biology is needed as not only will it increase our
understanding of the complex process of new blood vessel
formation but also it could potentially present syndecans as
molecular targets in anti-angiogenic therapies.
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